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Background: Depression is a common, debilitating and costly disorder. The best-evidenced psychological
therapy – cognitive–behavioural therapy (CBT) – is complex and costly. A simpler therapy, behavioural
activation (BA), may be an effective alternative.
Objectives: To determine the clinical effectiveness and cost-effectiveness of BA compared with CBT for
depressed adults at 12 and 18 months’ follow-up, and to investigate the processes of treatments.
Design: Randomised controlled, non-inferiority trial stratified by depression severity, antidepressant use and
recruitment site, with embedded process evaluation; and randomisation by remote computer-generated
allocation.
Setting: Three community mental health services in England.
Participants: Adults aged ≥ 18 years with major depressive disorder (MDD) recruited from primary care
and psychological therapy services.
Interventions: BA delivered by NHS junior mental health workers (MHWs); CBT by NHS psychological
therapists.
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Outcomes: Primary: depression severity (as measured via the Patient Health Questionnaire-9; PHQ-9) at
12 months. Secondary: MDD status; number of depression-free days; anxiety (as measured via the Generalised
Anxiety Disorder-7); health-related quality of life (as measured via the Short Form questionnaire-36 items) at 6,
12 and 18 months; and PHQ-9 at 6 and 18 months, all collected by assessors blinded to treatment allocation.
Non-inferiority margin was 1.9 PHQ-9 points. We undertook intention-to-treat (ITT) and per protocol (PP)
analyses. We explored cost-effectiveness by collecting direct treatment and other health- and social-care costs
and calculating quality-adjusted life-years (QALYs) using the EuroQol-5 Dimensions, three-level version, at
18 months.
Results: We recruited 440 participants (BA, n = 221; CBT, n = 219); 175 (79%) BA and 189 (86%) CBT
participants provided ITT data and 135 (61%) BA and 151 (69%) CBT participants provided PP data. At
12 months we found that BA was non-inferior to CBT {ITT: CBT 8.4 PHQ-9 points [standard deviation (SD)
7.5 PHQ-9 points], BA 8.4 PHQ-9 points (SD 7.0 PHQ-9 points), mean difference 0.1 PHQ-9 points, 95%
confidence interval (CI) –1.3 to 1.5 PHQ-9 points, p = 0.89; PP: CBT 7.9 PHQ-9 points (SD 7.3 PHQ-9 points),
BA 7.8 PHQ-9 points (SD 6.5 PHQ-9 points), mean difference 0.0 PHQ-9 points, 95% CI –1.5 to 1.6 PHQ-9
points, p = 0.99}. We found no differences in secondary outcomes. We found a significant difference in
mean intervention costs (BA, £975; CBT, £1235; p < 0.001), but no differences in non-intervention (hospital,
community health, social care and medication costs) or total (non-intervention plus intervention) costs. Costs
were lower and QALY outcomes better in the BA group, generating an incremental cost-effectiveness ratio
of –£6865. The probability of BA being cost-effective compared with CBT was almost 80% at the National
Institute for Health and Care Excellence’s preferred willingness-to-pay threshold of £20,000–30,000 per
QALY. There were no trial-related adverse events.
Limitations: In this pragmatic trial many depressed participants in both groups were also taking
antidepressant medication, although most had been doing so for a considerable time before entering the
trial. Around one-third of participants chose not to complete a PP dose of treatment, a finding common in
both psychotherapy trials and routine practice.
Conclusions: We found that BA is as effective as CBT, more cost-effective and can be delivered by MHWs
with no professional training in psychological therapies.
Future work: Settings and countries with a paucity of professionally qualified psychological therapists,
might choose to investigate the delivery of effective psychological therapy for depression without the need
to develop an extensive and costly professional infrastructure.
Trial registration: Current Controlled Trials ISRCTN27473954.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 46.
See the NIHR Journals Library website for further project information.
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Plain English summary
Depression is a major health problem that causes severe hardship, distress and disability to many people.Cognitive–behavioural therapy (CBT), which works by helping people change the way they think, is an
effective treatment for depression but its delivery requires a highly trained and professionally qualified
workforce. Behavioural activation (BA), which works by helping people change the way they behave, may
be an effective alternative to CBT and, because it is simpler, might be delivered more cheaply by less
specialised health workers.
In this study, we directly compared CBT with BA, allocating people by chance, so that half of our 440
research participants received BA and half received CBT, to see if people receiving BA were no worse off
than those treated with CBT. We also analysed cost-effectiveness – the differences in the costs of both
treatments related to their effectiveness – and interviewed participants and therapists for their views
on treatment.
We found that the people in both groups improved. We also found that at 6, 12 and 18 months after
people were allocated to either treatment, those receiving BA were not worse off in terms of symptoms of
depression than those receiving CBT, as measured by any questionnaires we used. We also found that the
total costs of health and social care were lower for people treated with BA and that it was more likely that
BA was cost-effective compared with CBT. Patients and therapists identified some challenges receiving and
delivering treatment, but found BA and CBT to be acceptable overall.
In conclusion, our trial has shown that BA is a clinically effective and cost-effective alternative psychological
therapy to CBT for the treatment of patients with depression.
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Scientific summary
Background
Depression is a common, debilitating and costly disorder. Many patients request psychological therapy but
the current best-evidenced therapy – cognitive–behavioural therapy (CBT) – is complex and costly. A
simpler therapy, behavioural activation (BA), may be an effective alternative.
Objectives
1. To assess the clinical effectiveness of BA compared with CBT for depressed adults in terms of
depression treatment response at 12 and 18 months.
2. To assess the cost-effectiveness of BA compared with CBT in terms of quality-adjusted life-years (QALYs)
at 18 months.
We undertook a secondary process evaluation to investigate the moderating, mediating and procedural
factors in BA and CBT that influence outcome.
Design
Randomised controlled non-inferiority trial.
Setting
Three English community mental health services.
Participants
Adults aged ≥ 18 years who met Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition
criteria for a major depressive disorder recruited from primary care and psychological therapy services in
Devon, Durham and Leeds, excluding people who were receiving psychological therapy, were alcohol or
drug dependent, were acutely suicidal or had attempted suicide in the previous 2 months, were cognitively
impaired, had bipolar disorder, or who had psychosis or psychotic symptoms.
Randomisation
We randomly allocated participants in a 1 : 1 ratio to either BA or CBT arms stratified according to
symptom severity on the Patient Health Questionnaire-9 (PHQ-9; < 19 vs. ≥ 19 points), antidepressant
medication (ADM) use (yes/no) and recruitment site.
Allocation concealment
The registered Peninsula Clinical Trials Unit allocated participants remotely using a password-protected
website after the researchers had collected and entered baseline data into a computer database.
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Blinding
It was not possible to blind participants or clinicians. We ensured that research assessors were blind
to participant allocation and we protected against assessment bias by using self-reported measures.
We recorded instances where researchers were unblinded.
Interventions
After 5 days of training, NHS mental health workers (MHWs) and therapists delivered a maximum of 20
face-to-face weekly sessions of 1 hour duration of either BA or CBT, with the option of four additional
booster sessions. MHWs and therapists received 1 hour of clinical supervision fortnightly from NHS
psychological therapists clinically experienced in BA or CBT.
Behavioural activation
Behavioural activation, delivered by MHWs at NHS Agenda for Change (AfC) band 5 grade, was a
structured programme increasing contact with potentially antidepressant environmental reinforcers and
reducing the frequency of negatively reinforced avoidant behaviours. Specific BA techniques included the
use of a functional analytical approach, self-monitoring, identifying ‘depressed behaviours’, developing
alternative goal-orientated behaviours and scheduling. The role of avoidance and rumination was
addressed through functional analysis and alternative response development.
Cognitive–behavioural therapy
Cognitive–behavioural therapy, delivered by NHS AfC band 7 therapists, was a structured programme to
identify and modify negative automatic thoughts, maladaptive beliefs and, if indicated, underlying core
beliefs. Specific CBT techniques included scheduling activity and mastery behaviours, the use of thought
records and modifying maladaptive beliefs and rumination content. The behavioural elements in CBT
focused on increasing activity with behavioural experiments to test specific cognitive beliefs rather than the
contextual, functional analytical approach of the BA trial arm.
Measures
Baseline information
We collected demographic data at baseline on gender, age, ethnic origin, education level, employment,
marital status, number of children, presence and duration of ADM treatment, previous history and age at
onset of depression, and presence of comorbid anxiety disorder(s).
Primary clinical outcome
Depression severity (as measured via the PHQ-9) at 12 months.
Secondary clinical outcome
Major depressive disorder status; number of depression-free days; anxiety (as measured via the Generalised
Anxiety Disorder-7 questionnaire); health-related quality of life (as measured via the Short Form
questionnaire-36 items) at 6, 12 and 18 months; PHQ-9 at 6 and 18 months.
Economic outcomes
Cost per QALY at 18 months post randomisation, derived from the EuroQol-5 Dimensions, three-level
version. We collected resource use data associated with delivery of BA and CBT from clinical records.
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We measured all other health and social care services used, including medication prescription using the
adult service use schedule. We measured productivity losses using the absenteeism and presenteeism
questions of the World Health Organization’s Health and Work Performance Questionnaire.
Process data
Behaviour (Behavioural Activation for Depression Scale); beliefs (Dysfunctional Attitudes Scale); rumination
(Ruminative Response Scale); hedonic tone (Snaith–Hamilton Pleasure Scale); per protocol (PP) treatment
adherence (from therapist case records); qualitative data via semistructured interviews to assess
acceptability of BA and CBT for participants and clinicians.
Adverse events
Deaths from whatever cause and all self-harm and suicide attempts.
Sample size
We powered the trial at 90% (α= 0.05) to detect a non-inferiority margin of 1.9 PHQ-9 points, inflating our
sample size by 20% for participant attrition. Consequently, we needed to recruit 440 participants, 220 per arm,
to detect a between-group non-inferiority margin of 1.90 in PHQ-9 points at one-sided 2.5% alpha.
Statistical methods and analyses
Clinical outcomes
We assessed equivalence of baseline characteristics and outcomes in the two groups descriptively.
We analysed primary and secondary outcomes in accordance with Consolidated Standards of Reporting
Trials guidelines for non-inferiority and equivalence trials, undertaking both intention-to-treat (ITT) and PP
analyses. We compared observed primary and secondary outcomes between groups 12 months after
randomisation using linear regression models adjusted for baseline outcome values and stratification/
minimisation variables. We extended primary analysis models to fit interaction terms to explore differences
in treatment effect from baseline symptom severity and ADM usage. We undertook secondary analyses
to compare groups at follow-up across 6, 12 and 18 months using mixed-effects repeated measures
regression. We ran sensitivity analyses for both primary and secondary analyses to assess the impact of
missing data using multiple imputation models. We calculated the relative proportions of participants
meeting criteria for ‘recovery’ (proportions of participants with PHQ-9 scores of ≤ 9 points) and ‘response’
(50% reduction in PHQ-9 scores from baseline).
Economic outcomes
We took the UK NHS and Personal Social Services perspective consistent with the UK National Institute for
Health and Care Excellence (NICE)’s reference case and examined a broader societal perspective, adding
productivity losses attributable to time off work, in a sensitivity analysis. We compared the costs and
cost-effectiveness of BA and CBT at the final 18-month follow-up to capture the impact of events such as
relapse, with unit costs from the 2013–14 financial year. We assessed cost-effectiveness in terms of QALYs
using the net benefit approach. We analysed differences in mean cost per participant at 18 months using
parametric t-tests, with the validity of results confirmed using bias-corrected, non-parametric bootstrapping.
We calculated incremental cost-effectiveness ratios (ICERs) and constructed cost-effectiveness planes using
1000 bootstrapped resamples from regression models of total health- and social-care costs and outcome by
treatment group, using these replications to calculate the probability that each treatment is the optimal
choice for different values a decision-maker is willing to pay for 1-unit outcome of improvement. We
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produced cost-effectiveness acceptability curves (CEACs) illustrating the probability that BA is cost-effective
compared with CBT, which is dependent on willingness to pay per QALY. We controlled for stratification
variables and baseline values of the variables of interest, truncating data to exclude influential outliers.
Process outcomes
Interactions between treatment allocation and each process covariate were investigated at 6, 12 and
18 months’ follow-up for PHQ-9. A series of models were performed, adjusting for the stratification
variables, trial site, baseline ADM use and baseline PHQ-9 score. Each model included the specific covariate
being investigated as a potential moderator and its interaction with treatment allocation. For mediation,
we used a structural equation modelling approach to evaluate the effect of each individual mediator at
each follow-up time, on the primary outcome. We included all mediators measured at a specific follow-up
time in an overall model for each follow-up point. Qualitative data were analysed using a framework
analysis combining deductive themes from the topic guides and inductive themes emerging from the data.
Transcripts were examined thematically across the whole data set as well as in the context of each
interview, using constant comparative techniques.
Results
We recruited 440 participants, randomly allocating 221 (50%) to the BA group and 219 (50%) to the CBT
group. Patient- and trial-level characteristics at baseline were well balanced between groups. Participants
received a mean of 11.5 [standard deviation (SD) 7.8] BA sessions or 12.5 (SD 7.8) CBT sessions. We found
that BA was non-inferior to CBT [ITT: CBT 8.4 PHQ-9 points (SD 7.5 PHQ-9 points), BA 8.4 PHQ-9 points
(SD 7.0 PHQ-9 points), mean difference 0.1, 95% confidence interval (CI) –1.3 to 1.5 PHQ-9 points,
p = 0.89; PP: CBT 7.9 PHQ-9 points (SD 7.3 PHQ-9 points); BA 7.8 PHQ-9 points (SD 6.5 PHQ-9 points),
mean difference 0.0, 95% CI –1.5 to 1.6 PHQ-9 points, p = 0.99]. Between 61% and 70% of ITT and PP
participants in both groups met criteria for recovery or response, with no difference in the proportions of
patients in each group. We found no difference between groups on secondary outcomes at any time
point. All findings were robust to sensitivity analyses.
Two (1%) non-trial-related deaths [one (1%) multidrug toxicity in the BA group and one (1%) cancer in
the CBT group] and 15 depression-related, but not treatment-related, serious adverse events (three in
the BA group and 12 in the CBT group) occurred in three (2%) participants in the BA group [two (1%)
patients who overdosed and one (1%) who self-harmed] and eight (4%) participants in the CBT group
[seven (4%) who overdosed and one (1%) who self-harmed].
We found a significant difference in mean intervention costs between the two groups, but no differences
in other categories of cost or in total health- and social-care costs. As costs were lower and QALY
outcomes better in the BA group than in the CBT group, this generated an ICER of –£6865, suggesting
that BA dominates CBT (i.e. is both cheaper and more effective). The CEAC showing the probability of
BA being cost-effective compared with CBT does not fall below 75% and is closer to 80% at standard
NICE-preferred willingness-to-pay levels of £20,000–30,000 per QALY. All findings were robust to
sensitivity analyses.
We found a weak moderating effect of baseline PHQ-9 score on treatment effect, with regard to PHQ-9 at
12 and 18 months’ follow-up, indicating that BA may be a better choice of treatment for patients with
higher baseline PHQ-9 scores. The only significant mediation effects were that overall treatment fidelity
mediated the effect of treatment on PHQ-9 at 12 months’ follow-up, with basic and overall treatment
fidelity mediating the effect of treatment on PHQ-9 at 18 months’ follow-up. Qualitative data showed
that, despite being challenging at times, BA and CBT were acceptable and feasible for participants, MHWs
and therapists, and effected changes in people’s specific symptoms and in their lives more broadly. Despite
experiencing initial difficulties that could be detected by some participants, with sufficient training,
experience and supervision, junior MHWs could feel confident in delivering BA effectively.
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Conclusions
Behavioural activation for depression is not inferior to CBT in terms of reduction of depression symptoms
and is cost-effective compared with CBT against commonly applied decision-maker willingness-to-pay
thresholds. We observed our results using both ITT and PP analyses, using a conservative non-inferiority
margin. Our results in both groups compare favourably with a meta-analysis of the effects of CBT that
estimate proportions of patients with remissions of around 50%. Our economic outcomes were driven by
the lower costs of the MHWs who delivered BA, compared with the more experienced psychological
therapists who routinely deliver CBT. Our study results, therefore, substantiate the hypothesis that BA
is as effective as CBT and that BA’s simplicity renders it suitable for delivery by junior MHWs with no
professional training in psychological therapies.
Baseline PHQ-9 score had a weak moderating effect on depression symptoms at 12 and 18 months’
follow-up, this interaction effect indicating that BA may be a better choice of treatment for patients with
higher baseline PHQ-9 scores. We found that only treatment fidelity reliably showed an interaction with
outcome, demonstrating the importance of MHWs and therapists adhering to clinical protocols. BA and
CBT were both acceptable and feasible for participants, MHWs and therapists. Importantly, junior MHWs
can deliver BA effectively, although they need training, experience and supervision to feel confident in
delivering BA.
Strengths and limitations
To date, COBRA is the largest trial of BA and one of the largest psychological treatment trials for
depression. We followed up participants for 18 months and our economic analysis is one of few in this
field. Therapists and MHWs working in three different routine NHS settings delivered treatment, providing
evidence of potential generalisability. We could not mask patients or clinicians to treatment allocation,
but used self-reported outcome measures and robust researcher-masking procedures to reduce unmasking
to < 5%.
In this pragmatic trial many depressed participants in both groups were also taking ADM, although most
had been doing so for a considerable time before entering the trial. Our levels of attrition and outcome
loss to follow-up were low, similar to other trials in this area, but are still a limitation. However, our
between-group inferences were robust to data imputation. Around one-third of participants chose not to
complete a PP dose of treatment, a finding common in both psychotherapy trials and routine practice.
Implications
For years, CBT has been the foremost psychological therapy recommended by therapists, researchers and
policy-makers. Our results challenge this dominance and suggest that BA could be a front-line treatment
for depression. Our most striking finding is that BA leads to comparable clinical outcomes for patients with
depression, but at a financial saving to clinical providers of 21% compared with the cost of provision of
CBT, with no compensatory use of other health-care services by patients. There are substantial implications
for the scalability of psychological treatment for depression in the UK and internationally, given the greater
availability and ease with which a BA workforce could be trained than could a CBT workforce.
Although many obstacles exist to successful dissemination in addition to training of MHWs, our findings
suggest that health services globally could reduce the need for costly professional training and infrastructure,
reduce waiting times and increase access to psychological therapies. Our findings have substantial
implications given the increasing global pressure for cost-containment across health systems in high-income
countries, and the need to develop accessible, scalable interventions in low- and middle-income countries.
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Our results, therefore, offer hope to many societies, cultures and communities worldwide, rich and poor,
struggling with the effect of depression on the health of their people and economies.
Trial registration
This trial is registered as ISRCTN27473954.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
This chapter uses material from Open Access articles previously published by the research team(see Rhodes et al.1 and Richards et al.2). © Rhodes et al.;1 licensee BioMed Central Ltd. 2014 This article
is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated and © The Author(s).2
Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Scientific background and review of current literature
Clinical depression is one of the most common and debilitating of the psychiatric disorders. It accounts for
the greatest burden of disease among all mental health problems, and is the second largest cause of
global disability.3 Lifetime prevalence has been estimated at 16.2% and rates of comorbidity and risk for
suicide are high.4–6 Depression is often recurrent, and without treatment many cases become chronic,
lasting > 2 years in one-third of individuals. Over three-quarters of all people who recover from one
episode will go on to have at least one more.7 In the UK, depression and anxiety are estimated to cost the
economy £17B in lost output and direct health-care costs annually, with a £9B impact on the Exchequer
through benefit payments and lost tax receipts.8 Globally, the economic impact of depression on
aggregate economic output is predicted to be US$5.36 trillion between 2011 and 2030.9
Reducing these substantial costs is a key objective for low-, medium- and high-income countries alike.
Antidepressant medication (ADM) and cognitive–behavioural therapy (CBT) are the two treatments with
most evidence of effectiveness, both of which are recommended by the National Institute for Health and
Care Excellence (NICE).10 Problems with ADM include side effects, poor patient adherence and relapse risk
on ADM discontinuation. Service user organisations and policy think tanks advocate greater availability of
psychological therapies, which many people prefer.11 CBT, which is of similar efficacy to ADM,12 has several
advantages: (1) it reflects the desire of many service users for non-pharmacological treatment; (2) it has
no physical side effects; and (3) it modifies the illness trajectory in that benefits continue after the end of
treatment, preventing recurrence.13 However, CBT has several disadvantages: (1) its complexity makes it
difficult to learn to implement in a competent fashion; (2) its efficacy is dependent on the skill of the
individual practitioner; (3) patients are required to learn quite high-level skills; and (4) the high cost of
training and employing sufficient therapists limits access to CBT.
As a consequence of the disadvantages above, many people do not receive adequate treatment, and,
even when treatment is given, many respond only partially or not at all.14 Despite the recent government
initiative in England – ‘Improving Access to Psychological Therapies’ (IAPT; URL: www.iapt.nhs.uk/) – no
more than 15% of people with depression will receive NHS-delivered CBT, and only 50% receiving CBT
will recover.15 It is therefore important to continue to test promising new treatments, especially if there are
indications that such treatments reduce the risk of symptom return, are applicable to a wide range of
depressed people including those with severe disease, are easy to implement in clinical practice and are
therefore potentially more accessible,16 and are a cost-effective use of resources.
Globally, health services require effective, easily implemented and cost-effective psychological treatments
for depression that can be delivered by less specialist health workers in order to close a treatment gap
that can be as much as 80–90% in some low-income countries.17 The English NHS, in order to meet public
and professional expectations, requires a simple, equivalently effective, easily implemented psychological
treatment for depression which can be delivered by less specialist (albeit appropriately competent) junior
mental health workers (MHWs) to treat many more people with depression in a more cost-effective manner.
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Rationale for the research
Behavioural activation (BA) is a psychological treatment based on behavioural theory that alleviates
depression by focusing directly on changing behaviour.18–20 This theory states that depression is maintained
by avoidance of normal activities. As people withdraw and disrupt their basic routines, they become
isolated from positive reinforcement opportunities in their environment. The combination of increased
negative reinforcement with reduced positive reinforcement results in a cycle of depressed mood,
decreased activity and avoidance which maintains depression.19 BA systematically disrupts this cycle,
initiating action in the presence of negative mood, when people’s natural tendency is to withdraw or
avoid.21,22 Although CBT incorporates some behavioural elements, these focus on increasing rewarding
activity and initiating behavioural experiments to test specific beliefs. In contrast, BA targets avoidance
from a contextual, functional approach not found in CBT (i.e. BA focuses on understanding the function of
behaviour and replacing it accordingly). BA also explicitly prioritises the treatment of negatively reinforced
avoidance and rumination. Furthermore, the BA rationale is easier to understand and operationalise for
both patients and MHWs than CBT, which also focuses on increasing activity, but primarily on changing
maladaptive beliefs.23 Moreover, there is some evidence that CBT is less effective when delivered by less
competent therapists.12,24
In the UK, CBT is delivered by professionally qualified senior MHWs (mainly clinical psychology,
nursing, occupational therapy, social work or counselling), who have obtained a further 1-year, full-time
postgraduate qualification in CBT. Their training is long and expensive and their employment grade is
costly compared with junior MHWs, who deliver much of the routine mental health care in the UK. The
relative simplicity of BA treatment may make it easier and cheaper to train junior MHWs in its application
than CBT, the argument of ‘parsimony’ first advanced by one of the early proponents of this approach,
Neil Jacobson.19 However, this is appropriate only if BA delivered in this way is as effective as, and more
cost-effective than, CBT.
Limitations of previous trials
A number of systematic reviews have attempted to address the more general question of BA effectiveness
compared with CBT.10,25–28 All have commented on the relatively poor quality of component studies. We
conducted a meta-analysis of randomised controlled trials (RCTs) of BA,25 and identified 12 studies with a
total of 476 patients. At the primary end point we found no difference between the groups on depression
symptom level [Hedges’ g = 0.102, 95% confidence interval (CI) −0.122 to 0.326; I2 = 29%; p = 0.372]
(Figure 1). At follow-up we found no difference between the groups on depression symptom level
(Hedges’ g = 0.395, 95% CI −0.032 to 0.822; I2 = 61%; p = 0.070).
In a subsequent update of this review26 we found no additional trials comparing BA with CBT. Many of the
trials included in our review were of limited methodological quality, all were underpowered for comparing
treatments, and most did not utilise diagnostic interviews for trial inclusion. Treatments in many cases did
not conform to modern clinical protocols for BA. Long-term outcomes were rarely reported, with average
follow-up only to 4 months. These results have been replicated in two recent Cochrane reviews of
behavioural therapies,27,28 which concluded that there was only low- to moderate-quality evidence that
behavioural therapies and other psychological therapies were equally effective and called for ‘Studies
recruiting larger samples with improved reporting of design and fidelity to treatment to improve the quality
of the evidence’.27
Most significantly, NICE10 reviewed the same evidence and regarded only a small subset of three trials31,38,40
as of sufficient quality to be able to contribute evidence of effect (Figure 2). In those studies no difference
was found between BA and CBT at primary end point (Hedges’ g = 0.139, 95% CI –0.4.00 to 0.122;
I2 = 1%; p = 0.296) or at follow-up (Hedges’ g = 0.135, 95% CI –0.456 to 0.186; I2 = 0%; p = 0.409).
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The conclusion of the NICE Guideline Development Group was that that the evidence base for BA was not
‘sufficiently robust’ for it to be recommended as an alternative to CBT. It was suggested that BA could be
an option for clinicians, but the limited evidence base should be considered when making this treatment
choice.10 Consequently, NICE made a clear research recommendation ‘to establish whether behavioural
activation is an effective alternative to CBT’ using a study which is ‘large enough to determine the
presence or absence of clinically important effects using a non-inferiority design’ (p. 256).10
Pilot work preceding this trial
In order to test uncertainties around our main objectives, we piloted BA in a Phase II RCT to examine
whether or not MHWs without previous specialist training in psychological therapy can effectively treat
depressed people using BA.41 We compared BA against usual care. Relatively junior NHS MHWs (‘band 5’ –
equivalent to a basic grade, qualified mental health nurse) with no previous formal training or experience
Study name Statistics for each study Hedges’ g and 95% CI
Lower
limit
Upper
limit
Hedges’
g p-value BA CBT
Gallagher 198231 0.297 –0.548 1.141 0.491 10 10
Jacobson 199638 –0.110 –0.568 0.349 0.639 28 50
Jacobson 199638 (AT) –0.169 –0.641 0.303 0.482 28 43
Dimidjian 200640 –0.674 –1.351 0.003 0.051 16 18
Dimidjian 200640 (LS) 0.134 –0.570 0.837 0.710 13 17
–0.139 –0.400 0.122 0.296
–2.00 –1.00 0.00 1.00 2.00
Favours BA Favours CBT
FIGURE 2 Meta-analysis of pre-COBRA (Cost and Outcome of BehaviouRal Activation) trial BA vs. CBT, subset of
high-quality included studies in NICE review. AT, automatic thoughts; LS, low severity.
Study name Statistics for each study Hedges’ g and 95% CI
Lower
limit
Upper
limit
Hedges’
g p-value BA CBT
Wilson 198329 –0.245 –1.175 0.686 0.606 8 8
Taylor 197730 0.102 –1.022 1.226 0.859 4 7
Taylor 197730 (CBT) 0.964 –0.328 2.257 0.144 3 7
Gallagher 198231 0.297 –0.548 1.141 0.491 10 10
Maldonado Lopez 198232 0.627 –0.325 1.579 0.197 8 8
Maldonado Lopez 198433 1.408 0.361 2.455 0.008 8 8
Skinner 198434 –0.054 –1.009 0.901 0.912 8 7
McNamara 198635 –0.236 –1.250 0.778 0.649 5 10
McNamara 198635 (CBT) 0.185 –0.827 1.198 0.720 5 10
Thompson 198736 –0.131 –0.627 0.365 0.605 30 31
Scogin 198937 0.458 –0.159 1.074 0.146 19 21
Jacobson 199638 –0.110 –0.568 0.349 0.639 28 50
Jacobson 199638 (AT) –0.169 –0.641 0.303 0.482 28 43
McKendree Smith 199839 0.631 –0.133 1.395 0.105 13 13
Dimidjian 200640 –0.674 –1.351 0.003 0.051 16 18
Dimidjian 200640 (LS) 0.134 –0.570 0.837 0.710 13 17
0.102 –0.122 0.326 0.372
–2.00 –1.00 0.00 1.00 2.00
Favours BA Favours CBT
FIGURE 1 Meta-analysis of pre-COBRA (Cost and Outcome of BehaviouRal Activation) trial BA vs. CBT primary
outcome point, all included studies. AT, automatic thoughts; LS, low severity.
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in psychotherapy delivered BA. These workers received 5 days’ training in BA and, subsequently, 1 hour of
clinical supervision, fortnightly, from a clinical nurse consultant or trained psychotherapist. Intention-to-
treat (ITT) analyses indicated a difference in favour of BA of −15.79 points (n = 47, 95% CI −24.55 to
−7.02 points) on depression (as measured via the Beck Depression Inventory-II), an effect size of −1.15
standard deviation (SD) units (95% CI −0.45 to −1.85 units). We also found a quality-adjusted life-year
(QALY) difference in favour of BA of 0.20 points (95% CI 0.01 to 0.39 points; p = 0.042), incremental
cost-effectiveness ratio (ICER) of £5756 per QALY and a 97% probability that BA is cost-effective at a
threshold value of £20,000.41
Conclusion
From our literature reviews and pilot work we concluded that BA was a potentially viable treatment for
depression when delivered by junior MHWs, but that, as NICE had suggested, a non-inferiority trial of BA
versus CBT was required to test whether or not BA was non-inferior to CBT and if BA could be a potentially
cost-effective alternative to CBT for depression. We now report the results of this randomised trial to
determine if BA is non-inferior to CBT in the treatment of patients with depression. This report is divided
into chapters detailing the methods and results of our primary clinical effectiveness and cost-effectiveness
questions followed by a chapter for our process evaluation. We conclude with a discussion chapter
summarising our results and considering their implications for the treatment of depression in the UK
and internationally.
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Chapter 2 Methods
This chapter uses material from Open Access articles previously published by the research team (seeRhodes et al.1 and Richards et al.2). © Rhodes et al.;1 licensee BioMed Central Ltd. 2014 This article is
published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated and © The Author(s).2
Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Research objectives
1. To assess the clinical effectiveness of BA compared with CBT for depressed adults in terms of
depression treatment response at 12 and 18 months.
2. To assess the cost-effectiveness of BA compared with CBT in terms of QALYs at 18 months.
In addition, we undertook a secondary process evaluation to investigate the moderating, mediating and
procedural factors in BA and CBT that influence outcome, the methods for which are covered in
Chapter 4.
Study design
We undertook a research assessor-blinded, multicentre, two-arm, non-inferiority, patient-level RCT for
people with depression, to test the effectiveness of a psychological intervention for depression, BA, against
the current gold standard, evidence-based treatment, CBT. We included clinical, economic and process
evaluations. The rationale for a non-inferiority trial is that we needed to establish whether or not the
clinical effectiveness of BA is not substantially inferior to CBT. Therefore, we powered our trial on the basis
of clinical non-inferiority, and analysed our data accordingly.42,43
Patient and public involvement
We involved patient and public involvement (PPI) representatives at all stages of the project. A PPI advisor
(NR) was a full member of the Trial Management Group (TMG). He attended all meetings of the TMG and
advised on patient-facing materials, including ethics materials and participant therapeutic manuals, and on
the conduct of the trial including project management, questionnaire development, data collection and
project dissemination. There was a PPI representative on the Trial Steering Committee (TSC) from a
depression consumer advocacy group who provided important checks and balances as part of the
independent TSC oversight of the trial.
All sites had excellent local PPI mechanisms. We followed national good practice guidance for researchers
on public involvement in research and the paying of PPI representatives actively involved in research.44 We
also worked with our PPI representatives to ensure that our dissemination strategies were inclusive and
accessible to other people who use services. In addition, the trial was co-ordinated from the University of
Exeter’s Medical School. The Medical School operates within a culture of PPI – guided by published
theories of participation, empowerment and engagement – through the National Institute for Health
Research (NIHR) Collaborations in Leadership in Applied Health Research and Care for the Peninsula Public
Involvement Group.
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Setting and participants
We recruited participants over a 20-month period from September 2012 to April 2014. Potential
participants were identified by clinical studies officers (CSOs) or practice staff from the electronic case
records of primary care and psychological therapy services in Devon, Durham and Leeds, indicating that the
person had been identified as currently depressed at least once during the previous 2 months. Practices or
services contacted patients to seek permission for researcher contact. The research team interviewed those
who responded, provided detailed information on the study, took informed consent and assessed people
for eligibility.
Inclusion and exclusion criteria
Inclusion
People aged ≥ 18 years with a major depressive disorder (MDD) as assessed by the Structured Clinical
Interview for DSM Disorders (SCID) and Diagnostic and Statistical Manual for Mental Disorders-Fourth
Edition (DSM-IV) were eligible to take part in the study.45 Researchers were trained to administer the SCID
using established training and inter-rater reliability procedures in use at the University of Exeter for all of
our trials.
Exclusion
People who were alcohol or drug dependent, acutely suicidal or cognitively impaired, had bipolar disorder,
psychosis or psychotic symptoms, ascertained at baseline by research interviews, were excluded. We also
excluded people currently undergoing psychological therapy.
Randomisation, concealment of allocation and blinding
Following interview, participants were allocated in a 1 : 1 ratio to either the BA or CBT arm stratified
according to their symptom severity on the Patient Health Questionnaire-9 (PHQ-9)46 (PHQ-9 of < 19 vs.
≥ 19 points), ADM use (currently using ADM or not) and recruitment site. The registered Peninsula Clinical
Trials Unit (PenCTU) allocated participants remotely after the researchers had collected and entered baseline
data into a computer database to ensure researcher blinding and allocation concealment. Investigators were
not informed of participants’ allocations. The computer-based system allocated the first 20 participants to
each arm on a truly random basis. For subsequent participants, allocation was minimised to maximise the
likelihood of balance in stratification variables across the two study arms. Concealment was ensured by the
use of a password-protected trial website and retaining a stochastic element to the minimisation algorithm.
The computer-based allocation and website were set up and maintained by PenCTU, independent of the
trial. The participant’s details were then sent to the relevant MHW to alert them to contact this person and
begin treatment. The general practitioner (GP) was then informed of their patient’s involvement in the study.
In this type of trial, in which interventions are complex and clearly different from each other, it is not
possible to blind participants or clinicians, so our procedures focused on helping to keep research workers
blind to participant allocation and by protecting the study against assessment interpretation bias through
the use of self-report measures. All research measures were applied to both groups, and researchers were
instructed to maintain blindedness by reminding participants at follow-up of the need not to discuss their
treatment with the researcher. We recorded instances where researchers were unblinded by patients
disclosing their treatment during interviews.
METHODS
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Sample size calculation
We estimated the non-inferiority margin for the primary outcome (PHQ-9) using two potential approaches
with reference to (1) the effect size of historical trials comparing BA versus control; and (2) the published
minimum clinically important difference for the primary outcome (PHQ-9) of 2.59 to 5.00 points.47 Based
on our meta-analysis, BA was superior to control in depression score by a mean of 0.7 SD units (95% CI
0.39 to 1.00 SD units) or 3.8 PHQ-9 points (95% CI 2.1 to 5.4 PHQ-9 points) (assuming a SD of 5.4 from
Lowe et al.).47 It has been proposed that non-inferiority margins be taken as ≈0.5 × mean control effect
size (i.e. 0.5 × 3.8 = 1.90 points) or as the lower 95% limit of the control effect size (i.e. 2.1 points).48,49
To ensure the adequacy of this trial to test non-inferiority between BA and CBT, we therefore examined a
number of potential scenarios taking into account the potential uncertainty in the non-inferiority margin
for the primary outcome.
We selected a conservative non-inferiority margin of 1.90 points and power of 90%. As a consequence,
we needed to recruit a total of 440 participants to detect a between-group non-inferiority margin of 1.90
points in PHQ-9 at one-sided 2.5% alpha, allowing for 20% attrition caused by dropouts and protocol
violators. Furthermore, although previous trials of CBT have shown little or no effects of clustering in
outcome by therapists, even when delivering group CBT,50,51 if we were to assume a small therapist
clustering effect (i.e. intracluster correlation coefficient of 0.01), this sample size would still have 80%
power for a non-inferiority margin of 1.90 points on the PHQ-9 at one-sided 2.5% alpha, allowing for
20% attrition.
Our sample size was inflated by 20% for participant dropout to take account of participants who might exit
the trial and refuse follow-up assessment, although our experience in running large primary care trials of
depression treatment is that attrition rates would be less than this. Therefore, we planned to recruit
440 participants to the trial, 220 per arm. A summary of the sample size calculations is provided in Table 1.
Recruitment
Randomised controlled trials are vulnerable to selection bias and threats to external validity if there are
systematic differences in behaviour between referring clinicians. We minimised this potential bias by
recruiting participants through searching general practice records and referral logs from primary care to
local depression and anxiety treatment services rather than by direct referral from GPs. We identified suitable
participants by examining electronic case records for all patients in each general practice or treatment
service. The search was conducted by practice staff or Clinical Research Network CSOs, identifying people
TABLE 1 Sample size calculation
Approach MCID (points) Power (%) Attrition rate (%) Sample size per groupa
50% BA control effect size 1.90 90 20 220
50% BA control effect size 1.90 80 20 160
LCI BA control effect size 2.10 90 20 180
LCI BA control effect size 2.10 80 20 135
Lower MCID 2.59 90 20 120
Lower MCID 2.59 80 20 90
LCI, lowest confidence interval; MCID, minimum clinically important difference.
a Calculated assuming a PHQ-9 SD of 5.4 points52 and a one-sided 2.5% alpha using nQuery v7.0 MTE0-6 (nQuery
Statistical Solutions, Cork, Ireland).
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with at least one identification code for depression recorded against their name in the last 2 months.
In primary care practices we searched for the codes most widely used by GPs to classify participants as
depressed. The list of potentially suitable participants was reviewed by GPs to identify any patients whom
had known exclusion criteria. The remaining patients were written to, inviting them to take part in the
study. For patients already referred to local psychological therapies services, we contacted those on the
waiting list. Letters were sent with a short participant information sheet, stamped and addressed envelope
and a ‘Permission for Researcher to Contact’ form to allow a researcher to contact them. If potential
participants did not return the form, they were contacted by telephone by practice staff or practice-based
Clinical Research Network CSOs to check that they had received the letter and asking them if they wished
to participate in the Cost and Outcome of BehaviouRal Activation (COBRA) trial. Potential participants
identified were interviewed by researchers on the telephone to confirm the presence of depressive
symptoms and to explain the trial fully. If positive on the screen, potentially eligible participants were
interviewed face to face by researchers to confirm eligibility, take consent, conduct a diagnostic interview
and collect baseline measures. Eligible, fully informed and consenting participants were then entered into
the study and randomised.
From our experience of previous trials, we calculated that 37% of potential participants interviewed at
baseline would be likely to decline participation, would not meet our inclusion criteria or would meet one
of the exclusion criteria. Therefore, we were required to interview 700 potential participants in order to
induct our planned sample size of 440 eligible participants into the trial. Following random allocation of
440 participants, a maximum of 20% attrition would lead to our target sample size of 366 participants.
In order to identify 700 people for baseline interview, we planned to contact around 3400 potential
participants through letter and/or telephone to inform them of the trial and offer them the chance to
participate. In order to do so, we needed to identify 5300 potential participants from a sensitive coded
search of practice case note records, as our existing data predicted that 1900 (approximately 36%)
of these would be excluded by GPs against known trial exclusion criteria. Identifying 5300 potential
participants was expected to generate at least 700 positive replies.
For an average-size practice of 7000 registered patients, we expected that searches would be likely to
identify around 37 potentially eligible participants per search. Four searches per practice would, therefore,
identify 148 potential participants per practice. Consequently, we planned to recruit at least 36 practices
(12 per site) to identify sufficient potential participants to meet our target number of 5300.
Trial interventions
We developed our BA and CBT intervention protocols in line with (a) published treatment
protocols,19,21,22,40,53,54 including that developed for BA and CBT in our trials;41,55 (b) advice from national
and international collaborators (Martell, Dimidjian, Hollon); and (c) NICE recommendations10 for duration,
and frequency, of BA and CBT. To recognise realities of real-world clinical presentations, our protocols
included behavioural and cognitive strategies for managing comorbidity, particularly anxiety, where this
is present in addition to depression. Therapists were able to provide participants with a maximum of
20 sessions over 16 weeks with the option of four additional booster sessions.10
Behavioural activation
The overall goal of BA is to re-engage participants with stable and diverse sources of positive reinforcement
from their environment and to develop depression management strategies for future use. MHWs delivering
BA followed a written treatment manual. Sessions were face to face, of 1 hour duration, with the option of
being conducted up to twice weekly over the first 2 months and weekly thereafter. The sessions consisted
of a structured programme increasing contact with potentially antidepressant environmental reinforcers
through scheduling and reducing the frequency of negatively reinforced avoidant behaviours. The central
behavioural technique was a functional analysis of the participant’s problems, based on a shared
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
formulation drawn from the behavioural model in the early stages of treatment, thereafter developed with
the patient throughout their sessions. Specific BA techniques included the use of a functional analytical
approach to develop a shared understanding with patients of behaviours that interfere with meaningful,
goal-oriented behaviours and included self-monitoring, identifying ‘depressed behaviours’, developing
alternative goal-orientated behaviours and scheduling. In addition, the role of avoidance and rumination
was addressed through functional analysis and alternative response development incorporating recent
trial evidence.56
We selected MHWs from NHS Agenda for Change (AfC) band 5 staff, such as mental health nurses and
psychological well-being practitioners (PWPs),52 who received 5 days’ training in BA. In line with the
programme developed and tested in our Phase II trial,41 training focused on the rationale and skills
required to deliver the BA protocol for depression and included sections on behavioural learning theory
and its application to depression, developing individualised BA formulations and specific techniques used in
sessions. Training was a mix of presentation and role-play with repeated practice and feedback. Workers
were competency-assessed at the end of training using standardised marking criteria consistent with the
BA protocol and further training was given if competency was not demonstrated in practical clinical
exercises. BA workers received 1 hour of clinical supervision, fortnightly, from the three site leads or other
members of the trial team who were clinically qualified in BA.
Cognitive–behavioural therapy
The overall goal of CBT is to alter the symptomatic expression of depression and reduce risk for
subsequent episodes by correcting the negative beliefs, maladaptive information processing and
behavioural patterns presumed to underlie the depression. Therapists delivering CBT followed a written
treatment manual. Sessions were face to face, of 1 hour duration, with the option of being conducted up
to twice weekly over the first 2 months and weekly thereafter. The sessions consisted of a structured,
collaborative programme. Treatment began with agreeing a problem list and goals for therapy, participants
learning the CBT model, behavioural change techniques, and moved on to identifying and modifying
negative automatic thoughts, maladaptive beliefs and, if indicated, underlying core beliefs. In later
sessions, learning was translated to anticipating and practising the management of stressors that could
provoke relapse in the future. Specific CBT techniques included scheduling activity and mastery behaviours,
the use of thought records and modifying maladaptive beliefs and rumination content. The behavioural
elements in CBT focused on increasing activity with practical behavioural experiments to test specific
cognitive beliefs. CBT did not take the contextual, functional analytical approach of the BA trial arm.
Cognitive–behavioural therapy was delivered by NHS AfC band 7 senior MHWs with a specialist
postgraduate diploma in ‘high-intensity’ CBT from an accredited university course. The CBT therapists also
received a 5-day orientation training to the specific COBRA trial CBT protocol, including its adaptation for
comorbidities, cognitive theory of depression, developing individualised cognitive formulations and specific
techniques used in sessions. Therapists were competency-assessed at the end of training using standardised
marking criteria consistent with the CBT protocol and further training was given if competency was not
demonstrated. CBT therapists also received a subsequent 1 hour of clinical supervision, fortnightly, from
established supervisors in the three sites with advice from other members of the trial team who were
clinically qualified in CBT.
Outcomes
An overview of our data collection timings is presented in Table 2.
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Baseline information
We collected demographic data at baseline through a purposely designed form. We recorded data on
gender, age, ethnic origin, education level, employment, marital status, number of children, presence or
absence of ADM treatment, previous history and age at onset of depression, duration of any ADM
treatment and presence of any comorbid anxiety disorder.
TABLE 2 Timing of data collection
Data
Source of
data Timing of data collection
Months after
baseline
Baseline Gender, age, ethnic origin,
education level, employment,
marital status, number of
children, presence or absence
of ADM treatment, previous
history and age at onset of
depression, duration of any
ADM treatment, and presence
of any comorbid anxiety
disorder
CRF Baseline
Primary outcome PHQ-9 CRF Baseline 6 12 18
Secondary
outcomes
DSM-IV depression status CRF Baseline 6 12 18
Number of depression-free
days
CRF 6 12 18
SF-36 CRF Baseline 6 12 18
Economic data EQ-5D-3L CRF Baseline 6 12 18
AD-SUS CRF Baseline 6 12 18
Process evaluation
data
Age at depression onset CRF Baseline
Number of previous depression
episodes
CRF Baseline
BADS CRF Baseline Therapy
session 4
Therapy
session 7
6
DAS CRF Baseline Therapy
session 4
Therapy
session 7
6
RRS CRF Baseline Therapy
session 4
Therapy
session 7
6
SHAPS CRF Baseline Therapy
session 4
6 12 18
Acceptability of BA and CBT Qualitative
interviews
Patients: on completion of
therapy
Clinicians: on completion of trial
involvement
Treatment mechanisms and
impact
Qualitative
interviews
Patients: on completion of
therapy
Clinicians: on completion of trial
involvement
AD-SUS, adult service use schedule; BADS, Behavioural Activation for Depression Scale; CRF, case report form;
DAS, Dysfunctional Attitudes Scale; EQ-5D-3L, EuroQol-5 Dimensions, three-level version; RRS, Ruminative Response Scale;
SF-36, Short Form questionnaire-36 items; SHAPS, Snaith–Hamilton Pleasure Scale.
METHODS
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Clinical data
We conducted follow-up assessments at 6, 12 and 18 months post-baseline assessment. Our primary
outcome was self-reported depression severity and symptomatology, as measured by the PHQ-9,46 at
12 months. The PHQ-9 is a nine-item questionnaire that records the core symptoms of depression with
established excellent specificity and sensitivity characteristics in a UK population.57 Our secondary outcomes
were DSM-IV MDD status and number of depression-free days between follow-ups, assessed by the
SCID,45 anxiety assessed by the Generalised Anxiety Disorder-7 (GAD-7) questionnaire58 and health-related
quality of life assessed by Short Form questionnaire-36 items (SF-36).59 We also assessed the relative
proportions of participants meeting criteria for ‘recovery’ (proportions of participants with PHQ-9 scores of
≤ 9 points) and ‘response’ (50% reduction in scores from baseline) on the PHQ-9. We also recorded the
presence of DSM-IV anxiety disorders at baseline and follow-ups.
Economic data
We took the UK NHS and Personal Social Services (PSS) perspective consistent with the UK NICE reference
case.60 A broader societal perspective was explored in sensitivity analysis to capture the effects of
productivity loss as a result of time off work due to illness, as depression is known to impact on an
individual’s ability to work and can result in substantial losses in the workplace.61 In addition, the use of
complementary therapies was included in a further sensitivity analysis following advice from the clinical
team that such therapies are commonly used by adults with depression. Narrower perspectives of
intervention and mental health care were also examined in sensitivity analyses.
We collected participants’ use of BA and CBT from clinical records, with additional resource information
(e.g. training, supervision and other non-face-to-face activities) collected from therapists and trainers. We
measured all other health and social care services used, including medication prescription using the adult
service use schedule (AD-SUS), designed on the basis of previous evidence of service use in depressed
populations.62 We measured productivity losses using the absenteeism and presenteeism questions of the
World Health Organization’s Health and Work Performance Questionnaire.63 The AD-SUS and the Health
and Work Performance Questionnaire were completed by patients in interviews with a research assessor at
baseline and at the 6-, 12- and 18-month follow-ups. At baseline, participants were asked to report service
use over the previous 6 months. At all follow-up points, participants were asked to report service use
since the last interview, to capture service use for the entire period from baseline to follow-up, even if
participants had missed intermediate interviews.
We measured effectiveness for the economic evaluation in terms of QALYs calculated using the EuroQol-5
Dimensions, three-level version (EQ-5D-3L), a non-disease-specific measure for describing and valuing
health-related quality of life, at baseline and at the 6-, 12- and 18-month follow-ups.64 The EQ-5D-3L
consists of five dimensions in the domains of mobility, self-care, usual activities, pain/discomfort and
anxiety/depression, each scored on three levels (no problems, some problems or extreme problems), and
classifies individuals into one of 243 health states. Health states are converted into a single summary index
utility score by applying weights to each level in each dimension derived from the valuation of EQ-5D-3L
health states in adult general population samples.65 QALYs were calculated as the area under the curve
defined by the utility values at baseline and each follow-up. It was assumed that changes in the utility
score over time followed a linear path.66
Process data
In addition to information on age at depression onset and number of previous episodes collected using the
SCID,45 we also collected data on changes in specific behaviour [as assessed via the Behavioural Activation
for Depression Scale (BADS)],67 changes in beliefs [as assessed via the Dysfunctional Attitudes Scale
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(DAS)],68 rumination [as assessed via the Ruminative Response Scale (RRS)],69 hedonic tone [as assessed via
the Snaith–Hamilton Pleasure Scale (SHAPS)],70 acceptability of BA and CBT for participants and clinicians
(assessed with qualitative methods), and per protocol (PP) treatment adherence (from therapist case
records). We collected qualitative data via semistructured interviews to access participants’, BA MHWs’ and
CBT therapists’ accounts of the mechanisms and impacts of treatment. Interviews focused on acceptability,
views of the role of cognitive and behavioural change strategies and broader impacts of treatment in
participants’ lives.
Intervention fidelity
We assessed the quality of, and adherence to, BA and CBT clinical protocols using audiotapes and written
records of therapy sessions, which MHWs and therapists were instructed to take, with participant permission,
for each clinical session. A random sample of tapes, stratified by therapist, therapy session and intervention,
were sent to independent experts in both treatments for competency rating using the Cognitive Therapy
Scale-Revised (CTS-R)71 (range 0–78, competency cut-off score = 36) for CBT and the Quality of Behavioural
Activation Scale72 (range 0–84, competency cut-off score = 42) for BA. Independent rating of recorded
therapy sessions was undertaken by the Oxford Cognitive Therapy Centre (Oxford Health NHS Foundation
Trust) and Dr Christopher Martell of the University of Wisconsin–Milwaukee, for CBT and BA, respectively.
Therapy ratings were used for several different purposes:
1. to assess each therapist’s competency, at the start of the trial, to deliver the interventions by rating the
first two therapy sessions undertaken
2. to monitor whether or not levels of competence/adherence were maintained throughout the trial.
We asked all therapists in both treatment groups to record their in-session activity by completing specially
designed therapy record sheets. These sheets included a list of therapeutic techniques specific to each type
of therapy, with a tick box against each element. Therapists indicated which of the techniques they had
used in each session.
Safety and adverse events
For adverse events (AEs), we recorded deaths from whatever cause, and all self-harm and suicide attempts.
The independent Data Monitoring Committee (DMC) reviewed all AEs and made relevant trial conduct
recommendations as a consequence.
Data analysis
We analysed and report primary and secondary outcomes in accordance with Consolidated Standards of
Reporting Trials (CONSORT) guidelines for non-inferiority and equivalence trials.43 All analyses were carried
out using an a priori statistical analysis plan prepared in the first 6 months of the trial and agreed with the
TMG, TSC and the DMC.
Equivalence of baseline characteristics and outcomes in the two groups were assessed descriptively. As
differences between randomised groups at baseline could have occurred by chance, no formal significance
testing was conducted. We also undertook a descriptive analysis of the baseline patient characteristics
according to the recruitment method (recruitment from psychological therapies waiting list vs. GP case
note review).
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We undertook both ITT and PP analyses. PP analysis provides some protection for any theoretical increase
in the risk of type I error (erroneously concluding non-inferiority).73 The ITT population was defined as all
randomised patients in the groups to which they were allocated with observed outcome data at follow-up.
The PP population was predefined by the TMG as those patients who met the ITT definition and received
eight or more treatment sessions for both groups. Although the CONSORT guidelines recommend a PP
approach (i.e. analysis according to actual treatment received) as the conservative non-inferiority analysis
option, given the potential biases of both PP and ITT analyses,43 we took the approach of the European
Medicines Agency, that security of inference depends on both PP and ITT analyses demonstrating
non-inferiority of the primary outcome.74 We, therefore, checked for non-inferiority in both the PP and
ITT populations. In order to check the security of inference of non-inferiority, sensitivity analysis for the
primary outcome was undertaken for the ITT imputed population and PP analyses based on different
definitions of adherence/protocol adherence.
The TMG predefined our PP population. We also conducted sensitivity analyses using different definitions of
PP adherence. We included varying proportions of PP participants in these sensitivity analyses populations,
depending on how much of each therapy they had received, ranging from 40% to 100% of planned
therapy sessions. Our analysis plan specified that, if non-inferiority was consistently shown by these
analyses, we would proceed to assess superiority of CBT compared with BA (i.e. the CI lower bound lies
above 0). If we found that conclusions were inconsistent across analyses, we planned to revert back to
primacy of the PP analysis to confirm or refute the non-inferiority hypothesis.
Our primary analysis compared observed primary and secondary outcomes between BA and CBT groups at
12 months after randomisation using linear regression models that adjusted for baseline outcome values
and stratification/minimisation variables (symptom severity, site, ADM use). Although we initially planned to
include therapist as a random-effects variable in our models, given the low levels of observed clustering we
took a parsimonious approach and fitted our models without inclusion of therapist. We also checked that
there was no difference in inference with and without the inclusion of a random-effects therapist term.
We estimated that the one-sided 97.5% CI for the between-group difference and non-inferiority of BA
compared with CBT was accepted (in a 0.025 level test) if the lower bound of the 97.5% CI lay within the
non-inferiority margin of –1.90 points in PHQ-9 score. We checked for non-equivalence of the primary
outcome at all follow-up points using the same approach. We extended the primary analysis models to fit
interaction terms to explore possible differences in treatment effect in baseline symptom severity and
ADM usage.
We undertook secondary analyses to compare groups at follow-up across 6, 12 and 18 months using a
mixed-effects, repeated measures regression approach. We also ran sensitivity analyses for both primary
and secondary analyses to assess the likely impact of missing data using multiple imputation models.
We also calculated the relative proportions of participants meeting criteria for ‘recovery’ (proportions of
participants with PHQ-9 scores of ≤ 9 points) and ‘response’ (50% reduction in the PHQ-9 scores from
baseline). Between-group differences are presented for continuous outcomes as CBT versus BA (i.e. CBT
minus BA) and for binary outcomes as BA relative to CBT (i.e. BA divided by CBT).
No interim inferential analyses were undertaken. However, the DMC requested (October 2013) a check of
the statistical power of the trial for the PP analyses. This calculation used the assumptions of our original
power calculation and was based on the observed level of attrition of the primary outcome at 12 months
and the proportion of patients who fulfilled the PP definition (eight or more treatment sessions; as of
January 2014). All analyses were undertaken using Stata v.14 (StataCorp LP, College Station, TX, USA).
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Economic analysis
Although studies designed to test equivalence of effects are considered to be a legitimate situation in which
a cost minimisation analysis (where costs alone are compared given equal outcomes) may be appropriate,75
the same may not be true for non-inferiority designs. Even in situations where equivalence or non-inferiority
are demonstrated, exploration of the joint distribution of costs and effects in a cost-effectiveness analysis
is recommended to represent uncertainty75 and to help interpret the economic results.76 For these reasons,
we prespecified that we would undertake a cost-effectiveness analysis irrespective of whether or not
non-inferiority in the primary clinical outcome was demonstrated. We assessed cost-effectiveness in terms of
QALYs using the net benefit approach.77 We explored Bosmans et al.’s methods76 for economic evaluations
alongside equivalence or non-inferiority trials, which requires specification of non-inferiority margins for
both costs and effects. However, as our prespecified method of economic evaluation was cost–utility
analysis, using QALYs, rather than cost-effectiveness analysis, using the PHQ-9, which was the measure on
which the hypothesis of non-inferiority is based, no non-inferiority margin for economic effects was
specified. In addition, there is a general lack of guidance on how to define an economically unimportant
difference in costs with which to estimate an appropriate non-inferiority margin for costs.
We compared the costs and cost-effectiveness of BA and CBT at the final, 18-month, follow-up to capture
the economic impact of events, such as relapse with unit costs from the 2013–14 financial year.78,79 We
discounted costs and QALYs in year 2 at 3.5%.60 We used complete-case analysis, with missing data
explored in a sensitivity analysis using multiple imputation by chained equations (MICE). Our primary
analysis took the NHS/PSS perspective preferred by NICE.80 The impact of productivity losses as a result of
time off work, known to be a substantial cost in depression,81 were explored in sensitivity analysis. In
addition, narrower cost perspectives were tested (e.g. an intervention perspective and a mental health-care
perspective), to ensure that the NHS/PSS perspective had not captured irrelevant costs that may hide the
true impact of BA and CBT on service use.
For each participant, a unit cost was applied to each item of service use reported to calculate the total cost
for the duration of the trial. All unit costs are summarised in Table 3.
We estimated intervention costs using the bottom-up costing approach set out by the Personal Social Services
Research Unit at the University of Kent.82 We based BA MHW costs on NHS AfC salary band 5 (salary range:
£21,909–28,462; US$31,662–41,130; €27,726–35,993) and NHS AfC band 7 (salary range: £31,383–41,373;
US$45,350–59,786; €39,738–52,388) for CBT therapists, including employer’s National Insurance and
pension contributions plus capital, administrative and managerial costs.79 We calculated a cost per hour
using standard working time assumptions,79 weighted to account for time spent on non-patient facing
activities, which was estimated based on the results of a survey of trial therapists.
We costed hospital services using unit costs from the NHS Reference Costs 2013–14.78 Unit costs for NHS
primary care and social care services were taken from nationally applicable published sources.79 Costs
for complementary services were taken from the NHS Choices website.83 The costs of medications were
calculated based on averages listed in the British National Formulary84 for the generic drug and using daily
dose information collected using the AD-SUS.
We valued productivity losses as a result of time off work due to illness using the human capital approach,
which involves multiplying the individual’s salary by reported days off work due to illness.85
We report differences in use of services between randomised groups descriptively as the mean by group
and as a percentage of the group who had at least one contact. We tested for differences in mean costs
per participant between groups using standard parametric t-tests, with the results confirmed using bias-
corrected, non-parametric bootstrapping.86 This is the recommended approach, despite the skewed nature
of cost data, as it allows inferences to be made about the arithmetic mean.87
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We explored cost-effectiveness using ICERs – the difference in mean cost divided by the difference in
mean effect88 – and cost-effectiveness planes constructed to show the probability that BA is more or less
effective and more or less costly than CBT. As ICERs are calculated from four sample means and are
therefore subject to statistical uncertainty, the planes were generated using 1000 bootstrapped resamples
from regression models of total cost and outcome by treatment group. These were then used to calculate
the probability that each of the treatments is the optimal choice, for different values a decision-maker is
willing to pay for a unit improvement in outcome (the ceiling ratio, λ). Cost-effectiveness acceptability
curves (CEACs) are presented by plotting these probabilities for a range of possible values of λ to explore
the uncertainty that exists around estimates of mean costs and effects, and to show the probability that
BA is cost-effective compared with CBT.89
All analyses were controlled for the following covariates: site, ADM use, symptom severity and baseline
measurement of the variables of interest. Additionally, data have been truncated to exclude influential
outliers (i.e. cases with total costs in the 99th percentile that make a significant difference to the results).90
Between-group differences for costs are presented for continuous outcomes as BA versus CBT (i.e. BA
minus CBT).
We carried out a number of independent sensitivity analyses to test assumptions made in the analysis:
1. the impact of including the use of complementary therapies
2. the impact of including productivity losses as a result of time off work as a result of illness
3. the impact of missing data, considered using MICE
4. the impact of taking an intervention perspective
5. the impact of taking a mental health-care perspective.
TABLE 3 Unit costs applied to economic data
Service Unit Cost (£)
BA Per hour 67.80
CBT Per hour 86.20
Medication Per daily dose Various
Inpatient Per night 527.17–602.52
Outpatient Per appointment 49.00–411.00
Accident and emergency Per attendance 108.96–266.85
Ambulance Per attendance 231.00
GP surgery Per minute of patient contact 2.90
Practice nurse Per minute of face-to-face contact 0.73
Case manager Per home visit minute 2.39
Community occupational therapist Per minute of face-to-face contact 0.68
Social worker Per minute 2.65
Advice service Per minute 1.05
Chiropractic/osteopathy Per minute 1.42
Homeopathy Per minute 1.67
Acupuncture Per minute 1.33
Massage therapy Per minute 1.13
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Process data analysis
A full description of the methods and analyses of our process data, including qualitative data, is presented
in Chapter 4. Based on recent reviews,91 exploratory analyses examined baseline variables that might
moderate outcome at multiple time points (6, 12 and 18 months) across the two treatments, including
depression severity, age at depression onset, number of previous episodes, and baseline levels of cognitive
and behavioural dysfunction, using the approach set out by Kraemer et al.92 Although the power to detect
moderate subgroup interactions was low, we were primarily interested in exploring the possibility of large
interactions that could inform subsequent clinical decision-making regarding treatment allocation.
Mediational analyses investigated the hypothesised mechanisms of change (for BA, changes in specific
behaviour such as reduced avoidance and rumination, learned capacity to apply behavioural principles
to modify the environment; for CBT, changes in beliefs and underlying information processing style),
pretreatment to mid-treatment, mid-treatment to post treatment across the trial arms using approaches to
testing mediation that allow multiple mediators in one model.92 The effects of the mediators on outcome
at 12 and 18 months were modelled. This approach to examining mediation ensures that changes in
putative mediators temporally precede changes in the primary outcome and allow baseline to post-
treatment change in symptoms to be statistically controlled, necessary to rule out reverse causality.93
Qualitative data analysis
Participant and therapist interviews were analysed using a framework approach94 combining deductive
themes from the topic guides and inductive themes emerging from the data. Some interviews were coded
independently to assess the reliability of coding and meetings were held to discuss and refine emerging
themes.95 Transcripts were examined thematically across the whole data set, as well as in the context of
each interview, using constant comparison techniques.96 Data were indexed and sorted using the identified
themes and subthemes, and were summarised in framework matrices.94 In keeping with the framework
approach, we interrogated the data, searching for comparisons and contradictions and keeping interpretive
notes. Alternative explanations or negative cases were identified, discussed and a consensus reached.95
Ethics issues
We conducted the trial in such a way as to protect the human rights and dignity of the participants as reflected
in the Helsinki Declaration.97 Participants did not receive any financial inducement to participate. The study
received National Research Ethics Committee (REC) approval from the South West REC in the UK (reference
number 12/SW/0029). Local REC and NHS research and development approvals were also given for each
recruitment site. To conform with data protection and freedom of information acts, all data have been stored
securely and anonymised wherever possible. No published material will contain patient-identifiable information.
Obtaining informed consent from participants
We determined informed consent by a two-phase consent process. Participants received a study
information sheet in the post and a form seeking their permission to be contacted by a member of the
research team, not at this stage to give consent to trial participation. The information leaflets were
produced using current guidelines for researchers on writing information sheets and consent forms98 and
informed by our consumer/lived-experience user representatives. Participants who wished to partake in the
trial returned their initial written consent to be contacted form to the site research team. Full informed
written consent was obtained through an interview by a researcher where the information sheet was fully
explained and where the opportunity to ask questions was given. The opportunity to withdraw from the
trial was also fully explained. Researchers seeking consent were fully trained and supervised by the chief
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investigator and site leads. Communication and recording systems were set up to enable the trial team to
monitor and act on participants’ wishes to withdraw from the trial.
Anticipated risks and benefits
All participants received usual GP care and, therefore, no treatment was withheld from participants in this
trial. Both arms were active psychological treatments with previously demonstrated efficacy and no known
iatrogenic effects. This trial may have in fact benefited individual participants, as CBT is not generally
available for the majority of people with depression. By participating in this trial, participants also received
an intensive level of monitoring such that any participants with worsening symptoms or who were at
suicidal risk were identified and directed to appropriate care. We recorded all instances of AEs as
detailed earlier.
Informing participants of anticipated risks and benefits
Participant information leaflets provided potential participants with information about the possible benefits
and known risks of taking part in the trial. Participants were given the opportunity to discuss this issue
with their GP or the trial manager prior to consenting. The trial manager would have informed the
participant if new information came to light that may have affected the participant’s willingness to
participate in the trial.
Management of suicide risk
Inherent in the nature of the population under scrutiny is the risk of suicide. We followed good clinical
practice in monitoring for suicide risk during all research and clinical encounters with trial participants,
developed for our previous trials.55,99 Where any risk to participants attributable to expressed thoughts of
suicide were encountered, we reported these directly to the GP (with the participant’s expressed permission),
or if an acute risk was present we sought advice from the GP immediately and followed locally established
suicide risk management plans. Systems were put into place to ensure that the chief investigator, trial
manager and researchers were informed if there were any risks to the participants’ safety.
Trial Steering Committee and Data Monitoring Committee
A TSC was set up and included an independent chairperson, an academic GP and at least two other
independent members, along with the lead investigator and some other study collaborators. The TSC
met at least once a year. The DMC was set up and was composed of an independent mental health
professional, statistician and clinician. The role of the DMC was to review serious AEs thought to be
treatment related and look at outcome data regularly during data collection.
Execution dates
The preparatory period started in March 2012. Recruitment ran from September 2012 to April 2014.
Follow-up lasted 18 months after randomisation and was completed by October 2015. Data analysis
and reporting were completed 12 months after this (September 2016). The entire study period lasted
54 months (March 2012 to September 2016).
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Chapter 3 Results of clinical and economic
analyses
This chapter uses material from an Open Access article previously published by the research team(see Richards et al.2). © The Author(s).2 Published by Elsevier Ltd. This is an Open Access article under
the CC BY license.
Participant flow and retention
Between 26 September 2012 and 3 April 2014, we recruited 440 participants, randomly allocating 221
participants (50%) to the BA group and 219 participants (50%) to the CBT group. We recruited to time
and target and the majority of participants were recruited from primary care (87%). Progress over the
course of recruitment and achievement of the target is shown in Figure 3. Participant recruitment and
retention is shown for both the ITT and PP analyses in the trial CONSORT diagram (Figure 4). There were
no protocol deviations.
Baseline characteristics of participants
Patient- and trial-level characteristics at baseline were well balanced between groups (Table 4). We also
found no evidence of a difference in patient characteristics between recruitment methods (Table 5). The
PHQ-9 primary outcome at baseline was negatively skewed, with a high proportion of participants scoring
towards the upper end of the distribution (Figure 5), and scores were similar between groups [BA, 17.7
PHQ-9 points (SD 4.8 PHQ-9 points); CBT, 17.4 PHQ-9 points (SD 4.8 PHQ-9 points)] (Table 6).
Delivery and receipt of the interventions
Ten MHWs provided BA [median 22 participants each (interquartile range 19–25 participants each)] and
12 therapists provided CBT [median 21 participants each (interquartile range 13–23 participants each)].
MHWs had a mean of 18 months’ mental health experience (SD 11 months’ mental health experience) and
CBT therapists had a mean of 22 months’ experience (SD 24 months’ experience) post CBT qualification.
We removed one CBT therapist from the trial in the early stages who did not meet acceptable competency.
Participants received a mean of 11.5 BA sessions (SD 7.8 sessions) or 12.5 CBT sessions (SD 7.8 sessions).
Three hundred and five participants (69%) completed the PP number of at least eight sessions [BA 147
(67%) participants, mean 16.1 sessions (SD 5.3 sessions); CBT 158 (72%) participants, mean 16.4 sessions
(SD 5.4 sessions)]. Participants completing fewer than eight sessions {135 participants (31%) [BA 74
participants (33%) and CBT 61 participants (28%)] completed a mean of 2.5 BA sessions (SD 1.9 sessions)
or 2.6 CBT sessions (SD 2.1 sessions)}.
Primary outcome: Patient Health Questionnaire-9 at 12 months
We present primary and secondary outcomes at 12 months in Table 6. We found no evidence of inferiority
of PHQ-9 score at 12 months in either the ITT [CBT 8.4 PHQ-9 points (SD 7.5 PHQ-9 points), BA 8.4
PHQ-9 points (SD 7.0 PHQ-9 points); mean difference 0.1 PHQ-9 points, 95% CI –1.3 to 1.5 PHQ-9 points;
p = 0.89] or PP [CBT 7.9 PHQ-9 points (SD 7.3 PHQ-9 points), BA 7.8 PHQ-9 points (SD 6.5 PHQ-9 points);
mean difference 0.0 PHQ-9 points, 95% CI –1.5 to 1.6 PHQ-9 points; p = 0.99] populations. The
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Screened by telephone
(n = 1307)
Interviewed at baseline
(n = 726)
Ineligible (n = 581)
• Did not meet inclusion criteria, n = 312
• Declined to participate, n = 141
• Not contactable, n = 128
Ineligible (n = 286)
• Did not meet inclusion criteria, n = 222
• Declined to participate, n = 15
• Not contactable, n = 49
Randomised
(n = 440)
Assigned CBT
(n = 219)
In PP population
(6-month follow-up)
(n = 152)
Had no data (n = 67)
• Did not receive at least 
   eight treatment 
   sessions, n = 61
• Declined or could not 
   be contacted, n = 6
Had no data (n = 24)
• Declined or could not
   be contacted, n = 20
• Withdrew, n = 4
In modified 
ITT population 
(6-month follow-up)
(n = 195)
Assigned BA
(n = 221)
In PP population
(6-month follow-up)
(n = 145)
Had no data (n = 76)
• Did not receive at least 
   eight treatment 
   sessions, n = 74
• Declined or could not 
   be contacted, n = 1
• Withdrew, n = 1
Had no data (n = 36)
• Declined or could not
   be contacted, n = 26
• Withdrew, n = 10
In modified 
ITT population 
(6-month follow-up)
(n = 185)
Assigned CBT
(n = 219)
In PP population
(12-month follow-up)
(n = 151)
Had no data (n = 68)
• Did not receive at least 
   eight treatment 
   sessions, n = 61
• Declined or could not 
   be contacted, n = 5
• Withdrew, n = 2
Had no data (n = 30)
• Declined or could not
   be contacted, n = 21
• Withdrew, n = 9
In modified 
ITT population 
(12-month follow-up)
(n = 189)
Assigned BA
(n = 221)
(b)
(a)
In PP population
(12-month follow-up)
(n = 135)
Had no data (n = 86)
• Did not receive at least 
   eight treatment 
   sessions, n = 74
• Declined or could not 
   be contacted, n = 9
• Withdrew, n = 3
Had no data (n = 46)
• Declined or could not
   be contacted, n = 31
• Withdrew, n = 15
In modified 
ITT population 
(12-month follow-up)
(n = 175)
Assigned CBT
(n = 219)
In PP population
(18-month follow-up)
(n = 147)
Had no data (n = 72)
• Did not receive at least 
   eight treatment 
   sessions, n = 61
• Declined or could not 
   be contacted, n = 8
• Withdrew, n = 3
Had no data (n = 39)
• Declined or could not
   be contacted, n = 24
• Withdrew, n = 14
• Died, n = 1
In modified 
ITT population 
(18-month follow-up)
(n = 180)
Assigned BA
(n = 221)
(c)
In PP population
(18-month follow-up)
(n = 137)
Had no data (n = 84)
• Did not receive at least 
   eight treatment 
   sessions, n = 74
• Declined or could not 
   be contacted, n = 4
• Withdrew, n = 6
Had no data (n = 45)
• Declined or could not
   be contacted, n = 22
• Withdrew, n = 22
• Died, n = 1
In modified 
ITT population 
(18-month follow-up)
(n = 176)
FIGURE 4 The trial CONSORT flow diagram. (a) 6-month follow-up, (b) 12-month follow-up and (c) 18-month follow-up.
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TABLE 4 Baseline trial, patient and minimisation characteristics by group allocation
Characteristic
Trial arm
All (n= 440)BA (n= 221) CBT (n= 219)
Trial characteristic
Method of recruitment, n (%)
Case notes 192 (87) 190 (87) 382 (87)
IAPT 29 (13) 29 (13) 38 (13)
Patient characteristics
Age (years), mean (SD) range 43.9 (14.1) 18–82 43.0 (14.1) 19–84 43.5 (14.1) 18–84
Gender, n (%)
Male 79 (36) 71(32) 150 (34)
Female 142 (64) 148 (68) 290 (66)
Number of episodes of depression including current
Mean (SD), n 7.0 (15.0) 192 6.3 (13.8) 192 6.7 (14.4) 384
Median (IQR) 3.0 (1–5) 2.0 (1–4) 3.0 (1–5)
First depression episode, age at onset (years), mean (SD) 27.2 (15.0) 26.3 (13.5) 26.7 (14.2)
Duration of antidepressant treatment (weeks)a
Mean (SD), n 106 (210), 157 81 (164), 168 93 (188), 325
Median (IQR) 21 (10–71) 18 (7–51) 19 (8–66)
At least one comorbid anxiety disorder, n (%) 131 (59) 141 (64) 272 (62)
Marital status, n (%)
Single 68 (31) 59 (27) 127 (29)
Cohabiting (not married) 29 (13) 25 (11) 54 (12)
Civil partnership 1 (1) 1 (1) 2 (1)
Married 84 (38) 92 (42) 176 (40)
Divorced/separated 39 (18) 42 (19) 81 (18)
Number of children, n (%)
0 74 (34) 72 (33) 146 (33)
1 35 (16) 31 (14) 66 (15)
2 67 (30) 69 (32) 136 (31)
3 31 (14) 27 (12) 58 (13)
≥ 4 14 (6) 20 (9) 34 (8)
Level of education, n (%)
No qualifications 25 (11) 30 (14) 55 (13)
GCSEs/O-levels 36 (16) 43 (20) 79 (18)
AS/A-levels 28 (13) 22 (10) 50 (11)
NVQ or other vocational qualification 54 (24) 71 (32) 125 (28)
Undergraduate degree 44 (20) 35 (16) 79 (18)
Postgraduate degree 28 (13) 14 (6) 42 (10)
Doctoral degree 2 (1) 1 (0) 3 (1)
Professional degree (e.g. MD) 4 (2) 3 (1) 7 (2)
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TABLE 4 Baseline trial, patient and minimisation characteristics by group allocation (continued )
Characteristic
Trial arm
All (n= 440)BA (n= 221) CBT (n= 219)
Ethnicity, n (%)
White British 204 (92) 197 (90) 401 (91)
Other 17 (8) 22 (10) 39 (9)
Stratification/minimisation variables
PHQ-9 points category, n (%)
< 19 118 (54) 118 (54) 236 (54)
≥ 19 103 (46) 101 (46) 204 (46)
Antidepressant use, n (%)
Yes 172 (78) 175 (79) 345 (78)
No 49 (22) 46 (21) 95 (22)
Site, n (%)
1 74 (33) 73 (33) 147 (33)
2 79 (36) 78 (36) 157 (36)
3 68 (31) 68 (31) 136 (31)
A-level, Advanced level; AS, Advanced Supplementary; GCSE, General Certificate of Secondary Education; IQR, interquartile
range; MD, Doctor of Medicine; NVQ, National Vocational Qualification; O-level, Ordinary level.
a Twenty participants (BA, n= 15; CBT, n= 5) who reported that they were using ADM at baseline did not report duration
of use.
TABLE 5 Baseline trial, patient and minimisation characteristics by recruitment method
Recruitment method
Recruitment method
All (n= 440)
Primary care
(n= 382) IAPT (n= 58)
Patient characteristics
Age (years), mean (SD) 43.6 (14.2) 42.7 (13.4) 43.5 (14.1)
Gender, n (%)
Male 122 (32) 28 (48) 150 (34)
Female 260 (68) 30 (52) 290 (66)
Number of episodes of depression including current
Mean (SD), n 6.9 (15.3), 327 5.6 (7.2), 57 6.7 (14.4), 384
Median (IQR) 3.0 (1–5) 3.0 (2–5) 3.0 (1–5)
Age at onset of first depression episode (years),
mean (SD)
27.0 (14.6) 25.6 (13.2) 26.7 (14.2)
Duration of antidepressant treatment (weeks)a
Mean (SD), n 84 (165), 290 167 (313), 35 93 (188), 325
Median (IQR) 18 (8–64) 23 (15–108) 19 (8–66)
At least one comorbid anxiety disorder, n (%) 246 (64) 26 (45) 272 (62)
continued
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TABLE 5 Baseline trial, patient and minimisation characteristics by recruitment method (continued )
Recruitment method
Recruitment method
All (n= 440)
Primary care
(n= 382) IAPT (n= 58)
Marital status, (%)
Single 112 (29) 15 (26) 127 (29)
Cohabiting (not married) 45 (12) 9 (16) 54 (12)
Civil partnership 2 (1) 0 (0) 2 (1)
Married 149 (39) 27 (47) 176 (40)
Divorced/separated 74 (19) 7 (12) 81 (18)
Number of children, n (%)
0 123 (32) 23 (40) 146 (33)
1 58 (15) 8 (14) 66 (15)
2 121 (32) 15 (26) 136 (31)
3 49 (13) 9 (16) 58 (13)
≥ 4 31 (8) 3 (5) 34 (8)
Level of education, n (%)
No qualifications 50 (13) 5 (9) 55 (13)
GCSEs/O-levels 71 (19) 8 (14) 79 (18)
AS/A-levels 44 (12) 6 (10) 50 (11)
NVQ or other vocational qualification 106 (28) 19 (33) 125 (28)
Undergraduate degree 66 (17) 13 (23) 79 (18)
Postgraduate degree 36 (9) 6 (10) 42 (10)
Doctoral degree 3 (1) 0 (0) 3 (1)
Professional degree (e.g. MD) 6 (2) 1 (2) 7 (2)
Ethnicity, n (%)
White British 353 (92) 49 (84) 402 (91)
Other 29 (76) 9 (2) 38 (9)
Stratification or minimisation variables
PHQ-9 category, n (%)
< 19 points 200 (52) 36 (62) 236 (54)
≥ 19 points 182 (48) 22 (38) 204 (46)
Antidepressant use, n (%)
Yes 309 (81) 36 (62) 345 (78)
No 73 (19) 22 (38) 95 (22)
Site, n (%)
Devon 145 (38) 2 (4) 147 (33)
Durham 157 (41) 0 (0) 157 (36)
Leeds 80 (21) 56 (97) 136 (31)
A-level, Advanced level; AS, Advanced Supplementary; GCSE, General Certificate of Secondary Education; IQR, interquartile
range; MD, Doctor of Medicine; NVQ, National Vocational Qualification; O-level, Ordinary level.
a Twenty (primary care, n = 19; IAPT, n= 1) participants who reported that they were using ADM at baseline did not
report duration of use.
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FIGURE 5 Distribution of primary outcome (PHQ-9 score) at baseline.
TABLE 6 Primary and secondary outcomes at 12 months
Outcome
Trial arm: n, mean (SD or %)
Between-group difference (CBT – BA) at
12-month follow-up: mean (95% CI), p-value
CBT BA Observed data only
Observed and
imputed data
Primary outcome
PHQ-9
Baseline 219, 17.4 (4.8) 221, 17.7 (4.8)
ITT 12-month follow-up 189, 8.4 (7.5) 175, 8.4 (7.0) 0.1a (–1.3 to 1.5), 0.89 0.2a (–1.1 to 1.7), 0.80
PP 12-month follow-up 151, 7.9 (7.3) 135, 7.8 (6.5) 0.0a (–1.5 to 1.6), 0.99 0.0a (–1.6 to 1.6), 0.99
Secondary outcomes
GAD-7
Baseline 219, 12.6 (5.1) 221, 12.7 (5.1)
ITT 12-month follow-up 176, 6.3 (6.0) 161, 6.4 (5.9) –0.1a (–1.0 to 1.3), 0.82 0.0a (–1.3 to 1.4), 0.96
PP 12-month follow-up 146, 6.0 (5.8) 129, 5.9 (5.5) 0.01a (–1.3 to 1.2), 0.95 –0.4a (–1.7 to 1.0), 0.60
SCID number of depression-free days
ITT 12-month follow-up 160, 129 (58) 150, 120 (56) 9a (–3 to 23), 0.13 7a (–7 to 20), 0.27
PP 12-month follow-up 138, 132 (55) 125, 119 (55) 13a (0 to 26), 0.06 8a (–4 to 21), 0.21
SF-36 v2 PCS
Baseline 65, 50.1 (13.1) 69, 51.4 (11.9)
ITT 12-month follow-up 168, 48.1 (12.2) 150, 49.9 (11.6) 1.6b (–1.0 to 4.2), 0.22 –1.4b (–1.1 to 4.0), 0.27
PP 12-month follow-up 144, 48.0 (12.2) 125, 49.9 (12.0) 1.6b (–1.3 to 4.4), 0.28 –1.3b (–1.5 to 4.1), 0.36
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non-inferiority of BA to CBT was accepted for both the ITT and PP populations, as the lower bound of the
95% CI (one-sided 97.5% CI) of the between-group mean difference lies within the non-inferiority margin
of –1.9 PHQ-9 points (Figure 6). We ruled out superiority of CBT to BA as the lower bound of the 95% CI
includes zero for the ITT and PP populations. The inference of non-inferiority was robust to sensitivity
analysis across different PP definitions (Table 7). Our predefined stratification variable subgroup analyses
(Table 8) showed no ITT or PP between-group difference by depression severity, ADM or site.
TABLE 6 Primary and secondary outcomes at 12 months (continued )
Outcome
Trial arm: n, mean (SD or %)
Between-group difference (CBT – BA) at
12-month follow-up: mean (95% CI), p-value
CBT BA Observed data only
Observed and
imputed data
SF-36 v2 MCS
Baseline 65, 23.2 (9.4) 69, 22.5 (7.8)
ITT 12-month follow-up 168, 41.7 (14.1) 150, 41.6 (14.0) 0.0b (–3.0 to 3.0), 0.99 0.0b (–2.8 to 2.9), 0.97
PP 12-month follow-up 144, 42.9 (13.6) 125, 42.3 (13.3) 0.5b (–3.7 to 2.7), 0.77 0.6b (–3.8 to 2.7), 0.73
n/N (%) n/N (%)
Odds ratio (BA/CBT)
(95% CI), p-value
Odds ratio (BA/CBT)
(95% CI), p-value
SCID depression
Baseline 219/219 (100) 221/221 (100)
ITT 12-month follow-up 37/163 (23) 31/154 (20) 0.9 (0.5 to 1.6), 0.71 0.9 (0.5 to 1.6), 0.70
PP 12-month follow-up 30/141 (21) 24/128 (19) 0.9 (0.5 to 1.7), 0.80 0.9 (0.5 to 1.7), 0.75
Recovery c
ITT 12-month follow-up 124/189 (66) 115/175 (66) 1.0 (0.6 to 1.5), 0.96 1.2 (0.7 to 1.9), 0.53
PP 12-month follow-up 104/151 (69) 94/135 (70) 1.0 (0.6 to 1.7), 0.96 1.2 (0.7 to 2.0), 0.47
Responsed
ITT 12-month follow-up 117/189 (62) 107/175 (61) 1.0 (0.9 to 1.1), 0.73 0.9 (0.6 to 1.4), 0.75
PP 12-month follow-up 100/151 (66) 87/135 (64) 0.9 (0.9 to 1.0), 0.64 0.9 (0.5 to 1.4), 0.55
MCS, Mental Component Scale; PCS, Physical Component Scale; v2, version 2.
a Models adjusted for baseline outcome score and stratification variables [symptom severity (PHQ score of < 19 points,
PHQ score of ≥ 19 points), site (Devon, Durham, Leeds) and ADM use (currently taking ADM, not currently taking ADM)].
b Models adjusted for stratification variables, but not baseline outcome score.
c Participants with PHQ-9 scores of ≤ 9 points.
d Participants with a 50% reduction from baseline PHQ-9 scores.
Study ID
–4
CBT-BA between-group difference (95% Cl)
ITT at 12 months 0.10 (–1.30 to 1.50)
PP at 12 months 0.00 (–1.50 to 1.60)
–2 0
Favours CBTFavours BA
1.9
FIGURE 6 Mean difference and two-sided 95% CI for the primary outcome of PHQ-9 at 12 months and
non-inferiority margin.
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TABLE 7 Primary analysis on primary outcome (PHQ-9 score) at 12 months: sensitivity analysis across definitions of PP
PP definition
Time point, mean (SD), n
Between-group
difference (CBT – BA):a
mean (95% CI), p-value
Baseline 12-month follow-up
CBT BA CBT BA
Standard PP definitionb
≥ 8 sessions attended 17.4 (4.9), 158 17.6 (4.6), 147 7.9 (7.3), 151 7.8 (6.5), 135 0.0 (–1.5 to 1.6), 0.99
Alternative PP definitionsb
≥ 0 sessions attended 17.4 (4.8), 219 17.7 (4.8), 221 8.4 (7.5), 189 8.4 (7.0), 175 0.1 (–1.3 to 1.5), 0.89
≥ 4 sessions attended 17.4 (5.0), 176 17.7 (4.6), 169 8.0 (7.4), 161 8.2 (6.8), 150 0.1 (–1.4 to 1.7), 0.86
≥ 12 sessions attended 17.8 (4.8), 115 17.7 (4.8), 109 8.6 (7.1), 112 7.6 (6.2), 105 –0.6 (–2.3 to 1.1), 0.52
≥ 16 sessions attended 17.8 (4.8), 83 18.3 (4.7), 77 8.8 (7.0), 81 8.6 (6.1), 75 0.2 (–1.9 to 2.3), 0.86
≥ 20 sessions attended 18.2 (4.7), 58 18.5 (4.6), 51 9.0 (6.7), 57 8.5 (6.1), 49 –0.4 (–3.3 to 2.5), 0.78
a All models adjusted for baseline outcome score and stratification variables [i.e. symptom severity (PHQ score of
< 19 points, PHQ score of ≥ 19 points), site (Devon, Durham, Leeds) and ADM use (currently taking ADM, not currently
taking ADM)].
b Based on observed data only.
TABLE 8 Predefined stratification variable subgroup analyses on the primary outcome at 12 months
Stratification
variable
Population
ITT PP
Between-group
difference (CBT – BA):a
mean (95% CI)
Interaction
coefficient (95% CI),
p-value
Between-group
difference (CBT – BA):a
mean (95% CI)
Interaction coefficient
(95% CI), p-value
Depression severity
PHQ-9
< 19 points
0.4 (–1.3 to 2.0) 1.1 (–1.8 to 3.9), 0.48 0.7 (–1.1 to 2.6) 1.9 (–1.2 to 5.0), 0.23
PHQ-9
≥ 19 points
–0.6 (–3.5 to 1.8) –0.9 (–3.5 to 1.7)
Receiving ADM
Yes 0.2 (–2.7 to 3.1) 0.2 (–3.2 to 3.7), 0.90 –0.4 (–3.5 to 2.7) 0.6 (–4.3 to 3.2), 0.74
No –0.1 (–1.7 to 1.5) 0.2 (–1.6 to 2.0)
Site
Exeter –1.2 (–3.6 to 1.1) –2.1 (–5.5 to 1.4) –1.2 (–3.9 to 1.5) –1.7 (–5.5 to 2.1)
Durham 1.0 (–1.6 to 3.6) –0.9 (–4.5 to 2.6) 0.6 (–2.2 to 3.4) –1.3 (–5.3 to 2.6)
Leeds –0.2 (–2.8 to 2.3) 0.49b 0.2 (–2.3 to 3.0) 0.64b
a All models adjusted for baseline outcome score and stratification variables [i.e. symptom severity (PHQ score of
< 19 points, PHQ score of ≥ 19 points), site (Devon, Durham, Leeds) and ADM use (currently taking ADM, not currently
taking ADM)].
b Global p-value.
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Response and recovery at 12 months
Between 61% and 70% of ITT and PP participants in both groups met criteria for recovery or response,
with no difference in the proportions of patients in each group who recovered or responded (see Table 6).
Primary and secondary outcomes at all follow-up points
Tables 9 and 10 show the repeated measures comparison of primary and secondary outcomes across time
points for both ITT and PP populations. For the primary outcome, there was no evidence of difference
TABLE 9 Descriptive analysis of primary and secondary outcomes at 6, 12 and 18 months, and p-value for repeated
measures analysis across all follow-up times: ITT analysis population
Outcome
Time point
Between-group
comparison, p-valuea,bBaseline 6 months 12 months 18 months
Primary outcome
PHQ-9, mean (SD), n
CBT 17.4 (4.8), 219 9.7 (7.3), 195 8.4 (7.5), 189 8.5 (7.2), 189 0.95
BA 17.7 (4.8), 221 9.8 (6.9), 185 8.4 (7.0), 175 8.3 (7.1), 176
Secondary outcomes
GAD-7, mean (SD), n
CBT 12.6 (5.1), 219 7.5 (6.0), 186 6.3 (6.0), 176 7.0 (6.2), 167 0.32
BA 12.7 (5.1), 221 7.5 (5.8), 176 6.4 (5.9), 161 6.4 (5.9), 165
SCID number of depression-free days, mean (SD), n
CBT – 66 (41), 171 130 (58), 160 125 (60), 161 0.06
BA – 70 (47), 164 120 (55), 150 129 (57), 153
SF-36 v2 PCS, mean (SD), n
CBT 50.1 (13.1), 65 48.4 (11.7), 107 48.1 (12.2), 168 48.8 (12.5), 167 0.64
BA 51.4 (11.9), 69 49.4 (12.1), 111 49.9 (11.6), 150 49.6 (12.5), 160
SF-36 v2 MCS, mean (SD), n
CBT 23.2 (9.4), 65 39.5 (12.4), 107 41.7 (14.1), 168 40.7 (14.4), 167 0.50
BA 22.5 (7.8), 69 37.5 (13.7), 111 41.6 (14.0), 150 42.3 (13.8), 160
Other outcomes
Recovery,c n/N (%)
CBT 13/219, 6 111/195, 57 134/189, 66 127/180, 59 0.88
BA 208/221, 6 97/185, 52 115/175, 66 116/176, 66
Response,d n/N (%)
CBT – 96/195, 49 117/189, 62 108/180, 60 0.94
BA – 91/185, 49 107/175, 61 108/176, 61
MCS, Mental Component Scale; PCS, Physical Component Scale; v2, version 2.
a Global p-value for treatment group–time point interaction.
b p-values for the SF-36 v2 outcomes were derived from the model that excluded baseline measurements.
c Recovery defined as follow-up score of ≤ 9 points on the PHQ-9.
d Response defined as a ≥ 50% reduction in the PHQ-9 score at follow-up compared with baseline.
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between the CBT and BA groups across observed or imputed outcomes over the period of the trial, as
indicated by a non-significant time by treatment effect interaction. Although there was some weak
evidence (p = 0.06) of a higher number of depression-free days at follow-up with BA than CBT in the ITT
analyses, this difference was not apparent in the PP analysis (p = 0.11).
Primary and secondary outcomes and clustering by therapist
There was evidence of a small, negligible clustering of primary and secondary outcome scores at follow-up
across therapists overall and within BA and CBT groups (intracluster correlation coefficient of ≤ 0.04).
TABLE 10 Descriptive analysis or primary and secondary outcomes at 6, 12 and 18 months, and p-value for
repeated measures analysis across all follow-up times: PP analysis population
Outcome
Time point
Between-group
comparison, p-valuea,bBaseline 6 months 12 months 18 months
Primary outcome
PHQ-9, mean (SD), n
CBT 17.3 (4.8), 158 9.1 (6.9), 152 7.9 (7.3), 152 8.0 (7.3), 147 0.51
BA 17.6 (4.6), 147 9.7 (6.7), 145 7.8 (6.5), 135 7.7 (6.7), 137
Secondary outcomes
GAD-7, mean (SD), n
CBT 12.6 (5.2), 158 6.9 (5.8), 149 6.0 (5.8), 146 6.5 (5.9), 141 0.45
BA 12.5 (5.0), 147 7.1 (5.6), 140 5.9 (5.4), 129 6.0 (5.7), 132
SCID number of depression-free days, mean (SD), n
CBT – 67 (40), 140 132 (55), 138 130 (59), 136 0.11
BA – 68 (46), 137 119 (55), 125 130 (56), 123
SF-36 v2 PCS, mean (SD), n
CBT 50.3 (12.4), 51 49.9 (10.9), 90 48.0 (12.2), 144 49.0 (12.6), 141 0.60
BA 50.4 (12.1), 46 49.9 (11.8), 87 49.9 (12.0), 125 49.6 (12.7), 130
SF-36 v2 MCS, mean (SD), n
CBT 23.4 (9.3), 51 40.2 (12.2), 90 42.9 (13.6), 144 41.6 (14.6), 141 0.58
BA 22.9 (7.8), 46 39.0 (13.3), 87 42.3 (13.3), 125 42.7 (13.8), 130
Other outcomes
Recovery,c n/N (%)
CBT 9/158 (6) 91/152 (60) 104/151 (69) 93/147 (63) 0.77
BA 7/147 (5) 75/145 (52) 94/135 (70) 96/137 (70)
Response,d n/N (%)
CBT – 81/152 (53) 100/151 (66) 95/147 (64) 0.40
BA – 67/145 (46) 87/135 (64) 88/137 (64)
MCS, Mental Component Scale; PCS, Physical Component Scale; v2, version 2.
a Global p-value for treatment group–time point interaction.
b p-values for SF-36 v2 outcomes were derived from the model that excluded baseline measurements.
c Recovery defined as follow-up score of ≤ 9 points on the PHQ-9.
d Response defined as a ≥ 50% reduction in the PHQ-9 score at follow-up compared with baseline.
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Missing data
Of the 440 participants recruited, 76 participants (17%) had missing primary outcome data at 12 months’
follow-up. The proportion of missing PHQ-9 data was higher in the BA than in the CBT group [46 (21%) vs.
30 (14%), ITT relative risk 1.15, 95% CI 1.0 to 1.32; p = 0.044]. Drop out from PP treatment was not
significantly different (PP relative risk 1.13, 95% CI 0.98 to 1.30; p = 0.84). Imputation of data for primary
and secondary outcomes at 12 months showed that, in accordance with the observed data analysis, no
difference existed between groups (see Table 6), supporting our conclusion of non-inferiority. The odds of
missing PHQ-9 data were higher for patients with increased baseline severity of depression (PHQ-9 ≥ 19,
odds ratio 1.6, 95% CI 1.0 to 2.6; p = 0.05), and increasing age (in years) was associated with lower odds
of missing PHQ-9 data (odds ratio 0.97, 95% CI 0.96 to 0.99). We found no evidence of an association
between missingness and any other baseline characteristic.
Blinding
Outcome assessors reported having been unmasked for 16 (4%) participants [five (2%) in the BA group
and 11 (5%) in the CBT group] as a result of participants informing assessors of their treatment allocation.
Safety and adverse events
Two (1%) non-trial-related deaths [one (1%) multidrug toxicity death in the BA group and one (1%)
cancer-related death in the CBT group] and 15 depression-related, but not treatment-related, serious AEs
(three in the BA group and 12 in the CBT group) occurred in three (2%) participants in the BA group
[two (1%) patients who overdosed and one (1%) who self-harmed] and eight (4%) participants in the CBT
group [seven (4%) who overdosed and one (1%) who self-harmed].
Intervention quality
Mental health workers and therapists met acceptable competency standards above our set thresholds,
as judged by our independently rated tapes: mean Quality of Behavioural Activation Scale score for BA
competence was 55 (SD 7.5) and mean CTS-R for CBT competence was 37.9 (SD 10.9).
Results of economic evaluation
Data completeness
At 18 months, full service use data for the entire follow-up were available for 159 (90%) of the
176 participants with outcome data in the BA group and 169 (93%) of the 180 participants with outcome
data in the CBT group, which was 75% of the total number randomised. One participant was identified
as an influential outlier in the CBT group and removed from the main analysis.
Service use
The use of most health services, social care services and complementary therapies was broadly similar
across the randomised groups over the 18-month follow-up. Some services were used only by those in one
group (case manager and homeopathy in BA; occupational therapist, community psychiatrist, advice
service and acupuncture in CBT), but these were all services used by < 2% of the sample. Service use
between baseline and the 18-month follow-up is detailed in Table 11.
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Medication
The use of prescribed, psychotropic medication is summarised in Table 12. ADM was prescribed most
frequently (around 80% of the full sample), followed by medication for anxiety or sleep (around 10% of
the full sample). Mood stabilisers and antipsychotics were both prescribed for < 2% of the sample. There
were no obvious differences in the proportion of participants in each group prescribed psychotropic
medication.
Productivity losses
Of those in employment [BA, n = 77 (48%); CBT, n = 71 (42%)], over the 18-month follow-up the mean
number of days off work did not differ between the groups (28.94 days in the BA group and 28.46 days
in the CBT group).
TABLE 11 Service use (unit) between baseline and 18-month follow-up
Service
Trial arm
BA (n= 159) CBT (n= 168)
Mean (SD) Range % using Mean (SD) Range % using
Inpatient stay (nights), n 0.55 (2.13) 0–20 25.79 0.74 (2.96) 0–25 27.98
Outpatient appointments (contacts), n 3.45 (5.25) 0–4 66.67 3.48 (5.94) 0–58 58.33
Accident and emergency (contacts), n 0.55 (1.09) 0–6 30.82 0.44 (0.96) 0–7 25.00
GP surgery (contacts), n 6.67 (8.49) 0–42 51.57 5.96 (8.18) 0–55 51.19
GP telephone (contacts), n 0.67 (2.75) 0–21 8.18 0.67 (2.49) 0–17 8.93
Practice nurse (contacts), n 2.02 (8.04) 0–82 18.87 1.35 (3.57) 0–25 17.26
Case manager (contacts), n 0.09 (1.19) 0–15 0.63 0.00 (0.00) 0 0.00
Occupational therapist (contacts), n 0.00 (0.00) 0 0.00 0.32 (3.00) 0–34 1.19
Psychiatrist (contacts), n 0.00 (0.00) 0 0.00 0.03 (0.36) 0–5 0.60
Social worker (contacts), n 0.06 (0.71) 0–9 0.63 0.04 (0.54) 0–7 0.60
Advice service (contacts), n 0.00 (0.00) 0 0.00 0.47 (6.10) 0–79 0.60
Chiropractor/osteopath (contacts), n 0.27 (2.05) 0–18 1.89 0.47 (4.70) 0–59 1.79
Homeopath (contacts), n 0.03 (0.32) 0–4 0.63 0.00 (0.00) 0 0.00
Acupuncture (contacts), n 0.00 (0.00) 0 0.00 0.45 (5.86) 0–76 0.60
Massage therapy (contacts), n 0.97 (4.92) 0–53 8.18 1.29 (6.32) 0–54 7.14
TABLE 12 Use of prescribed medication at any time between baseline and 18-month follow-up
Medication type
Trial arm, % of sample using
BA (n= 159) CBT (n= 168)
Antidepressants 79.87 82.74
Anxiety/sleep 10.06 11.31
Mood stabilisers 0.63 0.60
Antipsychotics 0.63 1.79
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Total costs
Total costs over the 18-month follow-up period are summarised in Table 13, including a breakdown of
costs by service-providing sector. We found a significant difference in mean intervention costs between the
two groups, but no differences in other categories of cost or in total cost.
Outcomes
Health-related quality of life
We found that the mean health utility scores (as measured via the EQ-5D-3L) were slightly higher in the BA
group than in the CBT group across the entire follow-up period, with resultant QALYs also higher for BA,
but the QALY difference was not significant (Table 14).
Cost-effectiveness
As observed costs were lower and QALY outcomes better in the BA group than in the CBT group,
this generated an ICER (the additional cost of one intervention compared with another divided by the
additional effects) of –£6865, suggesting that BA dominates CBT (i.e. BA is both cheaper and more
effective). The scatterplot of the bootstrapped cost and effectiveness pairs for BA versus CBT (Figure 7)
illustrates dominance of BA over CBT, with the point estimate and two-thirds of the scatter points (66%)
falling in the south-east quadrant of the cost-effectiveness plane, where BA replications are cheaper and
more effective than CBT ones.
TABLE 14 Mean EQ-5D-3L utility score between baseline and 18-month follow-up and resultant QALYs
Time point/QALY
Trial arm
Mean differencea
(BA – CBT) 95% CIa p-valuea
BA CBT
n Mean (SD) n Mean (SD)
Baseline 159 0.548 (0.307) 168 0.474 (0.317)
6 months 153 0.683 (0.310) 151 0.677 (0.310)
12 months 147 0.684 (0.341) 156 0.671 (0.348)
18 months 152 0.670 (0.311) 157 0.624 (0.335)
QALYs 152 0.985 (0.422) 157 0.935 (0.433) 0.050 –0.145 to 0.046 0.308
a Adjusted for site, ADM use, symptom severity and baseline covariates.
TABLE 13 Differences in costs (£) per participants between baseline and 18-month follow-up
Service
Trial arm, mean (SD)
BA – CBT, mean
differencea 95% CIa p-valueaBA (n= 159) CBT (n= 168)
Intervention 974.81 (475.02) 1235.23 (610.03) –262.29 –381.40 to –143.19 < 0.0001
Hospital 860.23 (1509.88) 927.26 (1975.64) –75.67 –451.75 to 300.42 0.692
Community health
and social care
644.36 (816.07) 944.25 (1726.17) –15.14 –304.90 to 274.62 0.918
Medication 103.20 (197.92) 117.64 (265.92) 2.15 –39.83 to 44.13 0.920
Total 2596.62 (1846.72) 3250.74 (3040.99) –343.24 –857.62 to 171.13 0.190
a Adjusted for site, ADM use, symptom severity and baseline covariates.
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The CEAC showing the probability of BA being cost-effective compared with CBT does not fall < 75% and
is closer to 80% at the standard NICE-preferred willingness-to-pay levels of £20,000–30,000 per QALY
(Figure 8).
Sensitivity analyses
Inclusion of the costs of complementary therapies and productivity losses (Table 15) increased the overall
mean difference in total cost between the two groups, making BA significantly less costly than CBT in
both cases (p = 0.039 with the inclusion of complementary therapies and p = 0.003 with the inclusion of
productivity losses). Narrower perspectives, focusing only on the cost of the interventions and the mental
health service perspective, had the same effect (p < 0.0001 in both cases). Figure 9 shows the CEACs
for the inclusion of complementary therapies and productivity losses and Figure 10 shows the CEACs
for the two narrower cost perspectives. In all cases, BA continues to have a higher probability of being
cost-effective compared with CBT at the NICE threshold of £20,000–30,000 per QALY.
6% of scatter points in
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4% of scatter points in
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–1000
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Difference in cost (£)
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Difference in QALY
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FIGURE 7 Scatterplot showing the bootstrapped mean differences in costs and effects of BA compared with CBT.
NE, north-east; NW, north-west; SE, south-east; SW, south-west.
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FIGURE 8 Cost-effectiveness acceptability curve showing the probability that BA is cost-effective compared with
CBT for different values of willingness to pay per QALY.
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TABLE 15 Results of the sensitivity analyses of economic data
Analysis type
Trial arm
Mean
differencea
(BA – CBT) 95% CIa p-valuea
BA CBT
n Mean (SD) n Mean (SD)
Impact on total costs (£)
Main analysis 159 2596.62
(1846.72)
168 3250.74
(3040.99)
–343.24 –857.62 to 171.13 0.190
Inclusion of complementary
therapies
158 2729.54
(2604.00)
168 3367.90
(3530.36)
–535.60 –1045.28 to –25.92 0.039
Inclusion of productivity
losses
152 3305.91
(3410.20)
166 4937.92
(6367.92)
–1726.37 –2870.80 to –581.93 0.003
Intervention perspective 159 992.73
(60.54)
168 1255.03
(88.16)
–262.30 –381.40 to –143.19 < 0.0001
Mental health-care
perspective
159 914.71
(67.86)
168 1253.85
(99.97)
–339.14 –472.64 to –205.64 < 0.0001
Imputation of missing
data
221 1841.67
(287.97)
219 2282.40
(423.94)
–440.73 –1007.70 to 126.26 0.127
Impact on QALYs
Main analysis 152 0.984
(0.422)
157 0.935
(0.433)
0.050 –0.145 to 0.046 0.308
Imputation of missing
data
221 1.224
(0.043)
219 1.198
(0.061)
0.026 –0.058 to 0.109 0.546
a Adjusted for site, ADM use, symptom severity and baseline covariates.
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FIGURE 9 Cost-effectiveness acceptability curve showing the probability that BA is cost-effective compared with
CBT for different values of willingness to pay for a QALY, including costs of complementary therapies and
productivity losses.
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Imputation of missing data increased the difference in total cost (£440.00 vs. £343.00 in the main
analysis), but reduced the difference in QALYs (0.026 vs. 0.050 in the main analysis), increasing the ICER
from –£6865.00 to –£16,951.00. Figure 11 shows the CEAC for the missing data analysis, which again
supports the likelihood that BA is cost-effective compared with CBT.
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FIGURE 10 Cost-effectiveness acceptability curve showing the probability that BA is cost-effective compared with
CBT for different values of willingness to pay for a QALY, from intervention and mental health-care perspectives.
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FIGURE 11 Cost-effectiveness acceptability curve showing the probability that BA is cost-effective compared with
CBT for different values of willingness to pay for a QALY, including imputed missing data.
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Chapter 4 Methods and results of the process
evaluation
This chapter uses material from Open Access articles previously published by the research team(see Rhodes et al.1 and Richards et al.2). © Rhodes et al.;1 licensee BioMed Central Ltd. 2014 This article
is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated and © The Author(s).2
Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Alongside the main clinical and economic evaluation, we undertook a process evaluation to investigate the
implementation of the intervention, moderators of outcome and possible mechanisms of effect. This
chapter consists of a description of our quantitative and qualitative methods, analyses and results.
Objectives
l To investigate factors that may moderate the effect of treatment allocation on outcome (PHQ-9 score),
and mechanistic and procedural factors that may mediate the effect of treatment on outcome.
l To obtain a more in-depth understanding of the ongoing mechanisms and impact of treatment from
participants and therapists including participants’ views of the role of cognitive and behavioural change
strategies and the broader impacts of treatment on participants’ lives.
Quantitative process study
Moderators: identifying patient subgroups who may receive differential
treatment effects
Having established no statistically significant difference in treatment effect between CBT and BA at any of
the three follow-up points (6, 12 and 18 months), for the PHQ-9 score, a further issue of clinical interest is
whether or not there are any specific subgroups of patients who would receive differential treatment
effects (e.g. increased benefit from one treatment compared with the alternative treatment). In the event
of identifying any such subgroups (defined by covariates that are known as moderators), these patients
could be offered the treatment that would confer the strongest benefit, taking into account their own
characteristics. To investigate this possibility, we extended the models used for the main analyses, by
adding an interaction term between treatment allocation and the potential moderator of treatment effect.
The potential moderators of treatment effect that we investigated include indicators of depression severity:
baseline PHQ-9 score, number of previous episodes of depression and age at onset of depression. We also
included other psychological variables measured at baseline: total BADS score, DAS score and total RRS
score. With regard to investigating whether or not patient preference for a certain treatment acted as a
moderator, we used information elicited on whether or not the patient had a treatment preference,
and if so whether the patient preferred CBT or BA, to derive three categories: (1) no treatment preference;
(2) received preferred treatment; and (3) received non-preferred treatment.
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Mediators: investigating potential mechanisms of therapy action
The traditional approach to causal mediation has followed the initial work of Baron and Kenny.100 This
approach is based on the existence of a significant effect of the independent variable on the mediator,
and on the dependent variable, and also a significant effect of the mediator on the dependent variable,
when the independent variable has been controlled for. However, this approach has received criticism, for
example with regard to the possibility of potential confounders between the mediator and the dependent
variable.101 In addition, it has been argued that a significant association between the independent variable
and the dependent variable is not required to demonstrate mediation.102,103
In a more complex situation, including more than one mediator in the structural model, such mediators
could be conceptualised as exerting their effect between the independent and dependent variables either
in sequence or in parallel to one another. In these analyses, all models that include multiple mediators are
structured so that the mediators are acting in parallel. More recent methods for causal mediation analysis,
for example using instrumental variables or potential outcomes (counterfactuals), have been developed,101
but are not considered further, because of the difficulty in identifying a suitable instrumental variable.
We used four process measures (PMs) as potential mediators:
1. BADS
2. DAS
3. RRS
4. SHAPS.
The BADS comprises four subscales (activation, avoidance, work impairment and social impairment) that
sum to give a total score. The RRS includes a subset of five items that consitute a reflection subscale. The
SHAPS revised score (Franken) was used for all analyses, owing to increased granularity compared with the
standard score, with each of the 14 items scored from 0 to 3, resulting in an overall score from 0 to 42.
Each measure was calibrated such that a higher score indicated a more clinically negative outcome so that
each measure was aligned with the directionality of the PHQ-9 primary outcome measure. Each mediation
analysis included the baseline score for the relevant mediator(s) in the model.
We used three mediators based on participants’ experience of their treatment:
1. proportion of sessions attended (out of a maximum of 24)
2. basic treatment fidelity
3. overall treatment fidelity.
Basic treatment fidelity was based on the proportion of core topics for the relevant therapy that were
covered during all attended sessions. There were six core topics for BA and seven for CBT; hence, the
number of topics was linearly rescaled on a score of 0–100. Inevitably, patients who received BA had a
propensity for an increased proportion of core topics covered, owing to the smaller number of potential
topics. The overall treatment fidelity was derived by linearly rescaling the proportion of mandatory topics
covered during all attended sessions (two for BA and four for CBT) on a scale of 0–100, then combining
with the score from 0 to 100 for basic quality therapy and dividing by 2 to produce a score from 0 to 100.
For the mediation analyses, the scores for proportion of sessions attended and the treatment fidelity
variables were reversed so that a low score indicated a more negative outcome. These measures were used
as potential mediators for the 12- and 18-month PHQ-9 follow-up only, as 210 participants had not
completed their final session at 6 months’ follow-up. Analyses to evaluate the potential mediators of the
treatment effect were performed for PHQ-9 measured at 6, 12 and 18 months; the potential mediators for
each PHQ-9 time point are set out in Table 16.
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TABLE 16 Variables investigated as potential mediators of the effect of treatment on PHQ-9 at the 6-, 12- and
18-month follow-ups
Outcome variable Mediator variable Time of measurement of mediator variable
PHQ-9: 6-month follow-up BADS total score PM1, PM2
BADS activation PM1, PM2
BADS avoidance PM1, PM2
BADS work impairment PM1, PM2
BADS social impairment PM1, PM2
DAS PM1, PM2
RRS total score PM1, PM2
RRS rumination score PM1, PM2
PHQ-9: 12-month follow-up BADS total score PM1, PM2, 6 months
BADS activation PM1, PM2, 6 months
BADS avoidance PM1, PM2, 6 months
BADS work impairment PM1, PM2, 6 months
BADS social impairment PM1, PM2, 6 months
DAS PM1, PM2, 6 months
RRS total score PM1, PM2, 6 months
RRS rumination score PM1, PM2, 6 months
SHAPS 6 months
Number of sessions N/A
Basic treatment fidelity N/A
Overall treatment fidelity N/A
PHQ-9: 18-month follow-up BADS total score 6 months
BADS activation 6 months
BADS avoidance 6 months
BADS work impairment 6 months
BADS social impairment 6 months
DAS 6 months
RRS total score 6 months
RRS rumination score 6 months
SHAPS 6 months, 12 months
Number of sessions N/A
Basic treatment fidelity N/A
Overall treatment fidelity N/A
N/A, not appropriate; PM1, process measure point 1 at treatment session 4; PM2, process measure point 2 at treatment
session 7.
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Having established that there is no evidence for a differential treatment effect between BA and CBT at any
of the follow-up time points, but that both treatments are equally effective, the purpose of the mediation
analyses is to investigate whether or not there are any differences in treatment mechanism between the
two therapies.
Methods
Moderation analyses
Potential interaction effects between treatment allocation and baseline PHQ-9 score, age at onset of
depression, number of past episodes of depression, baseline scores for BADS, DAS and RRS totals, and
treatment were investigated. Participants who reported their age at onset of depression as < 10 years of
age had their age at onset raised to 10 years, to bring them into alignment with the overall distribution of
age at onset. Participants who reported having experienced > 50 episodes of depression had their number
of episodes reduced to 50. The reported data on treatment preference were recombined into a categorical
variable with three levels, using ‘no treatment preference’ as the default category, with two comparator
categories: ‘had a preference and did receive preferred treatment’, and ‘had a preference and did not
receive preferred treatment’. For those participants who indicated a preferred treatment, no distinction was
made in the analyses between a preference for CBT and a preference for BA.
Interactions between treatment allocation and each covariate were investigated at 6, 12 and 18 months’
follow-up for PHQ-9. Separate analyses for the ITT and PP populations were performed. For the analyses
of PHQ-9 data at 6 months’ follow-up, the PP population was considered to be participants who had
completed eight or more therapy sessions before the date of the 6-month follow-up. Only participants
with observed data for all covariates included in each model were included within each analysis. A series of
models were performed, each model adjusting for the stratification variables, trial site, baseline ADM use
and baseline PHQ-9 score. Each model included the specific covariate being investigated as a potential
moderator and its interaction with treatment allocation.
Mediation analyses
Mediation population
Mediation analyses were performed on a subgroup of participants that excluded seven participants whose
process measure point 1 (PM1) and/or process measure point 2 (PM2) data were collected after 6 months’
follow-up. Otherwise, all analyses were conducted using the ITT population, and included only participants
with observed data.
Analysis methods
Unadjusted mean scores were reported for both treatment groups for PHQ-9 at all follow-up times, and
for the mediator variables at all recorded follow-up times, for the mediation population. We also produced
line plots to show the trajectories of individual participants by treatment group for PHQ-9 and each of the
PM variables, and investigated whether or not there was any between-group difference over time for
the PMs using a repeated measures model with adjustment for site, baseline PHQ-9 score and baseline
ADM use. We also investigated whether or not there was any difference between groups with regard to
proportion of sessions attended, basic treatment fidelity and overall treatment fidelity. Post hoc regression
models were performed to investigate the effects of basic fidelity and overall fidelity on PHQ-9 score at
12 and 18 months’ follow-up, with adjustment for treatment group, baseline PHQ-9 score, site and
baseline ADM use. The interactions between fidelity and treatment group were also investigated.
For the mediation analyses we used a structural equation modelling (SEM; command sem in Stata v.14)
approach to evaluate the effect of each individual mediator at each follow-up time, on the primary outcome,
PHQ-9 score. We also included all mediators measured at a specific follow-up time in an overall model for
each follow-up time for PHQ-9 measurement. All analyses adjusted for the stratification variables, baseline
PHQ-9 (measured as a continuous variable rather than dichotomised as for the stratification process), trial
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site and whether or not the participant was using ADM at baseline. We also adjusted for age at onset of
depression, as this was found to be a predictor (p < 0.05) of PHQ-9 score at all follow-up times. It was noted
that none of the three potential mediator variables (BADS total, RRS, DAS) examined at baseline as potential
predictors or moderators of PHQ-9 at any of the three follow-up times was significant. For the mechanistic
mediators (BADS, DAS, RRS and SHAPS), we adjusted all analyses for the baseline score, but not for any
other previous scores (if available). This approach takes account of both the participant’s initial state and
his/her change in state from baseline to follow-up. We report the total effect and indirect effect for each
mediator, with 95% bias-corrected CIs104 derived from bootstrapping with 5000 replications. All analyses
were performed using Stata v.14.
Results
Moderation analyses
The results of the analyses investigating interactions between treatment effects and selected covariates are
shown in Table 17. Across all three follow-up times, and in both the ITT and PP populations, there were no
statistically significant interactions between treatment group and the specified covariates. However, in the
PP population, at both 12 and 18 months’ follow-up, there was weak evidence (p < 0.1) for an interaction
between treatment group and baseline PHQ-9 score. This interaction was in the direction of participants
with higher PHQ-9 scores at baseline, and receiving BA, having lower PHQ-9 scores at follow-up than
with participants who received CBT. This treatment moderation effect of baseline PHQ-9 score is shown
graphically in Figure 12 for the 12-month follow-up. Weak evidence was found for a moderating effect of
baseline total RRS score on the treatment effect for PHQ-9 at 12 months’ follow-up, also in the PP
population. However, this effect was not observed at any other follow-up time points.
Mediation analyses
Table 18 shows the unadjusted scores for PHQ-9 and all mediator variables at all time points at which
the variable was recorded. Figures 13–17 show the treatment group mean scores and Figures 18–22
(see Appendix 2) show the individual participant scores, for all time points at which each variable was
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FIGURE 12 Margins plot of interaction, with 95% CIs, between the effect of treatment group and baseline PHQ-9
on PHQ-9 at 12 months’ follow-up using the PP observed data sample only (with adjustment for site and baseline
antidepressant use). a, Linear predictor of PHQ-9 at 12 months’ follow-up.
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recorded. For PHQ-9, the greatest reduction in mean scores occurred between baseline and 6 months’
follow-up, with a smaller reduction between 6 and 12 months’ follow-up. Mean scores were stable between
the 12- and 18-month follow-ups. On looking at the individual participant trajectories for PHQ-9 between
the follow-up times, there was wide variation among participants with regard to their personal PHQ-9
trajectory. Some participants had an evident reduction in PHQ-9 score between baseline and 6 months’
follow-up, which may be sustained in some cases but increased after the 6-month follow-up in others.
A similar wide variation in individual participant trajectories was observed across all process mediator
variables. No significant between-group difference across time points was found for any of the process
mediators (p-values for interaction between group and time point were > 0.1 for all process mediators across
all available time points). There was no significant difference between the treatment groups (CBT vs. BA)
for percentage of sessions attended (mean difference 4.4 sessions attended, 95% CI –1.7 to 10.5 sessions
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FIGURE 13 Mean PHQ-9 scores with 95% CI at baseline and at 6, 12 and 18 months’ follow-up, by treatment group
for the mediation population.
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FIGURE 14 Mean BADS total score with 95% CI at baseline, PM1 (session 4), PM2 (session 7) and at 6 months’
follow-up, by treatment group for the mediation population.
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attended). For basic fidelity (on a scale of 0 to 100), there was evidence that the fidelity for CBT was lower
than for BA (mean difference –12.1, 95% CI –17.6 to –6.7), although this may be artefactual because
of the different numbers of topics for the two therapies. Among participants receiving BA, 158 out of
220 (71%) completed all six of the core topics, compared with only 70 out of 218 (32%) participants who
received CBT completing all seven of the core topics, and only 132 out of 218 (61%) completed at least
six out of seven core topics. For overall fidelity, there was no significant difference between the groups
(mean difference –4.9, 95% CI –11.0 to 1.1), although again this may be arbitrary as a result of the
weighting system used to weight core and mandatory topics.
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FIGURE 15 Dysfunctional Attitudes Scale total score at baseline, PM1 (session 4), PM2 (session 7) and at 6 months’
follow-up, by treatment group for the mediation population.
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FIGURE 16 Ruminative Response Scale total score at baseline, PM1 (session 4), PM2 (session 7) and at 6 months’
follow-up, by treatment group for the mediation population.
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Using the SEM approach, at the 6-month PHQ-9 follow-up, when considered individually, each mediator
measured at PM1 mediated only a small proportion of the total effect of treatment (Table 19). None
of the mediators in the single mediator models or in the multiple mediator models was found to have a
statistically significant indirect effect of treatment allocation acting via that mediator.
At the 12-month PHQ-9 follow-up, with mediators measured at PM1, again the BADS variables appeared
to be the strongest individual mediators, with social impairment mediating 21% of the total effect of
treatment, and the total BADS score mediating –18% (Table 20).
For the overall treatment fidelity, the indirect effect of treatment group acting via this mediator was
statistically significant (–0.18, 95% CI –0.54 to –0.01), mediating –117% of the total treatment effect
(see Table 20). In the multiple mediator model, however, none of the mediators was found to have a
significant indirect effect. BADS avoidance, BADS social impairment, total RRS score, SHAPS, basic treatment
fidelity and overall treatment fidelity were found to mediate at least 10% in magnitude of the total
treatment effect.
At 18 months’ follow-up, the indirect effect of treatment via basic treatment fidelity in the individual
mediator model was statistically significant (observed effect 0.61, 95% CI 0.23 to 1.17) and associated
with a proportion of total effect mediated of 610% (Table 21). In the multiple mediators model, with
mediator variables measured at 6 months’ follow-up, this effect was not statistically significant, but was
associated with a proportion of total effect mediated of 77%. Similarly, the indirect effect via overall
treatment quality was statistically significant (observed effect 0.24, 95% CI 0.03 to 0.65) in the individual
mediator model, but this significant effect was not seen in the multiple mediators model.
Across the three PHQ-9 time points, the effects of the mediators varied considerably, with the proportions
of total effect mediated increasing at later time points, possibly as a result of the mediator variables
having a chance to stabilise at later measurement times, and also the PHQ-9 scores becoming more stable
on progressing through the follow-up period. The only mediator that was statistically significantly different
between the groups was basic treatment fidelity, which was a significant mediator of treatment allocation
at 18 months’ follow-up. Using individual regression models, both basic and overall treatment fidelity
were associated with the 12-month PHQ-9 score, with poorer fidelity being associated with higher PHQ-9
scores (p-values 0.020 and 0.023, respectively). Similarly, both basic and overall treatment fidelity were
significantly associated with the 18-month PHQ-9 follow-up, again with poorer fidelity being associated
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FIGURE 17 Snaith–Hamilton Pleasure Scale total score at baseline, and at 6 and 12 months’ follow-up, by treatment
group for the mediation population.
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TABLE 19 Results of the SEM analyses for mediation of treatment effect on PHQ-9 at 6 months’ follow-up
Mediator
Model
Single mediator Including all mediators
Indirect effect of
treatment
allocation acting
through mediator
(95% CI), n
Total effect of
treatment
allocation
(95% CI)
Proportion of
total effect
mediated by
indirect
effect (%)
Indirect effect
of treatment
allocation
acting through
mediator
(95% CI)
Proportion of
total effect
mediated by
indirect effect
(%)a
Mediators measured at PM1 (therapy session 4)
Total effect of treatment allocation
–1.84 (95% CI –3.79 to 0.04),
n= 158
BADS total 0.18
(–0.34 to 0.91), 163
–1.52
(–3.43 to 0.34)
–12 Not included Not included
BADS activation 0.12
(–0.51 to 0.75), 186
–1.52
(–3.45 to 0.32)
–8 0.13
(–0.11 to 0.81)
0.13
(–0.11 to 0.81)
BADS avoidance 0.11
(–0.17 to 0.71), 195
–1.34
(–3.14 to 0.51)
–8 –0.01
(–0.38 to 0.18)
–0.01
(–0.38 to 0.18)
BADS work
impairment
0.10
(–0.45 to 0.69), 198
–1.45
(–3.24 to 0.42)
–7 0.05
(–0.10 to 0.65)
0.05
(–0.10 to 0.65)
BADS social
impairment
–0.06
(–0.50 to 0.32), 184
–1.54
(–3.43 to 0.18)
4 0.04
(–0.12 to 0.52)
0.04
(–0.12 to 0.52)
DAS 0.13
(–0.26 to 0.71), 202
–1.73
(–3.46 to 0.16)
–8 0.18
(–0.12 to 0.84)
0.18
(–0.12 to 0.84)
RRS total 0.13
(–0.31 to 0.63), 206
–1.64
(–3.40 to 0.18)
–8 0.06
(–0.14 to 0.64)
0.06
(–0.14 to 0.64)
RRS reflection 0.04
(–0.09 to 0.39), 206
–1.60
(–3.36 to 0.21)
–2 Not included Not included
Mediators measured at PM2 (therapy session 7)
Total effect of treatment allocation
–2.63 (95% CI –4.87 to –0.32),
n= 126
BADS total –0.23
(–1.45 to 0.89), 129
–2.52
(–4.94 to –0.35)
9 Not included Not included
BADS activation 0.21
(–0.57 to 1.15), 153
–1.68
(–3.67 to 0.37)
–13 –0.01
(–0.47 to 0.19)
1
BADS avoidance –0.05
(–0.84 to 0.72), 154
–2.26
(–4.42 to –0.12)
2 –0.01
(–0.48 to 0.30)
0
BADS work
impairment
0.34
(–0.64 to 1.38), 160
–2.01
(–4.05 to –0.01)
–17 0.04
(–0.35 to 0.80)
–1
BADS social
impairment
–0.29
(–1.29 to 0.56), 147
–2.33
(–4.46 to –0.23)
13 –0.19
(–1.19 to 0.19)
7
DAS 0.23
(–0.54 to 0.93), 166
–1.95
(–3.95 to 0.20)
–12 0.10
(–0.16 to 0.84)
–4
RRS total –0.02
(–0.77 to 0.68), 167
–2.00
(–4.07 to –0.02)
1 –0.04
(–0.59 to 0.24)
2
RRS reflection 0.11
(–0.42 to 0.71), 167
–2.04
(–4.06 to –0.02)
–5 Not included Not included
a Proportions of total effect mediated are not required to sum to 100%.
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TABLE 20 Results of the SEM analyses for mediation of treatment effect on PHQ-9 at 12 months’ follow-up
Mediator
Model
Single mediator Including all mediators
Indirect effect
of treatment
allocation acting
through mediator
(95% CI), n
Total effect of
treatment
allocation
(95% CI)
Proportion of
total effect
mediated by
indirect effect
(%)
Indirect effect
of treatment
allocation
acting through
mediator
(95% CI)
Proportion of
total effect
mediated by
indirect effect
(%)a
Mediators measured at PM1
Total effect of treatment allocation
–0.58 (95% CI –2.61 to 1.59),
n= 154
BADS total 0.09
(–0.78 to 0.81), 158
–0.49
(–2.55 to 1.41)
–18 Not included Not included
BADS activation 0.01
(–0.69 to 0.61), 181
–0.79
(–2.74 to 1.09)
–1 0.08
(–0.27 to 0.69)
–14
BADS avoidance 0.02
(–0.47 to 0.49), 189
–0.82
(–2.76 to 1.14)
–3 0.01
(–0.20 to 0.45)
–3
BADS work
impairment
0.03
(–0.69 to 0.61), 192
–0.56
(–2.51 to 1.35)
–5 0.08
(–0.26 to 0.79)
–15
BADS social
impairment
–0.16
(–0.80 to 0.23), 179
–0.78
(–2.71 to 1.18)
21 0.00
(–0.24 to 0.24)
0
DAS 0.08
(–0.15 to 0.61), 198
–0.93
(–2.84 to 0.92)
–9 –0.18
(–0.90 to 0.13)
32
RRS total 0.09
(–0.41 to 0.66), 201
–0.98
(–2.88 to 0.83)
–9 0.10
(–0.09 to 0.73)
–17
RRS reflection 0.08
(–0.17 to 0.54), 201
–0.95
(–2.84 to 0.87)
–9 Not included Not included
Mediators measured at PM2
Total effect of treatment allocation
–0.84 (95% CI –3.23 to 1.58),
n= 125
BADS total –0.29
(–1.40 to 0.64), 128
–0.53
(–2.98 to 1.74)
55 Not included Not included
BADS activation –0.09
(–0.73 to 0.84), 150
–0.27
(–2.29 to 1.69)
–33 –0.04
(–0.72 to 0.14)
5
BADS avoidance –0.10
(–0.74 to 0.48), 150
–0.37
(–2.36 to 1.66)
26 0.00
(–0.38 to 0.52)
–1
BADS work
impairment
0.14
(–0.76 to 1.10), 156
–0.47
(–2.58 to 1.67)
–31 –0.03
(–0.91 to 0.78)
4
BADS social
impairment
–0.33
(–1.35 to 0.43), 145
–0.58
(–2.78 to 1.52)
57 –0.20
(–1.51 to 0.15)
23
DAS 0.11
(–0.42 to 0.67), 162
–0.57
(–2.58 to 1.49)
–19 –0.04
(–0.73 to 0.21)
5
RRS total 0.01
(–0.67 to 0.71), 163
–0.68
(–2.71 to 1.32)
–2 –0.03
(–0.63 to 0.43)
4
RRS reflection 0.20
(–0.23 to 0.90), 163
–0.72
(–2.73 to 1.28)
–28 Not included Not included
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TABLE 20 Results of the SEM analyses for mediation of treatment effect on PHQ-9 at 12 months’ follow-up
(continued )
Mediator
Model
Single mediator Including all mediators
Indirect effect
of treatment
allocation acting
through mediator
(95% CI), n
Total effect of
treatment
allocation
(95% CI)
Proportion of
total effect
mediated by
indirect effect
(%)
Indirect effect
of treatment
allocation
acting through
mediator
(95% CI)
Proportion of
total effect
mediated by
indirect effect
(%)a
Mediators measured at 6 months’ follow-up
Total effect of treatment allocation
0.30 (–1.37 to 1.95), n= 250
BADS total 0.09
(–0.77 to 1.05), 258
0.27
(–1.33 to 1.93)
33 Not included Not included
BADS activation –0.05
(–0.82 to 0.68), 281
–0.22
(–1.73 to 1.31)
25 0.00
(–0.29 to 0.35)
2
BADS avoidance –0.40
(–1.13 to 0.37), 285
–0.06
(–1.52 to 1.42)
720 –0.12
(–0.64 to 0.10)
–39
BADS work
impairment
0.24
(–0.46 to 1.04), 294
–0.26
(–1.82 to 1.17)
–94 0.02
(–0.13 to 0.39)
6
BADS social
impairment
0.26
(–0.52 to 1.09), 282
–0.06
(–1.58 to 1.53)
–463 0.06
(–0.11 to 0.52)
19
DAS 0.08
(–0.80 to 0.61), 296
–0.26
(–1.72 to 1.26)
33 –0.02
(–0.36 to 0.11)
–5
RRS total –0.31
(–0.99 to 0.41), 297
–0.30
(–1.82 to 1.16)
105 –0.11
(–0.59 to 0.19)
–38
RRS reflection –0.14
(–0.68 to 0.40), 297
–0.30
(–1.81 to 1.17)
47 Not included Not included
SHAPS 0.02
(–0.04 to 0.22), 298
–0.09
(–1.70 to 1.41)
–20 0.05
(–0.03 to 0.33)
17
Treatment fidelity mediatorsb
Proportion of
sessions attended
–0.04
(–0.28 to 0.04), 350
–0.14
(–1.49 to 1.30)
29 0.01
(–0.12 to 0.24)
2
Basic treatment
fidelity
0.33
(–0.03 to 0.83), 349
–0.15
(–1.55 to 1.27)
–216 0.07
(–0.79 to 0.76)
23
Overall treatment
fidelity
0.18
(0.01 to 0.54), 349
–0.15
(–1.55 to 1.27)
–117 0.05
(–0.43 to 0.72)
17
a Proportions of total effect mediated are not required to sum to 100%.
b Treatment fidelity mediators included in model with mediators measured at 6 months’ follow-up.
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with higher PHQ-9 scores (p-values 0.001 and 0.020, respectively), the basic fidelity remaining significant
when included in a model with overall fidelity (p-value 0.007). No evidence was found for a significant
interaction between treatment group and basic or overall fidelity, with regard to either 12 or 18 months’
PHQ-9 follow-up.
TABLE 21 Results of the SEM analyses for mediation of treatment effect on PHQ-9 at 18 months’ follow-up
Mediator
Model
Single mediator Including all mediators
Indirect effect
of treatment
allocation acting
through mediator
(95% CI), n
Total effect
of treatment
allocation
(95% CI)
Proportion of
total effect
mediated by
indirect
effect (%)
Indirect effect of
treatment
allocation acting
through mediator
(95% CI)
Proportion of
total effect
mediated by
indirect
effect (%)
Mediators measured at 6 months’ follow-up
Total effect of treatment allocation
–0.52 (95% CI –2.16 to 1.13),
n = 248
BADS total 0.06
(–0.76 to 0.96), 255
0.64
(–0.91 to 2.27)
9 Not included Not included
BADS activation –0.10
(–0.81 to 0.60), 278
0.14
(–1.42 to 1.64)
–75 0.00
(–0.15 to 0.22)
1
BADS avoidance –0.38
(–1.05 to 0.25), 283
0.19
(–1.32 to 1.69)
–196 0.02
(–0.13 to 0.37)
3
BADS work
impairment
0.17
(–0.52 to 0.90), 291
0.03
(–1.47 to 1.49)
653 0.11
(–0.07 to 0.64)
21
BADS social
impairment
0.25
(–0.47 to 1.11), 278
0.56
(–0.88 to 2.14)
45 0.12
(–0.29 to 0.71)
23
DAS –0.02
(–0.63 to 0.64), 294
0.03
(–1.44 to 1.52)
–76 0.00
(–0.23 to 0.21)
0
RRS total –0.31
(–0.93 to 0.32), 294
0.02
(–1.43 to 1.49)
–1600 –0.06
(–0.47 to 0.08)
–12
RRS reflection –0.09
(–0.51 to 0.35), 294
0.03
(–1.44 to 1.50)
–357 Not included Not included
SHAPS 0.00
(–0.11 to 0.08), 293
0.01
(–1.50 to 1.48)
–9 0.00
(–0.11 to 0.13)
0
Treatment fidelity mediatorsa
Proportion of
sessions attended
–0.04
(–0.28 to 0.04), 343
0.12
(–1.29 to 1.53)
–36 0.04
(–0.08 to 0.45)
7
Basic treatment
fidelity
0.61
(0.23 to 1.17), 342
0.10
(–1.28 to 1.54)
610 0.40
(–0.37 to 1.19)
77
Overall treatment
fidelity
0.24
(0.03 to 0.65), 342
0.10
(–1.28 to 1.54)
237 –0.05
(–0.67 to 0.46)
–9
Mediators measured at 12 months’ follow-up
SHAPS 0.04
(–0.10 to 0.29), 291
0.34
(–1.16 to 1.96)
11 Not included Not included
a Treatment fidelity mediators included in model with mediators measured at 6 months’ follow-up.
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Qualitative process study
Methods
Sample and design
At the baseline assessment all COBRA trial participants were asked whether or not they would be willing
to complete an additional interview at a later date to discuss their experiences of therapy. Participants for
the qualitative study were selected from those providing consent and were purposively sampled to ensure
a selection of participants from each recruitment site, both trial arms, some who had fewer than eight
sessions of therapy and some who had eight or more. Of those having eight or more sessions, we
purposively sampled some who remained depressed and others who were no longer depressed according
to the SCID45 at 6 months’ follow-up. Participants were invited to take part in the qualitative study via
letter, followed up by a telephone call from a researcher. Interviews were conducted as soon as possible
after therapy had ended and aimed to address the following research questions:
1. What are participants’ views on the acceptability of BA and CBT?
2. What are participants’ views on the role of cognitive and behavioural change strategies?
3. What are the broader impacts of BA and CBT on participants’ lives?
In addition, all 22 therapists and MHWs delivering therapy in the trial were invited by e-mail to take part in
an interview over the telephone with the trial manager to talk about their experiences of delivering
therapy. Those who did not respond to the invitation were not chased further. Semistructured interviews
were completed with six CBT therapists and seven BA MHWs.
Participant interviews were conducted over the telephone by Katie Finning (KF), and Rebecca Woodhouse (RW)
and Faye Plummer (FP), who were researchers working on the COBRA trial in Devon (KF) and Leeds (RW and FP).
All were given in-house training in qualitative interviewing, followed by assessment and feedback on their first
interview from David A Richards (DAR), trial chief investigator experienced in qualitative interviewing. Interviews
were completed across sites to ensure researcher blinding was maintained for main trial follow-ups (e.g. the
researcher in Devon completed interviews with participants in Leeds). Participants therefore had no prior
knowledge or relationship with their qualitative interviewer. A semistructured topic guide was developed by
DAR and KF based on the study aims and previous literature. Interview topics included general experiences of
treatment, acceptability and barriers to therapy, cognitive and behavioural change, and the impact of treatment.
Probe questions were used where necessary to help participants elaborate on their responses. The topic guide
was pilot tested on two participants and modified to include a question on important parts of therapy, and
probe questions were refined.
Therapist interviews were conducted over the telephone by Shelley Rhodes (SR), the COBRA trial manager
based in Devon, who was given in-house training in qualitative interviewing. A semistructured topic guide
was developed by DAR and SR based on the study aims and previous literature. Interview topics included
general experiences of delivering treatment, specific therapeutic strategies used, impact of treatment for
participants, perceived reasons for participants who did not improve, how COBRA trial patients compared
with patients seen in usual practice and the therapists’ personal experience of taking part in the trial.
Participant and therapist interviews were audio-recorded with participants’ prior consent and transcribed
verbatim. Transcripts were not returned to participants or therapists for comment but were double-
checked for accuracy by a second member of the research team. Participant interviews were conducted
separately from the main trial follow-ups to avoid bias and encourage open communication.
Analysis
Participant transcripts were analysed by KF, Lucy Moore (LM) and DAR using a framework approach,94 with the
assistance of QSR International’s NVivo 10 software (QSR International, Warrington, UK). Analysis began with
familiarisation with the transcripts and the development of an initial thematic framework, combining deductive
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themes from the topic guide and inductive themes emerging from the data. KF and LM coded three interviews
independently to assess the reliability of coding95 and meetings were held to discuss and refine emerging
themes. Transcripts were examined thematically across the whole data set, as well as in the context of each
interview, using constant comparison techniques.96 Data were indexed and sorted using the identified themes
and subthemes, and were summarised in framework matrices94 with the original transcripts being frequently
revisited to clarify contextual meaning. In keeping with the framework approach we interrogated the data,
searching for comparisons and contradictions and keeping interpretive notes. Alternative explanations or
negative cases were identified, discussed and a consensus reached.95 In the final stage of analysis, KF and DAR
met to discuss the findings in relation to the research aims and previous literature, focusing on drawing
conclusions and synthesising the findings into the overarching themes presented here.
Therapist/MHW transcripts were analysed by KF using the framework approach described above. A second
researcher independently coded three interview transcripts and provided an initial thematic framework,
which was compared and combined with the framework developed by KF. In the final stage of analysis,
KF and DAR met to discuss the findings and relate them to the research aims and previous literature,
focusing on drawing conclusions and synthesising the findings into the overarching themes presented here.
Results
Results of participant qualitative interviews
Thirty-six interviews were completed between April 2014 and May 2015. Interviews lasted between 15
and 75 minutes and were completed, on average, 4 months after treatment ended (range 1–17 months).
Participant demographics are provided in Table 22 and the distribution of interviews across the purposive
sampling frame can be seen in Table 23.
Results are presented under three main headings: acceptability of therapy, mechanisms of change and
impact of therapy, reflecting our three research questions. Quotes are presented to support analysis and
are labelled by participant ID number, therapy received, number of sessions, and for those who received
eight or more sessions, depression status at 6-month follow-up (depressed or not depressed). Views were
consistent across BA and CBT except where specified.
Acceptability of therapy
Participants’ views about the acceptability of therapy could be understood in terms of three subthemes:
elements of therapy, the therapist and barriers to therapy.
Elements of therapy
Many participants enjoyed therapy as an opportunity to learn about depression, themselves, and their
thoughts and behaviour. A few participants expressed a preference for one-to-one, face-to-face therapy
over alternative modes, and for many the length and regularity of treatment was considered beneficial:
It’s had a lasting effect and I think that may be to do with it being really quite in depth as you’re
going for an hour week . . . going once a week is helpful, which had been much better than going
once every 3 months for 6 years, it’s like you’re really working on it, like a car.
28 – CBT 10 sessions, not depressed
A small minority felt that therapy did not provide enough opportunity to talk about their feelings or the
history behind their depression, but for others not having to focus on the past was considered helpful:
I really loved the fact that I didn’t have to dwell on past experiences . . . I have seen therapists in the
past and that but none of it’s ever worked for me ‘cos all they want to do is go over the past and I’ve
never wanted to do that.
4 – BA 17 sessions, not depressed
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TABLE 22 Demographics of qualitative participants
Participant Therapy
Number of sessions
attended
6-month depression
status Gender
Age group
(years)
1 BA 1 N/Aa Male 55–64
2 CBT 3 N/A Female 75+
3 BA 14 Not depressed Male 35–44
4 BA 17 Not depressed Female 45–54
5 CBT 24 Depressed Female 45–54
6 BA 3 N/A Female 25–34
7 BA 13 Depressed Female 45–54
8 CBT 22 Depressed Female 35–44
9 BA 9 Depressed Male 35–44
10 CBT 20 Depressed Female 75+
11 CBT 13 Depressed Female 45–54
12 CBT 23 Not depressed Female 55–64
13 BA 12 Depressed Male 55–64
14 CBT 15 Not depressed Female 18–24
15 CBT 14 Not depressed Female 55–64
16 BA 13 Not depressed Male 65–74
17 BA 2 N/A Male 45–54
18 CBT 24 Depressed Female 55–64
19 CBT 14 Not depressed Male 35–44
20 BA 2 N/A Male 45–54
21 CBT 19 Depressed Male 55–64
22 BA 12 Not depressed Female 45–54
23 BA 17 Depressed Male 45–54
24 BA 8 Not depressed Female 35–44
25 CBT 21 Not depressed Female 55–64
26 BA 24 Depressed Female 35–44
27 CBT 22 Not depressed Male 35–44
28 CBT 10 Not depressed Female 55–64
29 BA 24 Not depressed Male 55–64
30 CBT 3 N/A Female 35–44
31 BA 4 N/A Female 35–44
32 BA 5 N/A Male 18–24
33 CBT 1 N/A Male 25–34
34 BA 8 Depressed Female 65–74
35 CBT 10 Depressed Female 35–44
36 CBT 6 N/A Female 25–34
N/A, not appropriate.
a N/A: depression status at 6 months’ follow-up was only included in the sampling frame for participants who had eight or
more sessions of therapy.
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A small number of participants in the BA group made additional comments that were not made by any of those
receiving CBT. This included a resistance to the general BA approach, considering it simplistic, superficial and
restrictive, and that it was a ‘poorer cousin’ of CBT because of its lack of consideration to thought processes:
I feel like your life’s more complicated or more complex than that . . . I think if you don’t actually kind
of go a little bit deeper and underneath things, you’re just sort of tinkering around with some of the
superficial stuff on the top and rearranging the furniture.
13 – BA 12 sessions, depressed
In both treatments, experiences of homework were mixed. On the one hand, it could be difficult, bringing
therapy into everyday life and having the potential to make mood worse. Some felt a pressure to complete
homework, and felt that it could create feelings of fear and failure. But many others considered homework
an important part of therapy, providing them with a feeling of owning their depression and gaining
control over their feelings, and reported that having things written down was helpful. These views were
not always distinct; some participants could recognise the benefits despite finding homework difficult:
People can give you information but you’ve got to put it into practice and act on it even if you might
think ‘Oh, this isn’t going to really help me’ . . . you’ve got to go through it and come out the other
side, haven’t you, to a certain degree?
7 – BA 13 sessions, depressed
The therapist
For many participants the therapist was a positive part of treatment: someone who was warm, patient
and understanding. Participants in both treatments viewed their therapist as an expert who had the skills
necessary to help them:
She was a lovely lady she gave me support when I needed it, she pushed me when I needed it . . . she
could see when my mind was playing games with me where I was trying to ignore it or move around
the situation, so for me she was very good.
4 – BA 17 sessions, not depressed
Some participants reported that the therapist played a particularly important role in helping them
overcome difficulties in therapy. Being able to adapt treatment, offering reassurance and not putting
pressure on participants were helpful skills when therapy was difficult, and addressing challenges with the
therapist was largely seen as a helpful process:
Speaking to the counsellor and just being honest and open about what was, the fears or the barriers . . .
because they were quite useful for her to understand, she could then fold that into the treatment as well.
27 – CBT 22 sessions, not depressed
TABLE 23 Number of qualitative interviews completed across the purposive sampling frame
Trial site
Trial arm, number of sessions attended; depression status at 6 months
BA CBT
≥ 8; depressed ≥ 8; not depressed < 8; N/A ≥ 8; depressed ≥ 8; not depressed < 8; N/A
Devon 3 2 2 4 1 1
Durham 1 2 2 2 3 0
Leeds 2 2 2 1 3 3
Total 6 6 6 7 7 4
N/A, not appropriate.
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A small minority of BA participants described their therapists as rigid, unauthoritative and lacking in
confidence, comments that were not made by any of those receiving CBT. Although discussed only by a
few participants in our sample, for those who did so it appeared to be a significant problem and was
discussed at length:
It did feel like there was a bit of a confidence issue going on or a lack of confidence from the
therapist’s side in some way. ‘Cos I sort of picked up that I needed to kind of make her kind of feel
like she was doing a good job with me.
13 – BA 12 sessions, depressed
Barriers to therapy
Work and family were particular features of life that could make therapy difficult. Getting to sessions could
be problematic, particularly for those with comorbidities, such as anxiety or chronic pain. A regular routine
of appointments was considered to make attendance easier but flexibility was also welcomed (e.g.
rearranging sessions or completing them over the telephone if particular barriers arose). There were also
emotional challenges to therapy; it could be hard to open up and talk about personal things, especially in
the beginning and for those who were not used to expressing their emotions. For some, depression itself
made it hard to put things into practice and affected their ability to understand components of therapy:
The whole point about mood which makes it bad is the fact that it’s impacting your ability to do . . .
the depression itself is a barrier to doing it. I actually can’t offer a solution that would make it easier,
but I believe that it wouldn’t work for everybody.
33 – CBT 1 session
Participants recognised the importance of their own attitude and commitment in helping them overcome
barriers to therapy:
Hard as it was I was determined to do it because I knew I had to to make a difference in my life.
4 – BA 17 sessions, not depressed
Mechanisms of change
Participants’ views about mechanisms of change could be understood in terms of three subthemes:
behaviour change, cognitive change and talking versus doing.
Behaviour change
Changes to behaviour were considered important by many participants in both treatments, and this
included avoidance, triggers, rumination and goal-oriented behaviour. Therapy enabled participants to
understand and overcome avoidance behaviours, and this could reduce anxiety:
I felt like a weight had been lifted and I could, I was in a sort of procrastination phase where I couldn’t
make decisions and I was just puttin’ things off . . . in gradual steps I started to be able to work my
way through problems and being able to prioritise.
19 – CBT 14 sessions, not depressed
Therapy helped participants recognise triggers for low mood and understand the consequences of their
response to triggers. Some described being able to choose different behavioural responses, control their
feelings with actions and think differently about triggers, and these changes could reduce the power
of depression. Therapy helped participants learn to set realistic, achievable goals and use behaviour to
improve their mood, as well as encouraging them to reengage with positive activities and act when feeling
low, helping to break the cycle of low mood:
When people are depressed I know it’s a circle, you don’t do anything, so you feel terrible, and then
you don’t do anything . . . this therapy forced me, pushed me to act, to do something. This is the first
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time that I’ve actually experienced that somebody tell me ‘Well let’s start doing this and you will feel
better’ and it happened.
24 – BA 8 sessions, not depressed
Both therapies encouraged participants to recognise the effect of rumination (i.e. repetitive unproductive
thinking, especially about the experience of depression) and, for many, allowed them to manage and
reduce time spent ruminating, which could improve mood and make life feel easier:
I care about people, my family and friends, now. As I say I didn’t before, I didn’t want to go anywhere,
didn’t want to see anyone, I just wanted to be left alone. And that’s the ruminating time; she got me
off that and I feel better for it.
23 – BA 17 sessions, depressed
Cognitive change
Cognitive change was discussed by some participants in both therapies, but was referred to more
frequently by those who received CBT. This included having more self-belief, blaming themselves less
when things go wrong and reduced beliefs of worthlessness:
It’s given me a different way of looking at things and I suppose that’s the way of believing in things,
I have more belief in myself, that has helped a lot.
12 – CBT 23 sessions, not depressed
Participants in both therapies reported a more positive style of thinking, the ability to replace negative
thoughts with positive thoughts and changing thoughts before entering a negative spiral. Other changes
included a reduced tendency to overthink or ruminate, fewer self-critical thoughts and more balanced
thinking. Some participants, particularly those who received CBT, described a sense of increased resilience,
such as the ability to reason when things go wrong and taking things less personally:
I used to be a bit like a bull in a china shop if I was upset I would take it all very personally but now
I’m more open minded . . . I think you don’t take everything so personally, makes me think more
rather than going to it head-long without thinking.
5 – CBT 24 sessions, depressed
Talking versus doing
This subtheme describes two typologies observed across both treatments, either prioritising opportunities
to talk or using therapeutic strategies to bring about change. For several participants, having someone to
talk to who was unbiased, non-judgemental and emotionally unconnected was the most important part of
therapy, and problems from the week could be ‘saved up’ to discuss with the therapist:
Irrespective of what therapy it was, I think just the opportunity for an hour a week to talk about how
you’re feeling was in some way therapeutic, irrespective of the specific techniques of the BA.
9 – BA 9 sessions, depressed
In contrast, for many the ‘doing’ side of therapy was critical and the specific strategies of BA and CBT
were considered helpful. The therapist was there not just to listen but to offer suggestions, and therapy
was perceived to encourage participants to be proactive, finding a way to help themselves:
I think a lot of people need more input than just listening and what I liked about it is that they make
very definite suggestions . . . you’d look for evidence and look at what is happening and then make
goals to try and work towards.
28 – CBT 10 sessions, not depressed
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Impact of therapy
Participants’ views about the impact of therapy could be understood in terms of three subthemes: impact
for self, impact for others and impact on the future.
Impact for self
In both therapies participants described no longer feeling depressed, enjoying life more and feeling like
their old self again, and for some these improvements were longer lasting than they had experienced with
other therapies:
Now I don’t feel so full of despair as I used to be. Sort of, oh it’s like taming the beast, really . . . it’s
given me the tools to get through day-to-day life and be more aware of moods and what effect they
have on me and how to change that mood.
12 – CBT 23 sessions, not depressed
Other participants described themselves as happier, as a result of therapy, or feeling they have a different
relationship with depression, leading to a feeling of acceptance. Several participants described therapy as
having enhanced the way they feel about themselves, including increased feelings of self-compassion and
improved self-esteem. Participants discussed positive influences of treatment leading to healthier lifestyles
such as cooking better meals, exercising or seeking help for other problems such as pain or disability.
Treatment was believed by some to have enabled them to get jobs, return to work after a period of being
signed off, or perform better at work. For some, therapy enabled them to reduce or stop their ADM, and
this could have further perceived benefits such as improved clarity of mind. Even those still meeting
diagnostic criteria for depression could perceive a wide-reaching impact of therapy:
I would just say thank you very much for all the help you’ve given me and it’s made an impact on my
life that I never would have thought. I thought I was on my own, but evidently I’m not.
23 – BA 17 sessions, depressed
Impact for others
Participants in both treatments discussed ways in which therapy influenced those around them. Many
perceived therapy to have helped their relationships and others described being more sociable or behaving
more kindly towards others:
We talk, which has never happened before. We talk for like, hours. And we don’t need to watch the
telly or listen to music or anything . . . so I’m more interested in what’s going on than the one-eyed
god. The television!
23 – BA 17 sessions, depressed
Impact on the future
Many participants described therapy as providing them with a ‘toolkit’ to take away, teaching them skills
that have enabled them to deal with life more effectively. For some these skills were becoming automatic
as they continued to put them into practice. Relapse prevention work was important, helping participants
learn to recognise the signs of depression and knowing how and when to ask for help. Having paper
copies of therapeutic tools to take away was considered helpful and many participants revisit these when
they feel low:
I think that this will probably be something I’ll do for the rest of my life, ‘cos I’m sure that for the rest
of my life I’ll have the ups and downs like everyone else does, but this will stop me going back to
those dark places.
11 – CBT 13 sessions, depressed
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Results of therapist qualitative interviews
Six CBT therapists and seven BA MHWs were interviewed in November and December 2015. Interviews
lasted between 25 and 59 minutes (mean 40 minutes). Therapist demographics are provided in Table 24.
Data are presented under three overarching themes: the therapeutic model, confidence in delivery and the
patients. Quotes are presented to support the analysis and are labelled by interview ID number, therapy
delivered and recruitment site.
The therapeutic model
This theme illustrates therapists’ views on the model of therapy that was delivered, including particular
elements of therapy that were considered beneficial and their experiences of using the treatment manuals
that they were trained to follow.
Elements of therapy
Mental health workers confirmed that, as intended, BA was an uncomplicated, logical and simple therapy
that they believed made sense to patients, allowing them to make quick gains and encouraging a good
therapeutic relationship. The majority of CBT therapists did not discuss the relative simplicity or complexity of
therapy, but the one that did expressed a view that CBT is a complicated therapy that is difficult to deliver:
I think the fact that the behavioural activation model was quite simplified, it wasn’t too complicated
for people, so that helped with the therapeutic relationship as well. Yeah, it’s an easy therapy to
explain to patients.
T10 – BA, Durham
Many therapists, particularly those delivering BA, described working longer term with patients in the
COBRA trial protocol than they would in usual practice, and this was seen as beneficial both for therapist
and patient, and allowed for a better therapeutic relationship:
It was really good to get the chance to work with people over a much longer period and get to know
them better . . . you form more of a relationship with them than you do when you’re working with
people for a shorter period of time, like six sessions.
T12 – BA, Leeds
TABLE 24 Demographics of therapists and MHWs who completed qualitative interview
Therapist characteristic Number of interviews (n= 13)
Recruitment site
Devon 5
Durham 3
Leeds 5
Therapy delivered
BA 7
CBT 6
Gender
Male 3
Female 10
Mean years since first qualified
BA 3.0
CBT 12.4
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Therapists in both treatments placed high value on relapse prevention. BA MHWs felt that it was useful for
patients to reflect on what they had learnt and have a plan to recognise and respond to signs of depression
in the future. Some BA MHWs commented that relapse prevention is not given a lot of attention in their
usual practice in IAPT, and this was considered an important addition. Likewise, CBT therapists believed
relapse prevention to be a core component of treatment that helped patients understand the changes made
and encouraged them to continue implementing them. Therapists expressed a view that the aim of CBT is
for patients to become their own therapist, and providing them with tools to take forward was important in
helping them achieve this:
One of the aims of CBT is for people to become their own therapist . . . it gives people a bit of
confidence and sense of hope for the future that there’s stuff within their power and control that they
can do to make changes.
T08 – CBT, Devon
For BA MHWs, another component of treatment considered particularly helpful, both for themselves and
for patients, was rumination. MHWs believed that rumination is a key problem in depression, and it was
therefore a frequently used technique that was considered to be applicable to many patients. It was noted
that rumination was not taught when they trained as IAPT PWPs and that it was a helpful addition to their
knowledge base, and something they continue to use in their clinical practice now:
Rumination, particularly, I think was quite helpful and very rarely is that used in standard step 2
practice, so I think that would be a really useful addition.
T07 – BA, Devon
Treatment manuals
Both BA MHWs and CBT therapists described the treatment manuals and patient worksheets as good,
well structured, clear and concise. CBT therapists commented that it was helpful to have a manual to
follow that could be taken off the shelf and used, providing useful and well-needed updates to the
CBT model:
The COBRA manual itself was really kind of clear and concise and helpful as well . . . whereas Beck’s
original book on depression, it’s very old, it really does need a bit of updating.
T02 – CBT, Devon
Therapists in both treatments described using the manuals flexibly, adapting therapy to meet individual
needs. For the BA MHWs, there was a focus on using the optional modules in the manual to achieve this,
whereas CBT therapists described a more core therapeutic skill of providing therapy using their own
experience to gauge where to take each patient.
Despite recognising the ability of therapy to be adapted for individual needs, some therapists felt restricted
by the treatment manuals and confused about how and when they could diverge from it. BA MHWs, in
particular, expressed frustration at being unable to address negative thoughts and felt that some patients
would have benefited from cognitive work. There was also anxiety about stepping outside the BA model
and avoiding ‘therapeutic drift’ towards CBT:
We all had quite a lot of anxiety around following the protocol and making sure we didn’t step
outside that and ‘Oh god don’t mention thoughts when you’re doing BA!’
T13 – BA, Durham
There was a view that the treatment manuals are not appropriate for everyone, and therapists could
experience difficulty in treating patients whom they considered to have more complex problems, such as
comorbid anxiety, personality disorders or a history of abuse, without working outside the treatment
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manual. This could be particularly challenging when therapists felt that, in usual practice, a patient would
have been referred to secondary care or more specialist services:
It impacted on the ability to follow the COBRA-specific protocol because it didn’t feel appropriate if
someone’s main thing was anxiety to keep plugging a depression model, so to keep a therapeutic
alliance going it was kind of necessary to focus on the anxiety.
T08 – CBT, Devon
Some patients were considered to struggle with the overall approach and structure of BA and CBT, and
therapists also recognised that both therapies can be demanding of patients, particularly with regards to
the requirement for homework:
Getting people to analyse what they’re doing and getting people not just do more but start to look at
activities and behaviours they can start to change. And I guess that’s asking quite a lot of people,
especially people on the severe end of depression.
T06 – BA, Leeds
Confidence in delivery
A common theme discussed by many therapists was how confident they felt in delivering COBRA trial
therapy. This included discussion on things that were seen to challenge their confidence, as well as
remarks about how confidence changed or improved, and the specific role of training and supervision in
helping to build confidence.
Challenges to confidence
There was a clear distinction in the way BA and CBT therapists talked about how COBRA trial treatment
compared with their usual practice. BA MHWs talked extensively about COBRA trial therapy as a new,
different way of working, which could be challenging and overwhelming for them, especially in the
beginning. BA was considered a big jump from their previous work and required learning lots of new skills
and techniques:
It was quite overwhelming in some respects, I think I went into it thinking that there wouldn’t be that
much difference to what I was already doing, but actually once I did the training I realised that there
was quite a big difference.
T13 – BA, Durham
A particular area in which BA MHWs lacked confidence was in making the transition from their prior role
in guided self-help in which they considered themselves to be a ‘coach’ for patients, to becoming more
collaborative in their relationship:
How you make that transition from just doing the kind of coaching style of PWP to this more
therapeutic, collaborative, I mean it’s still collaborative at PWP but it’s a bit more in depth in the BA
that we were doing, it was expected to be anyway.
T12 – BA, Leeds
For CBT therapists, however, COBRA trial treatment was considered familiar, and matched what they do in
their day-to-day clinical work:
It was familiar for any cognitive therapist that’s kind of like bread and butter really, the Beck model.
T02 – CBT, Devon
Other areas where therapists lacked confidence included working with patients with chronic conditions,
and a CBT therapist who considered herself to be more of a behavioural worker struggled to work
more cognitively.
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Improving confidence
Therapists in both treatments felt that they had learned a lot from their involvement in the COBRA trial. BA
MHWs described learning new skills and techniques, with particular references to formulation, rumination
and functional analysis. They described feeling more capable of delivering behavioural therapy and
continuing to use it now as an alternative to cognitive work. For those therapists who struggled with
confidence initially, this was considered to have improved over time and with good-quality training
and supervision:
We had really good supervision, so I think the training was really good to set you up for what was to
be expected and then once you got into it I think my confidence just started to build a lot more with
the actual techniques.
T13 – BA, Durham
Cognitive–behavioural therapy therapists, on the other hand, talked about the trial as an opportunity to
consolidate old knowledge, build on previous learning and ‘sharpen up’ their skills. Some described feeling
more confident in delivering cognitive therapy for depression now, as well as greater confidence in specific
areas such as doing better behavioural experiments, dealing with difficult patients or improved flexibility as
a therapist:
I’ve got more confidence now in being truly Socratic and curious and flexible in my approach, rather
than just chugging along with things . . . it got me to really make sure that I’m connecting with people.
T09 – CBT, Leeds
Role of training and supervision
Training and supervision was discussed extensively by therapists in both treatments. Training was described
as great, helpful and comprehensive, but was also hard work. For CBT therapists the training week was
seen as a ‘good refresher’, whereas for those delivering BA the training taught them lots of new skills.
Having a week of in-depth training on one therapy was considered a positive experience by both BA and
CBT therapists:
I learned a lot from the training and just things like learning about rumination, functional equivalence,
functional analysis, things like that that I hadn’t learned about from the PWP course . . . having the
chance to do a week in-depth about a particular treatment was really useful.
T04 – BA, Leeds
The training week, however, was also considered to be intense and overwhelming, particularly for those
delivering BA. One BA MHW thought the training week would have benefited from more attention to core
therapeutic skills such as collaborative working, which were considered to be a new way of working for them:
It was meant to be like proper therapy that’s very collaborative and we spend a lot more time doing all
that Socratic questioning, trying to get people to get the answer themselves and it’s a different skill
. . . maybe could have done more on that side of things in the training.
T12 – BA, Leeds
Supervision was described by therapists in both treatments as helpful, supportive and of high quality.
Therapists described the supervisors as knowledgeable ‘experts’ and this was considered to be an
invaluable experience which helped to build confidence:
Supervision from experts in the field as well . . . I’ve learned invaluable experience, I’ve sort of changed
me as a practitioner as well.
T10 – BA, Durham
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The quality of supervision was very good and so for me as a clinician that was very helpful I think, I
certainly came out of the trial having felt a lot more confident and that still stays with me in providing
CBT for depression.
T05 – CBT, Leeds
Having group supervision with other therapists was described as a beneficial process that allowed
therapists to learn from each other. Taking audio-recordings of therapy sessions to supervision was a
difficult experience for those in both treatments, but was also recognised as a useful practice from which a
lot could be learnt:
In supervision, where our recordings are played out amongst the group of supervisees . . . I did find
that difficult . . . but again, you can see how you can work through those things and I learned a
hell of a lot in the supervision sessions because of that, and then it was great actually, I loved it in
the end.
T01 – BA, Devon
The patients
This theme includes discussion of the patients treated in the trial, including how these patients compared
with those they would see in usual practice, perceived cognitive and behavioural change for patients,
and the broader impact of therapy on patients’ lives.
Comparisons with usual practice
There were two distinct views about how COBRA trial patients compared with patients treated in usual
practice. Therapists located in Durham, whether delivering BA or CBT, did not consider COBRA trial
patients to be any different from those treated in usual practice; there was a range of complexity and
willingness to engage, which mirrors usual practice:
At step 2 we see more complex people, I don’t think for me there was any change with the COBRA
people as such. Because some of them were mild to moderate but some of them were more complex.
T13 – BA, Durham
Therapists in Exeter and Leeds, on the other hand, tended to describe COBRA trial patients as having
more complex difficulties and being more difficult interpersonally than patients seen in usual practice.
No therapists described COBRA trial patients as being less complex than usual:
They were definitely more complex in terms of their history . . . some of them were quite different,
I think, to what I’d usually be working with.
T09 – CBT, Leeds
Cognitive and behavioural change
Behavioural change was discussed extensively by therapists in both treatments. Therapy was believed to
have led to significant changes in behaviour, and behavioural work was considered an important part of
both BA and CBT. A common theme was that patients had increased their contact with pleasurable
activities and re-engaged with the things they value:
You could actually see when they were talking about it how – oh, you know, it was just lovely to feel
the water over her skin . . . some patients were very descriptive in explaining that positive reinforcing
feeling of going back to an activity that they thought maybe they’d never try again.
T01 – BA, Devon
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Cognitive–behavioural therapy therapists described many cognitive changes resulting from treatment,
including overall changes to thinking style, less negative thinking and no longer predicting the worst to
happen. Therapists described changes to patients’ beliefs about themselves such as reduced feelings of
worthlessness, as well as changes to beliefs about others such as believing the world is not out to get
them. There were two distinct views from CBT therapists about the role of cognitive change. Some
believed this to be a big turning point for many patients, leading to improvements in overall quality of life,
and that behavioural change came as a result of cognitive change. The other view, however, was that
cognitive work was less important than behavioural work, and one therapist felt it was hard to
differentiate cognitive and behavioural change:
The whole treatment is about that really, it’s trying to get people to change the way they think and
get out of the kind of depressive thinking styles and then by doing that, that usually makes people
more active and less avoidant.
T08 – CBT, Devon
Cognitive change was discussed much less frequently by BA MHWs than by those delivering CBT. For those
who did discuss it, a common idea was that cognitive change came as a result of behavioural change:
When people start getting back to doing things that mean something to them and enjoying life, their
cognitions naturally change . . . not always straight away, there was often a bit of a cognitive lag but it
would catch up.
T06 – BA, Leeds
Patient outcomes
Therapists in both treatments considered therapy to have helped patients in broad and varied domains of
life. Both BA and CBT were believed to have helped improve many patients’ mood and other symptoms
of depression, including motivation, concentration, energy, sleep and feelings about themselves.
Many therapists felt that therapy had helped improve patients’ health and well-being. There was recognition
that depression can have consequences for physical health, and a belief that BA and CBT could have a
positive influence in this. Other improvements included patients taking better care of themselves, valuing
themselves more and improvements to their overall appearance:
Some people reported feeling physically unwell as well as mentally unwell, and you could see a
change in that, people’s energy levels and things.
T06 – BA, Leeds
Both therapies were considered to have helped patients sleep, with behavioural work believed to be
particularly important for this. Other improvements included eating better, exercising more and reduced
alcohol consumption. Therapists in both treatments described improvements to patients’ home and family
lives as a result of therapy, as well as improved relationships with others:
People’s home lives often, you know, depression can take its toll on everybody, so people often
reported that things were better at home.
T06 – BA, Leeds
A common theme across both BA and CBT was increased social contact and reduced social avoidance as a
result of therapy. Increased social contact was believed to have had a range of positive effects on patients
including improving confidence and, for those in CBT, reinforcing positive beliefs about themselves:
For a lot of my patients who I saw they were all – they’ve all been sociable people, they’re all from
large families, they’ve enjoyed that and for whatever reason, they’ve lost it. And I think socialising
reinforced to them that you are likeable, you do have a lot to contribute.
T11 – CBT, Durham
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Therapists in both treatments also considered therapy to have helped patients at work, including getting
back to work after a period of being signed off, getting a new job or being more productive at work:
One lady who struggled to get out of the door, over the doorstep, she actually, last year rang me to
give her a reference to do some voluntary work . . . and that even now, it makes me feel really – ‘cos
it was just fantastic! It’s life changing, isn’t it?
T11 – CBT, Durham
The results of the participant and therapist qualitative interviews will be discussed and interpreted in
Chapter 5.
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Chapter 5 Discussion and conclusions
This chapter uses material from an Open Access article previously published by the research team(see Richards et al.2). © The Author(s).2 Published by Elsevier Ltd. This is an Open Access article under the
CC BY license.
Summary of findings
We found that BA for depression is not inferior to CBT in terms of reduction of depression symptoms and is
cost-effective compared with CBT against commonly applied decision-maker willingness-to-pay thresholds.
We observed our results using both ITT and PP analyses, using a conservative non-inferiority margin. Our
economic outcomes were driven by the lower costs of the MHWs who delivered BA, compared with the
more experienced psychological therapists who routinely deliver CBT. Our study results, therefore,
substantiate the hypothesis that BA is as effective as CBT and that its simplicity renders BA suitable for
delivery by junior MHWs with no professional training in psychological therapies.19
Our process data found that, despite being challenging at times, BA and CBT were acceptable and feasible
for participants, MHWs and therapists, and effected changes in people’s specific symptoms and in their
lives more broadly. Despite experiencing initial difficulties that could be detected by some participants,
with sufficient training, experience and supervision, junior MHWs could feel confident in delivering BA
effectively. We found weak evidence for an interaction between treatment and baseline PHQ-9 score on
PHQ-9 at 12 and 18 months’ follow-up, indicating that BA may be a better choice of treatment for
patients with higher baseline PHQ-9 scores.
Summary of clinical outcomes
Both BA and CBT improved overall depression in the ITT and PP populations. At our primary end point of
12 months post randomisation, the mean PHQ-9 scores were 7.8 points (SD 6.5 points) in the BA group and
7.9 points (SD 7.3 points) in the CBT group, both below the commonly applied PHQ-9 threshold of 10 points
associated with a diagnosis of MDD. At baseline, the mean PHQ-9 score for the BA group was 17.7 points
(SD 4.8 points) and for the CBT group 17.4 points (SD 4.8 points), both groups being within the moderately
severe depression range (15–20 points). Our results demonstrate the unequivocal non-inferiority of BA
compared with CBT in both ITT and PP populations, as the between-group mean difference and 95% CIs lie
firmly within our a priori non-inferiority margin of –1.9 PHQ-9 points (ITT mean difference: 0.1 PHQ-9 points,
95% CI –1.3 to 1.5 PHQ-9 points; p = 0.89; PP mean difference: 0.0 PHQ-9 points, 95% CI –1.5 to 1.6
PHQ-9 points; p = 0.99). Our results were robust to sensitivity analyses exploring the effect of different PP
definitions, predefined subgroups and missing data.
In order to assist with clinical interpretation, we have also presented data that show there were no
differences between groups in the proportions of participants responding to treatment or recovering from
depression at 12 months post randomisation in either the ITT or PP analyses. In the PP population, 69–70%
of trial participants were rated as recovered (PHQ-9 ≤ 9 points) and 64–66% as having responded to
treatment (≥ 50% reduction in PHQ-9 score from baseline). The equivalent figures for the ITT population
were 66% and 61–62%. These outcomes were maintained at 18 months’ follow-up. We observed very
similar patterns for all of our secondary outcomes, including anxiety (as measured via the GAD-7
questionnaire) and health-related quality of life (as measured via the SF-36 questionnaire). We could not,
therefore, detect any differential treatment effect on any clinical outcomes between BA and CBT as
treatment for depression.
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Summary of economic outcomes
We found that resource use and resultant costs were similar for both BA and CBT groups at our primary
economic end point of 18 months. The only significant difference between groups was in mean
intervention costs between the two groups. There were no significant differences in other categories of
cost or in overall total cost. Although health-related quality of life was slightly higher in the BA group than
in the CBT group across the entire follow-up period, with resultant QALYs also higher for BA, the QALY
difference was not significant. Nonetheless, because observed costs were lower and QALY outcomes
better in the BA group than in the CBT group, this generated an ICER of –£6865, suggesting that BA
dominates CBT (i.e. BA is both cheaper and more effective). The probability of BA being cost-effective
compared with CBT does not fall < 75% and is closer to 80% at standard NICE willingness-to-pay
thresholds of £20,000–30,000 per QALY. Once again, these findings were robust to sensitivity analyses
using both broader and narrower cost perspectives and analysing the impact of missing data. Our findings
are therefore robust in suggesting that BA is cost-effective compared with CBT, driven principally by the
lower costs of employing junior MHWs to deliver this simpler treatment.
Summary of process evaluation
Our process analyses indicated a moderating effect (statistically significant interaction) of baseline PHQ-9
score on treatment effect, with regard to PHQ-9 at 12 and 18 months’ follow-up, although the evidence
for such an effect was weak in both cases. Our analysis further suggested that BA may be a better
choice of treatment for patients with higher baseline PHQ-9 scores. No significant differences were found
between the BA and CBT groups with regard to the process mediators, proportion of therapy sessions
attended and overall treatment fidelity, although basic treatment fidelity was found to be higher in the BA
group. The only statistically significant mediation effects were that overall treatment fidelity mediated the
effect of treatment (BA vs. CBT) on PHQ-9 at 12 months’ follow-up, with basic and overall treatment
fidelity mediating the effect of treatment on PHQ-9 at 18 months’ follow-up. However, these statistically
significant results were only seen in the models that included only one variable acting as a mediator
of treatment effect (as opposed to models that included several potential mediators). In terms of the
proportion of overall treatment effect mediated, basic treatment fidelity accounted for a high proportion
of treatment effect mediated at both the 12- and 18-month follow-ups.
In terms of qualitative data, BA and CBT were considered acceptable by patients, MHWs and therapists.
People liked the fact that the therapy offered them someone to talk to, gave them tools and techniques to
enable them to help themselves and was an opportunity for them to learn. This is consistent with previous
qualitative studies of change processes in cognitive therapy, which have found that patients value both
specific cognitive techniques (such as changing negative thoughts), as well as general psychotherapy
ingredients (such as a collaborative therapeutic relationship and the opportunity to learn).105–107 Participants
appreciated that therapy was long and regular and that they were not asked to spend a lot of time
focusing on the past, although some would have liked more time to talk about their feelings. Homework
was considered an important part of treatment for participants, allowing them to gain control of their
feelings, but it could also be challenging. This is consistent with previous research in which patients
receiving CBT for depression reported finding homework difficult for both emotional and practical reasons,
but that they understood its necessity in the therapeutic process.108 Therapists and MHWs, in particular,
appreciated working longer term with patients than in usual IAPT practice and believed this to be
beneficial both for themselves and for patients. Aspects of participants’ personal lives, such as work and
family, could make therapy challenging, and having other conditions like chronic pain or anxiety were
considered by some to be a barrier to treatment. Depression itself could also be a barrier, impacting on
participants’ ability to ‘do’ and making it hard to focus or understand therapy.
Clinically, in some cases, both MHWs and patients expressed the opinion that MHW practice could appear
to be somewhat rigid and that MHWs might lack confidence in their new BA role, although this had no
impact on our main finding of clinical non-inferiority of BA compared with CBT. Furthermore, the finding
that treatment fidelity mediated outcome suggests that adherence to the treatment protocol has more
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beneficial than deleterious effects. Nonetheless, strategies to boost both the appearance and actuality of
junior MHW practice will be considered later in this discussion.
Strengths and limitations
The COBRA trial is the largest trial of BA to date and is one of the largest trials of psychological treatments
for depression. We followed up participants for 18 months and our economic analysis is one of few in
this field. Therapists and MHWs working in three different routine UK care settings delivered treatment,
providing evidence of potential generalisability. We assessed therapy quality using independent raters and
ensured that treatment in both arms was delivered to the standard recommended in guidelines. Given the
nature of the intervention and comparator we could not mask patients or the MHWs or therapists who
were delivering the interventions to treatment allocation, but we used self-reported outcome measures
and robust outcome assessor-masking procedures to reduce researcher unmasking to < 5%.
At 21% and 14% for BA and CBT, respectively at 12 months, our levels of attrition and outcome loss to
follow-up were low at 12 and 18 months, similar to other trials in this area, but are still a limitation. Although
we found a between-group difference in attrition for the ITT analyses, this was not the case for the PP analyses,
suggesting that any differential attrition was an artefact of the trial and not of the treatments. Furthermore,
our between-group inferences were robust to data imputation. Although participants in the PP population
attended similar numbers of sessions to those in other CBT trials, 35% of participants overall chose to not
attend a minimal number of sessions, a problem well known to routine psychological therapies services.
This pragmatic trial carried out in routine environments means we were unable to quantify or control for
the contribution of ADM on outcomes. However, most participants who were taking medication had been
doing so for a considerable time before entering the trial, making it unlikely that our results were driven by
pharmacological treatment.
In terms of competency ratings, the ratings of our random sample of therapy tapes showed that both CBT
therapists and BA MHWs were, on average, performing above competency thresholds. In terms of CBT,
our mean sessional competency ratings (37.9) were very similar to the means reported in the CoBalT trial,55
another significant and large recent UK trial of CBT – 38.8, demonstrating that our therapists were
achieving competency levels consistent with other similar pragmatic effectiveness studies. However, on this
random sample of tapes some therapists were scoring below the threshold of competence for that specific
session as assessed by our external raters, although we would stress that all therapists had exceeded the
competence threshold at the end of their COBRA-specific protocol training course.
We note that our CBT therapists had received 1 year of postgraduate training in CBT, had passed similar
competency tests in order to qualify from these courses, had received an additional specialist training in
the COBRA protocol and were supervised by CBT experts. Most importantly, they were NHS employees
engaged in routine treatment for patients with depression in the UK NHS IAPT services; indeed they were
working for the NHS alongside their trial duties. Finally, the competency ratings from the CBT arm in our
trial are consistent with other research findings in the field.12,40 Therefore, although it may be possible to
train CBT therapists to achieve higher competency ratings, we suggest that these levels of competence
are those actually seen in routine clinical practice in IAPT services in the UK, results achieved following
substantial investment in therapists’ clinical training, and appear unrelated to clinical outcomes.
Furthermore, although the measures of competence for the BA MHWs and the CBT therapists are not
directly comparable, we note that the MHWs scored, on average, further above the competency threshold
than the CBT therapists on the relevant competency measure. This provides some, albeit weak and
indirect, supporting evidence for the proposition that it might be easier to train people to be competent
BA workers than CBT therapists, although this is moderated by the difficulties with the unknown
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psychometric properties of the BA competence measure in particular and we did not set out to test this
proposal directly.
The period between baseline and the 6-month follow-up was the period in which the main treatment
effect occurred; therefore, it is during this period that any mediation effect would be of greatest interest.
However, there may be difficulties in assessing the effect of potential mediators during this period because
of the variation in such mediators at the times when recorded during the first 6 months of treatment. Such
variation may be attributable to differences in the pace of therapy in terms of how quickly the patients
completed their sessions and engaged with the topics relevant to their therapy. At later stages of follow-up,
with regard to both the outcome and the mediator variables, it may be the case that the mediator variables
had become more stable and therefore better able to facilitate mediation analysis.
The wide variation among patients in their trajectories across time points within the follow-up period, with
regard to PHQ-9 and each mediator variable, may also be an impediment to distinguishing possible
mediation effects. However, little difference was noted between the CBT and BA groups in terms of the
mediating psychological variables, possibly indicating little practical difference in how participants
responded to the two forms of therapy. Owing to differences in the structure of therapy, the BA group
scored more highly for measures of treatment fidelity, although the proportion of sessions attended was
similar across the two treatment groups.
Considering differences in the pattern of mediation across outcome follow-up times, at the earlier follow-up
time of 6 months, the indirect effects of the mediators appeared to be accounting for only small proportions
of the total treatment effect. This may reflect lack of stability in the early phases of the trial, while many
participants were still undergoing therapy, with regard to both PHQ-9 and mediator scores.
In terms of moderators and mediators, COBRA was a large study that incorporated the collection of several
psychological variables that were potential mediators of treatment effect; these variables were collected at
several time points during the follow-up period of the trial. Also, the primary outcome, PHQ-9, was collected
at three time points (at 6, 12 and 18 months’ follow-up). The collection of data for several psychological
mediators at multiple time points has facilitated the comparison of how the two treatment groups
progressed over the study period, at the group level and at the individual participant level. However, the
large number of comparisons performed as a result of this brings about concerns regarding multiple testing
and the possibility of finding statistically significant results by chance. With regard to the mediation analyses,
only three statistically significant results were found when including a single mediator in each model, one
relating to PHQ-9 measured at the 12-month follow-up and two at the 18-month follow-up. These results
are consistent with the expectation of significant results occurring by chance. Therefore, these results should
be viewed with caution.
Similarly, of the 42 inferential tests for moderation across the ITT and PP populations, and the three follow-up
time points, none were found to be statistically significant at a p-value of < 0.05, although three moderation
analyses yielded a p-value of < 0.1. In view of the low power to detect interaction effects, and in view of the
number of tests performed, these possible interaction effects should also be viewed with caution.
The COBRA trial was the largest trial to date comparing CBT and BA and enabled an in-depth qualitative
analysis of patients’ and therapists’/MHWs’ experiences of these treatments alongside the clinical
effectiveness, cost-effectiveness and quantitative process analyses. To date, there have been very few
qualitative studies of this. Our purposive sampling method for our participant interviews ensured diversity in
our sample and we successfully interviewed participants from each recruitment site, both therapies, some
who completed the full course/ended treatment early and some who were still depressed/no longer
depressed, as well as both male and female participants across a range of ages. Similarly, we interviewed
therapists/MHWs from both treatments, from all three recruitment sites and with a range of backgrounds and
experience. However, the generalisability of our findings are limited to participants who were both eligible
and willing to participate in the COBRA trial, and participants who declined to take part in the qualitative
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study may also have had different views to those who agreed to be interviewed. Likewise, qualitative
interviews were only completed with 13 of the 22 therapists/MHWs involved in the trial, and those who did
not respond to the invitation to be interviewed may have had different experiences to those who did respond.
All interviews were carried out over the telephone as a result of the long-distance nature of cross-site
interviewing. This maintained researcher blindness for participant quantitative follow-ups and was crucial
for the integrity of the COBRA trial. Although some researchers have proposed that telephone interviewing
may be less effective than face to face,109 evidence suggests that telephone interviews yield the same
number and quality of data as those conducted face to face,110 and some argue that telephone interviewing
may even be preferable when participants are discussing sensitive topics.111 Finally, although we aimed to
interview participants as soon as possible after completion of therapy, in practice this was difficult because
of delays in obtaining information about therapy end dates, delays in the ability to recruit participants
quickly after this time point, and an overall difficulty recruiting participants who had fewer than eight
sessions of therapy, resulting in an extension of our qualitative recruitment period. A small number of
participants commented that at the time of their interview they found it difficult to remember specific
aspects of their treatment, and it is possible that participants who were interviewed soon after therapy
completion may have had different reflections on their experiences from those interviewed some time later.
We recruited participants from primary care, rather than specialist settings. Our results are, therefore,
applicable to the great majority of patients with depression in these settings. We excluded people who had
other major psychiatric diagnoses, people who are most likely to be found in specialist mental health
services. We did so because, notwithstanding their depression, people with diagnoses such as addictive
disorders, bipolar disorder or psychosis require specialist treatment for these disorders as their primary
psychiatric input. We excluded people with these conditions on the understanding that psychological
treatment for their depression would not be the first line of treatment offered. Therefore, for this
population, our results may not be generalisable.
Implications for health care
Our findings could have substantial implications for the scalability of psychological treatment for depression
in the UK and internationally,17 given the greater availability and ease with which a BA workforce could be
trained than could a CBT workforce. For many years, CBT has been the foremost psychological therapy
recommended by therapists, researchers and policy-makers. Our results challenge this dominance. Although
more work needs to be done than has been undertaken so far to find ways to effectively treat the 20–30%
of participants whose depression was unchanged by BA or CBT, our findings suggest that BA should be a
front-line treatment for depression, with significant potential to improve reach and access to psychological
therapy globally.
Our results in both groups compare favourably with a meta-analysis112 of the effects of CBT compared with
second-generation ADM. This analysis found no difference between ADM and CBT on rates of remission
between 12 and 16 weeks post randomisation (ADM, 40.7%; CBT, 47.9%; risk ratio 0.98, 95% CI 0.73
to 1.32). For comparison purposes, our ITT recovery rates (synonymous with remission in the meta-analysis)
at 18 months post randomisation were 66% for BA and 59% for CBT. Equally, in the meta-analysis
referred to above, response rates were 44.2% for ADM and 45.5% for CBT (risk ratio 0.91, 95% CI 0.77
to 1.07); for comparison, 61% of our participants receiving BA and 60% of those receiving CBT had
responded at 18 months. Thus, the proportion of participants in both treatment arms who experienced
long-term positive clinical outcomes was higher in our study than in this recent meta-analysis.
Our cost-effectiveness analyses show the high probability that BA is cost-effective and affordable compared with
CBT at standard willingness-to-pay thresholds. Our most striking finding is that BA leads to comparable clinical
outcomes for patients with depression, but at a financial saving to clinical providers of 21% compared with the
cost of provision of CBT, with no compensatory use of other health-care services by patients.
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Driving these savings is the fact that BA can be delivered by inexperienced MHWs with no professional training
in psychological therapies, with no lesser effect than that of more highly trained and experienced psychological
therapists giving patients CBT. Although training of MHWs is only one of many obstacles to successful
dissemination, our findings suggest that health services globally could reduce the need for costly professional
training and infrastructure, reduce waiting times and increase access to psychological therapies.17 Our findings
have substantial implications given the increasing global pressure for cost containment across health systems in
high-income countries, and the need to develop accessible, scalable interventions in low- and medium-income
countries. Such countries might choose to investigate the training and employment of junior workers over
expensive groups of psychological professionals. Our results, therefore, offer hope to many societies, cultures
and communities worldwide, rich and poor, struggling with the effect of depression on the health of their
people and economies.
The results of the moderation analysis did not provide any strong evidence for differential treatment effect
across subgroups of participants, although there was some weak evidence for a stronger beneficial effect
of BA among participants who were more severely depressed at baseline. This finding is consistent with a
previous study,40 and may indicate that, clinically, BA would be the preferred choice of therapy for more
severely depressed patients.
The mediation analyses indicated that the quality of therapy, with regard to coverage of core topics, is the
strongest mediator of treatment effect. Hence, this may provide guidance to therapists that they should
concentrate on including the core topics within their therapy sessions. The mediation effects of the
psychological mediators appear to be weaker than those of the mediators related to therapy fidelity, and
clear findings with regard to the mediation effects of the psychological mediators were not observed.
Our qualitative findings suggest that, despite BA being non-inferior to CBT in terms of clinical outcomes,
junior MHWs delivering BA could feel somewhat overwhelmed by the new skills they were learning and felt
an initial lack of confidence in their ability to deliver therapy effectively. This lack of confidence was unique to
BA, and was able to be detected by some patients. This is unsurprising given the new role that these workers
were being asked to undertake, unlike CBT therapists, who had already been trained and were experienced
in delivering CBT. BA delivered by therapeutically naive junior MHWs, therefore, requires good-quality
training, time for therapists to build confidence through practice and ongoing supervision from experienced
BA practitioners. Indeed, therapists/MHWs in both groups described training and supervision positively, and
the model of support provided in the COBRA trial appears to be effective and well regarded by those
delivering therapy. In particular, having a week of in-depth training, group supervision with peers and playing
out of audio-clips from therapy during supervision were elements of the COBRA trial support model that
were regarded as helpful, and should be considered for future implementation of BA and CBT for depression.
For CBT therapists, the COBRA trial treatment manual was generally considered to have been useful,
although there was also anxiety about the lack of flexibility permitted. When training therapists to follow
a therapeutic manual such as those used in the COBRA trial, therapists should not be too flexible in
their clinical practice at the expense of overall treatment fidelity, since our quantitative process analysis
demonstrated that fidelity predicts clinical outcomes. In addition, as outcomes for CBT in the COBRA trial
were superior to those seen in IAPT services,113 where therapists are not trained to follow a particular
depression treatment manual, consideration should be given to whether or not it would be beneficial to
routinely use such a treatment manual in IAPT.
Relapse prevention was an element of both treatments that was valued highly by therapists/MHWs and
patients. This is important because research has shown that, even when patients make significant clinical
improvements during therapy, they expect themselves to remain susceptible to depression and continue
to implement techniques learnt in therapy as a way of managing what they consider to be a chronic
condition.114 Previous work has also suggested that the long-term effects of CBT are attributable to patients
learning skills that they can continue to implement after therapy has ended.115,116 Relapse prevention is
therefore a crucial component of both therapy protocols, which should continue to be implemented.
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Implications for future research
Despite the encouraging nature of both our overall treatment outcomes and the cost-effectiveness and
non-inferiority of BA compared with CBT, there remain three issues that should be priorities for research.
The first is how to engage the considerable number of people with depression who either do not start, or
rapidly drop out of, psychological treatment. Neither treatment in our trial performed better than the other
in terms of this engagement and retention. Multiple contextual, specific and common therapeutic factors
may contribute to the hypothesis that some patients find psychological therapy either generically undesirable,
impractical or specifically inappropriate to their needs. It is unlikely that there is one simple solution – for
example, psychological treatments with a different theoretical orientation – that will overcome these diverse
factors impeding patient engagement. Nonetheless, research into ways in which patients can be engaged
more fully could be considered.
Second, even for the PP population, around 30% of people did not experience a clinically relevant change
in their depression symptoms, whether they received BA or CBT. It remains a possibility that matching
patients to treatments by specific patient-level moderator variables, as has been hypothesised by some
researchers,117 would lead to better outcomes. Unfortunately, in terms of depression severity, although a
phenomenon previously observed,40 our study has only provided weak evidence to support the hypothesis
that BA has a stronger therapeutic effect for patients who are more severely depressed at the onset of
treatment. In terms of potentially enhancing the mediating effect of a range of psychological variables,
despite previous studies of CBT55 reporting the mediating effect of changes in dysfunctional attitudes
and metacognitive awareness, we were unable to demonstrate any substantial effect of psychological
mediators on outcome. We are unable to recommend, therefore, that therapists enhance their therapeutic
focus on these areas with any guarantee of improving outcomes for patients. Our only substantive finding
that fidelity to a clinical protocol mediates outcome in both BA and CBT merely emphasises the importance
for MHWs and therapists of following an evidence-based clinical treatment closely in their work. Much
more prospective research using precision medicine approaches such as the Personalised Advantage
Index117 to test the potential of matching treatments to individual patient characteristics seems to
be warranted.
Third, Kanter and Puspitasari118 have noted that, ‘now that we have support for BA as a treatment that is
clinically effective and cost-effective, we can shift our efforts to focus on what is necessary to produce
sustainable large-scale BA implementation across diverse geographical and cultural settings’.118 The central
rationale of BA, now supported by our COBRA trial results, is that it is also a simple treatment suitable for
widespread dissemination beyond high-income countries. Knowledge for the sustainable dissemination
and implementation of BA as an effective health technology to low- and medium-income countries
remains suboptimal. Although there have been a number of studies in low- and medium-income
countries, including India, Iran and Iraq,119–121 the outcome data are equivocal as these studies either do
not use an optimum clinical protocol tested in RCTs, are underpowered, incorporate BA as one part of a
multicomponent complex intervention, or focus on very tightly defined populations. Nonetheless, these
international studies do provide some evidence for the cross-cultural face validity of BA.118 We now need
to identify the low- and medium-income countries workforce best able and available to deliver this simple
treatment. We need to determine if the face validity of BA can go some way to overcoming mental health
stigma and people’s reluctance to engage in treatment in different cultures. We need to engage with
organisations and cultures unused to the concept of evidence-based mental health therapies. Finally, we
need to apply our scientific methods in low and middle income countries contexts, not least our health
economic methods, as these data will drive recommendations to implement BA widely or not.
In summary, future research should focus on strategies to improve the initial engagement of depressed
people with psychological therapies, should examine ways to personalise and optimise the allocation
of a range of evidence-based treatments, and should take an implementation science approach to
dissemination and reach outside the high-income countries in which BA in particular has been developed
and tested.
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Appendix 2 Individual participant Patient Health
Questionnaire-9, Behavioural Activation for
Depression Scale, Dysfunctional Attitudes Scale,
Ruminative Response Scale and Snaith–Hamilton
Pleasure Scale scores
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FIGURE 18 Individual participant PHQ-9 scores at baseline (0 months) and at 6, 12 and 18 months’ follow-up for
each treatment group for the mediation population. (a) CBT and (b) BA. (continued )
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FIGURE 18 Individual participant PHQ-9 scores at baseline (0 months) and at 6, 12 and 18 months’ follow-up for
each treatment group for the mediation population. (a) CBT and (b) BA.
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FIGURE 19 Individual participant BADS total scores at baseline, PM1, PM2 and 6 months’ follow-up for each
treatment group for the mediation population. (a) CBT and (b) BA.
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FIGURE 20 Individual participant DAS scores at baseline, PM1, PM2 and 6 months’ follow-up for each treatment
group for the mediation population. (a) CBT and (b) BA.
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FIGURE 21 Individual participant RRS total scores at baseline, PM1, PM2 and 6 months’ follow-up for each
treatment group for the mediation population. (a) CBT and (b) BA.
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FIGURE 22 Individual participant SHAPS scores at baseline, 6 and 12 months’ follow-up for each treatment group
for the mediation population. (a) CBT and (b) BA.
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Appendix 3 Ethics documents
Dear Patient 
 
COBRA (Cost and Outcome of BehaviouRal Activation):  
A Randomised Controlled Trial of Behavioural Activation versus Cognitive 
Behavioural Therapy 
 
 
At this surgery we have decided to take part in a research study being co-ordinated 
at SITE DETAILS which may be of interest to you.  A new trial is taking place for 
depression comparing two psychological treatments for depression – Behavioural 
Activation and Cognitive Behavioural Therapy, both explained in the leaflet that 
comes with this letter.  Please take the time to read this and consider if participating 
in this research would be right for you. 
 
As stated in the information sheet, if you are interested in participating in the study 
please complete the “Permission for Researcher to Contact” form and send it 
freepost to the address given. If you have any questions, or are interested in finding 
out more about the study please ring the research team on the number listed.  
 
In the next week or so you may receive a call from the surgery to check that you 
have received this letter and to ask if you are interested.  To help the surgery please 
let the practice know if your telephone number has changed. 
 
If you are certain that you do NOT want to take part in the research you may return 
the slip at the bottom of this letter to the surgery and you will not be contacted again. 
 
Thank you for taking the time to read this letter. 
 
Yours sincerely 
 
Surgery GP’s name 
 
 
---------------------------------------------------------------------------------------------- 
I DO NOT want to take part in this study and DO NOT want a follow-up call 
 
Name: 
 
Signature: 
 
Please return to GP SURGERY ADMINISTRATOR NAME, at  
SURGERY NAME 
(COBRA: (Cost and Outcome of BehaviouRal Activation)  
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COBRA (Cost and Outcome of BehaviouRal Activation): 
A Randomised Controlled Trial of Behavioural Activation (BA) versus Cognitive Behaviour 
Therapy (CBT) 
 
Introduction: 
We are carrying out a trial that looks at two types of psychological therapy used in the 
treatment of depression. We are writing to you because your GP surgery has agreed to 
help us with this by sending information to you after you visited your GP reporting 
symptoms that are experienced by many people with depression.  
 
This letter asks you to consider taking part in the research study and for your permission 
for the researcher to contact you. 
 
What is the treatment that is being tested?  
This study is investigating the effects of two psychological therapies for depression. We 
are interested in whether a relatively simple treatment called ‘Behavioural Activation’ (BA) 
is as effective as ‘Cognitive Behavioural Therapy’ (CBT), which is widely used in the UK. 
Although both treatments are known to be helpful for people with depression we need to 
test to see if BA can be used instead of CBT for some people. We will also be comparing 
how much each treatment costs.  
What will happen to me if I take part?  
We are asking people from a number of different GP surgeries in this area if they would 
like to take part. If you decide you would like to do this, a researcher will interview you to 
see if you are eligible for the study and to explain it in more detail. If you are eligible and 
agree to take part you will receive one of the treatments. Both treatments involve a 
maximum of 20 appointments with a trained therapist over a four month period with 
possibly four more booster sessions later. Once you have been allocated to one of the 
treatments you will also be seen again for follow-up appointments with a researcher at six 
months, 12 months and finally at 18 months to complete a number of questionnaires.  
 
This study is a randomised controlled trial which means that once you have been 
interviewed by a researcher and have decided you would like to take part, the decision 
about which treatment you receive is made totally by chance. Therefore, half of our 
participants will be treated by Behavioural Activation and half by Cognitive Behaviour 
Therapy. What we then do is compare the progress and experiences of patients who 
received each of the two treatments.  
 
Will my taking part in this study be kept confidential?  
All information collected about you during the course of the research will be kept strictly 
confidential.  
 
How do I find out more?  
This is a very short summary about the study, if you would like to find out more you can 
return the ‘Permission for Researcher to Contact’ form at the end of this summary, or call 
the COBRA trial team on local site number. Someone working on the study will then 
contact you with more information about this study and arrange a time to meet you to 
answer any questions that you may have.  
 
Thank you for reading this and for considering taking part in this study
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‘Permission for Researcher to Contact’ Form 
Study Title: COBRA (Cost and Outcome of BehaviouRal Activation): 
A Randomised Controlled Trial of Behavioural Activation versus Cognitive Behaviour 
Therapy 
 
Patient’s GP Surgery name:  
 
I confirm that I have read and understand the summary sheet for the above study 
and I am happy for a researcher to contact me to discuss whether or not I would like 
to take part.  
I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being 
affected.  
 
Name........................................................................................ 
(Please print name)  
 
Address...................................................................................  
 
................................................................................................. 
 
................................................................................................ 
 
Signature..................................................................  
 
Telephone contact details:  
 
Day.................................................................  
 
Evening........................................................... 
 
Mobile...............................................................  
 
Email address................................................................................  
 
Return in enclosed pre-paid envelope to:  
 
Local Site Details 
 
Telephone No:  
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COBRA (Cost and Outcome of BehaviouRal Activation) – A Randomised Controlled Trial of 
Behavioural Activation versus Cognitive Behaviour Therapy 
CONSENT FORM 
 
Please see that the consent form is in two parts, you do not have to sign both parts: 
 
Part 1 on Page 1: 
This is the main consent for your general participation in the study and if you agree to taking part.  
 
Part 2 on Page 2 is optional; you can choose if you wish to take part.  
This is about whether you would agree to being audio/video recorded and being interviewed about 
your experiences of taking part in the study. It also includes a similar section about data collection.    
 
PART 1: MAIN STUDY CONSENT FORM 
 
Site Details: 
 
Please 
initial 
box 
 
1.  I confirm that I have read and understand the information sheet dated 21st May 
2012 (Version 4.0) for the above study and have had the opportunity to ask 
questions. 
 
 
2.  I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected. 
 
 
3.  I agree to my GP being informed of my participation in this study and updated 
with information from this study relevant to my medical care. 
 
 
4.  I understand that relevant sections of my medical notes and data collected during 
the study may be looked at by individuals, from regulatory authorities or from the 
NHS Trust, where it is relevant to my taking part in the research. I give permission 
for these individuals to have access to my records. 
 
 
5. I understand that data already collected as part of the research study can be 
retained for up to 20 years, even if I decide to withdraw from the study and that it will 
only be used for this study.  
 
 
6.  I agree to take part in the above study.  
When you have initialled the boxes above, please complete below including the date yourself. 
 
 
 
 
    
Name of Participant (BLOCK CAPITALS)  Date  Signature 
 
I have explained the study to the above patient and he/she has indicated his/her willingness to take part in the 
study. 
 
 
    
Name of Researcher (BLOCK CAPITALS)  Date  Signature 
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COBRA (Cost and Outcome of BehaviouRal Activation) – A Randomised Controlled Trial of 
Behavioural Activation versus Cognitive Behaviour Therapy 
 
PART 2: OPTIONAL CONSENT FORM 
 
Part 2: This section is optional; you can choose if you wish to take part or not and it will not 
affect your participation in the main part of the study.  
This consent form is about whether you would agree to: 
• Being audio/video recorded? 
• Being interviewed about your experiences of taking part in the study? 
• The data from one or both of the above in the optional consent being 
retained? 
• Non-identifiable data being shared for the purposes of health research only 
Please only initial the boxes that you wish to consent to, thank you. 
 
Site Details 
 Please only 
initial the 
boxes that 
apply 
 
1. I am willing to have some of my sessions with the health worker audio or 
video tape recorded and reviewed by experts in the UK and the US for 
research purposes only. 
 
 
 
2. I am willing to be interviewed about my experiences of taking part in the 
study and for this interview to be audio or video recorded for research 
purposes only. 
 
 
 
3. I agree to the data collected for this additional part of the above study 
being retained for up to 20 years, even if I decide to withdraw from the 
study and that it will only be used for this study.  
 
 
4. I agree to my data from this study being shared with other health 
researchers after my personal identifying information has been removed. I 
understand that it will only be used towards improving health outcomes by 
assessing the types of treatment that I have agreed to participate in for the 
main study. 
 
 
 
5. I agree to this additional part of the above study and consent only for the 
sections where I have clearly initialled in the boxes. 
 
 
 
     
Name of Participant (BLOCK CAPITALS)  Date  Signature 
 
I have explained the additional part of study to the above patient and he/she has indicated which parts apply. 
 
 
    
Name of Researcher (BLOCK CAPITALS)  Date  Signature 
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Appendix 4 Baseline case report form
Cost and Outcome of BehaviouRal Activation:  
 
A Randomised Controlled Trial of Behavioural Activation 
versus Cognitive Behaviour Therapy for Depression 
 
 
 
BASELINE CASE REPORT FORM 
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Details of this structured interview can be accessed at www.scid4.org/index.html.
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PHQ-9 
Over the last 2 weeks, how often have you 
been bothered by any of the following 
problems? 
(Use  to indicate your answer) 
 
Not  
at all 
 
Several 
days 
More 
than half 
the days 
 
Nearly 
every 
day 
       Little interest or pleasure in doing things  
0 
  
1 
 
2 
 
3 
       Feeling down, depressed, or hopeless  
0 
  
1 
 
2 
 
3 
Trouble falling or staying asleep, or sleeping too 
much 
 
0 
  
1 
 
2 
 
3 
       Feeling tired or having little energy  
0 
  
1 
 
2 
 
3 
       Poor appetite or overeating  
0 
  
1 
 
2 
 
3 
Feeling bad about yourself — or that you are a   
failure or have let yourself or your family down 
 
0 
  
1 
 
2 
 
3 
       Trouble concentrating on things, such as 
reading the newspaper or watching television 
 
0 
  
1 
 
2 
 
3 
       Moving or speaking so slowly that other people 
could have noticed?  Or the opposite — being 
so  fidgety or restless that you have been 
moving around a lot more than usual 
 
0 
  
1 
 
2 
 
3 
       Thoughts that you would be better off dead or 
of hurting yourself in some way 
 
0 
  
1 
 
2 
 
3 
(For office coding: Total Score _____  =  Add columns  ___     +     ___    +      ___   ) 
 
If you checked off any problems, how difficult have these problems made it for you to do 
your work, take care of things at home, or get along with other people? 
From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD PHQ). The PHQ was developed by Drs. Robert L. Spitzer, 
Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display  
or distribute. 
  
Not difficult  
at all 
Somewhat 
 difficult 
Very 
difficult 
Extremely 
difficult  
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GAD-7 
 
(For office coding: Total Score _____  =  Add columns  ___     +     ___    +      ___ ) 
 
If you checked off any problems, how difficult have these problems made it for you to do 
your work, take care of things at home, or get along with other people? 
The GAD-7 was developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, with an educational grant from Pfizer Inc. No permission required 
to reproduce, translate, display or distribute.  
 
 
Over the last 2 weeks, how often have you 
been bothered by the following problems? 
(Use  to indicate your answer) 
 
Not  
at all 
 
Several 
days 
More 
than half 
the days 
 
Nearly 
every 
day 
Feeling nervous, anxious or on edge  
0 
  
1 
 
2 
 
3 
Not being able to stop or control worrying  
0 
  
1 
 
2 
 
3 
Worrying too much about different things  
0 
  
1 
 
2 
 
3 
Trouble relaxing  
0 
  
1 
 
2 
 
3 
Being so restless that it is hard to sit still  
0 
  
1 
 
2 
 
3 
Becoming easily annoyed or irritable  
0 
  
1 
 
2 
 
3 
Feeling afraid as if something awful might 
happen 
 
0 
  
1 
 
2 
 
3 
Not difficult  
at all 
Somewhat 
 difficult 
Very 
difficult 
Extremely 
difficult  
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EQ-5D 
Details of this measure can be accessed at https://euroqol.org.
DOI: 10.3310/hta21460 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 46
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115
HEALTH STATUS QUESTIONNAIRE (SF-36v2) 
 
Details of this measure can be accessed at https://campaign.optum.com/content/optum/en/optum-outcomes/
what-we-do/health-surveys/sf-36v2-health-survey.html.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
 
 
DOI: 10.3310/hta21460 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 46
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
 
  
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
  
 
 
DOI: 10.3310/hta21460 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 46
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
Section A: Hospital Services 
 
A1 – Have you had a hospital admission (if baseline) in the last six months / (if follow-up) since you were last 
interviewed approximately [X] months ago? 
 
1 Yes Go to A2 
0 No Go to A3 
666 Research worker unable to evaluate Go to A3 
999 Not completed  Go to A3 
 
A2 – If yes, record details below 
 
Hospital 
code 
Speciality 
code Details if hospital=other and/or speciality=other Number of nights 
    
    
    
    
 
A3 – Have you been to hospital for an outpatient/day patient appointment (if baseline) in the last six months / 
(if follow-up) since you were last interviewed approximately [X] months ago? 
 
1 Yes Go to A4 
0 No Go to A5 
666 Research worker unable to evaluate Go to A5 
999 Not completed  Go to A5 
 
A4 - If yes, record details below 
 
Hospital 
code 
Speciality 
code Details if hospital=other and/or speciality=other 
Number of 
appointments 
    
    
    
    
 
A5 – Have you attended an accident and emergency (A&E) department (if baseline) in the last six months / (if 
follow-up) since you were last interviewed approximately [X] months ago? 
 
1 Yes Go to A6 
0 No Go to B1 
666 Research worker unable to evaluate Go to B1 
999 Not completed  Go to B1 
 
A6 - If yes, record details below 
 
Hospital 
code Details Admitted Ambulance 
Number of 
contacts 
  Yes/no Yes/no  
  Yes/no Yes/no  
  Yes/no Yes/no  
  Yes/no Yes/no  
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D8 – About how many HOURS altogether did you work in the past 4 weeks (28 days)? See examples for calculating 
hours worked below 
 
1 Hours Number of hours 
666 Research worker unable to evaluate  
999 Not completed  
 
 
D9 – On a scale from 0 to 10 where 0 is the worst job performance anyone could have at your job and 10 is the 
performance of a top worker, how would you rate the usual performance of most workers in a job similar to yours? 
Place a  in the circle below the number that best describes this. 
 
Worst performance      Top performance 
0 1 2 3 4 5 6 7 8 9 10 
           
 
 
D10 – Using the same 0-to-10 scale, how would you rate your usual job performance over the past year or two? Place 
a  in the circle below the number that best describes this. 
 
Worst performance      Top performance 
0 1 2 3 4 5 6 7 8 9 10 
           
 
 
D11 – Using the same 0-to-10 scale, how would you rate your overall job performance on the days you worked during 
the past 4 weeks (28 days)? Place a  in the circle below the number that best describes this. 
 
Worst performance      Top performance 
0 1 2 3 4 5 6 7 8 9 10 
           
 
 
Examples for Calculating Hours Worked in the Past 4 weeks 
40 hours per week for 4 weeks = 160 hours 
35 hours per week for 4 weeks = 140 hours 
40 hours per week for 4 weeks with 2 8-hour days missed = 144 hours 
40 hours per week for 4 weeks with 3 4-hour partial days missed = 148 hours 
35 hours per week for 4 weeks with 2 8-hour days missed and 3 4-hour partial days missed = 112 hours 
Employment and time off work section taken from the WHO Health Productivity Questionnaire (HPQ), questions B5-B11. 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
End of interview.  
 
 
 
 
 
 
AD-SUS designed by Sarah Byford at the Institute of Psychiatry 
For further information please contact: 
Centre for the Economics of Mental Health 
XXXX  
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Code missing data as follows: 
 
555 Not applicable 
666 Research worker unable to evaluate 
999 Not completed  
 
 
Hospital speciality codes for sections A2 and A4 
 
1 Mental health 22 Infectious Diseases  
2 Asthma clinic 23 Maxillo-Facial Surgery 
3 Audiological Medicine  24 Nephrology  
4 Blood Transfusion  25 Neurology  
5 Cardiac Surgery  26 Neurosurgery  
6 Cardiology 27 Obstetrics 
7 Clinical Haematology 28 Occupational Therapy 
8 Colorectal Surgery  29 Oncology  
9 Dental Medicine  30 Ophthalmology  
10 Dermatology  31 Oral Surgery 
11 Diabetic Medicine 32 Orthopaedics 
12 Dietetics  33 Pain Management  
13 Endocrinology  34 Physiotherapy  
14 ENT  35 Plastic Surgery  
15 Family Planning Clinic   36 Podiatry  
16 Gastroenterology 37 Rheumatology  
17 General Medicine  38 Sleep Studies  
18 General Surgery  39 Speech therapy 
19 Genito-Urinary Medicine  40 Thoracic Medicine/Surgery  
20 Gynaecology  41 Urology  
21 Hepatology  42 Other – please give details 
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Hospital codes for sections A2, A4 and A6 
 
Hospital codes for sections A2, A4 and A6 contd. 
 
 Devon  Durham 
1 Bovey Tracey Hospital 19 Bensham Hospital 
2 Budleigh Salterton Hospital 20 Bishop Auckland Hospital 
3 Crediton Hospital 21 BMI Woodlands Hospital 
4 Exmouth Hospital 22 Cherry Knowle Hospital 
5 Heavitree Hospital 23 Chester Le Street Hospital 
6 Honiton Hospital 24 Cobalt NHS Treatment Centre 
7 Moretonhampstead Hospital 25 Darlington Memorial Hospital 
8 Nuffield Health, Exeter Hospital 26 Dunston Hill Hospital 
9 Ottery St Mary Hospital 27 Freeman Hospital 
10 Paignton Hospital 28 Great North Children’s Hospital 
11 Royal Devon and Exeter Hospital 29 Hundens Lane Day Hospital 
12 Seaton Hospital 30 North Tyneside General Hospital 
13 Sidmouth Hospital 31 Northern centre for cancer 
14 Tiverton and District Hospital 32 Nuffield Health, Newcastle-upon-Tyne 
15 Torbay Hospital 33 Nuffield Health, Tees Hospital 
16 Victoria Hospital 34 Palmer Community Hospital 
17 Whipton Hospital 35 Peterlee Community Hospital 
18 Other Devon (please specify) 36 Primrose Hill Hospital 
  37 Priory Hospital Middleton St George 
  38 Prudhoe Hospital Site 
  39 Queen Elizabeth Hospital 
  40 Ryhope General Hospital 
  41 Sedgefield Community Hospital 
  42 Shotley Bridge Hospital 
  43 Sir G B Hunter Memorial Hospital 
  44 South Tyneside District Hospital 
  45 Spire Washington Hospital 
  46 St Nicholas Hospital (Newcastle Upon Tyne) 
  47 Sunderland Royal Hospital 
  48 The Royal Victoria Infirmary 
  49 Tyneside Surgical Services  
  50 University Hospital of Durham 
  51 University Hospital Of Hartlepool 
  52 University Hospital Of North Durham 
  53 University Hospital Of North Tees 
  54 Weardale Hospital 
  55 West Lane Hospital 
  56 West Park Hospital 
  57 Other Durham (please specify) 
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Hospital codes for section A2, A4 and A6 (contd) 
 
 Leeds 77 The Mount Hospital, Leeds 
58 Airedale General Hospital 78 Mount Vernon Hospital, Barnsley 
59 Barnsley Hospital 79 Nuffield Health, Leeds Hospital 
60 BMI The Duchy Hospital 80 Pinderfields Hospital 
61 BMI The Huddersfield Hospital 81 Pontefract Hospital 
62 Bradford Royal Infirmary 82 Seacroft Hospital 
63 Calderdale Royal Hospital 83 Shipley Hospital 
64 Castleford and Normanton District Hospital 84 Spire Elland Hospital 
65 Chapel Allerton Hospital 85 Spire Leeds Hospital 
66 Clayton Hospital 86 Spire Longlands Consulting Rooms 
67 Dewsbury and District Hospital 87 Spire Methley Park Hospital 
68 Eccleshill Community Hospital 88 St James's Hospital 
69 Harrogate District Hospital 89 St Lukes Hospital 
70 Huddersfield Medical Services HQ 90 St Mary’s Hospital 
71 Huddersfield Royal Infirmary 91 The New Selby War Memorial Hospital 
72 Keresforth Centre 92 The Yorkshire Clinic 
73 Lascelles Younger Disabled Unit 93 Westbourne Green Community Hospital 
74 Leeds General Infirmary 94 Westwood Park Diagnostic Treatment Centre 
75 Leeds Road Community Hospital 95 Wharfedale Hospital 
76 Lynfield Mount Hospital 96 Other Leeds (please specify) 
    
   Other 
  97 Other unknown (please specify) 
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Medication codes for section C 
 
Name  
 Antidepressants  Antipsychotics (cont'd) 
1 Agomelatine/valdoxan 41 Benperidol/Anquil 
2 Amitriptyline/Triptafen 42 Chlorpromazine hydrochloride/Largactil 
3 Amoxapine/Asendis 43 Clozapine/Clozaril/Denzapine/Zaponex 
4 Citalopram/Cipramil 44 Flupentixol/Depixol/Fluanxol 
5 Clomipramine 45 Haloperidol/Dozic/Haldol/Serenace 
6 Dosulepin/Dothiepin/Prothiaden 46 Levomepromazine/Nozinan 
7 Doxepin/Sinequan/Sinepin 47 Olanzapine/Zyprexa 
8 Duloxetine/Cymbalta/Yentreve 48 Paliperidone/Invega 
9 Escitalopram/Cipralex 49 Pericyazine 
10 Fluoxetine/Prozac 50 Perphenazine/Fentazin 
11 Flupentixol/Fluanxol/Depixol 51 Pimozide/Orap 
12 Fluvoxamine/Faverin 52 Prochlorperazine 
13 Imipramine/Tofranil/Triptafen 53 Promazine 
14 Isocarboxazid 54 Qeutiapine/Seroquel 
15 Lofepramine/Gamanil/Feprapax/Lomont 55 Resperidone/Risperdal 
16 Maprotiline/Ludiomil 56 Sulpiride/Dolmatil/Sulpol 
17 Mianserin 57 Trifluoperazine/Stelazine 
18 Mirtazepine/Zispin 58 Zuclopenthixol acetate/Clopixol acuphase 
19 Moclobemide/Manerix 59 Zuclopenthixol/Clopixol 
20 Nortriptyline/Allegron/Motival 60 Other antipsychotic (please specify) 
21 Paroxetine/Seroxat  Sleeping tablets/medication for anxiety 
22 Phenelzine/Nardil 61 Alprazolam 
23 Reboxetine/Edronax 62 Buspirone/Buspar 
24 Sertraline/Lustral 63 Chloral hydrate/welldorm 
25 Tranylcypromine 64 Chlorazepate/Tranxene 
26 Trazodone/Molipaxin 65 Chlordiazepoxide 
27 Trimipramine/Surmontil 66 Clomethiazole/Heminevrin 
28 Tryptophan/optimax 67 Diazepam 
29 Venlafaxine 68 Flurazepam/Dalmane 
30 Venlafaxine XR 69 Loprazolam 
31 Other antidepressant (please specify) 70 Lorazepam 
 Mood stabilizers 71 Lormetazepam 
32 Carbamazepine/Tegretol 72 Meprobamate 
33 Lamotrigine/Lamictal 73 Nitrazepam 
34 Lithium carbonate/Comcolit, Liskonum 74 Oxazepam 
35 Lithium citrate/Li-Liquid, Priadel 75 Temazepam 
36 Valproate/Depakote, Convulex 76 Triclofos sodium 
37 Other mood stabilizer (please specify) 77 Zaleplon/Sonata 
 Antipsychotics 78 Zolpidem/Stilnoct 
38 Aripiprazole/Abilify 79 Zopiclone/Zimovane 
39 Amisulpride/Solian 80 Other sleeping tablet/medication for anxiety (please specify) 
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Units 
 
1 Milligrams (mg) 6 Inhalers 
2 Microgram (mcg) 7 Bottles 
3 Grams (g) 8 Packs 
4 Millilitres (ml) 9 Other – give details 
5 Tubs/tubes   
 
Frequency 
 
1 Once daily 7 As needed, about three times a week 
2 Twice daily 8 As needed, about twice a week 
3 Three times daily 9 As needed, about once a week 
4 Four times daily 10 As needed, about once a fortnight 
5 Once weekly 11 As needed, about once a month 
6 Once per fortnight 12 Other – give details 
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Details of this measure can be accessed at http://repository.upenn.edu/cgi/viewcontent.cgi?
article=2994&context=edissertations.
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Appendix 5 Risk and adverse event documents
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In emergencies, if no answer call 999)
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Appendix 6 Participant results newsletter
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Appendix 7 Behavioural activation clinical
practice manual
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This manual contains all the necessary information you will need in order to initiate 
and undertake Behavioural Activation (BA) treatment programmes with patients in 
the COBRA trial.  
Section 1 has some information about the COBRA trial itself. Section 2 outlines 
some general principles of session timing, duration, frequency and safety. Sections 3 
and 4 describe the two treatments being tested in the COBRA trial – BA and 
Cognitive Behavioural Therapy (CBT) in very broad terms.  
Sections 5 and 6 will give you a very good summary of what a course of BA 
treatment in the COBRA will look like, describing the phasic nature of the COBRA 
protocol and a summary of the content of each phase. Section 6, in particular, gives 
a schematic overview of a COBRA BA treatment programme. 
Section 7 then goes on to describe the core BA techniques – self-monitoring, 
functional analysis and activity scheduling. It also briefly describes some of the 
Phase II modular specific techniques you will be using. 
Section 8 then goes on to detail the structure of clinical sessions at all stages of a BA 
treatment programme. You should follow these structures very closely as your 
adherence to the overall structure, sessional structure and specific therapeutic 
content will be critical in ensuring fidelity to the clinical protocol COBRA is testing. 
Section 9 consists of a series of helpful ‘therapist notes’ on each of the principle 
techniques you will be asked to employ. Think of these as aide memoires. They will 
help you refresh your memory when it comes to employing these techniques. 
Section 10 lists some of the key scientific references underpinning the COBRA trial. 
This is followed by Appendices A-L, consisting of the therapeutic tools such as 
diaries you will need to use throughout any treatment programme.  
Please consult this manual frequently. Bring it with you to supervision and use it to 
help you become confident and competent at delivering the COBRA BA clinical 
protocol. If you would like to personalise it, please do, and if you have any 
suggestions for additional materials, the trial team will be happy to listen. 
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Clinical depression is one of the most common and debilitating of the psychiatric 
disorders. It accounts for the greatest burden of disease among all mental health 
problems, and is expected to become the second-highest amongst all general health 
problems by 2020.  
 
COBRA is a Randomised Controlled Clinical Trial of two psychological interventions 
– Behavioural Activation (BA) and Cognitive Behaviour Therapy (CBT) – to establish 
if there are important clinical and cost differences between them. In detail, the 
COBRA programme of research seeks to answer two interlinked questions: 
1. What is the clinical effectiveness of BA compared to CBT for depressed adults in 
terms of depression treatment response measured by the PHQ9 at 12 and 18 
months? 
2. What is the cost-effectiveness of BA compared to CBT at 18 months? 
 
In addition, we will undertake a secondary process evaluation to investigate the 
moderating, mediating and procedural factors in BA and CBT which influence 
outcome. 
 
BA and CBT are both active psychological treatments which have previously 
demonstrated positive effects for people with depression, and are recommended by 
NICE guidelines for the treatment of depression. Half the participants in the COBRA 
trial will receive BA and half CBT, allocated on a random basis.  
 
Participants will be assessed for eligibility by a COBRA researcher using a structured 
clinical interview. If eligible, they will be asked to complete a number of 
questionnaires with the researcher. They will then be randomly allocated to one of 
the treatments by the Peninsula Clinical Trials Unit in Plymouth using a process 
concealed from the research team ensure the team are blind to allocation. 
Participants will also be seen again for follow-up appointments with a researcher at 
six months, 12 months and finally at 18 months to complete a number of 
questionnaires. The research study will last for four years, but each participant’s 
involvement in the study will be for eighteen months. 
 
The study will be taking place in three sites; Devon Durham and Leeds with the lead 
centre being the University of Exeter’s Mood Disorders Centre. COBRA will begin in 
March 2012, the first participant will start treatment in September 2012 and the study 
will end in April 2016. Participants will be recruited from August 2012 until April 2014.  
 
The trial is funded by a UK National Institute for Health Research (NIHR) Health 
Technology Assessment Programme Clinical Evaluation and Trials grant. 
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 Frequency and duration of appointments 
Participants will receive a maximum of 20 sessions over 16 weeks with the option of 
four additional booster sessions.  
 
Sessions will be face to face, of one-hour duration maximum. 
 
Therapists and participants have the option of having sessions up to twice weekly 
over the first two months of the trial and weekly thereafter.  
 
The final few sessions may be spaced out further if clinically appropriate. 
 
 Risk assessment and management 
Risk will be assessed at every appointment. At the first appointment a full risk 
assessment will include enquiry on suicide, self-harm, neglect of self, neglect of 
others, harm to others and harm from others. Risk will be assessed in terms of 
thoughts, plans, actions taken in support of any plans, and preventative factors. At 
subsequent appointments risk will be reviewed against the assessment conducted in 
the first appointment to assess any change in the patient’s risk status.  
Where any factors are detected which leads the therapist or mental health worker to 
believe that there is a danger that the patient will harm themselves or others through 
action or neglect, a risk management plan will be initiated. This plan will follow the 
principles of the Mood Disorders Centre’s policy on risk and any specific actions 
taken will be determined by the specific policies in place at the NHS clinical provider 
site. All risks identified and any actions taken will be documented and discussed in 
supervision and with the COBRA trial manager, site lead and chief investigator. 
 
 Collecting routine outcome measures 
Over recent years, it has become standard practice for therapists and mental health 
workers to ask patients to complete short clinical outcome scales at every clinical 
encounter. Measures are used to assist both parties track progress, identify setbacks 
and provide data for individual patient progress and overall service evaluation. In 
COBRA, we use the same procedure at every session. Measures are collected from 
the patient during the early part of the appointment and discussed briefly before 
moving onto the main session content. Occasionally measures may lead to a change 
in the session agenda. Measures are always discussed in supervision. 
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Behavioural Activation (BA) is a psychological treatment alleviating depression by 
focusing directly on changing behaviour based on behavioural theory. This theory 
states that depression is maintained by avoidance of normal activities. As people 
withdraw and disrupt their basic routines, they become isolated from positive 
reinforcement opportunities in their environment. They then end up stuck in a cycle 
of depressed mood, decreased activity and avoidance. BA systematically disrupts 
this cycle, initiating action in the presence of negative mood, when people’s natural 
tendency is to withdraw or avoid. BA targets avoidance from a contextual, functional 
approach not found in CBT – i.e., BA focuses on understanding the function of 
behaviour and replacing it accordingly. BA also explicitly prioritises the treatment of 
negatively reinforced avoidance and rumination.  
 
The overall goal of BA is to re-engage participants with stable and diverse sources of 
positive reinforcement from their environment and to develop depression 
management strategies for future use. BA sessions consist of a structured 
programme increasing contact with potentially antidepressant environmental 
reinforcers through scheduling and reducing the frequency of negatively reinforced 
avoidant behaviours. Treatment is based on a shared formulation drawn from the 
behavioural model in the early stages of treatment, thereafter developed with the 
patient throughout their sessions. Specific BA techniques include the use of a 
functional analytical approach to develop a shared understanding with patients of 
behaviours that interfere with meaningful, goal-oriented behaviours and include self-
monitoring, identifying ‘depressed behaviours’, developing alternative goal orientated 
behaviours and scheduling. In addition the role of avoidance and rumination will be 
addressed through functional analysis and alternative response development. 
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The overall goal of CBT is to alter the symptomatic expression of depression and 
reduce risk for subsequent episodes by correcting the negative beliefs, maladaptive 
information processing and behavioural patterns presumed to underlie the 
depression Sessions consist of a structured, partially didactic programme. Treatment 
begins with patients learning the model, behavioural change techniques, and moves 
on to to identifying and modidfying negative automatic thoughts, maladaptive beliefs 
and underlying core beliefs. In later sessions, learning is translated to anticipating 
and practicing the management of stressors that could provoke relapse in the future. 
Specific CBT techniques include scheduling activity and mastery behaviours, the use 
of thought records and modifying maladaptive beliefs. The behavioural elements in 
CBT focus on increasing activity together with practical behavioural experiments to 
test specific cognitive beliefs. CBT does not take the contextual, functional approach 
of BA, nor does CBT explicitly prioritise the targeting of avoidance and rumination.  
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a. Phase I 
Phase I represents the introduction and application of the core BA methods. The first 
session is an assessment where the worker gathers information on the patient’s 
presenting problem and describes the BA model. Phase I then moves on to 
undertake the core activities associated with successful BA – establishing the link 
between mood and behaviour, developing functional analysis, linking this to the 
patient-specific BA formulation, and setting and reviewing activity scheduling 
exercises. The phase ends with several sessions using the TRAP/TRAC method for 
introducing alternative behaviours. 
b. Phase II 
Phase II consists of a series of mandatory and optional therapeutic ‘modules’ which 
are undertaken as a tailored response to the patent’s presenting problems. The 
TRAP/TRAC method is used to anchor modular activities throughout, but specific 
activities are also undertaken dependent on the module being applied. Mandatory 
modules are on rumination and problem solving. Optional modules include sessions 
on functional equivalence incorporating values, anxiety, punishment, communication 
and alcohol/substance use. 
c. Phase III 
Phase III is focussed on planning to maintain progress and reduce relapse potential. 
In this phase worker and patient acknowledge the necessity to manage the 
forthcoming ending of therapy and move on to self-planning without clinical 
assistance, identifying signposts for action (relapse triggers), reviewing progress on 
goals and valued activities so far, identifying action to meet remaining goals and 
valued activities, and identifying help-seeking triggers and action to be taken. The 
TRAP and TRAC method is used to plan further activity using specific modular 
techniques for increasing access to mood enhancing activities and reducing or 
replacing avoided behaviours. 
d. Booster phase 
These appointments are optional with a very flexible content. Worker and patient 
undertake a review of difficulties experienced and identify specific therapeutic 
techniques from the core Phase I stage or any modules in Phase II which may need 
refreshing, practice or further work. Relapse prevention activities may also be 
undertaken. 
e. Transition and review appointments 
These sessions are an opportunity for worker and patient to review progress, reflect 
on activities undertaken so far and move to the next Phase. The formulation is 
revisited, progress against goals and valued activities is checked, the therapeutic 
rationale is repeated, remaining activities are identified and a plan is developed for 
the next phase 
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a. Self-monitoring 
 
Self-monitoring is the recording of activities and emotions by patients. It is used to 
inform the content and direction of almost all other clinical techniques in BA. Self-
monitoring is one of the core building blocks upon which the whole BA treatment 
approach stands.  
 
Self-monitoring records provide an initial baseline against which change can be 
monitored during the course of treatment. The records then allow patient and 
therapist to monitor the progress of treatment and identify specific treatment targets. 
Records include details of activities engaged in and emotions experienced. Patients 
complete records frequently, at least daily and often hourly, mostly as ‘homework’. 
However, some patients can complete self-monitoring records during one-to-one 
treatment sessions, particularly in the early stages of treatment or when specific 
details are missing from homework records. 
 
Patients and therapists should always pay close attention to records. They can 
identify connections between behaviours and feelings, the overall pattern of feelings 
and activities, disruptions to routine, and patterns of avoidance. Gathering this 
information helps patients and therapists identify areas for change including the 
potential to increase positively reinforced activities and reduce negatively reinforced 
avoidance behaviours.  
 
Self-monitoring leads on to the other core techniques of activity scheduling and 
functional analysis covered in the next sections. 
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b. Functional analysis 
 
Functional analysis is the study of an individual patient’s pattern of behaviour and its 
variability. It is used to determine the contexts under which desired and undesired 
behaviours occur. The results of functional analysis guide interventions to 
systematically and therapeutically increase or reduce target behaviours.  
 
Functional analysis is a core behavioural approach to understand why certain 
behaviours occur more frequently and why others less so. A functional analysis will 
include information on ‘antecedents’, ‘behaviours’ and ‘consequences’. Antecedents 
are often known as ‘triggers’. In depression many environmental, personal or social 
triggers can act as cues for behaviours such as avoidance with the consequence 
that a person disengages with the world leading to increased depression. Therapists 
use functional analysis in BA to unpick this general pattern and understand its 
personal manifestation for individual patients.  
 
We use two acronyms in BA to illustrate the process of functional analysis: 
• ABC: Antecedents ⇒ Behaviour ⇒ Consequences 
• TRAP: Triggers, Response, Avoidance Pattern – where ‘Response’ refers to 
the emotional feelings experienced when the trigger occurs. 
 
Therapists and patients use functional analysis to find out detail about the conditions 
under which the trigger, target behaviour and consequence occur and under what 
conditions do they do not occur by asking questions about when, where and with 
who. Therapists also help patients understand the function of behaviour, particularly 
how patients respond to triggers and how their response might be maintaining 
negative feelings. 
 
Another acronym – TRAC: Triggers, Response, Alternative Coping – is used to help 
patients plan alternative behavioural responses to the trigger and emotional 
response. These might include recognising TRAPs, exerting environmental control 
by disrupting the trigger cues, and developing alternative responses through 
planning a TRAC. The method BA therapists use to help patients do this is to 
develop a formal a ‘contingency plan’. This is a strategy for the patient to use when 
the trigger, or the threat of the trigger, occurs. This is often known as an: ‘if-then’ 
plan. These contingency plans are developed in response to triggers that act as 
warning signs, together with the personalised functional analysis. 
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c. Activity scheduling 
 
Activity scheduling is the final core component of the three-legged stool that makes 
up BA. Self-monitoring provides knowledge of the patient’s individual behavioural 
context. Functional analysis provides information on the triggers and reinforcers for 
these behaviours. Activity scheduling is the reshaping of the patient’s behaviour 
towards behaviours that are less depressogenic.  
 
Activity scheduling is all about planning. We encourage the patient to plan activities 
in a purposeful way. Activities are selected that have a clear focus and are drawn 
from the insights of the functional analysis. Planned activities may include new 
‘functionally equivalent’ behaviours to replace activities that are no longer possible in 
a person’s changed life. Activities may be a return to old behaviours that have been 
dropped or avoided. Activity schedules may be explicitly about reducing current 
behaviours that are actually depressogenic. Some scheduled activities may be used 
to disrupt depressed thinking or behaviours in the face of known danger signs and 
triggers. 
 
The main message to give about activity scheduling is that it runs throughout the 
whole course of a BA programme. We do not rely on new, positively reinforcing 
behaviours appearing by chance. We plan them into a person’s life. Planned 
behaviours all have a clear rationale, are best if they represent the implementation of 
a person’s value set, and are often designed in an experimental way. Patient’s act as 
scientists in their own personal laboratory, investigating the impact of reducing 
negatively reinforced avoidance and increasing positively reinforced behaviour. What 
we expect is that if we understand the triggers and contingencies, once we schedule 
in the behaviours the reinforcement effects will take over and help shape the 
person’s behaviours in a more positive direction. 
 
Alongside self-monitoring record forms, activity scheduling records will be the most 
frequently used and discussed tools in the behavioural activationists armoury. 
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d. Introduction to Phase II modular techniques 
 
Rumination 
This module describes how the BA approach, and in particular, functional analysis, is 
used to treat rumination. Rumination is a covert mental process common in 
depression that can be approached therapeutically as behaviour, using antecedent, 
behaviour and consequence ideas to understand the function of rumination and 
identify alternative responses. Techniques for helping reduce rumination include 
disrupting cues, finding alternative responses when cues appear, and developing 
concrete thinking. 
 
Problem solving 
Although BA is underpinned by an overall problem-solving stance throughout 
treatment, therapists can also use problem solving as a discrete clinical technique. 
Problem solving is a step-wise programme of problem definition in concrete, 
behavioural terms, identification of potential solutions, implementation of at least one 
solution and evaluation of the results. Problems may be primary or secondary and 
avoidant coping or skills deficits may prevent the resolution of problems.  
 
Functional equivalence 
A functionally equivalent behaviour is one that ‘does the job’ of the original 
behaviour. Therapists help patients identify and substitute functionally equivalent 
behaviours throughout BA work, particularly when a patient is engaging in a 
behaviour that works well for them in some ways, but has some significant negative 
consequences, and when a patient would like to do more positively reinforced 
activities but cannot undertake some of the behaviours that s/he engaged in 
previously. This module describes the technique of functional equivalence in more 
detail and the selection of alternative, value-based, activities that patients find 
appealing, particularly in situations where they cannot undertake behaviours they 
previously engaged in. 
 
Anxiety 
Most patients with depression also experience significant symptoms of anxiety. As 
patients engage with their environment, anxiety is likely to be a problem that will 
require attention at some point. Although the goal of BA is to treat depression, using 
the same functional analytical approach can help with anxiety also. Therapists 
undertake functional analysis using TRAP and TRAC sheets to do this. We gather 
information about anxiety and apply the TRAP technique to consider its maintenance 
and the short and long-term consequence of associated avoidance. From here 
therapists and patients use TRAC to explore alternative behaviours that will help the 
patient undertake more activity. This in turn gives the patient positive reinforcement 
and encourages future ‘outside in’ behaviour to overcome anxiety.  
 
Punishment 
BA typically involves reintroducing behaviours that used to be reinforced when the 
person was not depressed or finding alternative behaviours that may serve the same 
function for a person. One difficulty that occurs in treatment is that sometimes when 
a person tries to reintroduce a behaviour that s/he once found easy or enjoyable, 
now the same activity is experienced as very difficult and unrewarding. These types 
of clinical situation can be understood in behavioural terms in that a behaviour that in 
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one context was rewarded is now in another context punished. As with any 
behaviour that is punished, the activity will reduce in frequency. This module 
provides some guidance on how to deal with this type of situation. 
 
Communication 
Interpersonal concerns, specifically communication difficulties, underlie many 
behavioural activation problems. Sometimes they are a TRAP/TRAC in their own 
right, at other times communication difficulties can be a barrier to achieving 
behavioural TRACs. This module focuses on finding communication strategies that 
work for individual patients in their own contexts, rather than teach overall 
interpersonal behaviours such as assertiveness. Communication TRACs are patient 
led –therapist work with patients so that they generate their own communication 
strategies and solutions.  
 
Alcohol & substance use 
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The following pages detail the structures of individual sessions to be conducted 
as part of the COBRA trial. There are separate pages for: assessment early, mid 
and late Phase 1 appointments; the transition and review appointment between 
phase 1 and II; phase II appointments; the transition and review appointment 
between phase II and the relapse prevention phase; the relapse prevention 
phase appointments; and the booster sessions.  
 
These session guides should be followed closely. They are the essential 
structure to the COBRA BA protocol. Individual sessions have different session 
specific content, the details of which are described in the ‘therapist notes’ section 
of this handbook. Please use the technique specific instructions to tailor sessions 
but start and finish sessions according to the session guides in the following 
pages. 
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1. Introductions and orientation 
 
2. Information gathering 
a. Main problem identification  
b. Autonomic, Behavioural and Cognitive symptoms 
c. Functional analysis including Triggers and Impact 
d. Risk assessment 
e. Sessional measures and feedback 
f. Past history, previous treatments and response, other current 
treatments, alcohol and drug use, co-morbidities 
 
3. Information giving  
a. BA rationale 
b. Treatment session, duration and content details, role of worker 
 
4. Shared decision making  
a. Diary introduction 
b. First steps 
 
5. Summarise and check out collaborative understanding of session 
 
6. Agree new activities 
 
7. Appointment planning 
 
8. Ending 
Clinical tools associated with this session: 
BA Assessment Worksheet (Appendix A) 
Self-Monitoring Record Form (Appendix D)  
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1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record forms 
 
5. Session specific therapeutic content 
a. Review BA rationale 
i. Introduce simple functional analysis: mood/behaviour link 
ii. Link to formulation diagram 
b. In session functional analysis ABC exercise  
c. Instruction on use of functional analysis ABC sheet between sessions 
remembering recency and recollection principle of completing sheets 
based on self-monitoring record 
d. Discuss and record goals 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
 
Clinical tools associated with these sessions: 
Formulation Diagram (Appendix B) 
Functional Analysis ABC Sheet (Appendix C) 
Self-Monitoring Record Form (Appendix D) 
Goals Sheet (Appendix E) 
Valued Activities Worksheet (Appendix F)  
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1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record form 
 
5. Session specific therapeutic content 
a. Review use of functional analysis ABC sheets on self-monitoring 
record  
b. Introduce principle of activity scheduling for increasing access to mood 
enhancing activities 
c. Introduce and complete an example activity planning tool 
d. Discuss goals in relation to activity scheduling 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
 
Clinical tools associated with these sessions: 
Functional Analysis ABC Sheet (Appendix C) 
Self-Monitoring Record Form (Appendix D) 
Goals Sheet (Appendix E) 
Activity Planning Tool (Appendix G)  
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1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record forms 
 
5. Session specific therapeutic content 
a. Review use of functional analysis ABC sheets on self-monitoring 
record  
b. Review use of activity planning tool 
c. Introduce TRAP/TRAC using example of negatively reinforced 
avoidance from self-monitoring record form 
d. Undertake further activity planning for increasing access to mood 
enhancing activities and TRAP to TRAC for avoided behaviours 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
 
Clinical tools associated with these sessions: 
Functional Analysis ABC Sheet (Appendix C) 
Self-Monitoring Record Form (Appendix D) 
Activity Planning Tool (Appendix G) 
TRAP & TRAC Worksheet (Appendix H)  
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1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record forms 
 
5. Session specific therapeutic content 
a. Revisit formulation 
b. Check progress against goals and valued activities 
c. Repeat rationales 
d. Identify remaining activities 
e. Develop overall plan for next phase 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
 
Clinical tools associated with this session: 
Formulation Diagram (Appendix B) 
Self-Monitoring Record Form (Appendix D) 
Goals Sheet (Appendix E) 
Valued Activities Worksheet (Appendix F) 
Activity Planning Tool (Appendix G)  
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1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record forms 
 
5. Session specific therapeutic content 
a. Review use of TRAP/TRAC and activity planning tools 
b. Introduce rationale for additional module 
i. Identification of specific issue to be addressed 
ii. Identification of personal examples of specific issue 
iii. Information giving about specific issue and module techniques 
c. Apply functional analysis 
d. Undertake specific modular exercises in session 
e. Plan further activity using specific modular techniques within functional 
analysis and TRAP to TRAC frameworks alongside continued activity 
planning for increasing access to mood enhancing activities and TRAP 
to TRAC for avoided behaviours 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
 
Clinical tools associated with these sessions: 
Functional Analysis ABC Sheet (Appendix C) 
Self-Monitoring Record Form (Appendix D) 
Activity Planning Tool (Appendix G) 
TRAP & TRAC Worksheet (Appendix H) 
And any additional clinical tools associated with chosen modules, e.g. Rumination 
Monitoring Form (Appendix I), Problem Solving Worksheet (Appendix J) or Anxiety 
Cycle Template (Appendix K).  
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1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record forms 
 
5. Session specific therapeutic content 
a. Revisit formulation 
b. Check progress against goals and valued activities 
c. Repeat rationales 
d. Identify remaining activities 
e. Develop overall plan for next phase 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
Clinical tools associated with this session: 
Self-Monitoring Record Form (Appendix D) 
Goals Sheet (Appendix E) 
Valued Activities Worksheet (Appendix F)
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
176
1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record forms 
 
5. Session specific therapeutic content 
a. Introduce concept of maintaining progress and/or reducing relapse 
potential 
b. Acknowledge necessity to manage forthcoming therapeutic ending 
c. Consider following topics: 
i. Moving to self-planning without clinical assistance 
ii. Identifying signpost for action (relapse triggers) 
iii. Review goal and valued activities progress so far 
iv. Identify action to meet remaining goals and valued activities 
v. Identify help-seeking triggers and action to be taken 
d. Plan further activity using specific modular techniques within functional 
analysis and TRAP to TRAC frameworks alongside continued activity 
planning for increasing access to mood enhancing activities and TRAP 
to TRAC for avoided behaviours 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
 
Clinical tools associated with these sessions: 
Functional Analysis ABC Sheet (Appendix C) 
Self-Monitoring Record Form (Appendix D) 
Goals Sheet (Appendix E) 
Valued Activities Worksheet (Appendix F) 
Activity Planning Tool (Appendix G) 
TRAP & TRAC Worksheet (Appendix H) 
Relapse Prevention Worksheet (Appendix L)  
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1. Setting the session agenda 
2. Sessional measures 
3. Risk review 
4. Review of self-monitoring record forms 
 
5. Session specific therapeutic content 
a. review of difficulties experienced  
b. identification of specific core or modular therapeutic techniques to 
revisit 
c. relapse prevention activities 
 
6. Summarise and check out collaborative understanding of session 
7. Agree new activities 
8. Manage any other business from agenda 
9. End by agreeing next appointment time and place 
 
Clinical tools associated with these sessions: 
Self-Monitoring Record Form (Appendix D) 
Relapse Prevention Worksheet (Appendix L) 
And any additional clinical tools associated with revisited modules. 
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 Introduction and general description of the module/technique 
Self-monitoring is the recording of activities and emotions by patients during the 
hours, days and weeks of treatment. Recording is usually done repeatedly during the 
day, using a specifically designed record sheet. 
Self-monitoring is so core to BA, it is initiated early on in the course of therapy and 
provides information throughout. Martell and colleagues (2001) identify the following 
eight key functions of self-monitoring, although this list is not exclusive: 
• Assess the patient’s overall level of activity 
• Provide information on the connections between mood and activity 
• Assess the range of emotions the patient experiences 
• Give information as to which activities are associated with feelings of mastery 
or pleasure 
• Assess the range of activities engaged in by the patient 
• Guide the selection of activities to increase, based upon their effects upon 
mood 
• Identify and monitor avoidance behaviours 
• Evaluate progress towards valued goals 
The module/technique in detail 
Step 1: The rationale for self-monitoring 
Self-monitoring begins with the careful provision of a rationale. Here is an example: 
“In this therapy we are going to be looking at how changing what you do can change 
the way you feel. But in order to know which changes might be helpful ones, it is 
important that we know how the different things you do are linked to how you feel. I 
could just ask you, but it can be difficult to remember all of the different things we do 
every hour of every day, and exactly how we felt when we did them. So this might 
not give us the information we are looking for. Therefore, I am going to invite you to 
keep a record of what you do each day, and how you feel.” 
It can be helpful to compare changing patterns of behaviour to breaking a habit. For 
example,  
“Doing BA can be a bit like trying to break a set of habits: you are trying to learn to 
do certain things differently to get a better outcome. The first step in changing a habit  
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is noticing that you are doing it. Keeping a record of your activities and how you feel 
will help you with this.”  
Patients can be invited to think about times they have tried to break a habit, in 
particular the need to be aware of what the negative consequences of the habit 
were, and the need to be aware of when the habitual behaviour was happening. 
Step 2: Introducing self-monitoring in detail 
Self-monitoring involves the use of a record form (see Appendix D) in which patients 
write down activity, mood and intensity, even on an hourly basis. In terms of the 
approach that patients should be encouraged to take, Martell and colleagues (2010, 
p.70) suggest that patients should be encouraged to “act like scientists, examining 
their lives in detail, and to closely examine and record even the small things that they 
might otherwise think are unimportant”. 
Recording Activity 
Therapists should encourage patients to be relatively detailed when recording 
activity. The prompt questions “Who? What? Where?” can be used to facilitate this. 
For example rather than writing “TV” it can be more helpful to write “watching TV in 
my room alone”. Therapists should include the idea that rumination is an activity to 
be recorded, and encourage patients to note down periods of rumination as part of 
their self-monitoring. 
Recording Mood 
Patients should identify and label the emotions they experience in connection with 
each activity, and rate these according to how intense they are, for example on a 
scale of 0-10. Initially it can feel more manageable for some patients to begin by 
rating merely how positive or negative they felt (from -10 = very negative to +10 = 
very positive), rather than identifying discrete emotions.  
Frequency 
Patients should complete the self-monitoring records as frequently as possible, 
ideally on an hourly basis. If this is not acceptable to patient or manageable, the 
frequency of rating can be broken down in several ways: 
• Records can be physically filled in at less frequent points throughout the day. For 
example a patient might fill in their record at lunchtime for the hours of 8am to 
1pm, at teatime for the hours from 1pm to 5pm, and just before bed for the hours 
from 5pm to 10pm. 
• Patients can complete records for set periods of the week only, for example 
hourly Monday 9-12, Tuesday 12-3, Wednesday 5-10, and so on. These periods 
should span different times of day and likely patterns of activity. 
• The patient can be invited to record less frequently throughout the week but to 
have a couple of set days when s/he records hourly. 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
182
It is important that the added value of frequent recording is emphasised. This can be 
demonstrated when the patient completes a practice record in session (see below). 
S/he can be asked to contrast the ease of completion and richness of information 
when the previous hour is recorded, compared to the previous day. 
When planning frequency of record completion it is important to establish a specific 
plan for putting self-monitoring into action. Therapists need to agree with patients 
exactly records will be completed, how the patient will remember to do so, what 
practical steps does s/he will take to make self-monitoring happen, for example by 
putting a copy of the record in a bag taken to work. 
In-Session Practice 
Completing a self-monitoring record in session can be an extremely valuable 
exercise to identify potential misunderstandings or challenges in completion. It 
provides the patient with an initial positive experience of this new challenge, and 
helps them to understand exactly what is involved in the task. In-session exercises 
can include recording the day so far or the previous couple of days. 
Homework 
Self-monitoring is principally a between-session homework task. In addition to 
negotiating goals around frequency of completion, therapists should ask patients to 
identify any possible barriers to completion and these can be problem solved. Below 
we identify potential solutions to record completion challenges faced by patients. 
Step 3: Reviewing self-monitoring records 
Therapists and patients should review all self-monitoring records from the previous 
week together. In general the therapist is interested in what was learned from 
completing the record. There are some specific exercises that can be undertaken 
when reviewing the record. Martell and colleagues (2010) identify five questions that 
can guide therapists in exploring the record with the patient: 
1. What connections are there between activity and mood? 
From the patient’s record it may be possible to identify both activities that are 
associated with better mood, and activities associated with worse mood. In some 
cases, the same activity will be associated with different mood states, reflecting 
differences in the context or in supplemental behaviours engaged in by the patient 
on each occasion. Particular exercises might involve: i) asking the patient to spot any 
changes in mood state, and then to explore the activities that occurred before, during 
and after this change; ii) asking the patient about whether they notice any patterns in 
the relationship between what they did and how they felt; iii) asking the patient 
whether there are any activities they notice that are missing from their records which 
in the past would have had a strong effect on mood, particularly positive ‘anti-
depressant’ activities.  
 
2. What is the overall pattern of mood and emotion over the week? 
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Some patients will report a wide range of feelings, and intensities of feeling, across 
the week whilst others will report having limited emotional variation. In the latter 
case, therapists can explore this further with patients. This may lead to exploration of 
the range of potential – but absent – emotions and their features, as described in the 
previous section. 
3. What is the patient’s routine like and have there been any disruptions to this? 
Often when people are depressed their routine can be affected. Conversely, 
disruptions to routine can often promote depression. Variations in daily routines can 
contribute to some physical symptoms of depression such as tiredness and appetite 
disturbance whereas regular routines can feel containing and comforting (Martell, 
2010). Self-monitoring records provide therapists with an opportunity to explore the 
patient’s routine in terms of features such as: sleep-wake times, meal times, and 
patterns of work and social contact. Therapists can ask patients to consider 
relationships between these aspects of routine and their mood states. 
4. Can any avoidance patterns be identified? 
Self-monitoring records can be used to highlight patterns of avoidance. For example, 
some activities that might be expected in the record might be entirely absent, such 
as social contact outside of work. In such cases it is important to explore with the 
patient whether s/he is turning down opportunities for such contact, and whether they 
are avoiding these opportunities to manage negative emotions that arise when social 
opportunities are on the horizon. Indeed, instances of increased negative emotions 
can sometimes indicate the presence of avoidance patterns. Therapists can ask 
patients to describe what triggered the emotion, what they did in response to the 
negative feeling and what the consequences of this were. Conversely, an absence of 
strong negative feelings in someone who reports severe emotional difficulties in their 
present life may reflect the use of avoidant coping strategies. These may include the 
drugs or alcohol to numb emotions. 
5. Where should the therapist and patient look to initiate change? 
Gathering information in the areas outlined above will help the patient and therapist 
identify areas for change to both increase positively reinforced activities and reduce 
negatively reinforced avoidance behaviours. This leads on to the other core 
techniques of functional analysis and activity scheduling covered in subsequent 
sections. 
Often the review will also highlight difficulties encountered by the patient in 
completing the record. If the patient was not able to meet his / her completion goals 
with respect to recording the therapist should be alert to the patient having attempted 
the task, and reinforce the value of this. All information gained is useful, even 
information as to why the record was not completed. 
 
Issues that can arise when reviewing self-monitoring records: 
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• Blocks of time with little detail or variation in terms of mood and activity. When 
this happens we explore it further with the patient. It may be that the patient did 
not use hourly ratings, in which case we can compare this block of time with a 
period in which hourly ratings were used. We can then encourage more frequent 
rating. We can also use visualisation to help the patient ‘recreate’ the block of 
time, and provide greater details about moods and activities. Finally, we can 
explore the potential presence of particular mental activities over this period, such 
as rumination. 
• Difficulty in identifying emotions. It can be helpful to talk with the patient about the 
range of possible emotions that can be experienced, including positive or neutral 
feelings. We can then list these and if necessary we can assist the patient to 
determine how s/he would know which feeling was present by asking them to 
identify associated physical sensations, thoughts, behaviours etc. 
• Not completing the record. Incomplete or absent record keeping is very common, 
particularly at the beginning of a BA programme. There are three common 
reasons for incomplete records:  
1. Practical issues, for example, difficulty writing, difficulty remembering to 
complete the record. We can use problem-solving to overcome these practical 
barriers, for example by suggesting the use of alternative methods of 
recording such as an audio recorder or computer.  
2. The patient feels that the benefits of recording do not outweigh the costs. 
Here, we can explore the patient’s beliefs about the costs and benefits of 
recording and revisit the BA rationale. Patients may identify potential costs 
such as a fear of making depression worse, fear of ‘realising’ how little s/he 
does and how much ‘worse’ s/he is since becoming depressed. In order to 
address these ideas, we can try and help the patient with the idea that a first 
step towards changing depression is to know where you stand with it, using 
the ‘habit metaphor. Next we can encourage the patient to complete a record 
of the previous day in the session itself. We can also advise the patient to 
break the recording task down into smaller chunks, for example recording 
every other day, and then observing the effects of doing so. 
Finally, we can introduce the TRAP pattern by showing how the triggering 
effect of remembering it is time to complete the record produces an emotional 
response such as feeling anxious or hopeless, followed by an avoidance 
pattern of putting the record away without completing. We can explain the 
consequences of not completing the record, for example it does not solve the 
problem, it leads to feelings of guilt, and in response we can explore 
alternative behaviours such as taking a small step towards completion. 
3. The patient believes that s/he has to be in the right frame of mind to complete 
the record.  
This is an opportunity for us to revisit the ‘outside in principle of acting first to 
change how we feel, even if we do not feel like it. We can reinforce this by 
inviting the patient to recall times when s/he did something to help themselves 
despite not feeling like it with the consequent positive effects.  
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List of therapy materials used in this module and/or with this technique 
Self-Monitoring Record Form (Appendix D) 
 
Useful references: 
Addis , M.E. & Martell, C.R. (2004). Overcoming depression one step at a time (pp. 
23-44).Oakland, CA: New Harbinger Publications.  
Martell, C.R., Addis, M.E. & Jacobson, N.S. (2001). Depression in context: strategies 
for guided action (pp.70-88). New York: W.W. Norton. 
Martell, C.R., Dimidjian, S. & Herman-Dunn, R. (2010). Behavioural Activation for 
depression: A clinician’s guide (pp. 71-75). New York: The Guilford Press. 
Moore, R.G. & Garland, A. (2003). Cognitive therapy for chronic and persistent 
depression (pp. 172-197). Chichester, U.K.: John Wiley & Sons Ltd. 
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Introduction and general description of the module/technique 
 
Functional analysis is the study of an individual patient’s pattern of behaviour and its 
variability. It is used to determine the contexts under which desired and undesired 
behaviours occur. The results of functional analysis guide interventions to 
systematically and therapeutically increase or reduce target behaviours. A functional 
analysis will include information on ‘antecedents’, ‘behaviours’ and ‘consequences’. 
 
The module/technique in detail 
 
Step 1: Conduct a functional analysis 
 
We use patients’ self-monitoring charts to discuss their patterns of behaviour that are 
helpful or unhelpful. We do this in order to understand the individual links between 
behaviours and outcomes, and the circumstances under which specific behaviours 
result in negative or positive outcomes. 
 
We use two acronyms to help the process of functional analysis: 
 
• ABC 
• TRAP/TRAC 
 
Although these acronyms are helpful tools, they are not an end in themselves. We 
merely use the ABC and TRAP/TRAC strategies to help patients understand when 
behaviour results in specific desired or undesired outcomes. 
 
ABC analysis - Antecedents ⇒ Behaviour ⇒ Consequences 
 
1. examine the patient’s self-monitoring record form/discuss recent events  
2. look for instances where low mood and behaviour, or a lack of behaviour, are 
associated  
3. alternatively look for when improved mood or performance and a target behaviour 
are associated  
4. examine the record for antecedents or triggers for these instances 
5. discuss the consequences of the behaviour or lack of it  
 
TRAP – Triggers, Response, Avoidance Pattern  
 
1. Triggers are identical to ‘antecedents’ and are factors that precipitated a specific 
kind of response  
2. Response is an emotional or physical response 
3. Avoidance Pattern is the behaviour that the individual engaged in  
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Critical features to consider in the functional analysis 
 
• What is the context in which the behaviour occurs? We should consider when, 
where, how, and with whom behaviours do or do not occur. This will give us clues 
as to behavioural antecedents and functions, as well as ways to leverage 
change. For example, if unwanted target behaviours tend to occur in certain 
places or with certain people, these contextual factors can be examined as 
triggers. Once we have used the functional analysis to determine what specific 
element of that place or person is problematic, we then have scope for controlling 
the environment to reduce the behaviour. For example, if a patient is prone to 
become bored when sitting at home, plans might be made to make the 
environment more stimulating. Another example is if being in a hurry or trying to 
do too much is associated with a stressed response and avoidance, making 
plans to be more focused and less in a rush may reduce the target behaviour.   
 
• What is the function of the behaviour? People engage in most behaviours for 
good reason. This is quite a normalizing message to give to patients. One way 
we can look at this with the ABC and TRAP models is to discuss the short and 
long-term consequences of behaviours. For example, people often engage in 
avoidance behaviours because they are negatively reinforcing. The more we 
avoid uncomfortable activities such as talking to someone else about an 
uncomfortable topic, the more short-term relief we feel and the more likely we will 
avoid the same activity again. However, there are usually negative long-term 
consequences of such avoidance in that the problem does not go away and may 
hang like a black cloud over our head. In a functional analysis it is important to 
understand the short-term advantages of avoidance as well as the long-term 
disadvantages. 
 
Look for patterns of behavioural responses to understand how a patient might 
habitually respond to particular antecedents. Understanding patterns can help us 
to design activities that whilst specific to certain contexts are also be 
generalisable. We can use the antecedents or triggers to help patients identify 
warning signs for particular habitual patterns of behavioural responses. 
Identifying such cues to habits enables the patient to consciously act to “nip the 
habit in the bud”. 
 
• Obvious and subtle avoidance. Avoidance can happen in both obvious and subtle 
ways. Clear-cut examples of avoidance behaviours include lying in bed, calling in 
sick to work and avoiding paperwork. However, people often avoid in less 
obvious ways. For example, they can over-engage in behaviours in one domain 
of their life to the detriment of other important areas, for example staying on at 
the office late to avoid dealing with difficult situations at home, or spending a lot 
of time out socialising to avoid having to look for work. Avoidance can also be 
more subtle or covert such as avoiding eye contact in social situations or 
ruminating about difficulties. Because avoidance behaviours can become a habit, 
people may have difficulty identifying their behaviour as avoidance, particularly 
when it is subtle.  
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Look for what isn’t being done, as much as what is being done. We can discuss 
‘important’, ‘routine’, ‘necessary’ and ‘pleasurable’ activities and the balance 
between them. If there is considerable imbalance then that may be a clue about 
specific activity areas that are being avoided.  
 
This series of questions will reveal the triggers and consequences of behaviours and 
the environments under which they are more or less likely to occur. We can then 
formulate the potential function of the behaviour and begin to choose interventions 
for the target behaviour. Critically, with functional analysis, all behaviours are fair 
game: “everything is grist to the mill”. For example, if a patient was to return and 
report that they did not complete homework, we can perform a functional analysis on 
times when homework has been done or not to understand what influences 
completion and then take this into account in future planning. 
 
 
Step 2: Identify alternative behaviours 
 
Once we have undertaken a functional analysis we can start to identify alternative 
behaviours in response to the triggers. These alternative behaviours are varied and 
can include exerting environmental control to disrupt the triggers, or developing 
alternative responses such as increased approach behaviours. It is here that the 
TRAP/TRAC acronym really helps. We can help patients to recognise TRAPS and to 
shift to TRAC – Trigger Response, Alternative Coping – using questions like “What is 
the TRAP here?”; "So what could get you back on TRAC?" 
 
Questions for identifying alternative behaviours 
 
1. “Let’s think of all the possible alternative approaches to this, no matter how wild 
or simple they might seem.” We can ask the patient to write all of the ideas down, 
no matter how unlikely a response it seems at first. Later, patients can choose 
which behaviours might work well and pick the most likely one. 
 
2. “Have you had similar situations in the past, perhaps when you weren’t 
depressed, when you dealt with this kind of a situation in a way that you felt was 
more helpful for you? What did you do?” By obtaining explicit and detailed 
comparisons of contrasting situations, such as a time when a similar behaviour 
such as trying to problem solve was helpful, can help us understand alternative 
behaviours and contextual influences.  
 
3. “If you knew someone else with a problem like this, what would you recommend 
they do?”   
 
Interventions emerging from the functional analysis 
 
1. Altering environmental triggers directly when the functional analysis reveals 
aspects of the environment that increase the likelihood of unwanted target 
behaviours including approach, avoidance, and rumination. 
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2. Replacing behaviours with ones that break the trigger/avoidance pattern or lead 
to more positive and valued activities. These latter behaviours are covered in 
more detail in the functional equivalence section of this handbook. 
 
Simple homework exercises set up as behavioural experiments can be tried from as 
early as session 1 or 2 to influence behaviours by disrupting the antecedent triggers. 
 
Examples might include changing a routine, creating a tidier work-space, focussing 
on one thing at a time. When designing such alterations of the environment, it is 
important to determine which aspect of a situation is central to behaviours such as 
avoidance or rumination. For example, if being by oneself is a trigger for lower mood, 
this might reflect being alone, feeling lonely, experiencing a lack of encouragement, 
a sense that activities feel pointless done on their own, and/or a general lack of 
structure. Further questioning (“thought experiments”) can find out what aspect of 
being alone patients find most difficult and what they really value about being with 
someone else.  We then use this information to inform the environmental change 
that is likely to be most useful. For example, if a lack of encouragement is the main 
reason for why being on one’s own is problematic, then the contingency plan may 
examine ways to increase self-encouragement. 
 
We can actually test these ideas ‘experimentally’ to examine the consequences of 
changing the patient’s environment. For example, we can structure a test where the 
patient listens to the radio in the morning to move their focus away from feelings of 
tiredness. If being alone is a trigger, we can test the effect of increased social 
contact. If sad music in the car triggers negative ruminations, we can test the effect 
of replacing it with alternative music when the trigger occurs. There are many such 
examples, all of which will flow from our detailed functional analysis. 
 
Finally, we can address avoidance directly by increasing the patient’s daily structure, 
their activities, and their routines. This is not necessarily an example of the functional 
equivalence principle, but a more basic introduction of activities which most people 
use to structure their lives. It is still important to identify activities which make sense 
to patients and those which they find desirable or useful. These activities will not 
necessarily be pleasurable. However, routines do anchor many people to a sense of 
emotional safety. Simple things such as a regular walk, doing some tidying, and 
clearing up the dishes may not be the most pleasurable of activities but they can 
begin the process of activation. 
 
Step 3: Develop a contingency plan 
 
Once alternative behaviours are identified, we should draw up a contingency plan 
with the patient. This is known as the ‘if-then’ or TRAC plan. The patient uses this 
plan in response to triggers identified in the functional analysis.  
The “if” component describes the warning signs and context that triggers the 
problematic behaviour. The “then” component describes the alternative behaviour to 
enact in response to the trigger. For example, for a patient who tends to avoid 
confrontation, the contingency plan might be: “if I notice that I disagree with 
someone, then I will practise expressing my point of view”. Patients should write 
down such plans explicitly as part of their homework plans. Because avoidant 
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behaviour is often habitual, repeated practice at utilising the alternative response is 
required before it becomes more automatic and well-established. 
Contingency plans usually consist of two types of strategy: 
• Strategies to break up avoidance and rumination patterns often focused 
around activity scheduling and problem-solving. These are covered in more 
detail in the respective sections of this manual. 
 
• Strategies to replace avoidance and rumination patterns. Usually, these 
should be activities that are valued by patients. These are covered in more 
depth in the Rumination and Functional Equivalence section of this manual.  
The core principle of a contingency plan is to identify the triggers for unhelpful 
avoidant behaviour as early as possible and to replace the avoidant behaviour with 
approach behaviour, thereby “nipping in the bud” the avoidant behaviour. 
 
We can suggest any strategy or technique within the BA repertoire as an alternative 
response to interrupt or replace any identified avoidance behaviour. We select a 
alternative behaviour that is consistent with the antecedents preceding the target 
behaviour identified in step 1. The alternative behaviour must fit the original 
behaviour’s hypothesised function. The exact contingency plan made will need to 
depend upon the specific patient-centred details shaped by the functional analysis. 
Any contingency plan is initiated in real life when the specific trigger for the target 
behaviour occurs. We select alternatives based on the functional analysis described 
earlier utilising if-then, TRAP, and TRAC plans. A number of possible alternative 
behaviours are described below.  
 
Exerting environmental control on target behaviour 
 
• If avoidance tends to occur at a regular point in the day, then planning a more 
active schedule at that time may be helpful. For example, for the patient who 
tends to sit down and do nothing in a lounge chair on return from work, 
preventing this sitting down and scheduling in other activities may disrupt the 
reduction in mood. 
 
• If a patient tends to lie in bed, getting out of bed and doing something else would 
be an important part of the contingency plan.   
 
Alternative behaviour 
 
• Breaking tasks down into smaller steps 
 
If an activity seems too big for patients to do, it can feel like it is overwhelming 
and impossible to do, causing the patient to become avoidant or feel hopeless. It 
can help to break the task down into the smallest steps possible, choose the first 
smallest step necessary to start moving forwards, and to start on that. 
 
• Opposite action 
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If an unwanted target behaviour is linked to a particular negative emotion or 
feeling (i.e. the Response in TRAP), we need to instigate a plan that generates 
an alternative emotion. For example, if the danger trigger is feeling low and 
lacking in energy, the solution could be to undertake a behaviour that is positive 
and energising.  
 
Patients can sometimes get stuck because they are waiting to “feel right”, “be in 
the right frame of mind” or “feel good enough” to act on one of their plans. We 
should encourage patients to practice acting towards a goal and acting “as if” the 
desired state or outcome was present. For example, patients can practice acting 
as if self-esteem was high and they felt really good about what they did. 
 
Shifting the focus to “acting as if” and following through a plan despite how s/he 
feels can be an important lesson. It can establish the idea that feelings can follow 
actions, rather than actions follow feelings. 
 
• Activity scheduling and building up approach behaviours 
 
Where the target behaviour-to-be-reduced acts as a form of direct avoidance 
(e.g., not seeking work; not talking to family about a problem), it is particularly 
helpful to examine the pros and cons of this behaviour and to encourage patients 
to try the actual avoided activities in the real world. We can set up a behavioural 
experiment where the patient attempts to approach and address difficulties 
directly. There is an important idea about learning to try things out in the real 
world, learning from experience, and providing the opportunity for success. In 
terms of short versus long-term outcomes, it is helpful to review how whilst 
avoidance can avoid the risk for short-term failure, it also avoids long-term 
opportunities for positive events and experiences. When selecting approach 
behaviours, it is important to bear in mind the functional analysis and chose 
events that are likely to be meaningful, relevant, and valued by the patient. The 
likelihood of completing planned activities can be increased by setting up 
situational contingencies for the behaviour such as putting it in a schedule, the 
patient telling other people what they are going to do and engaging their support, 
and setting up physical surroundings that are conducive to facilitate the activity. 
For example, if the plan is to increase exercise, it is helpful to make plans to 
ensure the relevant sporting kit is easily to hand, that the sporting facilities are 
nearby and open, and the time for exercise is unlikely to be encroached upon, 
e.g. Packing up swimming trunks, goggles and towel in a bag and taking it to 
work, so that the patient can go straight to the swimming pool from work. It can 
also be helpful to collaboratively order potential approach activities in terms of 
difficulty and then plan to gradually move through this hierarchy starting with the 
easiest actions. For further details see the later section on activity scheduling.  
 
• Progressive muscle relaxation 
 
This is useful when there are clear physical stress response and anxiety triggers 
for the avoidance behaviour and where the patient is using the avoidance to 
reduce anxiety and/or anger. In this situation, relaxation may provide a more 
functional alternative.  
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• Communication  (for further details see Communication Module) 
 
When the identified avoidant behaviour is focused on interpersonal situations and 
involves not addressing issues with other people, work on improving 
communication might be helpful. 
 
• Rehearsal and role-playing in the session 
 
When planning new approach behaviours that patients are less confident about 
and feel more hesitant about, especially those involving a social interaction, it 
may be helpful to explicitly rehearse the behaviour and role-play performing the 
action in the therapy session.  
 
• Problem-Solving 
 
Avoidance can reflect a failed attempt at problem-solving and planning. 
Therefore, teaching the patient to practice a systematic problem-solving system, 
using a recognised and logical set of steps, can thus be a useful alternative. For 
further details, see later module. 
 
 
The Rumination module also provides detailed examples of functional analysis 
and the development of contingency plans.  
 
 
 
 
 
List of therapy materials used in this module and/or with this technique 
 
Functional Analysis ABC Sheet (Appendix C) 
TRAP & TRAC Worksheet (Appendix H) 
 
Useful references: 
Addis , M.E. & Martell, C.R. (2004). Overcoming depression one step at a time (pp. 
23-44).Oakland, CA: New Harbinger Publications.  
Martell, C.R., Addis, M.E. & Jacobson, N.S. (2001). Depression in context: strategies 
for guided action (pp.70-88). New York: W.W. Norton. 
Martell, C.R., Dimidjian, S. & Herman-Dunn, R. (2010). Behavioural Activation for 
depression: A clinician’s guide (pp. 71-75). New York: The Guilford Press. 
Example TRAP → TRAC 
 
Trigger (perceived criticism)   Trigger (perceived criticism 
Response (increased anxiety)    Response (increased anxiety) 
Avoidance -       Alternative 
Pattern (rumination)     Coping (problem-solving) 
 
 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
194
DOI: 10.3310/hta21460 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 46
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
195
Introduction and general description of the module/technique 
As noted in the page summary earlier, activity scheduling is the final core component 
of BA. Self-monitoring helps us understand the patient’s individual behavioural 
context. Functional analysis gives us information on the triggers and reinforcers for 
these behaviours. Activity scheduling is the planned reshaping of the patient’s 
behaviour towards those that are less depressogenic.  
The module/technique in detail  
Because activity scheduling runs throughout BA, schedules may look quite different 
at different stages of treatment. However, throughout therapy, activities are always 
selected with a clear and specific purpose in mind. There should always be a reason 
why certain activities are scheduled into a person’s plan. 
The most likely reason is that scheduled behaviours have been selected will be 
because they represent an alternative to either avoidance or short-term but 
ultimately self-defeating behaviours. We cannot rely on new, positively reinforcing 
behaviours appearing by chance. We plan them into a person’s life. 
It is helpful to think about activity scheduling in seven steps, summarised below. 
1. Identify situations and behaviours from the self-monitoring record forms that are 
associated with the patient’s low mood 
 
2. Ask the patient to consider alternative behaviours. These may be anything at all, 
not necessarily ‘anti-depressant’ activities. They may be even more likely to lead 
to depressed mood. It is, however, important to consider the full range of 
alternatives at this stage.  
 
3. Ask the patient to select one or more of these alternative behaviours and 
schedule them into a weekly plan (see Appendix G), often as small steps, not 
giant leaps. 
 
4. As noted in the section on functional analysis, we should encourage patients to 
adopt an ‘experimental’ attitude to their activity scheduling. What we mean by this  
is for them to be curious about the outcome of the new scheduled behaviour(s). 
Rather than a test of perseverance, instigating new behaviours is a test of the 
effect of these behaviours on patients’ mood. 
 
5. Once patients have decided what new behaviours to try and have planned them 
into their weekly schedule, they should implement them. It is better if this plan 
includes trying the behaviours more than once if possible. It is better that one 
new behaviour is tried a number of times than many different behaviours 
implemented only occasionally. 
 
6. We should encourage patients to evaluate the results of implementing these new 
behaviours in terms of the impact it has on their mood. Records kept in the 
activity schedule self-monitoring log should, therefore, include a rating of activity 
AND mood. 
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7. We now have to ensure patients continue with the experimental attitude. They 
should not expect ‘quick fixes’. New activities should be tried repeatedly, 
scheduled in regularly and examined in terms of the outcomes. We should 
encourage patients to think about a two-three week schedule of activities where 
similar new behaviours are planned carefully on a regular basis. 
 
The seven activity scheduling steps in more detail 
1. Identifying situations associated with low mood 
We use the self-monitoring record forms to identify when a patient is feeling low. 
Taking this situation, time of the day etc., we then investigate what was happening 
during this time. Matching behaviours to mood is the first essential step. The most 
useful mood-behaviour pairings are those that happen more than once, often as a 
regular pattern. We are trying to help patients find predictable times, situations and if 
possible, regular behaviours that are all linked to low mood. 
2. Generating ideas for alternative behaviours 
Once we have helped the patient to identify the time-situation-behaviour-mood 
examples in step 1, we can help them to think of new ‘alternative’ behaviours. It does 
not matter whether these behaviours are realistic or fanciful, likely to be helpful or 
make the situation worse. The main objective in step 2 is to think of as many 
different alternatives to the current behaviour as possible, since the current 
behaviour is linked to low mood. Even this process itself can be helpful, since it 
highlights to patients that they may have choices, something many depressed 
people feel that they lack. 
3. Selecting new behaviours and scheduling them into a weekly plan 
By now, one or more situations associated with low mood should be accompanied by 
a list of alternative behaviours. The next stage is to help the patient select one or 
more activities that you and they believe might improve mood in these situations. 
During the early stages of therapy, we have to walk a tightrope between over 
stretching and doing too little. It is far better to choose activities that the patient feels 
they have a reasonable change of completing. However, many patients can easily 
get into a ‘boom and bust’ cycle where they attempt too much too soon. Once the 
activities are selected they should be scheduled. Using an activity scheduling record 
sheet is absolutely essential so that patients have a clear plan of what they will do 
and when they will do it. 
4. Experimenting 
This is not so much a step as an overarching attitude. We must encourage patients 
to think curiously about what effect the new behaviour has on their mood. It may 
make them feel better; it may make them feel worse. This is where we can reiterate 
the ‘outside-in’ principle. We should make sure that patients are not waiting to feel 
better before they implement an alternative behaviour. The main thing is to see what 
the outcomes of the new scheduled behaviour(s) are. If you really instigate this 
manner of thinking then you guard against disappointment, since any result is going 
to be useful for discussions at the next appointment. There is no success or failure, 
just interesting information to review and reflect on. 
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5. Implementing alternative behaviours 
Quite simply, this step is when the patient leaves the appointment with a plan and 
they complete the activities specified in that plan. Very importantly, they should 
record these activities and their mood during them, using the self-monitoring record 
forms used earlier. You should advise the patients to make sure they are fully 
involved in implementing the planned behaviours, focused on them and not 
distracted or thinking about something else. Secondly, you should advise patients to 
wait until the behaviour is finished before evaluating it. Finally, all experiments need 
replication. Implementing alternative behaviours is no different. Remind patients to 
try the new activities several times. 
6. Evaluating the effect of the alternative behaviours 
The great beauty of record keeping is that we can use them to compare progress. 
Self-monitoring record forms with new activities scheduled on them can be 
compared with old sheets. The important piece of information to compare is how the 
mood ratings have shifted or not in response to the new behaviours. This is the ‘raw 
data’ from which we can evaluate the success or failure of the alternative 
behaviours. This data tells us much about the impact of behaviours on mood. We 
use these ratings as major discussion points in our next session or sessions. We 
should always focus on what we can learn, and what the ratings tell the patient about 
mood and behaviour links. It is not a success or failure conversation. It is a learning 
conversation. 
7. Continuing to experiment 
As stated above, regular and repeated practice is the way to embed new, more 
helpful behaviours into someone’s life. There are no really quick fixes. We need to 
help people make the new more helpful behaviour a very regular part of their lives. 
Each week’s activity records should be scheduled to this effect. 
Of course, this is only desirable if the new behaviour has had a positive effect. If not, 
more experiments are needed, trying out new behaviours in new situations. 
Recording this carefully, including ratings of mood will help patients understand the 
connection between mood and behaviour and make the ‘outside-in’ link. If the 
experiment has not been successful the first step is to check to see if the patient was  
fully involved in what they were doing. Secondly, if this was true, we can help them 
select another behaviour, reflecting on what it was about the previous one that did 
not do the trick. Avoid giving in too easily, however. Often it might be a good idea to 
try an alternative behaviour a few times before giving up. Finally, make sure patients 
record their mood soon after undertaking the alternative behaviour. When people are 
depressed they often find it difficult to remember exactly how they felt at the time of 
doing something, particularly if their mood is very low. What we want are accurate 
ratings, not inaccurate retrospective accounts. 
Other points 
Activity scheduling in the early stages of treatment can take one of two forms. Either, 
the self-monitoring will have identified very clearly that some basic activities are just 
not happening, or a patient will want to replace obviously negative behaviours with 
alternatives. The latter is an example of how problem solving as a state of mind runs 
right through BA. Initially, selection of behaviours may not flow from a TRAP/TRAC 
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analysis. It may be absolutely obvious that a person needs to do something 
immediately to stabilise their situation. It is important that patients do not wait to feel 
ready to do these things, but do them to help feel better over time. 
Generally, however, we encourage patients to plan activities in a purposeful way. 
Activities are selected that have a clear focus and are drawn from the insights of the 
functional analysis. Planned activities may include new ‘functionally equivalent’ 
behaviours to replace activities that are no longer possible in a person’s changed 
life. Activities may be a return to old behaviours that have been dropped or avoided. 
Activity schedules may be explicitly about reducing current behaviours that are 
actually depressogenic. Some scheduled activities may be used to disrupt 
depressed thinking or behaviours in the face of known danger signs and triggers. 
The main message to give about activity scheduling is that it runs throughout the 
whole course of a BA programme. Planned behaviours all have a clear rationale, are 
best if they represent the implementation of a person’s value set, and are often 
designed in an experimental way. Patients act as scientists in their own personal 
laboratory, investigating the impact of reducing negatively reinforced avoidance and 
increasing positively reinforced behaviour. What we expect is that if we understand 
the triggers and contingencies, once we schedule in the behaviours the 
reinforcement effects will take over and help shape the person’s behaviours in a 
more positive direction. 
Alongside self-monitoring record forms, activity scheduling records will be the most 
frequently used and discussed tools in the behavioural activationists armoury. 
Activity scheduling is not a particularly difficult behavioural activation technique, but it  
can be done badly, nonetheless. Once a patient has got familiar with the idea of self-
monitoring situations, behaviours and mood, we can use functional analysis to help 
identify a way out of the TRAPs people find themselves in. Selecting alternative 
behaviours to address these TRAPS and get on TRAC is the trick to activity 
scheduling. Activity scheduling may seem like only the planning of things to do. It is 
much more than that, however. It is the pathway out of depression. Our job as 
therapists is to provide patients with a map of that path. 
List of therapy materials used in this module and/or with this technique 
Self-Monitoring Record Form (Appendix D) 
Activity Planning Tool (Appendix G) 
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Introduction and general description of the module/technique 
 
This module is based on the development and evaluation of treatments for 
rumination (BA for rumination; concreteness training) conducted by Watkins over the 
last 15 years. It includes material directly adapted from existing manuals (copyright 
retained, © Watkins, 2004, 2008, 2009, 2011). For further details please see Watkins 
et al., 2007; Watkins, 2007, 2009; Watkins et al., 2009; Watkins et al., 2011; Watkins 
et al., 2012. 
 
Rumination is repetitive negative thought, a covert mental process common in 
depression. It tends to focus on self, negative mood, problems and difficulties. 
Rumination is characterised by judgemental, evaluative thinking and often includes 
negative comparisons, focused on the meanings and implications of events, for 
example, “Why me?” “Why can’t I feel better?”  
 
From a BA perspective, rumination is a form of avoidance that has been negatively 
reinforced in the past through the removal of aversive experiences. The 
reinforcement of rumination may involve:  
 
1. Superstitious reinforcement, i.e., a false association between rumination and a 
positive outcome as a result of the person interpreting ruminating and the positive 
outcome occurring close together, as connected 
 
2. Partial reinforcement, i.e. there have been times when rumination was useful and 
intermittently functional. This ‘intermittent reinforcement schedule’ means that it is 
hard for the behaviour to reduce when no longer of value 
 
3. Poor discrimination between repetitive thinking which is helpful, such as helpful 
thinking about problems in a problem-solving manner, and unhelpful brooding. 
 
The potential avoidant functions of rumination are numerous but may include: 
avoiding job challenges or the tedium of the daily grind; avoidance of the risk of 
failure or humiliation by putting off doing something by thinking about it instead; 
cognitive avoidance or worry through mental preparation, planning and attempted 
cognitive problem-solving; pre-empting other’s criticism and anticipating potential 
negative responses through second guessing or mind-reading to avoid actual 
criticism; controlling one’ feelings; making excuses. 
 
The view taken by contextual-functional approaches to depression such as BA 
(Martell, Addis & Jacobson, 2001; Watkins et al., 2007) is that rumination may be 
more frequent and extensive if it has been learned in the course of someone’s life in 
response to particular environments with perceived positive consequences. This 
module describes how the BA approach, and in particular functional analysis, is used 
to treat rumination (see Watkins et al., 2007, 2011). To do so, we have to think about  
rumination as a behaviour and undertake rumination-focussed BA exercises just like 
we do for physical behaviours themselves.  
 
The key elements of this rumination module are: 
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• A patient-centred assessment with a clear rationale for the focus on rumination, 
building on the idea that rumination is learnt behaviour. We incorporate the 
patients’ developmental history into our rationale. 
• Practice at spotting rumination, avoidance, and early warning signs, using formal 
homework such as monitoring records that also include reports of rumination. 
• Functional analysis to examine the context and functions of rumination, when 
rumination occurred what preceded it and what its consequences were.  
• The development of contingency plans, involving different and more helpful 
responses to rumination triggers.  
• The use of experiments to examine whether rumination is adaptive or not and to 
try out alternative strategies. 
• Increased activity and reduced avoidance, building up routines, and increasing 
non-ruminative activities, explicitly targeting behavioural changes. 
• Exercises to provide experience of using attention as a counter to rumination to 
establish alternative thinking styles, such as problem-solving or a focus on being 
engaged and absorbed in the world rather than in one’s head. 
• A focus on the patient’s values to minimise rumination about non-valued areas 
and to encourage activity in line with values. 
 
The module/technique in detail 
 
Step 1: Rationale and explanation of rumination 
 
It is usually helpful to provide patients with information on rumination and to check 
that it matches their personal experience. We can acknowledge rumination as a 
common, understandable, but unhelpful process. This strengthens our rationale and 
helps to develop the therapeutic alliance. The rationale builds on the established 
functional-contextual approach used throughout BA. The history and development of 
rumination can be identified and made sense of with the patient. Most patients find 
that the explicit recognition of rumination and worry is very helpful as it may not have 
been discussed with them before.  
  
Summary of the treatment rationale: 
 
Recurrent negative thinking and avoidance are the central engines maintaining 
depression. Both avoidance and rumination are quite normal and functional in limited 
amounts under the right circumstances. However, when used excessively or when 
they are out of balance, they can become a problem. Excessive use occurs because 
of past learning that rumination was at least temporarily beneficial. Because it was 
learnt, it can be replaced with a new more helpful strategy. Therapy teaches patients 
to learn a new personalised and more adaptive approach. This leads onto the 
functional analysis. The joint development of this rationale can be used to explicitly 
normalize rumination, e.g., discussing how we all ruminate some of the time, and 
how it makes sense to ruminate under the patient’s particular circumstances. 
 
After this general rationale, we can review the patient’s own experience, talking 
through the overall effects of rumination including recent examples. We can get a 
sense of how it may have developed as a learnt behaviour, and generate evidence 
of how it is unhelpful. By reviewing the development of rumination as a learned 
behaviour we can see how the development of rumination makes sense in the 
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context of the individual’s life. For example, ruminating about how someone else 
thinks about you could act as a means to second guess a difficult parent and avoid 
criticism and abuse. The problem arises where rumination has become 
overgeneralized to other situations. 
 
This initial rationale phase therefore includes assessment of rumination generally 
and specifically. The purpose is to understand where rumination is a major problem 
involving extensive unproductive dwelling on negative material, examine the 
consequences of rumination, identify rumination as the target of therapy and explain 
what rumination is, using examples from the patient’s own experience. The focus is 
on identifying rumination as recurrent, repetitive thinking about self, mood, problems 
and difficulties that is unhelpful and in which patients get stuck. We can use terms 
such as ‘rumination’, ‘brooding’, ‘worry’, ‘getting stuck in my head’, ‘going round and 
round in my head’, etc. It is good practice to use the term that makes most sense for 
the patient and reflects their own use of language. 
 
It is noteworthy that rumination has been implicated in both anxiety and depression, 
so targeting of rumination may be particularly beneficial for addressing such co-
morbidity. 
 
An important part of this rationale is the identification of rumination as a learnt habit, 
i.e. as an automatic TRAP response triggered by particular circumstances. This idea 
is straightforward, plausible to patients, and naturally leads into a discussion of how 
it might change. The discussion on change can begin through the identification of 
triggers for rumination, and then considering either removing those environmental or 
internal triggers and/or learning of new habits through repeated practice of an 
alternative response to the same trigger. It can be useful to reflect on any lessons 
learnt from a patient’s prior experience of changing habits, for example study habits, 
exercise habits, eating habits and smoking habits. 
 
Step 2: Functional analysis 
 
In addressing rumination, we use exactly the same functional analytic principles as 
used more generally in BA. We apply this to understanding the particular functions of  
rumination including understanding, self-motivation, planning, avoiding, etc. 
 
The functional analysis is then used to help patients:  
• Recognise warning signs for rumination as cues for the ‘rumination habit’ 
• Develop alternative strategies and contingency plans which are incompatible 
responses to that of rumination and which either interrupt the bout of rumination 
or replace the function of rumination with a more constructive alternative such as 
approach behaviour, problem-solving, compassion, absorption, connecting with 
experience, assertiveness or relaxation.  
• Alter the environmental and behavioural contingencies maintaining rumination, 
towards more self-fulfilling activities.  
• Shift towards more helpful thinking.  
 
This plan can incorporate the TRAP and TRAC plans typically used in BA with a 
focus on rumination. 
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Antecedents: common triggers for rumination include: 
  
• Stressful situations, for example, when there is too much to do, when being 
judged, when bored, when being criticised, when reminded of a particular event.  
• Certain places, for example, at home, private space, in bed, at school or college 
or work. Many people report that they ruminate in particular places such as when 
lying in bed, when sitting down for a coffee. Individuals may have got into 
routines where they tend to ruminate at particular places and times. Identifying 
the routine and then shifting away from it can be a useful approach to break out 
of the rumination. 
• Certain times of the day. The most common times reported for ruminating are first 
thing in the morning just after waking up and in the evening, at the end of the day, 
often lying in bed, not able to sleep. Frequent rumination at these times makes 
sense because these are times when someone may anticipate or reflect on the 
day, and also tend to occur when less physically active and when there is less 
external distraction. 
• A number of physical and bodily responses are common warning signs for 
rumination, including tension in the shoulders, neck or back, feeling wound up, 
anxious, irritated and frustrated. Other warning signs include a person’s tone and 
volume of voice becoming louder and more critical, becoming hot/ flushed, 
increased heart rate, butterflies in stomach, sinking feeling, heavy feeling, upset 
stomach. 
• Certain behaviours can be a risk factor for rumination, for example, becoming 
inactive, lying around and not doing much, putting things off, rushing around, 
avoiding people, confronting people, withdrawing, thinking rather than doing. 
• Particular aspects of thinking are also common warning signs and triggers for 
rumination, for example attention narrowing onto a single concern or problem and 
becoming closed and rigid into a kind of ‘tunnel vision’, finding it hard to 
concentrate on other things, thinking becoming chaotic, muddled, messy and 
woolly, a mind that is ‘whirring’ and jumping from one thing to another, self-doubt,  
thinking that is moving away from the particular situation to consider other 
situations, self-criticism, focusing on how the way things are going is different 
from how one expects or wants them to be. Much of this way of thinking can be 
seen as “Why?” thinking. 
 
Identifying these warning signs can be used to try to help patients ‘nip rumination in 
the bud’ by engaging in counter-ruminative activities before the bout of rumination 
gains momentum. For example, for physical triggers, activities such as relaxation to 
reduce stress and arousal may be helpful in preventing thinking escalating into a 
bout of rumination. For external environmental triggers, leaving the situation or 
changing the environment can prevent the rumination. If a mental sign such as 
narrowing attention is a warning sign for rumination, a useful alternative may be a 
deliberate attempt to expand attention outwards to the world rather than inward on 
the self. This strategy is described by Martell and colleagues as connecting with the 
environment, in which the patient pays close attention to the world by going for a 
walk for example, and being as aware as possible of the sights and sounds of the 
countryside.  
 
Behaviour: the function of rumination. During the functional analysis we provide 
some explanation of how rumination as a habit makes sense, usually because 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
204
patients’ past experiences have taught them that rumination provided an initially 
helpful function. Habits tend to develop through repeated practice of an action and 
when the action gets some pay-off it is reinforced. It is therefore useful to find an 
alternative response that has the advantages and not the disadvantages of 
ruminating, an alternative behaviour that has some of the same pay-offs but without 
the downsides making it more likely that the new helpful response will persist.  
 
Consequences: examining the consequences of rumination provides further 
information about the function of the ruminative behaviour. 
 
Here is a list of common functions for worry and rumination that we can use to check 
with the patient to see if they are consist with their behaviours: 
 
• To help predict what could go wrong and prevent bad things from happening 
• To try and understand and problem solve a problem or difficulty 
• To motivate and stop letting things slip 
• To try and be certain about the best way to do something before acting 
• Because it is safer to “do it in my head” than to take a risk in the real world 
• To put off doing something 
• To punish  
• To try and mind-read and second guess others  
• To change emotions 
• To avoid becoming the kind of person a patient does not want to be 
• To avoid the risk of failure or embarrassment  
• To justify the way a patient is feeling 
• To stop letting go of something important 
 
For example, for a patient who ruminates in response to feeling angry, and for whom 
the consequence of rumination is to reduce anger but maintain depressed feelings, 
we would formulate the rumination as serving the function of controlling anger. 
Further exploration of the patient’s history might then reveal that he had a very 
violent and aggressive parent and that he is afraid of becoming like him and losing 
control of his temper – such that for him being angry is very aversive. Thus, 
rumination for him is focused on putting himself down and minimising his own 
importance and acts as a form of avoidance that is negatively reinforced because it 
serves to reduce this aversive anger. This is despite rumination being a trigger for 
his depressed feelings.  
 
Step 3: Contingency plans for disrupting rumination 
 
We can suggest any strategy or technique within the BA repertoire as an alternative 
response to interrupt or replace rumination. We select the alternative behaviour that 
is consistent with the antecedents to the rumination and fits the hypothesised 
function. The exact contingency plan made will need to depend upon the specific 
patient-centred details shaped by the functional analysis. Like any contingency plan, 
it is initiated when a specific trigger for rumination occurs. We select alternatives to 
rumination based on the functional analysis described earlier utilising TRAP and 
TRAC plans (or formulated as if-then plans, as described in the functional analysis 
section).  
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Exerting environmental control on rumination. 
 
• If rumination tends to occur at the point that a patient is sitting down at the end of 
the day and beginning to reflect on the day, then planning a more active schedule 
at that time may be helpful 
 
• If a patient ruminates when listening to sad music, a simple environmental 
change would be to play different music 
 
• If a patient tends to ruminate when lying in bed, getting out of bed and doing 
something else might break the rumination.  
 
In each of these cases, the change in behaviour could be investigated as an 
experiment to determine its effect on rumination and other symptoms.  
 
Interrupting rumination. 
 
• Slowing things down 
 
We can use this when patients describe situations where they have too much to 
do. In these cases they might feel anxious, experience physical reactions such as 
a pounding heart, try to do everything at once, and have thoughts which jump 
from one to another. If rumination occurs when patients are trying to do too many 
things at once, it might help to slow things down and to focus on only doing one 
thing at a time, to pace themselves, and to prioritize what they are doing. 
 
• Becoming more active 
 
Here the opposite situation is the case, where patients are bored and don’t have 
anything to do, are inactive, and experience ruminative negative thoughts. In this 
case we can encourage patients to plan to be more active and do something 
interesting, enjoyable, or merely useful at those times. It might also be useful if 
the patient clarifies their schedule and sequence of activities over the week to 
identify particular times that tend to have more ‘dead time’ so they can plan to be 
more active at those times.  
 
• Breaking tasks down into smaller steps 
 
If a looming deadline or other activity seems too big for patients to do, it can feel 
like it is overwhelming and impossible to do, causing the patient to become 
stressed and start ruminating. It can help to break the task down into the smallest 
steps possible, choose the first smallest step necessary to start moving forwards, 
and to start on that. 
 
• Opposite action 
 
If rumination is linked to a particular emotion or feeling, it can be helpful to have a 
plan that generates an alternative emotion. For example, if patients ruminate 
when feeling tense or irritable, they can plan to do something calming or relaxing 
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to head off the tendency to ruminate. Even simple examples like looking down at 
the ground when feeling sad can be changed to standing straight and looking up. 
Changing activity is another example, when patients would rather stay at home 
they can use this as a trigger to go outside and do something active. Opposite 
action means acting in a way that is different than the emotion felt so that patients 
actually act themselves into feeling differently. This doesn’t mean patients 
pretending not to feel their emotion since it may be perfectly appropriate to do so. 
Opposite action just means that patients decide it is not helpful to act on the 
emotion they are feeling in the moment. 
 
Other behavioural techniques to counter rumination. 
 
• Activity scheduling and building up approach behaviours 
 
Where rumination acts as a form of direct avoidance it can be helpful to examine 
the pros and cons of this behaviour and to encourage patients to try the actual 
avoided activities in the real world. We can set up a behavioural experiment 
where the patient attempts to approach and address difficulties directly. Even 
when patients do try out something in real life and it doesn’t end up the way they 
wanted, they can learn something by it, namely that many things in life can only 
be addressed through trial and error, learning how to do it through experience 
rather than by ruminative analysis. It is important to explore and experiment with 
patients whether some skills and abilities are best developed through experience 
rather than conceptual analysis, e.g., “Can you become good at interacting with 
others just by thinking about it?”  Rumination is often more frequent when 
individuals are busy with activities that they feel they are obligated to do 
(“responsibilities”, “chores”) but do not enjoy. Building in activities that individuals 
are excited and enthusiastic about can be important to reduce such rumination. 
 
• Progressive muscle relaxation 
 
This is useful when there are clear physical stress response triggers for 
rumination and where the patient is using rumination to control their feelings and 
reduce arousal such as anxiety or anger. 
 
• Communication 
 
When rumination is focused on interpersonal situations and the avoidance of 
addressing issues with other people, some work on improving assertiveness and 
communication might be helpful. 
 
• Rehearsal and role-playing in the session 
 
Rumination often involves thinking over and over again about possible future 
events and the outcomes of trying a new thing. Patients typically get caught up in 
thinking through the implications of such action in terms of “What will happen?” 
This function of rumination concerns trying to be certain about will happen or to 
avoid bad things happening. In these situations, the strategy is to teach the 
patient to replace repeated thinking about the possible outcomes with ‘concrete 
rehearsal’ of what the patient will say and do. This move from abstract to 
DOI: 10.3310/hta21460 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 46
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
207
concrete thinking, as preparation for going and doing the activity can be 
enhanced through rehearsal and role-playing in the session. 
 
 
• Problem-Solving 
 
Rumination can be a failed attempt at problem-solving and planning. Therefore, 
teaching the patient to practice a systematic problem-solving system, using a 
recognised and logical set of steps, can thus be a useful alternative (see section 
on Concrete thinking later and module on Problem Solving). 
 
• Increasing absorption and connection with experience  
 
One of the common effects of rumination is that it can interfere with the ability to 
connect directly with the reinforcing experience of a rewarding activity. For 
example, even though a patient may be doing an activity such as going for a run 
that they previously experienced as rewarding and pleasurable, if s/he is 
ruminating this may block any rewarding effect. This may be because: the focus 
of the patient’s attention is internal and self-focused rather than on the activity 
itself; their rumination is abstract or evaluative and may involve negative 
comparisons such as “I used to be much better at this” or “This is harder than I 
expected.” Ruminations in this type of situation often occur in the form of an 
internal ‘running commentary’ on the activity that interferes with the potential 
benefit of the increased activity. Finding ways to become more absorbed and 
connected with experience is therefore a useful means to interrupt rumination 
and to optimise the impact of activity scheduling.  
 
Absorbed “flow” states tend to involve: a deep and effortless involvement in 
activity with a merging of action & awareness. In order to optimise absorption, 
activities should be challenging but manageable and patients should focus 
directly on the task in hand in the here and now. It is better if the patient focuses 
outwards towards the external environment with an activity that provides 
immediate feedback, for example, when playing a musical instrument one can 
hear immediately whether the right note is played. Activities that have a delay 
between activity and outcome (such as waiting for a response from others) 
should be discouraged. Activities where patients can feel a sense of control and 
which are rewarding – valued as an end in itself – are particularly helpful for 
absorption. 
  
Helpful versus unhelpful repetitive thought 
 
An important element within any functional analysis of rumination is to recognise that 
sometimes dwelling on a problem can be helpful, for example, when problem-
solving, or when coming to terms with an upset or loss. This is a reason why people 
learn to ruminate – because there have been times when thinking through a difficulty 
has paid off. We need to help an individual recognise when repetitive thinking is 
helpful or unhelpful, and to tell the difference between rumination and problem-
solving.  
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Identifying at least two episodes of repetitive thinking that have different outcomes 
(one helpful versus one unhelpful; one relatively short vs. one relatively long) will 
help the patient unpack these differences. We should painstakingly investigate the 
sequence of each bout in specific detail, including the environment in which it 
occurred (external context and internal state) and the moment-by-moment sequence 
of thought, feeling, behaviour, consequence. This involves detailed questioning to 
recreate the scene of the event and a moment-by-moment fine-grained analysis of 
how it occurred. Asking about When, Where, Who, What, How will help the patient to 
describe the actual behaviours that occurred, including internal behaviours such as 
what the patient is saying to her/himself, his/her attitude to the situation, what s/he is 
attending to; the way they are approaching the situation etc. Once we have two 
detailed descriptions of the bouts, we can compare the details to identify differences 
between them that provide clues as to factors that determined whether the bout was 
helpful or unhelpful. We can help the patient test these factors in behavioural 
experiments and incorporate them into future contingency plans.  
 
Concrete versus Abstract Thinking 
 
Rumination is often characterised by abstract thinking focused on the meanings and 
implications of events. Patients will often ask, “why did this happen? Why me? What 
does this mean about me?, Why can’t I get better? Why is this so difficult? Why do 
other people treat me like this?” Patients thinking in an abstract way focus on 
evaluating the reasons, meanings, consequences, and implications of behaviours 
and events rather than the specifics of a situation. Abstract thinking leads to patients 
overgeneralising beyond the details of the situation, losing perspective, and finding it 
difficult to solve problems because thinking ends up being remote from the 
immediate situation. When talking over examples of bouts of rumination with 
patients, it is useful to note down the full list of “Why” type questions that someone 
asks himself or herself.   
 
In contrast to abstract thinking, people can also think in a more concrete way 
characterised by the what, when, where and how questions that provide a detailed 
grounding in the situation, for example, “How did this happen? What did I do? What 
did he do? How did this problem start? How can I move forward from here?”  Being 
concrete and specific tends to be helpful because it gives someone more cues as to 
how to solve a problem. There is greater detail about the situation and what was 
done, events are kept in proportion, and a more active approach is likely because 
people are focussing on behaviours that can change rather than on personal 
characteristics that are harder to change.  
 
We use functional analysis of rumination to determine whether patients are thinking 
in abstract or concrete ways. This distinction is often an important factor determining 
whether thinking about a problem becomes unhelpful rumination or useful problem 
solving. We can then teach patients to practice asking themselves the more helpful 
“How?” questions in response to rumination warning signs. 
 
 A useful within session behavioural experiment is the ‘How vs. Why’ experiment, in 
which we prompt patients to think about a recent rumination situation. We first ask 
the patient to imagine that situation as vividly as possible and whilst imagining 
him/herself in that situation, prompt him/her to ask themselves ‘Why’ type questions. 
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Ideally, we prompt the patient with the “Why” type questions identified in previous 
functional analysis of rumination. We then ask the patient to reimagine the same 
situation accompanied by prompting with ‘How’ questions as noted above. We rate 
mood, confidence, energy etc. before and after each type of practice using 0-10 
scales to give patient’s first–hand experience of the impact on mood of thinking in 
these two different ways. Typically, patients will report better mood, confidence, 
energy or generation of solutions in the How condition than the Why condition. This 
can provide a dramatic demonstration of how their approach to a problem can 
influence outcome. This experiment can then be followed by building the use of How 
questions into contingency plans in response to triggers for rumination. This can be 
facilitated by audio-taping the session and giving the patient the tape to remind them 
of the exercise. 
 
One helpful technique is to give patients a cue-card as a reminder to ask themselves 
the following questions when faced with warning signs of rumination.  These 
questions may also be useful prompts for the How-Why experiment. 
 
1. Focus on sensory experience and notice what is specific and distinctive 
• Ask yourself: “What is happening? How? Where? When? With whom? How 
is it different and unique from other events?” 
2. Notice the process by which events and behaviours unfold 
• Be aware of the sequence of events, what comes before, and what follows 
after each action and event. Notice the series of steps, of actions and 
events that lead up to an event. 
• Look out for clues or warning signs.   
• Look out for turning points. Notice any points or steps where a different 
decision, action or circumstance might change the outcome. 
• Ask yourself “How did this come about? What are warning signs? What 
might change the outcome?” 
3. Focus on how you can move forwards 
• Plan. Ask yourself how you can break things down into discrete, 
manageable steps which you can take to move forward into helpful action. 
• Act. Take the first step in the chain of actions (whether mental or physical) 
that you can do to deal with a given difficulty and then follow the sequence, 
step by step, dealing with new difficulties as they arise and acknowledging 
your own progress when things go well 
• Ask “How can I move forwards? How can I break this down into smaller 
steps? What is the first step I can take?” 
 
As noted earlier, the use of such alternative behaviours is best practised in the 
session and then repeated over several weeks to enable the behaviour to become 
well-established.  
 
A good guideline that a patient has shifted into more concrete thinking is that their 
description of events is focused on explicit behaviours rather than interpretations, 
and that it produces a clear visual image of what happened in the therapist’s mind. 
For example, a patient may describe an event as “He insulted me”. This is still 
somewhat abstract as it describes an interpretation of the behaviour rather than an 
actual physical behaviour. Asking concrete questions (as above) to help the patient 
describe the behaviour in terms of observable physical acts (“He turned away from 
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me when I asked him a question”) can be very helpful in clarifying the situation. (See 
Modules on Problem-Solving and Communication for further examples of 
encouraging concreteness). 
 
There are also a number of rules-of-thumb that can help patients discriminate 
between helpful and unhelpful thinking.  
 
First rule of thumb: Is this an unanswerable question? 
Is the focus of your thinking the kind of question to which most people would find it 
hard to have a definitive answer? Is it the kind of question where the possible answer 
keeps changing or is too open-ended? If it is, then it may not be helpful to keep 
thinking about it. This is particularly the case when it comes to understanding people, 
emotions, and when asking existential and philosophical questions, for example, 
“Why me?” questions. 
 
Second rule of thumb: Stop worrying if it leads nowhere after a period of time 
Keep in mind how long you have been worrying. It is helpful to be aware of how 
much time you spend going over and over something in your mind before you find a 
solution, come up with an idea, or make a decision. How long does it normally take 
to come up with a useful answer or make a decision? People often report that 
effective thinking mostly leads to an answer in about half an hour of concentrated 
thinking, whilst unhelpful rumination can go on for hours without leading to a solution. 
Moreover, people often report that the solutions to problems come to mind when 
they are not even thinking about the problem but when they go to do something else,  
freeing up their mind to relax and be more creative, so that the problem can be 
worked on subconsciously.  
 
Third rule of thumb: Ask yourself “Are these thoughts leading to a decision or 
action?” If not, your thoughts are probably too abstract and unhelpful. 
If your thoughts about a problem just lead to more thoughts, then you are probably 
being too abstract and you are likely to end up in a spiral of worrying, 
overgeneralizing, and inactivity. However, when your thoughts about a problem lead 
to a response to the problem, whether that it is a plan or a decision, or to some kind 
of action to deal with the problem, then your thoughts are concrete and it is much 
more likely to be helpful thinking rather than unhelpful worrying. The plan or decision 
could include deciding to do nothing or to accept something or to let go of something. 
This ‘concrete thinking’ is exactly what you should do when confronted with 
difficulties or stressful events: – this is where asking “How?” could be helpful, as it 
makes it more likely that you are ‘problem solving’.   
 
Exercises with patients associated with the module/technique 
 
TRAP and TRAC exercises; ABC. 
 
List of therapy materials used in this module and/or with this technique 
 
Functional Analysis ABC Sheet (Appendix C) 
 
TRAP & TRAC Worksheet (Appendix H) 
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Rumination Monitoring Form (Appendix I) 
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Introduction and general description of the module/technique 
 
Patients with depression may experience difficulties with solving problems for a 
number of reasons.  
 
First, as emphasised by the contextual approach underpinning BA, patients may 
become depressed because of changes in their circumstances which represent 
problems they cannot easily solve. These can be thought of as primary problems.  
 
Second, the consequences of depression such as low energy and motivation, and 
increased avoidance can create further problems in the patient’s life which may lead 
to the patient feeling overwhelmed with problems. These can be thought of as 
secondary problems.  
 
Third, Martell and colleagues (2010) highlight the potential for depression to impair 
problem-solving abilities. This may be as a result of impaired ability to plan, manage 
and remember important activities or through an increase in over-general and 
abstract styles of thinking, leading to rumination. 
 
Finally, some patients with depression may never have had the opportunity to learn 
effective problem solving skills, for example because attempts to actively problem 
solve were not modelled or positively reinforced in early life, or because passive 
means of problem solving such as allowing others to deal with difficulties on one’s 
behalf were reinforced. 
 
The general approach we take as therapists in Behavioural Activation work could be 
described as a problem-solving one: we support the patient to clearly define in 
behavioural terms the difficulties they are struggling with, identify, try out, and 
evaluate means of solving the problem. Thus, therapists and patients are engaged in 
problem-solving by conducting functional analysis, selecting and implementing 
alternative behaviours, and evaluating the results of this. In BA problem solving 
tends to be woven through the fabric of the sessions, and does not necessarily 
involve the therapist ‘teaching’ the patient an explicit set of steps to be followed. That 
said, for some patients it may be appropriate to move from supporting them in 
solving their problems to explicitly equipping them with a framework to use for this. 
 
The module/technique in detail 
 
This module describes the overall problem solving approach in two ways. Initially, we 
will consider the general problem solving therapy attitude as a series of steps in a 
therapeutic conversation. Secondly, we will outline the formal seven step problem 
solving approach which can be taught to patients. 
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1. Problem solving as a therapeutic conversation 
 
Step 1: Defining the problem in concrete, behavioural terms 
 
If the patient has stated their problem in abstract terms it is important to elicit a 
specific behavioural description of it. For example, Clara has the problem “I feel tired 
all of the time”: a specific description might be “When the kids come home from 
school I notice that I feel tired and overwhelmed at the prospect of spending time 
with them. Three times this week I made an excuse to my partner that I needed to do 
some housework instead of spend time with them, even though I did very little of it. I 
felt guilty the whole time, and then when we ate dinner together I was beating myself 
up about it in my head so much I didn’t join in with the conversation.” 
 
Useful questions to help patients define their problem include: 
 
• Can you tell me about a time recently when this problem flared up? 
• Can you tell me about a time in the last week when you noticed that this 
problem got in the way of what you needed or wanted to be doing? 
• If I had been with you last week, what would I have seen happening when this 
problem was going on for you? 
• If we could wave a wand and get rid of this problem overnight, what would you 
be doing differently tomorrow that would tell you the problem had gone away? 
 
Step 2: Identifying alternative behaviours and selecting one to try 
 
Once we have a concrete description of the problem, possible means of addressing 
it can be discussed. Questions that can help this process include: 
• What might you do differently? 
• What have you thought about trying? 
• Have there been any times when this problem occurred and you were able to 
deal with it effectively? 
 
We can undertake this step formally by listing (see Appendix J) or less formally as 
part of the session conversation, in each case making sure that the relative 
advantages and disadvantages of each option are discussed. In Clara’s case, 
watching a DVD with the children may suit her but not the children’s needs. A better 
plan might be to engage them in a more energetic outdoor game to burn off their 
energy. 
 
Step 3: Planning to implement the new behaviour 
 
Once a suitable behaviour has been identified, we help the patient identify the steps 
s/he needs to take to put the solution into action. The plan should be concrete and 
specific. Some solutions will require preparation in advance. For Clara, setting up the 
garden for an outdoor game. For many others, explaining the plan to partners. 
Ideally we are aiming for the patient to schedule in a specific set of behaviours for 
the coming week, for example “Tonight after the kids are in bed I will tell my husband 
what I am planning to do. On Tuesday I will go out at 3pm and set up the garden for 
a game of football. When the kids come home I will invite them to play football for 15 
minutes, after which I will return to the housework. During the game of football I will 
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be in goal – this feels like it will be less tiring for me than running about.” In planning 
to implement a solution further challenges may come to light. It may be necessary to 
break the solution up into smaller steps, some of which can be completed before the 
next session. 
 
Once a plan has been formed, we can encourage the patient to visualise putting the 
solution into action. By asking the patient to ‘see’ a video in his or her mind’s eye of 
the solution in action, s/he is encouraged to think in concrete terms about the steps 
involved. As well as visualising the potential benefits of the solution this process can 
reveal previously unnoticed barriers to its implementing which can be then be 
addressed. This technique is described in detail in the next section. 
 
Step 4: Reviewing  
 
In the next therapy session the chosen behavioural solution is reviewed. Patients are 
encouraged to be specific about what happened, what behaviours were enacted and 
what the consequences were. When solutions are difficult or painful patients often 
report affective consequences “it made me feel anxious”. We should specifically ask 
them to what extent enacting the solution solved the problem they were addressing. 
Lessons learned from this can then be used to determine the next step. 
 
Issues to be aware of whilst solving problems with patients 
 
• Whilst primary problems can be the ‘big’ issues that patients have difficulty with, 
and that may have contributed to the onset of depression, these can often be 
very challenging to address. Therefore it can be more motivating for patients to 
begin solving secondary problems, in other words, difficulties that have arisen as 
a consequence of the affect evoked by the primary problem. For example, a 
patient may have difficulties in his relationship with his wife (primary problem). 
This situation leads him to feel sad and anxious (secondary problem). Unable to 
resolve the situation he turns to ‘solving’ the problem of his negative mood by 
drinking alcohol and spending his spare time surfing the internet (avoidant 
coping). Therapy might involve first working with him to find other ways of 
responding to negative mood that are more adaptive in terms of serving his 
valued goals, before moving on –if appropriate – to exploring ways of responding 
to the difficulties in his relationship. 
 
• It can be useful to identify whether the problem is contributed to by an avoidance 
pattern, a skills deficit, or a combination of the two. For example, the patient may 
be engaging in a particular behaviour because it functions as a means of 
avoiding negative emotion (in other words, they are caught in a TRAP). In such 
situations, the patient is trying to solve the problem of feeling bad, but his or her 
attempts at ‘solving’ the negative feeling are not effective in the long term, and do 
not improve the situation that has triggered the bad feelings. In Clara’s case, she 
may be responding to feelings of being tired and overwhelmed by the prospect of 
spending time with her children by avoiding doing so, resulting in temporary relief, 
but intense feelings of guilt in the longer term. Alternatively, or in addition, she 
may not know how to spend time with her children in a way that is rewarding for 
all involved and does not place excessive demands on her energy levels, i.e. she 
does not currently have the skills to do this. These possibilities have different 
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implications for solving the problem: if avoidance is a key factor, the skills around 
TRAP/TRAC are highly relevant; if the patient is prevented from solving the 
problem because s/he does not possess the necessary skills to do so, patient 
and therapist may need to look at how these skills can be acquired or practiced 
(for example planning for and role playing an anticipated conversation in which 
particular communication skills are needed). 
 
• Various factors can make it difficult for patients to solve problems, and resort to 
avoidant means of coping with the surrounding emotions. However these 
responses are understandable in the context of patient’s’ learning histories. The 
therapist’s stance should be one of validating the patient’s natural desire to avoid, 
whilst at the same cheerleading him or her through the process of making 
changes. 
 
Exercises with patients associated with the module/technique 
 
Visualising enacting the solution 
 
Once a potential solution has been identified, visualisation can be used to solidify the 
plan, anticipate challenges and anticipate positively reinforcing aspects of engaging 
in the behaviour.  
 
The patient is asked to close his or her eyes if comfortable to do so, and to recreate 
in their mind’s eye the situation s/he will be in right before enacting the solution. The 
therapist asks the patient to see the situation as if through his or her own eyes 
(rather than seeing themselves from a detached perspective), and to talk the 
therapist through what s/he is doing in the present tense, for example “I am walking 
through the back door towards the shed. I am opening the shed door and looking for 
the football..”. At the start of the exercise the therapist can ask the patient to describe 
sensory details such as sounds, smells, temperatures, etc. to help themselves 
recreate the situation and feel immersed in it. If the patient becomes overgeneral 
about the steps s/he is enacting, for example “the kids come home and we play 
football”, s/he can be invited to go back and talk through the physical steps s/he is 
taking as this part of the video unfolds. 
 
After the exercise is complete the patient can be asked about the extent to which 
s/he was immersed in the visualisation, and then about what they learned from it, 
and what changes s/he would make to the plan as a consequence. 
 
2. Teaching problem–solving as a formal technique 
 
In addition to the less formal means of helping patients to solve problems outlined 
above, therapists may formally ‘teach’ problem solving to patients. This involves 
several steps: 
 
1. Introducing the idea of problem solving and giving a rationale. This might involve 
explaining to patients that depression can be associated with difficulties in 
problem solving for the reasons outlined in the introductory section, and then 
looking together at the potential benefits of learning, or reconnecting with, 
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problem-solving skills. The patient can be introduced to the idea that there is a 
series of steps that can be followed when faced with a problem to solve. 
 
2. Setting out the steps to be followed, namely:  
 
1) identifying the problem and determine the costs and benefits of attempting to 
solve it versus not doing so 
 
“Identify the problem as clearly and precisely as possible. Each problem should 
be broken down into its smaller parts, for example, a financial problem can be 
broken down into the components of debt, income and expenditure. Ask 
yourself: What?, When?, Where?, With whom? and How often? questions to 
help you describe the problem in detail. Then ask yourself: What is the result of 
this problem?” 
 
2) generating solutions 
 
“Identify as many potential solutions as you can. At this stage, reject nothing, no 
matter how apparently ridiculous solutions may seem. If the problem has been 
broken down, write solutions for each stage.” 
 
3) analysing strengths and weaknesses of all the potential solutions 
 
“List each solution’s strengths and weaknesses to assess the main advantages 
and disadvantages of each solution. Advantages and disadvantages can refer to 
likelihood of success, ease or difficulty of carrying out, resources needed for 
example money, etc.” 
 
4) selecting a solution to try 
 
“Choose a solution based on step 3. Remember to choose a solution which has 
a realistic chance of being successfully carried out for example choosing a 
solution with no funding when money is required will lead to automatic failure.” 
 
5) planning implementation of the chosen solution  
 
“Many solutions require careful planning. Write down the steps required to apply 
your chosen solution and list resources. The steps should be specific, linked and 
realistic. Use the ‘Four Ws’ – What, When, Where, With whom - again to help 
plan the implementation” 
 
6) implementing of the chosen solution 
 
“Carry out the plan identified in stage 5. Record your progress in a simple diary.”  
 
7) reviewing implementation and making further plans. 
 
“Regularly review how well your chosen solution is sorting out the original 
problem. The advantage of problem solving is that alternative options always 
exist. If the solution has worked, continue carrying it out. If not, go back and 
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choose another solution.” 
 
3. Practicing working through the steps in session. 
 
4. Helping the patient to generalise the skill of problem solving across areas of 
difficulty, and outside of the therapy room. 
 
Whilst this is a similar process to the less formal one outlined earlier, the following 
may be different: 
• The costs and benefits of attempting to solve versus not attempting to solve 
the problem can be explored 
• Generating solutions can be done as a ‘brainstorming’ process whereby the 
patient is invited to generate as many possible solutions as s/he can, without 
censoring them. Helpful questions include: 
o What have you thought about doing but dismissed? 
o What have other people suggested? 
o What would you suggest to a friend in your situation? 
o What have you tried in the past? 
• When solutions are evaluated, this can be done using an explicit rating 
process, such as scoring each out of 5 for manageability and for helpfulness. 
• Once the patient has started to use problem-solving, the therapist can help 
the patient to consolidate and generalise the skill by: 
o Putting together prompts or reminders of the steps to follow as a 
flashcard 
o Involving the patient’s network in supporting problem solving by, for 
example, inviting them to a session in which the purpose of and steps 
in problem solving are shared 
o Handing over more and more responsibility to the patient for i) 
identifying when problem solving is needed; ii) initiating the process; iii) 
directing the process 
 
List of therapy materials used in this module and/or with this technique 
 
Problem Solving Worksheet (Appendix J) 
 
Useful references: 
 
D’Zurilla, T.J. & Nezu, A.M. (1982). Problem solving therapy: A social competence 
approach to clinical intervention (2nd ed.). New York: Springer. 
 
Martell, C.R., Addis, M.E. & Jacobson, N.S. (2001). Depression in context: strategies 
for guided action (pp.126-135). New York: W.W. Norton. 
 
Martell, C.R., Dimidjian, S. & Herman-Dunn, R. (2010). Behavioural Activation for 
depression: A clinician’s guide (pp. 109-127). New York: The Guilford Press.
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Introduction and general description of the module/technique 
 
Sometimes patients may engage in behaviours that have a clear pay-off which they 
value, but at the same time result in undesirable consequences. For example, Joe 
sometimes shouts at his partner in order to win an argument: the desirable 
consequence is that his partner gives in to his point of view, however an undesirable 
consequence is that his behaviour is ultimately damaging to their relationship. In 
such situations the therapist and Joe may look to find alternative behaviours that fulfil 
the same key function, for example a behaviour that helps Joe to put forward his 
point of view effectively, but that has fewer disadvantages. Such behaviours may be 
termed ‘functionally equivalent’ in that they do the same job as the original 
behaviour, but are substituted because they have fewer adverse costs. 
 
Another circumstance in which therapist and patient may look to institute functionally 
equivalent behaviours is when the patient used to engage in particular 
“antidepressant” activities that were positively reinforced, but is no longer able to 
engage in these behaviours. For example, Clive derived great enjoyment and 
satisfaction from his hobby of sailing. However his current financial circumstances 
mean that he is no longer able to take part in this activity. Using the notion of 
functional equivalence, his therapist may help him to identify activities that are 
currently available to him that might bring about some of the same benefits as sailing 
did. 
 
The module/technique in detail 
 
When to look for functionally equivalent behaviours 
 
Therapists and patients use the concept of functional equivalence very frequently 
throughout BA work, whether or not this is acknowledged. For example, during 
activity scheduling therapist and patient will be involved in conversations about which 
‘antidepressant’ activities can be scheduled in, based upon what is known about 
what works for that patient. When some of the original activities are not possible, the 
search for alternatives that fulfil the same role is a search for functionally equivalent 
behaviours. 
 
When patients have identified TRAPs and have started to explore alternatives to 
avoidant behaviour, therapist and patient often look for new behaviours that will have 
some of the benefits of the old behaviour, but with fewer medium to long term costs. 
Thus helping patients to identify and institute functionally equivalent behaviours is 
not limited to this particular module: it can occur at any point throughout BA. 
 
However, this module may be particularly relevant if your patient is struggling with 
either of the issues outlined in the previous section, namely if he or she: 
• Is ‘stuck’ in repeating an ultimately unhelpful behaviour because of the 
benefits it brings. 
• Is finding it difficult to increase levels of antidepressant behaviours because 
circumstances prevent him or her engaging in those that worked in the past. 
Using the idea of Functional Equivalence when working with ‘unhelpful’ behaviours 
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The first step is to conduct a functional analysis of times when the behaviour in 
question appears. This will bring to light potential triggers of the behaviour, and 
importantly the short and long term consequences. These consequences may be in 
terms of the effect on mood, physical state, cognition, or changes in the external 
world, for example, changes in other people’s behaviour. When exploring potential 
consequences the following questions may be helpful: 
 
• What are the benefits of doing X in this situation? 
• You have told me that doing X causes you problems, but that you find you 
keep doing it. That suggests that there is probably some sort of pay-off from 
doing it, even if it doesn’t seem like it now. What do you think it might be? 
• When you start doing X, where are you hoping or expecting it will get you? 
• If you didn’t do X anymore, what problems would this cause? 
• What are the costs of doing X in this situation? 
• You have told me that doing X can be really helpful for you, but are there any 
downsides? 
• If you didn’t do X anymore, would there be any positive consequences? 
 
If the patient wishes to change the behaviour, the process is then essentially one of 
problem solving. The next step is to explore potential alternatives that will bring the 
same or similar benefits but with fewer costs. For example, in Joe’s situation he 
might generate ideas about different ways to get his point across to his partner, other 
than shouting. The problem solving module gives tips on supporting patients in 
generating alternative behaviours, for example asking him what has worked in the 
past, what he has thought about trying, and so on. The rumination module gives 
suggestions about possible functions and alternatives for rumination. 
 
The patient then chooses a preferred option, following discussion about the 
feasibility and likely consequences of ideas raised. This option is implemented as 
part of homework, and the consequences reviewed. 
 
Using the idea of Functional Equivalence when increasing positively reinforced 
behaviours 
 
Very often, people with depression are in contexts where previously positively 
reinforced behaviours are no longer possible, for example because of the loss of a 
job or a relationship, or changes in financial circumstances or physical health and 
mobility. In such instances, the task of the therapist is to help the patient find out 
what it was about his or her past activities that worked. Understanding this is the key 
to helping the patient discover alternative activities that are most likely to be 
rewarding. Replacing past activities with new ones that merely look the same is less 
likely to be successful. 
 
For example, to say to Clive, who used to enjoy sailing, “what about going on a boat 
trip?” without knowing what it was about sailing that he particularly liked may ignore 
some important alternative possibilities. On further discussion Clive may reveal that it 
was the contact with nature that he particularly liked, or the fact he was absorbed in 
a difficult physical task, or the exercise sailing provides, or the status of being 
someone who is seen to own a boat. Each of these suggests a different set of 
alternative activities. 
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Some useful questions: 
 
• What was it about X that you particularly liked? 
• When you stopped doing X, what did you miss most about it? 
• People might enjoy doing X for different reasons. For you, what were the 
reasons you did X? 
 
At this point it may be helpful to have an explicit conversation about what the patient 
values. Coming up with an abstract set of values can be used as a way of searching 
out new activities that are in line with these values. This process is described in the 
section below. 
 
Similarly to the process outlined in the previous section, the next step is to explore 
alternative behaviours. Useful questions might include: 
 
• We have spoken about some of the things you liked about X. Are there any 
other things you have done that have brought you any of these benefits? 
• We’ve spoken about how it’s not possible for you to do X anymore in the 
same way you used to. Is there some way you can do some version of X that 
brings you some of the benefits it did? 
• What are you already doing that brings you some of the things you used to 
get from X? 
 
Once alternative behaviours are identified, we then encourage the patient to 
schedule in one or more of these, and we review the impact of doing them at the 
next session. Importantly, as well as the general impact of doing these and what was  
learned about the activity, the therapist should ask about the extent to which 
engaging in the new behaviour brought about some of the sort of positive 
consequences associated with the old behaviour. 
 
Exercises with patients associated with the module/technique 
 
Identifying Values 
 
Step 1: What are values? 
When trying to schedule in positively reinforced behaviours the therapist might 
introduce the idea of values by looking for themes in the patient’s past and present 
‘rewarding’ activities, for example: “you have mentioned a few things that felt 
important and meaningful for you to do, such as sailing, teaching art, and playing the 
guitar in a band. What do those things say about what really matters to you? About 
what you value most in life?” Alternatively or additionally the therapist might explicitly 
introduce the concept of values, for example “Often we find that the activities that are 
the most rewarding are those that are in line with our values.”   
 
Therapist and patient might then go on to agree what a value is. In terms of how 
these are seen in the current approach, values are what give meaning to our lives 
and to our actions: they are what we consider to be important to us. Examples of 
values are honesty, responsibility, curiosity, closeness, and many more. Values are 
different from goals: a goal is something you aim towards, whilst a value is a 
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direction that you travel in. Whilst you can succeed or fail in attaining a goal, for 
example going to the gym twice a week all year, saving £500 by Christmas, you 
cannot fully achieve or fail at a value, because acting in accordance with a value 
such as honesty is an ongoing process which is sometimes easier and sometimes 
harder. All you can say is that you are moving in the direction of the value, or not. A 
useful metaphor here is that of traveling east – you can always head in that direction, 
even if you get diverted, yet you never actually get to ‘East’. 
 
It can also be helpful to note the relationship between values and depression. From 
a BA perspective, this would be viewed as follows. Often people feel most fulfilled 
when they act in ways that are in line with their values. One view of depression is 
that we become more vulnerable to it when we end up acting in ways that are 
removed from what we really value. There are lots of reasons why this might 
happen, for example, other people’s expectations, fear of failing or of feeling bad. 
However, the end result is that much of what we spend our time doing doesn’t feel 
meaningful to us. Extending the metaphor above of travelling east, depression is like 
a big mountain range that appears in front of us – suddenly travelling east becomes 
much harder. It is still possible, but it will need small steps, and it might be necessary 
to keep checking we are going in the right direction. 
 
Step 2: what are your values? 
This may have emerged from the previous conversation. If not, the patient could be 
asked directly to think of some examples of values a person might hold, saying 
whether or not they would apply to them. It can be important with some patients to 
determine whether the values mentioned feel valuable to them, or whether they 
represent only values imposed upon them by others. 
 
Step 3: What are you already doing that is in line with your values? 
Sometimes a discussion about values can be disheartening for someone with 
depression as it can be a reminder about what has been lost or ‘failed’ at, or it may 
imply that some huge change of behaviour is required. Therefore, it can be valuable 
to look at how the patient is already living according to his or her values every day. 
These acts may not be large, for example a patient who values being adventurous 
might have suggested a new café to meet a friend in. A patient who values being 
close to family might have spent an extra five minutes reading a story to his son in 
the morning.  
 
Step 4: how can you include more ‘valued’ activities in your life? 
Having identified some key values, the patient can then use this ‘direction of travel’ 
to work out some activities that fit in with it. These can be considered as potential 
anti-depressant behaviours and scheduled in. We can then review the effect on 
mood and other outcomes of attempting the behaviour. It is important to remember 
that because values are abstract and not limited to a particular activity, even if one 
activity fails or is not possible it is still possible to find other ways of living in 
accordance with a value. 
 
Further applications of values work: 
 
1. The notion of valued activity can be used to help find alternatives to 
avoidance behaviours, in other words to build TRAC from TRAP. For 
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example, Jenny might have a TRAP in which, after breakfast, she finds 
herself alone at home with nothing to do, knowing everyone else is going to 
work (trigger). She feels sad and ashamed (emotional response) and in 
response she watches daytime TV (avoidance behaviour), which distracts her 
temporarily but does not ‘solve’ the problem. This leads her to feel more 
ashamed in the longer term when she reflects on what she has done with her 
day. In this instance it is difficult for Jenny to solve the primary problem in that 
she wants to work but has had no success in finding a job despite trying hard. 
She continues to work towards this goal but cannot do it every hour of every 
day. What should she do as an alternative? One possibility is for her to 
consider activities that are in line with her values. These may be things that 
have been positively reinforced in the past, or may be new activities. 
 
2. Responding to setbacks and “failures” 
 
Even when we end up acting out of line with our values, we can still respond 
to this situation in a way that fits them. For example, Raj values being close to 
his family. Therefore he sets himself the goal of being home from work once a 
week in time to have dinner with his children and put them to bed. One day he 
finds he cannot make it because of work commitments. Whilst he has not met 
his goal for that week, he can still act in line with his value. He does this by 
calling up his family in advance, apologising and arranging to be home early 
another night, an agreement he sticks to. Therefore, when a patient reports 
that they have ‘failed’ in living according to their values it can be helpful to 
ask: “how might you respond to this situation in a way that fits with the value 
of X?”; “Can you resolve this situation in a way that shows you value of: being 
close to your family; honesty; looking after the environment?” 
 
List of therapy materials used in this module and/or with this technique 
 
Functional Analysis ABC Sheet (Appendix C) 
 
TRAP & TRAC Worksheet (Appendix H) 
 
 
Useful references: 
ACT text 
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Introduction and general description of the module/technique 
 
Mixed anxiety and depression is much more common than depression alone. Anxiety 
is likely to be a problem that will require attention at some point, particularly when the 
patient engages with the environment. This issue should have been identified 
through assessment and during phase 1 of BA treatment. If a problem has been 
identified it is appropriate to reach an agreement at review session 7 to work on the 
problem during phase 2.   
 
The rationale for attending to anxiety in BA is a process that will be familiar to both 
the therapist and the patient by this point, as it will have been used previously to deal 
with depressive avoidance. We use the familiar functional analysis via TRAP and 
TRAC sheets. We use the information gathered about anxiety and apply the TRAP 
system to consider the short and long term consequence of associated avoidance 
which maintains anxiety. From here TRAC can be used to explore changes in 
behaviour that will help the person activate. This in turn should facilitate positive 
reinforcement, encouraging future ‘outside in’ behaviour to overcome the anxiety. 
This is an ongoing and gradual process. The goal of BA in this study is to treat 
depression but using the same approach can also help with anxiety. This shared 
understanding is used to instil hope that change is possible using the BA model 
where anxiety blocks changing depressed behaviour. 
 
Key elements that underpin the BA approach to anxiety are: 
 
• Anxiety can occur to a person for a number of reasons and build up slowly 
• The way we try to cope with feelings by trying to escape or avoid them can 
often result in ongoing problems with anxiety in exactly the same way as 
depression. This is by a process of negative reinforcement which maintains 
avoidance. 
• Using the same gradual step by step approach to changing the coping 
behaviours that we have learnt for depression, we can also break the cycle of 
anxiety 
• The BA approach aims to make such changes collaboratively, learn from what 
we see and gradually emerge from a depressed cycle. Sometimes we also 
need to break this cycle for anxiety  
 
The module/technique in detail 
 
Step 1. 
 
The first step to engaging the person in the BA approach to anxiety is to complete a 
functional analysis of the problem. At this point you should identify an example of a 
situation, preferably from scheduling records, over the past week where it seems 
anxiety has blocked an ‘outside in’ behaviour. You as a therapist will have been 
thinking about how this fits with the TRAP/TRAC structure and the BA cycle. This is 
important as we aim to keep BA simple and provide the patient the same structure to 
understand their problems and how to plan to address them.  Firstly, we provide an 
overall description of how you plan to address anxiety in BA such as: 
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“As we have discussed this treatment is behavioural in nature, which means 
that we will work toward changing your behaviour as a method for improving 
your thoughts, mood, and overall quality of life. This can work just as well for 
anxiety if we apply the same principles. We have developed some 
understanding of the current situation you are in and you have been able to 
start to make changes in order to move forward. We call this working from 
‘the outside in’ rather than the ‘inside out’. We have used the TRAP and 
TRAC sheets and seen how the short term relief you get by avoiding can 
result in longer term difficulties which in turn keep you stuck in depression. 
The same principle applies with anxiety, when faced with a situation the 
discomfort you feel such as [recap the symptoms the patient has disclosed] is 
relieved when you escape. This relief feels better than the anxiety, hence you 
will escape more and also then begin to avoid the situation. This can be a 
problem if the situation is one that you need to overcome to break your cycle 
of depression.  How does that sound? Can we use a TRAP form now to 
understand in more detail a specific situation.” 
 
The aim of this manual is not to put words in your mouth but to guide you. You can 
see from the above example the aim is to give a general explanation.  
 
Step 2 
 
The next step is to tailor this to the person using the TRAP form and information 
gathered therein. The role of therapy is to develop a shared understanding using this 
approach and then work out the most productive way to make changes. The process 
should be a collaborative discussion.   
 
An example of a TRAP sheet regarding anxiety is outlined below 
 
Trigger: What situation, activity, or thinking occurred? 
 
Going to the library to get some books to read, I opened the door and it was very 
busy 
 
 
Response:  What was my response to the trigger?  (What did I do or feel?) 
 
I felt overwhelmed, my heart started beating fast, I was scared to look at anyone and 
just wanted to get out  
 
 
Avoidance-   
Pattern: What did I do to stop my discomfort? 
 
I left the situation without my books and went home and had a cup of tea. 
 
What are the activities that seemed difficult or painful to do? 
 
Stay in the library choose my books and speak to the librarian at the desk 
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In what way was by behaviour immediately effective in stopping my discomfort? 
 
As I left my heart slowed down and I stopped worrying about what people might say 
to me or what I might say to them. I felt relief 
 
What are possible long-term consequences of my behaviour? 
 
I like reading but cannot afford to buy books, the library is a place I might be able to 
meet like minded people 
 
After doing the above activity (or inactivity) am I MORE or LESS depressed?  (circle 
which) 
 
Later in the day I felt worse, I thought I will never get past this and went to bed, lying 
thinking about my problems 
 
 
 
 
Then go on to review your shared rationale and how this TRAP fits in the attempts to 
cope box, maintaining the isolation from valued activities. 
 
Step 3 
 
The next step, as used previously in changing depressed avoidance is to use the 
TRAC form to plan to make changes. When dealing with anxiety remember these 
golden rules in planning behaviour change. Any changes should be: 
 
• Graded: start with easier behaviours that the person feels they can manage. 
• Sustained: the aim is to get used to the situation so the person has to be able 
to stay long enough for this to happen. 
• Repeated: once is rarely enough, as per the above point the aim is to get 
used to the situation. 
• Focussed: it may feel right to try to distract from the situation that a person is 
in but this will impact negatively on their ability to get used to the situation. 
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Check out again the person’s understanding of this rationale and complete a TRAP 
form derived from the TRAP you have identified (see example below). Build this into 
scheduling and agree to review at the next session. Check the patient has 
understood the content and how the same approach is used for anxiety and 
depression in BA. 
 
Step 4 
 
Review the changed behaviour and what happened. Consider this in the BA cycle 
and if it could be built up, what would the potential benefits be. 
 
Trigger: What situation, activity or thinking occurred? 
 
Going to the library to get some books to read opened the door and was very busy 
 
 
Response:  What was my normal response?                                           
 
I felt overwhelmed, my heart started beating fast, I was scared to look at anyone and 
just wanted to get out  
 
Alternative: 
 
Coping:  What new activity can I try? 
Plan to go at a quiet time and sit and read for 30 mins before leaving to get used to 
being there before going back on a Saturday 
 
When will I do it?                                                     
At 11 am on Tuesday, Wednesday and Friday as these are quiet times. 
 
How will I do it? 
(break into small steps)               
I will go in at 11 and pick a book to read,  
I will make sure I sit facing the room and look around regularly. 
I will say goodbye to the librarian before I leave 
 
 
In what way may this help me over time?                                            
 
It will help me get used to going in there and build up my confidence the librarians 
will get to recognise me., 
 
How does it help me break out of TRAP?                            
 
I want to be a member of the library and join the book club. I have wanted to do this 
for a while but not had the energy or confidence to do so. This will help build my 
social circles and confidence and I enjoyed reading in the past. 
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Trouble shooting  
   
• The patient cannot identify a specific anxiety situation. 
Look in the diary at times where they have avoided situations and use this as 
a discussion. Ask what led them to raise anxiety as a problem and to specify 
when it is worse or better, in those times what are the fears they have? 
 
• The patient cannot break down into small steps. 
Help out and think about if the large anxiety can be split into smaller sections. 
If it is not possible with the situation think of another easier one to practice on 
first. 
 
• The patient does not feel this approach will work. 
Explore if what they are doing now is working, from a collaborative standpoint. 
It probably is in short term for the anxiety, but explore the longer term impact 
on anxiety and the focus of this treatment, depression. Have an open 
discussion about the pros and cons of working on anxiety and what is there to 
lose. 
 
Exercises with patients associated with the module/technique 
 
TRAP and TRAC exercises; ABC. 
 
List of therapy materials used in this module and/or with this technique 
 
TRAP & TRAC Worksheet (Appendix H) 
Anxiety Cycle Template (Appendix K) 
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Introduction and general description of the module/technique 
 
Behavioural activation involves reintroducing behaviours that used to be reinforced 
when the person was not depressed or finding alternative behaviours that may serve 
the same function for a person. One difficulty that occurs in treatment is that a 
person may try to reintroduce a behaviour that s/he once found easy or enjoyable, 
but that now the activity is experienced as very difficult and unrewarding.  
 
An example would be a person who used to enjoy meeting up once a week with 
friends for coffee, but who has not done this for some months because of her low 
mood. As a between-session task she tries to go out for coffee with her friends as 
she used to. However, she reports in the next session that she felt uncomfortable all 
the time she was there, that she ended up saying very little, and she thought her 
friends would all have enjoyed it more if she had not come along. She mentioned 
that she ended up making an excuse to leave early, and afterwards she spent some 
time ruminating about how bad her situation was because she couldn’t even do 
something as simple as meet up with her friends.  She has cancelled her next 
meeting with her friends.  
 
What happened here and more generally in these types of situation can be 
understood in behavioural terms. A behaviour that in one context was rewarded is in 
another context punished. As with any behaviour that is punished, behaviour theory 
predicts that the activity will reduce in frequency. 
 
This section provides some guidance on how to deal with this type of situation. The 
suggested strategies that can be used also draw on behavioural principles. One 
important principle that features several times here is that short-term rewards tend to 
control behaviour more than long-term rewards. In other words, an immediate 
consequence of a behaviour is likely to have much more influence on whether that 
behaviour occurs again, than a consequence that occurs a long time after the 
behaviour.  
 
This basic behavioural principle can be used to help understand lots of behaviours, 
such as why a person who is trying to diet may, when hungry, eat a very fatty and 
sugary snack. The instant reward of the unhealthy but pleasurable treat exerts more 
control over the behaviour of eating the snack than the longer-term consequence of 
dieting which is losing weight. Another example is why people continue to 
overindulge in drinking alcohol despite the experience of hangovers the next 
morning. Here, the short-term effect of feeling relaxed and happy outweighs the 
long-term result of the hangover in the morning. This basic behavioural principle, of 
the controlling effect of short-term rewards, known as contingencies, can be used to 
understand the clinical situation that is the focus of this section. We can use this 
principle to structure the intervention so that the therapist and patient can work 
together to deal with this scheduling difficulty.    
 
As with other phase II modular techniques, there is no expectation that the strategies 
described in this section will be used with every participant. They should be used if 
the difficulty described above occurs during activity scheduling.  
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The strategies will be used predominantly as ‘session specific therapeutic content’ in 
phase II sessions. However, if this emerges as a significant difficulty earlier in 
treatment it may be necessary to introduce at least some of the techniques earlier.  If 
this additional module is covered in detail during phase II it will also be necessary to 
review this work during the later stages of therapy. Clinical judgement will be 
required in determining when to introduce the strategies outlined here and how long 
to spend on them. 
 
The module/technique in detail 
 
If a person reports that previously enjoyed behaviours are now punishing we should 
use this module. However, the therapist should carry out a number of therapeutic 
behaviours themselves before introducing the rationale for the additional module. 
• Empathise: demonstrate empathy and understanding for the difficulty the 
patient found with the activity scheduling (for example, ‘It sounds like that was 
really difficult for you.’) 
• Reinforce the behaviour: provide reinforcement for the attempt to try out the 
activity (for example, ‘Although it was really difficult for you, it’s really good to 
see that you had a shot at doing it.’) 
• Normalise: make it clear to the patient that this difficulty often occurs in this 
type of treatment (for example, ‘This type of thing quite often happens at 
some point during this type of treatment.’) 
• Expectancy of change: emphasise that although the patient found it difficult, 
there are specific things you and the patient can work on together to help deal 
with this difficulty; the difficulty is surmountable (for example, ‘Shall we have a 
think about how we might be able to deal with this?)   
 
The therapist must make a clinical judgement about how much time needs to be 
devoted to these preliminary therapeutic tasks before moving on to introduce the 
rationale for this module, but often they can all be achieved in a few sentences 
seamlessly interwoven into the review of the between-session tasks. 
 
Introducing the rationale for this module 
Discuss with the patient how it looks like s/he found some of the activity scheduling 
difficult this week. Use a collaborative approach to find out whether the patient thinks 
it would be useful to spend some time working on this in the session.  
 
T: ‘It looks like you had a really good go at meeting up with your friends, but it turned 
out to be difficult.’ 
C: ‘The thing is that I used to find it really enjoyable, but I didn’t enjoy any of it. It was  
awful.’  
T: ‘Would it help if we spent sometime during this session trying to get our head 
around what was going on, and what we might be able to do about it to help?’ 
  
 
 
 
Identification of specific issue to be addressed 
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The specific issue that is addressed in this module is that an activity was 
experienced as aversive, difficult and so on even though in the past the same activity 
was something that was enjoyable, straightforward or rewarding in some way.  
 
Identification of personal examples of the specific issue 
This difficulty may have occurred over several weeks and several activities. Use an 
open-ended questioning style to encourage the patient to identify several examples. 
Ask if s/he can think of other examples unrelated to the formal scheduling in which 
an activity that is easy or enjoyable when not depressed has come to feel very 
difficult or aversive when depressed.  
 
Information giving about specific issues and module techniques  
Re-emphasise that this is a very common difficulty in depression. Discuss how there 
are several strategies that may be able to help here.  
 
Apply functional analysis 
Use standard functional analysis techniques described elsewhere in this manual as 
your basic approach here. Conduct a functional analysis of one or more of the 
difficult situations.  
 
One aim of the functional analysis is to gain an understanding of how the behaviour 
is now being punished. It is possible, even likely, that the behaviour is being 
punished in more than one way. Try to identify the different punishing consequences 
of the behaviour. It may also help to discuss how this contrasts with how the 
behaviour is reinforced when the person is not feeling low.  
 
An additional aim is to help the patient understand the consequences of the 
punishment, i.e. that the behaviour is likely to decrease, and how this can then be 
understood in TRAP-TRAC terms, just like many other examples you may already 
have discussed. If the behaviour is punished it is likely to reduce. This may lead to 
avoidance coping in which a short-term gain, for example, reduction of unpleasant 
feelings, is at the expense of a longer-term gain, for example engaging in activities 
that are needed to help improve mood.  
 
If the functional analysis identifies that one of the reasons the person is not finding 
the behaviour rewarding is the presence of rumination or not fully engaging with the 
experience, it may be necessary to consider using strategies from the rumination 
module.  
 
Exercises with patients associated with the module technique 
 
Once a connection is made that this situation may well be understood as a specific 
example of a more general phenomenon of avoidance coping, the patient may be 
able to generate strategies that could be applied here that s/he has used with other 
avoidance behaviours.  
 
 
 
These may include: 
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• Remembering the basic BA principle of experimenting with a behaviour long 
enough to see what its impact is over the longer term rather than abandoning 
a behaviour too soon 
• Breaking the activity up into smaller, more manageable sections 
 
Additional strategies that it may be useful to try: 
 
Detailed planning of the activity in the session 
One strategy is to plan in great detail the particular activity that the participant will try 
out. This will include planning in detail exactly when, where, with whom etc. the 
person will try out the activity. If these are not clearly specified well in advance, the 
decision to disengage in a difficult behaviour may be made as a result of the short-
term consequence occurring. If this is the case, then the potential short-term reward 
of not performing the behaviour, for example, feelings of relief, removal of anxiety, 
may exert more control over the behaviour than the longer-term benefit of doing the 
activity such as feeling less depressed in the long-run. However, if a decision to 
engage in a particular behaviour is made well in advance, the advantage of the 
short-term avoidance in controlling the behaviour is reduced.   
 
If it is difficult to achieve this level of specification in the session, other strategies 
may be to encourage the person to write down the night before very specific plans 
for the next day, particularly if there is diurnal mood variation where the person feels 
very low in the morning, but less low in the evening. Again, this may help overcome 
the controlling effect of short-term rewards controlling behaviour the next day.  
 
Pair an immediate reward with the currently punishing consequence 
As discussed above, if a particular activity is being punished in the short-term it may 
reduce even if there is a long-term benefit to the behaviour. Another strategy to 
overcome the controlling effect of the short-term punishing contingency is to pair an 
immediate reward with the activity to compete with the punishing consequence. For 
example, the person who found it difficult to meet up with friends could reward 
herself immediately after completing the activity by doing something in town that she 
finds easy and enjoyable, such as meeting up with her partner to go to the cinema. 
Selecting the reward may require some discussion with the patient. The principles 
here are to ensure that the reward can be delivered feasibly and immediately and will 
be experienced as sufficiently rewarding to counteract the immediate punishment 
that may have occurred.  
 
Identify a functionally equivalent but easier to achieve behaviour as a stepping stone 
If the patient finds the idea of trying a particular activity again very difficult, because 
of how punishing it was in previous activity scheduling, it may be worth trying to 
identify a ‘functionally equivalent’ behaviour. A functionally equivalent behaviour is 
one that would have the same intended reinforcement as the behaviour that is found 
to be very difficult at the moment. For example, the person who found going along to 
the coffee shop very distressing may not want to repeat the behaviour next week. If 
the intended consequence is to gain pleasure from social interaction, then it may be 
worth working with the patient to find other behaviours that would have the 
equivalent function of obtaining social interaction, but that s/he would be more willing 
to try. For example, while the patient may not want to go to the coffee shop in the 
next week she may be willing to phone one of the friends to meet up. If this is 
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achievable, the therapist and patient can work on moving towards the goal of going 
to the coffee shop in subsequent sessions. 
 
This should not necessarily be a first line strategy, because it can feed into 
avoidance. However, if the patient is unwilling to try a behaviour again, then thinking 
in terms of functionally equivalent behaviours and seeing these as a stepping stone 
to the more difficult behaviours may be a useful option. There is more detail on this 
type of strategy in the functional equivalence module. 
  
Planning further activities 
Use the strategies discussed in the session to generate specific activities for the 
following week.
List of therapy materials used in this module and/or with this technique 
Activity Planning Tool (Appendix G) 
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Introduction and general description of the module/technique 
 
Interpersonal concerns, and specifically, communication difficulties underlie many 
behavioural activation problems. Sometimes they are a TRAP/TRAC in their own 
right, at other times they are a barrier to achieving behavioural TRACs. For example, 
a patient may have a self-care goal/TRAC but is struggling to achieve it because 
s/he needs their partner to help watch the children during the times s/he wants to 
implement the self-care activity. 
 
This module is premised on the principle that improving communication helps 
improve support, a key factor associated with mental well-being. It focuses on 
keeping strategies idiographic – that is, finding communication strategies that work 
for the patient in the context(s) they are in. This module does not adopt ideas that 
there is a right or wrong way to behave interpersonally, for example, in an ‘assertive’ 
way. Communication TRACs are patient led – the therapist should work with the 
patient so that s/he generates their own solutions.  
 
It is important to understand interpersonal behaviours in the context of core BA 
principles. We all do behaviours for a reason. At one point they may have worked, 
but they may not be working in this context. Also, we must work to be concrete. It is 
easy to get abstract very quickly with interpersonal concerns. Stick with 
understanding specific, concrete behaviours.  
 
Look for conversational patterns – for example, patterns of avoiding communication, 
particular types of conflict or misunderstanding. Although most of the ‘work’ will be 
done on specific conversations, if you pick those that are representative of a pattern 
of behaving, then you will have a bigger impact.  
 
The module/technique in detail 
 
Step 1: Help participant to gain an understanding of support needs, both 
instrumental and emotional, and the way that communication contributes to 
difficulties in support 
 
Modify the monitoring sheet to focus on interpersonal situations and links with mood. 
This can be done in several ways: 
• Prospectively – each day ask patients to record interpersonal events 
alongside their mood. For patients who identify interpersonal concerns as 
significant and want to work on this module, another way to accomplish this 
task is to have the participant record their best or worst moment each day. 
These will often be interpersonal in nature. 
• Prospectively – ask patients to identify interpersonal goals, for example areas 
they want to improve on interpersonally, then ask them to record instances 
related to goals and related mood during the week.  
• Retrospectively – review monitoring logs for instances that are interpersonal 
in nature. Examine what interpersonal behaviours were engaged in or not.  
 
Hints:  
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• It’s important to look as much for what is not there as what is there. Do not 
just look for conflict. Look for a failure to do behaviours that might otherwise 
be expected, for example, partner comes home, patient is exhausted after a 
day with the children. Partner says, “where’s dinner?” and then sits down. The 
patient continues to get on with caring for their children and making dinner. 
The main problem recorded on monitoring sheet is an argument with one of 
the children over bath time. In fact the real problem is lack of support from 
partner.  
o Look for situations where the two individuals in the problem situation 
may have different expectations or desired outcomes for the situation. 
They may not speak about it, thus there may not be overt conflict, but 
there may be covert conflict. It can be useful to ask, “what did you want 
from the situation? What did the other person, to the best of your 
knowledge, want from the situation.”  
• Do not necessarily take assertions such as “my partner/family member/friend 
is great. We have a fabulous relationship. S/he is a really wonderful partner” 
at face value. Look for unbalanced descriptions. ‘All great’ may be a sign that 
things are in fact not so. Often there are two things that may underlie a “s/he 
is great” description – (1) concerns about admitting to self that things are not 
great and what the implications this may have for the relationship, (2) social 
prescriptions about how to speak about one’s partner/family (this may take 
some trust/rapport building).  
 
Step 2: Use an interpersonal monitoring chart to identify interpersonal or 
communication TRAPS 
 
The idea in this step is to narrow the interpersonal problem down to difficulties with 
communication and to identify specific communication problems.  
 
TRAP – Triggers, Response, Avoidance Pattern 
Triggers: I needed to ask my husband whether he could do the bedtime routine on 
his own once a week so I could go swimming. 
Response Worried, Frustrated, Isolated, Low. Worried about what he might say  
Avoidance Pattern Silence! I could not bring myself to ask him  
Consequences short term: I felt relieved I did not have to have the conversation at 
first. Then I just felt really frustrated with myself. Long term: Feels like I am never 
going to be able to make changes and get some life back for me. This makes me 
feel very isolated and low.  
 
Step 3: Communication analysis 
Primary concept: breaking down communication. It is important to be concrete and 
understand the specific factors contributing to poor communication. Hint:  ask the 
patient to describe the situation as if you were a fly on the wall, or as if it was a 
movie transcript. For example, a mother who would like her ex-partner help her with 
childcare.  
“I phoned him up and said that I needed him to take Daniel one night this week. He 
said that he couldn’t as he’s busy all week and taking him this weekend. I couldn’t 
believe how selfish he was being and told him so.” 
What this conversation looks like after breaking it down more: 
• Marie: Hi.  I need you to take Daniel this Wednesday evening. 
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• Ex-husband: I can’t this week as I have a late work meeting and won’t be home until 
gone eight. 
• Marie: Look, I really need some support and a break here 
• Ex-husband: I really can’t this Wednesday. I am having him at the weekend so you 
can get a break then 
• Marie: I do really need some time here – you are being really unhelpful 
• Ex-husband: Marie, I really can’t.  Also, this is a really bad time. I am just about to go 
into a meeting.  Plus I am taking him at the weekend. 
• Marie: You really are selfish.  Every time I talk to you I am reminded about just how 
selfish you are. 
Slams down phone.  
 
Hint: this often takes a considerable amount of time. Plan for 20 minutes.  
 
Step 4: Getting on communication TRAC 
Conversation planner: help patient get back on TRAC with communication.  
• Building communication confidence: starting with manageable communication 
changes. Questions to ask: Can you get it done? - Is the conversation manageable? 
- Do you need to break down the conversation further? Hint, if the situation is quite 
tricky, it may be a good idea to try out new conversational patterns with a ‘safer’ 
person and then working up to the target individual. If someone else was in my 
situation, what would they request? How would I feel if someone asked this from 
me? 
• Ask the person to examine their TRAP and ask, “what did you want from the 
situation?” The aim is help the individual achieve their goals in a way that works 
for both them and the other person. This is quite important as many depressed 
individuals worry that if they ask for something for themselves they will be over 
riding the needs of the other individual.  
THE FOLLOWING SECTION WILL BE AMENDED 
• Often question B can get quite abstract. Use the goal pyramid (see below) to 
assist you and the patient in breaking down the goal to something that is concrete 
and achievable.  
• Use conversation planner to generate specific goals for the conversation and to 
plan the context in which the conversation might occur.  
• Use TRAC model to plan out moving the TRAP to TRAC.  
• Role play new behaviour, allowing for at least ten minutes. 
• Plan for contingencies.  
 
Exercises with patients associated with the module/technique 
 
 
List of therapy materials used in this module and/or with this technique 
 
Self-Monitoring Record Form (Appendix D) 
 
TRAP & TRAC Worksheet (Appendix H) 
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Introduction and general description of the module/technique 
 
This section is designed to give a brief introduction into the management of alcohol 
or substance use in the COBRA trial. It is not designed to cover in detail the issues 
associated with the use of such substances. Those deemed to have dependency 
should have been screened out of the study at baseline assessment. It is of note 
however that people with depression may often use alcohol or non-prescribed drugs 
for a number of reasons, both positive and negative, in a way that is consistent with 
our behavioural understanding. All actions will have a consequence; if we 
understand the relationship between the action and the consequence, short and long 
term we will be able to intervene as necessary. We must note that BA is a 
collaborative treatment; there must be a shared understanding that the 
alcohol/substance constitutes a problem that the person wished to alter. This is 
consistent with the motivational interviewing approach that describes states of 
change as pre-contemplation, contemplation, action and relapse. Further details of 
MI are not included in this section but can be accessed and discussed in 
supervision. Our focus in this treatment is to use the stages of BA of self-monitoring, 
functional assessment goal setting and scheduling to help the person move through 
these MI stages to action that places them in touch with positive reinforcement in 
their environment. These issues should be discussed in supervision.    
 
The module/technique in detail 
 
Step 1: Draw links between alcohol and substance use and problems in 
activation/mood. 
 
Primarily this is an extension of the use of the self-monitoring diary. If there is a 
suspicion that these problems are present this should be discussed in an open way 
and linked back to the BA rationale. This allows the person to consider the 
relationship between mood states/movement towards goals and their use of 
alcohol/drugs. 
 
“It seems that on occasions you have reported that you were drinking alcohol, I 
wonder how much you are drinking on an average week. Are we able to look at this 
on your self monitoring forms?” 
 
This is used collaboratively to allow the person to consider the issue and 
contemplate to what degree it is a problem and if they wish to address it. 
 
Step 2: Use functional analysis to consider the relationship between the 
alcohol/substance use and consequence  
 
When a situation has been identified it is important to consider it with the person in 
an open way to explore the consequence it has. At this point it is important not to 
appear judgemental or prescriptive. 
“OK last week we discussed the degree to which you use alcohol and how 
helpful/unhelpful this was for us as we try to help you manage your depression. You 
were going to keep a record of when you drank over the past week, how have you 
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found that? When you look at the form do you notice any relationships with your 
mood?” 
 
Followed up by: 
 
“Perhaps we can look at this in more detail now, I would like to consider your 
drinking like the other behaviours we have looked at in treatment, that is to be open 
and consider the consequences, both good and bad, and how they relate to your 
overall goal. We can use the same structure we have used before” 
 
At this point an ABC form can be used, this is preferable to a TRAP (although it may 
be possible to move on to use a TRAP/TRAC approach) as the consequence cannot 
always be seen as avoidance. 
 
Antecedent: Cue to the drinking behaviour 
 
Behaviour: Drink 
 
Consequence: Escape from painful feelings (negative reinforcement of drinking) 
                        Get a buzz; engage with social circles (positive reinforcement)    
 
If negatively reinforced avoidance is the clear consequence of drinking/substance 
use then it is possible to move forward and use TRAP/TRAC. If the consequence is 
drinking is positively reinforced it is advised to look at the longer term consequence, 
such as feeling lethargic and stay in bed the next day.  This is the related back to 
rationale cycle and treatment goals. 
 
This stage again works with the person to contemplate changes to be made. 
 
Step 3: Identify new behaviours to be tried at risk times and schedule these in diary 
 
This moves to an action stage, and the scheduling follows the same stages as 
outlined earlier in this section. Remember behaviours should be specific and clear 
and collaboratively set. 
 
It is of note that we see new behaviours that are useful as those that move the 
person towards their goals and provide positive reinforcement. This is experimental 
and it is important we are open and evaluate the consequences of any new 
behaviours in subsequent sessions.       
 
Exercises with patients associated with the module/technique 
 
As we are viewing these problems as the same as other problematic behaviours 
discussed throughout this manual there are no new exercises to be added. The 
flexible use of self-monitoring, functional assessment and scheduling are exercises 
that will have already been repeatedly used in clinical sessions. It is important we 
use the same approach applied consistently using the same exercises to allow the 
participant to view their drinking/substance use behaviour in this way and not add 
undue complication to the BA treatment.   
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List of therapy materials used in this module and/or with this technique 
 
Self-Monitoring Record Form (Appendix D) 
 
Functional Analysis ABC Sheet (Appendix C) 
 
TRAP & TRAC Worksheet (Appendix H) 
 
Activity Planning Tool (Appendix G) 
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COBRA Trial CBT Protocol 
Clinical Practice Manual 
COBRA Trial Behavioural Activation Protocol 
Clinical Practice Manual  
XXXX
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Appendix 8 Cognitive–behavioural therapy
clinical practice manual
COBRA Trial CBT Protocol 
Clinical Practice Manual 
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This manual contains the necessary information you will need in order to initiate and 
undertake cognitive-behavioural therapy (CBT) with patients in the COBRA trial.  
Section 1 has some information about the COBRA trial itself. Section 2 outlines 
some general principles of session timing, duration, frequency and safety. Sections 3 
and 4 describe the two treatments being tested in the COBRA trial – BA and 
Cognitive Behavioural Therapy (CBT) in very broad terms.  
Sections 5 and 6 will give you a very good summary of what a course of CBT 
treatment in the COBRA trial will look like, describing the phasic nature of the 
COBRA protocol and a summary of the content of each phase. Section 6, in 
particular, gives a schematic overview of a COBRA CBT treatment programme. 
Section 7 then goes on to describe the core CBT techniques – 
assessment/orientation, activity scheduling, cognitive restructuring and relapse 
prevention. It also briefly describes some of the modular specific techniques you will 
be using for co-morbid presentations. 
Section 8 then goes on to detail the structure of clinical sessions at all stages of a 
CBT treatment programme. You should follow these structures very closely as your 
adherence to the overall structure, sessional structure and specific therapeutic 
content will be critical in ensuring fidelity to the clinical protocol COBRA is testing. As 
part of assuring treatment integrity tapes from all therapists will be formally assessed 
by independent assessors from the Oxford Cognitive Therapy Centre, initially with 
formative feedback and across treatment as a whole summatively to describe the 
trial CBT. 
Section 9 consists of a series of helpful ‘therapist notes’ on each of the principle 
techniques you will be asked to employ. Think of these as aide memoires. They will 
help you refresh your memory when it comes to employing these techniques. 
Section 10 lists some of the key scientific references underpinning the COBRA trial. 
This is followed by Section 11 (Appendices), consisting of the therapeutic tools such 
as diaries that you will need to use throughout any treatment programme.  
Please consult this manual frequently. Bring it with you to supervision and use it to 
help you become confident and competent at delivering the COBRA CBT clinical 
protocol. If you would like to personalise it, please do, and if you have any 
suggestions for additional materials, the trial team will be happy to listen. 
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Clinical depression is one of the most common and debilitating of the psychiatric 
disorders. It accounts for the greatest burden of disease among all mental health 
problems, and is expected to become the second-highest amongst all general health 
problems by 2020.  
 
COBRA is a Randomised Controlled Clinical Trial of two psychological interventions 
– Behavioural Activation (BA) and Cognitive Behaviour Therapy (CBT) – to establish 
if there are important clinical and cost differences between them. In detail, the 
COBRA programme of research seeks to answer two interlinked questions: 
3. What is the clinical effectiveness of BA compared to CBT for depressed adults in 
terms of depression treatment response measured by the PHQ9 at 12 and 18 
months? 
4. What is the cost-effectiveness of BA compared to CBT at 18 months? 
 
In addition, we will undertake a secondary process evaluation to investigate the 
moderating, mediating and procedural factors in BA and CBT that influence 
outcome. 
 
BA and CBT are both active psychological treatments which have previously 
demonstrated positive effects for people with depression, and are recommended by 
NICE guidelines for the treatment of depression. Half the participants in the COBRA 
trial will receive BA and half CBT, allocated on a random basis.  
 
Participants will be assessed for eligibility by a COBRA researcher using a structured 
clinical interview. If eligible, they will be asked to complete a number of 
questionnaires with the researcher. They will then be randomly allocated to one of 
the treatments by the Peninsula Clinical Trials Unit in Plymouth using a process 
concealed from the research team to ensure the team are blind to allocation. 
Participants will also be seen again for follow-up appointments with a researcher at 
six months, 12 months and finally at 18 months to complete a number of 
questionnaires. The research study will last for four years, but each participant’s 
involvement in the study will be for eighteen months. 
 
The study will be taking place in three sites; Devon Durham and Leeds with the lead 
centre being the University of Exeter’s Mood Disorders Centre. COBRA will begin in 
March 2012, the first participant will start treatment in September 2012 and the study 
will end in April 2016. Participants will be recruited from August 2012 until April 2014. 
 
The trial is funded by a UK National Institute for Health Research (NIHR) Health 
Technology Assessment Programme Clinical Evaluation and Trials grant. 
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 Frequency and duration of appointments 
Participants will receive a maximum of 20 sessions over 16 weeks with the option of 
four additional booster sessions.  
 
Sessions will be face to face, of one-hour duration maximum. 
 
Therapists and participants have the option of having sessions up to twice weekly 
over the first two months of the trial and weekly thereafter where this is clinically 
indicated (e.g., with a severely depressed client and twice weekly sessions would 
support initial behavioural work). 
 
The final few sessions may be spaced out further if clincially appropriate to support 
relapse prevention. 
 
 Risk assessment and management 
Risk will be assessed at every appointment. At the first appointment a full risk 
assessment will include enquiry on suicide, self-harm, neglect of self, neglect of 
others, harm to others and harm from others. Risk will be assessed in terms of 
thoughts, plans, actions taken in support of any plans, and preventative factors. At 
subsequent appointments risk will be reviewed against the assessment conducted in 
the first appointment to assess any change in the patient’s risk status.  
Where any factors are detected which leads the therapist or mental health worker to 
believe that there is a danger that the patient will harm themselves or others through 
action or neglect, a risk management plan will be initiated. This plan will follow the 
principles of the Mood Disorders Centre’s policy on risk and any actions taken will be 
determined by the specific policies in place at the NHS clinical provider site. All risks 
identified and any actions taken will be documented and discussed in supervision 
and with the COBRA trial manager, site lead and chief investigator. 
 
 Collecting routine outcome measures 
Over recent years, it has become standard practice for therapists and mental health 
workers to ask patients to complete short clinical outcome scales at every clinical 
encounter. Measures are used to assist both parties to track progress, identify 
setbacks and provide data for individual patient progress and overall service 
evaluation. In COBRA we use the same procedure at every session. In the CBT arm 
this will be the Beck Depression Inventory (BDI). Measures are collected from the 
patient during the early part of the appointment and discussed briefly before moving 
onto the main session content. Occasionally measures may lead to a change in the 
session agenda. A summary of all therapists’ outcomes on the BDI is always 
discussed in supervision.  
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Behavioural Activation (BA) is a psychological treatment alleviating depression by 
focusing directly on changing behaviour based on behavioural theory. This theory 
states that depression is maintained by avoidance of normal activities. As people 
withdraw and disrupt their basic routines, they become isolated from positive 
reinforcement opportunities in their environment. They then end up stuck in a cycle 
of depressed mood, decreased activity and avoidance. BA systematically disrupts 
this cycle, initiating action in the presence of negative mood, when people’s natural 
tendency is to withdraw or avoid. BA targets avoidance from a contextual, functional 
approach not found in CBT – i.e., BA focuses on understanding the function of 
behaviour and replacing it accordingly. BA also explicitly prioritises the treatment of 
negatively reinforced avoidance and rumination.  
 
The overall goal of BA is to re-engage participants with stable and diverse sources of 
positive reinforcement from their environment and to develop depression 
management strategies for future use. BA sessions consist of a structured 
programme increasing contact with potentially antidepressant environmental 
reinforcers through scheduling and reducing the frequency of negatively reinforced 
avoidant behaviours. Treatment is based on a shared formulation drawn from the 
behavioural model in the early stages of treatment, thereafter developed with the 
patient throughout their sessions. Specific BA techniques include the use of a 
functional analytical approach to develop a shared understanding with patients of 
behaviours that interfere with meaningful, goal-oriented behaviours and include self-
monitoring, identifying ‘depressed behaviours’, developing alternative goal oriented 
behaviours and scheduling. In addition the role of avoidance and rumination will be 
addressed through functional analysis and alternative response development. 
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The overall goal of CBT is to alter the symptomatic expression of depression and 
reduce risk for subsequent episodes by correcting the negative beliefs, maladaptive 
information processing and behavioural patterns presumed to underlie the 
depression. Sessions consist of a structured, partially didactic programme. 
Treatment begins with patients learning the model and behavioural change 
techniques, then moves on to identifying and modifying negative automatic thoughts, 
maladaptive beliefs and underlying core beliefs. In later sessions, learning is 
translated to anticipating and practicing the management of stressors that could 
provoke relapse in the future. Specific CBT techniques include scheduling activity 
and mastery behaviours, the use of thought records and modifying maladaptive 
beliefs. The behavioural elements in CBT focus on increasing activity together with 
practical behavioural experiments to test specific cognitive beliefs. CBT does not 
take the contextual, functional approach of BA, nor does CBT explicitly prioritise the 
targeting of avoidance and rumination.  
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CBT for depression (Beck et al., 1979) is a manualised approach that has been 
demonstrated to have proven efficacy and effectiveness in numerous treatment 
trials. In this trial, therapists will use two seminal treatment manuals in this area (A.T. 
Beck et al., 1979; J.S. Beck, 2011). Several innovations in CBT since the publication 
of the original manual have emphasised approaches that help to individualise 
treatment (Kuyken, Padesky & Dudley, 2009) and overcome cognitive and 
behavioural avoidance (Moore & Garland, 2003). Moreover, there has been much 
clinical innovation in CBT that has been about ensuring core behavioural and 
cognitive strategies are as acceptable and potent as possible (e.g., J.S. Beck, 2011; 
Westbrook, Kennerly & Kirk, 2011; Padeksy & Mooney, 1990). Therapists will make 
use of cognitive and behavioural tools or approaches that have become part of the 
mainstream tool kit of well-trained CBT therapists. 
In addition, we anticipate that a significant proportion of patients will present with 
psychiatric co-morbidities. Based on our previous trials and the epidemiological data 
these are most likely to be generalised anxiety disorder, social phobia, panic 
disorder and simple phobia. As with real world CBT, therapists will need to address 
patients’ presenting problems including any co-morbid presentations. Therapists will 
use CBT case conceptualisation to understand how beliefs and strategies link 
patients’ presenting issues and use evidence-based CBT models and protocols 
appropriate to the individual patient’s presentation. In line with recommended 
standard CBT practice, therapists will record patients’ depressive symptoms at each 
session using the BDI to monitor treatment progress and amend their 
conceptualisation and treatment plan if patients do not progress as anticipated.  
 
Primary CBT protocols and evidence summaries used by therapists in the trial: 
 
• Depression (unipolar):  
o Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979). Cognitive 
therapy of depression. New York: Guilford Press. 
o Moore, R. G., & Garland, A. (2003). Cognitive therapy for chronic and 
persistent depression. Chichester: Wiley. 
 
• Social Phobia:  
o Clark, D.M. (1997). Panic disorder and social phobia. In Clark, D.M. & 
Fairburn, C.G. (Ed.) Science and Practice of Cognitive Behaviour 
Therapy (pp.119-154). Oxford: Oxford University Press. 
 
• Panic:  
o Clark, D. M. (1986). A cognitive approach to panic. Behaviour 
Research and Therapy, 24, 461-470.  
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• GAD:  
o Dugas, M.J. & Robichaud, M. (2006). Cognitive-behavioral treatment 
for generalized anxiety disorder: From science to practice. New York: 
Routledge. 
 
• Post-traumatic Stress Disorder:  
o Ehlers, A., Clark, D. M., Hackmann, A., McManus, F., & Fennell, M. 
(2005). Cognitive therapy for post-traumatic stress disorder: 
development and evaluation. Behaviour Research and Therapy, 43(4), 
413-431. 
o Harvey, A. G., Bryant, R. A., & Tarrier, N. (2003). Cognitive behaviour 
therapy for posttraumatic stress disorder. Clinical Psychology Review, 
23(3), 501-522. 
 
• Personality disorders:  
o Beck, A. T., Freeman, A., Davis, D., & Associates. (2003). Cognitive 
therapy of personality disorders (Vol. Second Edition). New York: 
Guilford. 
 
• Eating disorders:  
o Fairburn, C. G., Cooper, Z., & Shafran, R. (2003). Cognitive behaviour 
therapy for eating disorders: a "transdiagnostic" theory and treatment. 
Behaviour Research and Therapy, 41(5), 509-528. 
o No summary to date, but see Roth, A., & Fonagy, P. (2005). What 
works for whom: A critical review of psychotherapy research (Vol. 
Second Edition). New York: Guilford. 
 
When addressing co-morbidities therapists may wish to use disorder specific 
measures to assess severity and to monitor progress. The manuals may suggest 
such measures or alternatively therapists may use bespoke tools for assessment / 
evaluation.  
 
CBT normally progresses through several phases (A.T. Beck, 1979; J.S. Beck, 
2011): 
a. Phase I 
Phase I represents the introduction of the core CBT methods. The first session is an 
assessment where the worker gathers information on the patient’s presenting issues 
and illustrates the CBT model with respect to the presenting issues. A list of 
collaboratively agreed presenting issues and SMART treatment goals is generated. 
Phase I then moves on to socialise the client to CBT and start to introduce some of 
the core therapeutic activities with the intention to achieve some early symptom 
gains. This typically includes linking mood, thinking and behaviour through a 
descriptive case formulation and setting up some behavioural monitoring/activation.  
b. Phase II 
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Phase II moves into cognitive interventions focused first on automatic thoughts and 
then moving on to working with conditional assumptions, using thought records and 
other in-session and homework tools. Typically a theory driven cross-sectional case 
formulation would be used here. Behavioural experiments are central to testing and 
reframing conditional assumptions. 
c. Phase III 
Phase III is focused on planning to maintain progress and reduce relapse potential 
by working on beliefs and behaviours that will confer resilience in the face of future 
stress. If appropriate, a longitudinal case formulation is used to anticipate and plan 
for set-backs. 
d. Booster phase 
These appointments are optional with a very flexible content. Therapist and patient 
undertake a review of the difficulties experienced and identify specific therapeutic 
techniques from the core Phase I stage or any modules in Phase II which may need 
refreshing, practice or further work. Relapse prevention activities may also be 
undertaken. 
e. Transition and review appointments 
These sessions are an opportunity for therapist and patient to review progress, 
reflect on activities undertaken so far and move to the next Phase. The list of 
presenting issues and goals is reviewed and the formulation is revisited. A revised 
set of presenting issues and goals is developed for the next phase. 
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a. Socialisation to the CBT model 
 
Socialising the client to the CBT model includes the development of a shared sense 
of the treatment rationale. This includes the understanding of depression in relation 
to the 5 areas approach (Padesky & Mooney, 1990; Kuyken et al., 2009), and that 
change is possible though working on this model. Doubts and concerns are openly 
discussed and can be tested as part of treatment. Formulation of a presenting issue 
can help to apply this directly to the client’s situation and add a sense of face validity, 
cautious optimism, and begin to indicate treatment. This also helps to socialise the 
client to the style of CBT as one that is collaborative, Socratic and involves two 
experts in the room (the client as expert in their difficulties and the therapist as an 
expert in CBT).  
 
Structural aspects of the treatment are also outlined including agenda setting, 
homework between sessions, the empirical nature of treatment, use of measures, 
confidentiality agreements, the treatment contract, and frequency and duration of 
appointments. 
 
b. Goal setting 
 
Goal setting involves the shared development and agreement with the client on the 
specific goals for treatment in each of the problem areas identified. This is a further 
aid to the collaborative nature of the work to ensure that both therapist and client 
have the same aims in mind for treatment. Goals are important in making the 
expectation of treatment explicit and appropriate (as opposed to the unrealistic goal 
of never feeling anxious or placing expectations on the behaviour of others). Setting 
goals is important in identifying explicitly the possibility of change, and can help 
focus the client upon this possibility. Goals also help to underline the active focused 
nature of CBT treatment and that progress can be evaluated and reviewed. Goals 
also serve an important motivational function in providing a point of focus against 
which current patterns of activities, changes and future patterns can be judged as 
helpful and/or worthwhile. 
 
Goals developed should be consistent with the ‘SMART’ notion of goals in being; 
Specific, Measurable, Achievable, Realistic and Time limited. Goals may be 
developed further through being prioritised, graded and expressed in positive terms.  
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c. Activity scheduling 
 
Physical and social inactivity is a key feature for many people with depression. 
Periods of inactivity may be seen to lead to reduced experience of mastery and 
pleasure and increased negative thinking, typically rumination and self-criticism. 
Activities or tasks which the depressed person may previously have completed with 
ease or with enjoyment become challenging and may be avoided. Cognitions related 
to performance (I will fail, I will not enjoy it) may reduce further the motivation and 
likelihood of engaging in tasks. Activity scheduling is a strategy aimed at addressing 
low levels of motivation, inactivity and rumination and increasing activity that is 
associated with mastery and pleasure.  
 
By recording a person’s activity on an hour by hour basis and tracking mood over 
this time a picture can be built up to see the impact of the level and range of activity 
(or inactivity) upon the person’s level of depression. This is discussed with the client 
to identify those behaviours that impact negatively upon mood and those which help 
to improve mood. Where there is an absence of activity that improves mood this can 
be built into the person’s day to maintain momentum. 
 
This will allow the development of links between behaviour and emotion and 
subsequently cognition. Activities can be developed on the basis of increasing 
helpful activity, planning these at difficult times of the day and expanding the 
repertoire of behaviour. Prior activities that the person has enjoyed or selection of 
events from a pleasant events schedule (see J.S Beck, 2011) can be planned into 
the activity schedule. 
 
Barriers to engaging in activities can be helped though a range of strategies 
including problem solving, challenging negative automatic thoughts, planning and 
grading activities and cognitive rehearsal.  
 
Progress may be reviewed through a mood rating, scores for enjoyment (pleasure) 
and scores for achievement (mastery). The initial focus is upon changing the 
behaviour in advance of shifts in emotion. Small single point shifts in mood (up or 
down one point out of 10) are seen as significant and indicate future change. 
Changes in behaviour may need to be emphasised as having to reach a ‘therapeutic 
dose’ before improvements are noticed.  
 
As changes in mood (however small) are noted, these provide evidence to challenge 
any negative automatic thoughts associated with the task (e.g. ‘I can’t do anything’, 
‘nothing will make a difference,’ ‘these trivial events prove how pathetic I am’). 
It is important to keep this work focused on the collaboratively agreed presenting 
issues and goals.  
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d. Introduction to automatic thoughts – cognitive strategies 
 
Depression is characterised by a number of cognitive features. This includes Beck et 
al’s ‘cognitive triad’ that outlines depressive thinking in relation to the self, current 
experience and the future.  Negative views of the self are often characterised by 
thoughts that one is defective, useless, or inadequate. In this way difficult 
experiences are attributed to the self. This can also then lead to strong self-criticism. 
The second component leads the person to interpret their current experience 
negatively, with insurmountable problems or difficulties leading to a sense of defeat.  
The final element is about the future as difficult, expectation of failure and 
hopelessness.  
 
Automatic thoughts are an expression of this triad and occur habitually, automatically 
and involuntarily. A number of different categorisations of styles of automatic thinking 
have been developed, but all serve to fit perception with the negative triad. This then 
subsequently impacts upon the person’s emotions, behaviour and physical 
experiences and vice versa. These will often be raised in relation to the effectiveness 
of therapy and out of session tasks proposed.  
 
By practicing the identification and self-monitoring of these the client can become 
more aware of their presence and impact and begin to work to challenge these. 
Typically this may lead to the use of diary thought records and review of evidence to 
work towards a more balanced interpretation of events. This may well lead to 
planned behavioural experiments and the identification of patterns of thinking and 
behaviour that are more consistent with the client’s smart goals. Other cognitive 
strategies may include the use of survey methods to check for accuracy of cognitions 
and may be collected by the client, therapist or both. It is important to keep this work 
focused on the collaboratively agreed presenting issues and goals.  
 
e. Cognitive-Behavioural strategies – behavioural experiments 
 
‘The best way to increase the believability of your alternative or balanced thoughts is 
to try them out in your day to day life.’ (Greenberger & Padesky, 1995). 
Verbal challenging of thoughts is often followed by or developed through the use of 
behavioural experiments. This is often an important step in moving from an ‘in the 
head’ understanding through to a more felt sense of change by putting new or 
alternative understandings into practice; namely ‘walking the talk.’ Behavioural 
experiments are planned experiential activities based on experimentation or 
observation which the client does within or between therapy sessions.  
 
The primary purpose is to obtain new information which may help to test the validity 
of the patients’ existing beliefs, construct and test new more adaptive beliefs and 
contribute to the development and verification of the formulation. This will most often 
follow a process of identifying the cognition, developing an alternative and testing 
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these out on the basis of a clear prediction on how things will go according to these 
different perspectives. For an excellent overview of using behavioural experiments 
see Bennett-Levy et al. (2004). It is important to keep this work focused on the 
collaboratively agreed presenting issues and goals.  
 
f. Underlying assumptions/rules 
 
Underlying assumptions and rules represent the conditional level of belief and are 
typically captured in a cross-sectional case conceptualisation of the client’s 
presenting issues. These are the highly individualised conditional and generalised 
rules or terms of reference a person may hold, are usually functional and which 
dictate behaviour. Padesky (1994) has proposed that these are often best expressed 
in an If ________ then _______ format. For example, in depression this may be, ‘If I 
make a mistake at work, then I am worthless’ or ‘If my partner and I argue, then it 
means s/he will leave me.’ A collaborative articulation of conditional assumptions is a 
pre-requisite for testing beliefs using behavioural experiments. 
 
The same rule can be expressed negatively (If I don’t do something) or positively (If I 
do something). If I don’t make a single mistake and everyone says how well I am 
doing then I am okay; versus If I make a single mistake then I am worthless. 
Distress may be alleviated on a temporary basis by being able to meet the conditions 
for coping (the ‘if’ part of the rule). This however is seldom possible and does not 
normally support long-term change. The emphasis of intervention at this stage is 
therefore on the development of alternative more adaptive beliefs that provide a 
better fit with the person’s goals for treatment (e.g. If I make a mistake at work, then 
I am just like everyone else, and I can learn from it and develop). 
 
A possible example of an underlying assumption expressed as a rule is: ‘I must do 
things perfectly.’ This reflects the rigid, overgeneralised, absolute and extreme 
nature of problematic rules. Themes present within rules tend to be ones of 
achievement, acceptance, love or control. Violation of rules tends to be associated 
with extreme/excessive emotional reactions (anger, sadness, fear). Rules are likely 
to be activated in situations relating to individuals’ specific vulnerability. However 
they are often not conscious and are uncovered through the development of cross 
sectional formulations and themes occurring across time and events, or through 
specific techniques, such as the downward arrow technique; e.g. ‘if I can’t provide for 
my family, then my wife will be cross’. 
 
Socratic methods are used to review evidence for and against the belief, tracking the 
impact of the belief upon the person’s goals, and the generation of an alternative 
belief. Further experimentation is then used to strengthen conviction in this 
alternative and support its use over and above the original rule. This will very likely 
require patients do a lot of practice within sessions and as homework. It is important 
to keep this work focused on the collaboratively agreed presenting issues and goals.  
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g. Relapse prevention 
 
Relapse prevention is activity undertaken with the client to make explicit the learning 
and skills development that has taken place across the course of treatment. By 
helping the client to become aware of the specific skills used in self-formulation and 
which techniques are helpful, the chance of the client engaging with these skills and 
maintaining coping after treatment is enhanced. Explicit awareness of skills is 
typically identified alongside anticipated future difficulties and rehearsal of skills that 
would be helpful in this context. Relapse prevention can include further short, 
medium and long-term goals that the client will continue to work towards following 
the end of treatment, and a plan for how self-therapy will be continued. 
 
The emphasis upon coping may also be enhanced with the use of resilience 
formulation. This is the application of the same Beckian formulation model, but 
populated with the thoughts, feelings, behaviours and physical sensations 
associated with progress, alleviation of distress and meeting the goals for therapy. 
This may well include alternative underlying assumptions or rules for living 
developed over the course of treatment (See Kuyken et al., 2009).  
 
 
 
 
DOI: 10.3310/hta21460 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 46
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
285
 APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
286
 The following pages detail the structure of individual sessions to be conducted as 
part of the COBRA trial. There are separate pages for: assessment, Phase I early, 
mid and late sessions, the Phase I to Phase II transition, Phase II sessions, the 
Phase II to III transition, the relapse prevention sessions and the booster sessions.  
These session guides are the essential structure to the COBRA CBT protocol. 
Individual sessions have different session specific content, the details of which are 
described in the ‘therapist notes’ section of this handbook. Please use the technique 
specific instructions to tailor sessions but start and finish the sessions according to 
the session guides in the following pages. 
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9. Introductions and orientation 
 
10. Information gathering 
a. Brief description of problems (problem list): 
                         Development: precipitants, time course, predisposing factors   
b. Description of problem behaviour (typical example) 
                         Behavioural, cognitive, emotional, physical 
c. Contexts and modulating variables: Situational, behavioural, cognitive,    
affective, interpersonal, physiological   
d. Maintaining factors: Situational, behavioural, cognitive, affective, 
interpersonal, physiological 
e. Avoidance 
f. Coping resources 
g. Sessional measures and feedback 
h. Psychosocial situation: Family, relationships, accommodation, 
occupation, social relationships, hobbies/interests 
i. Past history, previous treatments and response, other current 
treatments, alcohol and drug use, co-morbidities 
j. Risk assessment 
 
11. Information giving 
a. CBT rationale 
b. Treatment session, duration and content details, role of worker 
c. Descriptive formulation of a typical presenting issue 
 
12. Homework setting 
a. Setting appropriate task: Further measures, complete activity record 
 
13. Summarise and check out collaborative understanding of session 
 
14. Appointment planning 
 
15. Ending 
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10. Setting the session agenda 
11. Sessional measures – review of measure completed on arrival in waiting area 
12. Risk review 
13. Review goals – develop SMART elements 
 
14. Session specific therapeutic content 
e. Review typical example of presenting problem 
f. Descriptive formulation of typical presenting issue 
g. Illustrate bi-directional nature of 5 areas approach 
h. Consider role of behaviour 
i. Talk through activity schedule and scoring (Mood overall, option of 
additional rating for achievement and enjoyment), and practice by 
completion of current day 
j. Set homework as activity recording for the week – problem solve any 
barriers to this 
 
15. Manage any other business from agenda 
16. Summarise (ideally client summarises), major feedback from client about 
therapy/therapist 
17. End by agreeing next appointment time and place 
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10. Setting the session agenda 
11. Sessional measures 
12. Risk review 
13. Review of activity schedule 
 
14. Session specific therapeutic content 
a. Review use of activity schedule 
b. Check for omissions and distortions 
c. Begin to demonstrate relationship between activity and affect 
d. Linking this to descriptive formulation of difficulty- beginning to note 
NATs linked to this 
e. Addressing NATs that have interfered with the homework 
f. Identification of behaviours that nurture and those that deplete 
g. Planning increase in nurturing behaviours 
h. Setting behaviour change as homework and problem solving barriers 
 
15. Manage any other business from agenda 
16. Major summary and feedback 
17. End by agreeing next appointment time and place 
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10. Setting the session agenda 
11. Sessional measures 
12. Risk review 
13. Review of activity recording sheets 
 
14. Session specific therapeutic content 
a. Development of role of NATs in activity and developing links between 
the 5 areas 
b. Identifying and recording NATs 
c. Considering thinking bias 
d. Developing diary thought record (DTR) 
e. Generating alternatives – linking DTR to Behavioural experiments (BE) 
f. Linking different responses to goals 
g. Homework linked to developing use of DTR and BEs 
 
15. Manage any other business from agenda 
16. Summarise and major feedback 
17. End by agreeing next appointment time and place 
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10. Setting the session agenda 
11. Sessional measures 
12. Risk review 
13. Review of DTR and BEs 
 
14. Session specific therapeutic content 
a. Revisit formulation 
b. Check progress against goals 
c. Address remaining treatment interfering processes 
d. Consider cross sectional formulation from descriptive formulations 
developed 
e. Develop overall plan for next phase 
 
15. Manage any other business from agenda 
16. Summarise and major summary 
17. End by agreeing next appointment time and place 
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10. Setting the session agenda 
11. Sessional measures 
12. Risk review 
13. Review of DTR and BEs 
 
14. Session specific therapeutic content 
a. Introduce role of cross sectional formulation 
b. Develop cross sectional formulation 
c. Link to conditional levels of belief (underlying assumptions)/rules for 
living 
d. Develop alternative conditional beliefs (underlying assumptions)/rules 
for living 
e. Linking different rules/assumptions to impact on goals 
f. Undertake specific exercises to challenge problematic conditional 
beliefs and build strength in alternatives 
g. Delivery of cognitive and behavioural interventions in line with the 
above 
 
15. Manage any other business from agenda 
16. Summarise and major summary 
17. End by agreeing next appointment time and place 
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10. Setting the session agenda 
11. Sessional measures 
12. Risk review 
13. Review of homework/out of session task 
 
14. Session specific therapeutic content 
a. Revisit formulation 
b. Check progress against goals 
c. Repeat rationales 
d. Identify remaining activities 
e. Consider need for longitudinal focus versus relapse prevention for 
progress to date 
 
15. Manage any other business from agenda 
16. Summarise and major summary 
17. End by agreeing next appointment time and place 
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10. Setting the session agenda 
11. Sessional measures 
12. Risk review 
13. Review of homework/out of session task 
 
14. Session specific therapeutic content 
a. Introduce concept of maintaining progress and/or reducing relapse 
potential 
b. Acknowledge necessity to manage forthcoming therapeutic ending 
c. Develop coping blue print, consider inclusion of: 
i. High risk situations 
ii. Early warning signs  
iii. Formulation developed 
iv. Coping in line with goals 
v. Resilience formulation 
vi. Goals for the future (short, medium and long term) 
d. Plan Longitudinal formulation if appropriate 
e. Intervention strategies at conditional level of belief (continua methods, 
alternative conditional beliefs, point-counterpoint) 
 
15. Manage any other business from agenda 
16. Summarise and major summary 
17. End by agreeing next appointment time and place 
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10. Setting the session agenda 
11. Sessional measures 
12. Risk review 
13. Review of homework/out of session task 
 
14. Session specific therapeutic content 
a. review of difficulties experienced  
b. review of formulation 
c. identification of specific therapeutic techniques to revisit 
d. relapse prevention activities 
 
15. Manage any other business from agenda 
16. Summarise and major summary 
17. End by agreeing next appointment time and place/end 
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A number of sources provide information on the structure and focus of a CBT 
assessment. This information will focus upon the guidance developed from A.T. 
Beck at al (1979); J.S. Beck (2011); Kirk (1989) and Moore and Garland (2003). 
 
Initial contact with the client can serve a number of purposes, not least of which is to 
develop an individual formulation of how the cognitive model applies to this client’s 
difficulties. This necessitates an understanding of how problems have developed and 
how they are maintained. This will help to devise the treatment plan and may help to 
predict difficulties in treatment. The development of assessment and formulation is 
also used to develop the collaborative sense of treatment and to convey that the 
therapist understands the difficulties the client describes. Through this approach the 
therapist aims to inspire a sense of hope and to start to form a good therapeutic 
alliance. Formulation of a client’s presenting issue from information gathered is also 
an optimal way of socialising the client to the model and the expectations for 
treatment. 
 
The main aims of a CBT assessment may therefore be considered as: 
 
• Generating a ‘list of presenting issues (problem list)’ 
• Identifying SMART goals for treatment 
• Assessment of factors maintaining the problem(s)/current situation 
• Socialising to the model and treatment 
• Generating a descriptive formulation (5-part model or hot cross bun) 
• Assessment of the development of presenting issues  
• Assessment of the client’s view of presenting issues and treatment 
 
Setting the boundaries and expectations: 
 
The structural elements and expectations of treatment should be explicit and 
transparent. This includes discussion of arrangements with regard to: 
 
• Consent to treatment, recording and information collection (measures) and 
sharing. 
 
• Confidentiality arrangements, with particular respect to storing of materials 
(notes, recordings), supervision arrangements, information sharing, and when 
the law requires information to be shared (e.g. risk to self or others) and how 
this will happen. 
 
• Treatment as an active process with an expectation upon out of session work 
between meetings, and an active collaborative experimental approach. 
 
• Arrangement for timing, frequency and location of meetings, including the 
setting of a treatment contact and any limitations in terms of the maximum 
length of treatment and non-attendance. 
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Assessment and generating the presenting issues list: 
 
Current symptoms and problems are assessed in order to develop the list of 
presenting issues (sometimes known as the ‘problem list’). This requires the 
collection of information about what the client feels they are intending to gain help 
with. Basic information is then collected regarding the onset, duration and course of 
difficulties. 
 
During this phase it is particularly important to use the client’s words, to listen 
carefully and communicate caring concern to the client, with validation of the 
difficulty that the client is experiencing.  This is placed alongside instilling optimism 
for the possibility of change. Validating statements such as ‘This is obviously very 
difficult/upsetting for you’ and summarising the client’s discussion and checking for 
understanding are important.  
 
To generate the list of presenting issues it is helpful to ask the client what he/she 
sees as the main problems. These can then be explored subsequently in greater 
detail once a brief description of each has been elicited. Difficulties may then be 
prioritised by the client in order of difficulty and focus. The area of greatest concern 
can then be explored in greater detail by discussion of a typical example. 
 
The presenting issues list can then be added to over the course of the assessment 
and reviewed as the client discusses each of their presenting issues in turn. These 
may be added to and revised over the course of treatment.  
 
Development of the problem: 
 
Assessment of developmental factors in CBT is focused upon information that is of 
direct relevance to the development and maintenance of the presenting issue which 
is being focused upon.  
 
Onset, duration and course: 
 
Difficulties may have a clear onset, or may be more likely to have developed 
gradually over a succession of events and time. The course of events may also vary 
for the individual, perhaps persisting steadily or coming in waves with marked 
fluctuation. It may be helpful to track long standing fluctuations on an event time 
chart. Changes in presentation may also be considered in light to any treatment or 
intervention entered into. It may also be the case that the factors leading to the onset  
of difficulties may vary from those that are now maintaining it. Any clear predisposing 
factors that made the client more vulnerable to the difficulties currently presenting 
may also be noted from the perspective of understanding why difficulties have 
developed and to aid what that may mean for treatment now. 
 
Description of the problem behaviour: typical example 
 
Once an overview of the presenting issues has been identified, it is helpful to 
consider a detailed example of the main (highest priority) presenting issue. It is 
important to check that the example to be discussed is typical of the presenting 
issue.  
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Ask the client to then give you detail regarding that example. If this is difficult for the 
client to explain, it may be helpful for the person to close their eyes and imagine the 
scene as it was happening.  
 
The therapist can then assess the example from the 5 areas approach by 
considering: 
 
The context or environment: 
Where was the client, when was it, what were they doing, who else was involved, 
how were you feeling physically, how where you feeling emotionally? 
 
Emotions: 
Clients will most often be feeling aware of how they are feeling emotionally in 
situations. People will often seek to avoid or control their experience of emotions 
which can play a large part in their maintenance. The emotions the person 
experiences will therefore need to be assessed. A person with a diagnosis of 
depression will typically not only be feeling a strong sense of sadness, but may also 
experience anxiety, anger and shame amongst other emotions. How did that 
person’s emotional state impact upon their thinking, behaviour and physical 
sensations? 
 
Behaviour: 
Within depression as noted above, the behaviours that a person engages with will be 
aimed at managing or avoiding certain emotion experience (but then becomes 
maintaining of this). What is it that the client is doing to manage his or her situation? 
 
Common behavioural responses to depression are withdrawal, isolation and 
rumination. Avoidance is common within depression and can serve to maintain the 
person’s sense of failure or self-criticism.  
 
Within the specific example: How did the person react in that situation? What did 
they do in order to manage how they are feeling? What was the impact of that 
behaviour? What did they hope to achieve by that behaviour? How does the person 
feel about responding in this way; do they see it as a problem or something that is 
helpful? How does it fit with their hopes for the future? 
 
Thoughts: 
What are the NATs or other cognitions that were maintaining of the person’s 
difficulty? What was going through your mind at that point? Is that typical for you? 
How much do you believe this? How does this thought make you feel? What do you 
want to do when you have this thought? 
 
Physical sensations: 
How does the person feel physically in this situation? Does this typical pattern of 
events led to other physical difficulties, such as poor concentration, poor sleep, poor 
memory, lethargy, shaking, numbness, pain or other physical sensations. Physical 
embodiment of depression is not uncommon and may even impact upon your client’s 
presentation in the room in terms of their posture, eye contact or level of 
engagement and energy. 
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Socialising to the model (CBT rationale) and the bidirectional relationships 
between areas: 
 
This information can then be collaboratively used to develop a descriptive 
formulation of this presenting issue to provide some psycho-education regarding the 
focus of CBT work. Socratic exploration of the impact of each area upon another and 
that this relationship is bidirectional is important.  
 
• When you were in this situation what was going through your mind? 
• When you were thinking this way how did that make you feel?  
• The more you had these feelings what happened to these thoughts?  
• When you were thinking and feeling this way what did you do in order to 
manage this?  
• What was the impact of this upon these thoughts and these feelings, etc? 
• What do you think this might mean about what is important for you to move 
forward? 
 
Below is an example of descriptive conceptualisation for a man who experienced 
depression and anxiety that was impacting his work and home life. 
 
 
Once a typical example had been explored other examples or presenting issues 
could be explored with exploration around the 5 areas to consider other modulating 
and maintaining factors. 
Behind on my work at the office.  
 Sitting at home thinking about 
work, and remember making a 
mistake 
Behaviour 
Sit on my own;  
Avoid Claire 
Physical  
Reactions 
Tense, tearful 
Thoughts 
I have messed it up 
I am useless at my job 
I am a failure (9) 
 
Moods 
Sad,  
low (9) 
 
My Life 
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Modulating variables and maintaining factors: 
It may be important to assess for other factors outside of the typical example which 
impact upon the person’s presentation.  
 
Are there contexts when the difficulties are more or less present, or when the client 
had been able to show increased coping in the past. Are difficulties more prominent 
in the presence of others? What are the relationships like with key others in the 
person’s life and how do these impact upon the person’s presentation? Are there 
short and long term impacts upon the person’s pattern of behaviour? 
 
Moore and Garland (2003) provide some useful questions to elicit further information 
regarding emotions, cognitions cognitive processes and behaviour. 
 
Coping resources: 
 
It is also important in the assessment of depression to be able to see and build upon 
the coping resources and resilience that a person has. These may well provide a 
good platform for further competence and may be the starting point for expansion 
into alternative coping in line with the persons preferred sense of their future. 
 
These may also be considered from the same five areas approach. Has the person 
had times when he/she has been able to engage in difficult events and find that 
he/she was able to cope? What activities, roles or friendships has the person been 
able to maintain despite the difficulties he/she is experiencing? It is important to keep 
these explicit and these may even be formulated. 
 
Psychosocial situation: 
 
Consider the broader context within which difficulties are occurring; some of which it 
may be possible to help access professional support for and other may be facilitated 
through problem solving. This broader context includes; family, relationships, 
accommodation, occupation, debt, unemployment, social relationships, and physical 
health concerns. 
 
Goals: 
 
As part of the assessment and formulation it is important to have a developing sense 
of the client’s goals for treatment. Initially this may be broad and is shaped up further 
over time. Goals can be helpful to provide a clear shared sense of what the client 
and therapist are both working towards through treatment and how they will know if 
this is being achieved. What would the client like to be different by the end of 
treatment? How would things look if the difficulties were no longer present, and how 
would others know about or see this change? This beginning will be shaped into 
SMART goals at this or subsequent sessions. 
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Goal setting: 
 
The collaborative setting of goals for treatment should be developed in SMART 
terms. SMART stands for: 
 
Specific: what would that look like?  
 
Measurable: how would you know, what would have changed? 
 
Achievable: does this goal involve changing things that are under your control? 
 
Realistic: is this something you can see happening? Would other people say this is a 
realistic goal? 
 
Time constrained: when would you like this to have changed by?  
 
Goals should also be expressed in positive terms (what will be present) rather than 
negative terms (things being absent). In other words, rather than ‘feeling less 
depressed’ (negative statement of goal) the therapist might enquire, ‘So if you were 
feeling less depressed, how would you be feeling instead’, and ‘how would you know 
that this had happened, what would others notice?’  
 
On this last question goals may also be best expressed in concrete operational 
terms. In other words, how would this impact upon the person’s behaviour, what 
would we see them doing. By expressing goals in these terms they can be easier to 
measure.  
 
Goals developed may also be prioritised: 
 
Do you need to tackle any of these goals right away to avoid a crisis? 
Which goal would make the most immediate improvement to your life? 
Is there another goal you need to reach first before you can accomplish this 
one? 
Which of these goals is most important to you? 
Which of these goals would be the easiest?  
 
Goals may also be broken down into smaller steps to shape performance in 
approximating towards goals with manageable steps helping to increase the 
possibility of engagement.  
 
Questions for eliciting goals (Moore & Garland, 2003): 
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What goals would you like to work towards in treatment? 
 
In what ways would you like things to be different? 
 
What would you like to change most about your current circumstances? 
 
What things have you stopped doing since you became depressed which you 
would like to resume? 
 
Are there things that you have started doing since you became depressed 
which you would like to change? 
 
What would you be doing differently if you were not depressed? 
 
On a recent trial with a depressed population (Thomas et al. 2011), difficulties 
related to goal setting were often cognitive in nature, such as; 
 
‘I can’t set goals, or things will go wrong’ 
‘If I set goals then I’ll only fail and feel worse’  
‘I can only cope 1 day at a time’. 
 
There are cognitive responses which are amenable to the same interventions as 
other thoughts. It has been helpful to conduct behavioural experiments on these 
thoughts, to break goals down further into smaller more manageable steps and to 
consider the impact of these thoughts on the possibility of change. 
 
Homework setting 
 
Why set homework? 
 
Homework is set in CBT to develop alternative understandings, provide a structure 
for gathering data and testing hypotheses (used in sessions) and the transfer of in- 
session skills to a real world setting. Homework is also focused upon maintaining 
skills use and preventing relapse. It also reflects the stance in CBT of developing 
skills in order to develop the client’s autonomy rather than reliance. Perhaps most 
importantly, setting and completing homework makes progress in treatment more 
likely, more rapid and longer lasting (Kazantis et al., 2000). 
 
How do we set homework? 
 
In setting any homework tasks, it is important that the therapist provides a clear 
rationale for tasks undertaken, and that this rationale is checked and understood. 
Tasks must be developed through negotiation and collaboration. Tasks which are 
empowering and jointly developed rather than imposed are more likely to be 
completed. A clear description of tasks with precise goals should be developed and 
the content of these should flow naturally from material in the session. 
 
The nature of the rationale should include the idea of this as a no lose or win-win 
scenario. If an experiment is undertaken and positive changes take place as a result 
then we win. If homework is undertaken and difficulties emerge, then through 
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discussing these difficulties, understanding them and developing skills to manage 
and overcome them we really win. 
 
Homework should be explored with sufficient time in the session to work with the 
client to explore potential obstacles and how these may be overcome. This includes 
open discussion to elicit client reactions, and to take feedback on this. Does the task 
seem useful, meaningful, purposeful, manageable and clear? 
 
What to set as homework? 
 
At the beginning of treatment this may well be set by the therapist to begin to form 
the expectation of homework as a weekly occurrence.  The homework developed 
should be a continuation of the content of the session. As an intervention and 
development of understanding, this should be linked to the formulation and help to 
develop the client’s skills. 
 
Initially homework tasks may be more psycho-educational, including reading 
materials provided, listening to a recording of the session or working up to goals for 
treatment. These may then develop as the work progresses towards testing new 
beliefs, exploration of beliefs and alternatives, experiments with new behaviours and 
the use of strategies to overcome obstacles. 
 
Homework should be adjusted according to the difficulty that the client has in 
completing the task, and care should be taken not to overload clients. During a more 
acute phase of depression small and specific tasks are likely to be more appropriate. 
As symptoms relief is achieved, then more complex tasks may be negotiated. 
 
Within depression the client may often report feeling unsure as to what the 
homework task was. Tasks should therefore be simple, explicit and concrete. This 
may also be helpful where the client may have worries regarding not completing the 
task correctly. For example, asking a client to keep a thought diary of negative 
automatic thoughts may be aimed at recording 5 examples of this, rather than the 
client feeling that they needed to capture every experience of this. This should be 
rehearsed within the session, with the client having a clear understanding of the 
rationale for this.  
 
Review of homework should always be a priority for the next session. Failure to do 
this may result in reduced motivation for work between sessions, a feeling of 
disinterest or disrespect on the therapist’s behalf, or a sense of having done this 
work or being unworthy of this interest. Learning developed from experiments should 
ideally be recorded by the client and related to the formulation. 
 
Tips for homework setting: 
 
Ensure homework is collaboratively set 
Check the client understanding of both the task and the rationale 
Rehearse the task wherever possible 
Elicit client reactions to the task 
Identify together any possible barriers to completion and problem solve these 
(the win-win approach) 
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Formulate barriers to completion 
Don’t give up setting homework 
Consider any therapist interfering cognitions in effective homework setting 
(e.g. ‘there’s no point’, ‘I’ll just give a task, there isn’t time to set one 
together’). 
Relate the task to the formulation (see diagram below) 
 
Improving Access to Psychological Therapies - High Intensity
Consider from CTS-R
Conceptualisation
Affect
PhysiologyBehaviour / 
planning
Cognition
What will you learn about
your situation if you are able
to complete the task?
Do you want to 
try this?
How anxious 
will you 
feel?
What will you do if you feel very tired 
or have palpitations
What will be useful to do 
to check that belief or 
thought out?
What might prevent 
you from carrying 
out the task?
What thoughts might 
interfere with you 
carrying out this task?
 
Useful questions to ask yourself: 
 
Did I give a rationale underpinning the assignment? 
Did I check the client was confident in being able to take on the task? 
Did the client see the relevance of the task? 
Was the homework adequately planned within the session? 
Were obstacles to the homework discussed? 
Was the most appropriate task set? 
Was it consistent with the content of the session? 
Will the client learn something useful from engaging in this task?  
 
Obstacles to homework: 
 
Client does not do homework. How could you respond? 
Use this as the focus of the session. 
Assess what led to difficulties in completion 
 Were there any practical difficulties (cost, opportunity, other priorities)? 
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Beliefs or emotional response to the task? 
Did the client understand the task? 
Did the client understand the rationale?  
 
Partial completion of homework; how do you respond? 
Reinforcement/shaping 
Problem solving  
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Depression is characterised by long periods of inactivity and rumination. Reduced 
levels of activity with negative thinking and low mood are conceptualised as forming 
a vicious cycle for depression. Once the client has been socialised to the model, 
standard treatment within CBT leads to behavioural activation.  
 
Impact of depression upon behaviour: 
Reduction in activity, increase in withdrawal/avoidance 
Increased engagement with rumination 
Reduction in sense of enjoyment and achievement 
Energy often focused upon maintaining chores and duties 
Loss of contact with support network and protective factors 
Activities maintained may become aversive (I did it poorly, no-one was 
interested, I’m much worse at it). 
 
Improving Access to Psychological Therapies - High Intensity
Depressive symptoms:
tiredness, lack of confidence, 
poor concentration, low 
motivation
Decrease in 
activity:
e.g. stop playing 
football, stop 
phoning friends
Stop initiating 
new activities: 
e.g. work contract 
ends and do not 
initiate new one
Avoidance of 
challenging 
situations / 
behaviours: 
e.g. turn down invite 
to party
 
 
 
Step 1: The first stage of activity scheduling is to monitor the client’s level of activity.  
 
This involves asking clients to record their activity on an hour by hour basis and to 
rate their mood at that time. This may be broken down further into rating of 
achievement (a sense of mastery) and enjoyment, though for many clients this may 
remain as a global rating of mood overall. Typically these will be given a rating out of 
10 where 0 amounts to none at all and 10 being the highest level. One of the key 
points to emphasise here is that a client is never doing ‘nothing’. When you are 
sitting in a chair thinking things over and over, this is your activity. In depression it 
may be important to rate ‘mood’ overall out of 10 where the client is unable to break 
this down further, and may experience strong NATs about their ability to complete 
the task. 
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The therapist and client then consider this recording to consider the activities that 
help to improve mood and are more consistent with the client’s goals and those 
which deplete the client further. This can help to emphasise the links between 
activity and emotion; and may well be helpful in identifying cognitions that are 
maintaining difficulties (e.g. none of this will do any good’) as well as helping to 
challenge this thought as activation progresses. The capacity to change behaviour 
and experience a direct impact on mood is also important in developing a sense of 
agency as being the agent for change. 
 
This will be best rehearsed in the session and the brief nature of description and 
scoring can help to overcome client concerns about the level of difficulty in 
completing the task.  
 
Improving Access to Psychological Therapies - High Intensity
Monday Tuesday Wednesday
Get up, 
shower and 
dress
E = 3
A = 3
Lie in and 
watch TV
E = 2
A = 1
Get up, 
shower and 
dress
E = 2
A = 2
9 – 10am Eat breakfast 
and read 
paper
E = 5
A = 2
Get up, 
shower and 
dress
E = 2
A = 3
Answer 
emails and 
drink coffee
E = 4
A = 5
 
Step 2: Monitor and review. Identifying activities that promote positive mood and 
nurture the client in line with their treatment goals and activities that deplete the 
client and lead to lower mood ratings.  
 
This means being sensitive to activities that raise or lower mood by a single point 
and that planning and developing positive activities at key times for vulnerability can 
increase a sense of agency and the possibility of change. 
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Once the client has completed the activity record, this data is then used to provide a 
baseline for the overall level of activity and mood. The therapist and client review 
those activities completed and consider: 
 
Which activities increased the rating of mood (and enjoyment and 
achievement) or maintained improved mood levels? 
Which activities reduced mood or maintained low levels of mood (and 
enjoyment and achievement)? 
Were there times of the day when mood was most vulnerable? 
Which patterns were most consistent with the person’s goals? 
And on the basis of the above, what would be important in the coming 
week? 
 
In essence, step 2 includes steps to increase frequency and intensity of rewarding 
behaviour: 
 
Identify sources of reward 
 
Increase rewarding behaviour  
Intensify/increase existing behaviours 
 Enhance skills in behaviours that bring reward 
 
Decrease avoidance behaviour 
 
Enhance self-reinforcement 
 
Additional behaviours that may help promote positive mood may be drawn from prior 
experience/activity, be activities that the person has recently withdrawn from, may be 
activities that the person has previously considered, may be drawn from lists of 
suggested possible activities. 
 
Helpful Questions/Considerations 
 
How is time being used? 
 
Are activities planned or spontaneous? 
 
Are activities rewarding? Monotonous? ‘Shoulds’? Alone/with others? 
Ruminative? 
 
Which activities are associated with most/least E and A? – list 
 
How do activities relate to life goals? 
 
What did you learn from this?  
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Step 3: Scheduling & review: During this stage the therapist is working to engage 
the client in activities of daily living and tackle biological symptoms of depression 
(e.g. concentration and memory deficits, lack of energy, procrastination). This stage 
may also include addressing those cognitions that prevent engagement with the 
task. A model of looking at TICs (Task Interfering Cognitions) and TOCs (Task 
Orienting Cognitions) has been developed by Burns (1989). 
 
The concept of TICs and TOCs is aimed at addressing the negative thoughts that 
clients’ may have when planning tasks. This approach helps to identify the process 
and impact of negative thoughts and in this way awareness and alternative 
responses can be facilitated. Some thoughts (TICs) are tracked as obstacles to the 
task in hand (e.g. ‘I can’t do it’) and the consequences of them made explicit. The 
validity of these thoughts can then be tested through activity and experimentation. 
TOCs represent the thoughts that are helpful in allowing the person to attempt the 
task in hand (e.g. ‘I can give this a try’).  
 
Common problems in activity scheduling: 
 
Moore and Garland (2003) provide guidance on managing challenges in monitoring 
activity levels in clients with depression. Below is a summary of some of the issues 
considered. 
 
The client has difficulty in completing an activity schedule: 
 
Don’t 
 Give up in monitoring of activities 
 Conclude that the client is too unmotivated to make progress 
 Pressurise or lecture the client that not doing tasks will stop them from getting 
better (as this is likely to lead to thoughts that trying only leads to failure and 
therefore future engagement is reduced further) 
 
Do: 
Find out about the reasons for difficulty 
Simplify the monitoring procedure (e.g. rate mood overall rather than 
enjoyment and achievement, simplify the recording form to am and pm). 
Monitor activity monitoring in the session 
Frame the task as an experiment to find out more about the difficulties 
 
The client gets no sense of mastery or pleasure (or enjoyment) from their activities: 
 
Activities previously performed may have become less satisfying through a number 
of possibilities including tiredness, applying a high standard of expectation for 
performance, being duty-focused activities or the sense of anhedonia. 
 
Don’t: 
 Try to persuade the client that the things that they are doing are in fact 
satisfying 
 Make numerous suggestions of activities that the person may find pleasurable 
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Do: 
Check that ratings accurately reflect satisfaction gained when performing the 
activity 
Identify if previously satisfying activities are being overlooked or may have 
become unsatisfying 
Elicit and highlight thoughts which may deprive the client of potential 
satisfaction 
Use graded task assignment to simplify tasks 
Test ratings of mood, enjoyment and pleasure on reducing excessive activity 
levels 
 
Graded task assignment refers to increasing the likelihood of success in setting new 
behaviours by breaking down tasks into small, manageable steps. Each small step is 
reinforced in its own right. The moving through steps is aided by identifying and 
challenging barriers to completion. This may lead to cognitive challenging or 
strategies to manage anxiety provoking situations such as exposure response 
prevention. Graded task assignment aims to reduce the client’s experience of 
difficulty (and the chances of taking this as evidence of failure) by encouraging 
progress towards goals with manageable steps, to increase the frequency of rewards 
through repeated completion of these steps, and to judge progress in light of the 
difficulties that they are facing (Fennell, 1989). 
 
The therapist is confronted by a barrage of negative automatic thoughts as to why 
graded task assignment is not going to work 
 
Clients may often report thoughts in relations to activity scheduling on themes of: ‘it 
won’t do any good’ or ‘it will make me feel worse’. A sense of low expectation for the 
task may relate to rules applied by the person for them to be effective, i.e. task 
perfectly completed. 
 
Don’t: 
Attempt to modify a barrage of automatic thoughts 
Accept the person’s assertion (e.g. this won’t do any good) 
 
Do: 
 Remain focused upon the task in hand  
 Draw the client’s attention to the negative thoughts 
 Use the TICs/TOCs technique 
 Formulate the consequences of the negative thinking 
 
Engaging in the task results in a worsening of depressive symptoms 
 
Whilst in general terms engagement in activity leads to some alleviation of 
depressive symptoms, it is also possible that clients will report feelings of exhaustion 
and lowering of mood when engaging with tasks.  
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Don’t: 
Disbelieve the client or dispute that they feel worse 
Press on with assigning activities as though everything was going well 
Give up on assigning activities 
 
Do: 
Take the limitations imposed by depressive symptoms fully into account 
Break down tasks into smaller chunks or less demanding tasks 
Draw attention to the effects of deprecatory thoughts about starting with small 
activities 
 Weigh up the pros and cons of engaging in small activities 
 
The effects of depressive symptoms on energy levels, concentration and pain levels 
are all too real and have physical effects that could perhaps be measured. It may be 
important for clients to acknowledge this difficulty. This may highlight the client to see 
the difficulties in aiming for an immediate non-depressed level of activity and 
functioning. This is replaced by breaking down tasks into feasible steps forward. The 
role of the therapist therefore includes helping to strike the balance between what is 
an appropriate level of demand when goal setting in the context of the constraints 
imposed by depressive symptoms. 
 
The client’s hopelessness and avoidance are so entrenched that suggesting any 
activity provokes a hostile reaction 
 
The level of difficulty and hopelessness that a client may experience in depression 
could lead to any suggestions for engagement in activity being experienced by the 
client as a failure of the therapist to understand their difficulties. Therapist 
suggestions may be seen as attacking or insulting. 
 
Don’t: 
Give up or become quiet and withdrawn 
Insist that the client carry out the suggested task 
Rely solely on questioning 
Retaliate or become angry or critical of the client 
 
Do: 
Try to maintain activity and structure in the session 
Focus on understanding the client’s reaction 
Make educated guesses about this reaction and share them with the client 
 Return to formulating and socialising the client to the cognitive model 
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Much of CBT intervention is focused on developing the client’s skills to identify, test 
and challenge negative automatic thoughts (NATs). The focus of techniques 
designed to develop these skills is on symptomatic relief and the management of 
difficulties in life. Negative automatic thoughts are the situation-specific thoughts of 
which patients are often largely unaware. They are automatic, habitual and plausible 
for the recipient.  
 
Improving Access to Psychological Therapies - High Intensity
Early experience
Core beliefs
Dysfunctional / 
conditional assumptions
Beck’s model of 
Depression
Critical incident Beliefs / assumptions 
activated
Negative Automatic Thoughts
(cognitive triad: self, world, future)
Biases in thinking / 
systematic logical 
errors
EmotionsPhysical sensations
Behaviours
 
 
The first step in managing NATs is to be able to catch and identify them. This is the 
first step of cognitive skills developed in treatment. Typically the experience of 
unpleasant emotions is taken as a trigger to consider the situation in which the 
emotions occur and then to identify the associated negative automatic thoughts.  
 
Changes in mood are a signal to the presence of NATs. The client can be helped to 
begin the process by rating (0-10) and becoming aware of changes in emotion. 
Socialising clients to rating their emotions can also help to increase their sensitivity 
to changes in strength and nuances of emotions when challenging NATs. Then ask 
the client to consider in what situation these feelings were occurring. What were they 
doing, or thinking, who were they with, where were they and what were they doing? 
Clients should then be asked to consider what was going through their mind when 
they began to feel this way and to rate how much they believe this thought (0-10). 
This can lead into further descriptive formulation (hot cross bun) and homework 
based upon practising this skill. Recording of NATs identified will typically be 
completed with the use of a thought diary, such as those provided by Greenberger 
and Padesky (1995).  
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These skills may be facilitated by the therapist in noticing shifts in emotion as they 
occur during the session and exploring the above steps with the client through the 
Socratic Method. 
 
Questions to help elicit NATs: 
 
What was going through your mind just before you started to feel this way? 
What does this say about you? 
What does this mean about you? Your life? Your future? 
What are you afraid might happen? 
What is the worst thing that could happen if this is true? 
What does this mean about how the other person thinks/feels about you? 
What does this mean about the other person(s) or people in general? 
What images or memories did you have in this situation?  
 What images went through your mind? 
 
Beck at al (1979) highlight strategies for the detection of automatic thoughts as: 
1. Catching thoughts as they occur and recording them at the time that they 
occur. 
2. Setting aside some time each evening to replay events that led to the 
thoughts as well as the thoughts themselves. 
3. Identifying specific environmental events leading to feelings of depression; are 
there times or events that often lead to low mood and what is the meaning of 
these events to the person? This may even lead to deliberate engagement 
with these environmental events to help to identify cognitions, which are then 
focused upon in treatment to work to symptomatic relief.  
 
Fennell (1989) identifies some common difficulties in working with clients to identify 
NATs including: 
 
a) Client avoids recording thoughts: 
 
Strong feeling of depression may make it difficult for the client to diffuse from the 
emotional experience in order to identify their thoughts. Awareness may at time 
increase the level of negative affect. Therefore for those who find this difficult the 
development of behavioural interventions to alleviate low mood may be critical. 
Additionally, it is important for clients to have a clear sense from socialisation of the 
rationale for this approach to facilitate engagement. Awareness however, may be 
particularly helpful for clients to begin to address those distressing thoughts in order 
to move forward. 
 
b) Therapist and client find it difficult to identify the NATs: 
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Where clients are unable to identify any NATs it may be helpful to socratically 
question the personal significance of events (e.g. ‘what does this mean to you, what 
does it say about you/your situation/your future?’) Moore and Garland (2003) also 
identify this difficulty when working with depression and suggest that therapists: 
 
Don’t: 
 Become abstract and try to describe the definitive features of an automatic 
thought 
 Assume there is necessarily avoidance or resistance at work 
Do: 
 Consider words, images and meanings 
 Persist with standard techniques, including review of upsetting events, mood 
changes occurring in session and automatic thought records 
 
Among further difficulties and strategies identified by Moore and Garland (2003) is 
the challenge that: 
 
The client refuses to discuss upsetting situations 
 
Avoidance may take many forms in depression, including intentional cognitive 
avoidance as a strategy to try to manage distress. It may therefore be particularly 
challenging for clients using this strategy to be asked to deliberately focus upon and 
record their thoughts.  
 
Don’t: 
Insist that the client discusses the upsetting situation 
Change focus to an unrelated area 
 
Do: 
Identify the client’s thoughts about discussing upsets 
Use these thoughts to illustrate the cognitive model 
Discuss the pros and cons of not thinking about upsetting things 
Approach discussion of upsetting situations in a graded fashion 
Point to the possibility that particular underlying beliefs may be magnifying 
upsets. 
 
By developing awareness of NATs, clients may also be helped to identify patterns in 
their thinking which can help to increase their awareness, create distance from them 
and manage them. 
 
Systematic logical errors: Reasoning biases 
 
Mind reading is making assumptions about what others are thinking. 
 
Emotional Reasoning is using how you feel to infer what is going on. 
 
 Discounting is ignoring evidence that contradicts your view. 
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Labelling is putting a global label on an incident of a certain type without 
responding to what is specific and different about that incident. 
 
Arbitrary inference is drawing a specific conclusion in the absence of evidence 
or when the evidence is contrary to the prediction. Jumping to conclusions. 
 
Selective abstraction is focusing on a detail out of context whilst ignoring other 
important features of the situation. Mental filter/tunnel vision.  
 
Overgeneralisation is drawing a general conclusion on the basis of one or 
more isolated incidents and applying across the board to related and 
unrelated situations. 
 
Magnification/catastrophisation is exaggerating the significance or importance 
of an event in a negative direction. Fortune telling. 
 
Personalisation is inappropriately relating external events to oneself. 
 
Dichotomous thinking is judging events as either good or bad, black and white 
thinking. All-or-nothing thinking. 
 
Making ‘should’ or ‘must’ statements is having an over-precise idea of how 
you or others should behave, not taking into account situational factors. 
 
Further examples of thinking errors are available, one example being Moore and 
Garland (2003, p.389). 
 
Once the client has identified NATs the next step is to question the thoughts and 
track their impact upon the person’s mood, how they fit with the client’s SMART 
goals, and the validity of the thoughts. There are a number of methods to help the 
client test automatic thoughts. 
 
Methods: 
Reviewing evidence for and against (thought records)  
 
Behavioural experiments – this will be expanded further in relation to 
underlying/conditional assumptions 
 
Responsibility pies - Attribution of blame/responsibility beliefs   
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 Surveys – ‘everyone thinks/does this don’t they?’ 
 
 Looking at the origins of the thought 
Can you remember when you began to hold this view? 
Are there times in the past when X happened and you did not think 
this? 
What experiences have led you to think this?  
 
 Role playing the thought 
 Client argues FOR the thought, therapist argues AGAINST it.  
 Then swap roles   
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Thought records 
 
Thought records as identified below are typically worked through with the client to 
begin to challenge the NATs identified. The example below is based on Greenberger 
and Padesky (1995) and provides prompting questions that the therapist and client 
can work through together in the session, prior to use between sessions. 
  
The client is asked to consider current and historical factual evidence that is 
consistent with both the ‘hot thought’ (the thought with the most emotion attached) 
and evidence that is not consistent with the thought. This information may be 
currently available, or experiments may need to be carried out in order to test the 
thoughts. The use of thinking bias may be helpful in considering how information that 
is not consistent with the hot thought is excluded, or processes such as ‘emotional 
reasoning’ (‘I feel it therefore it must be true’) that may treat emotions as if they were 
facts. 
 
Improving Access to Psychological Therapies - High Intensity
THOUGHT RECORD
1. Situation 2. Emotions 3. Automatic 
thoughts
4. Evidence 
that supports 
the hot thought
5. Evidence 
that does not 
support the 
hot thought
6. Alternative / 
balanced 
thoughts
7. Re-rate 
moods 
now
8. What 
should I do 
now?
Brief 
description 
of what was 
happening, 
what you 
were doing 
at the time?
Describe 
each emotion 
in one word. 
Rate the 
intensity of 
the emotion 
from 0-100%
What was going 
through your 
mind?
What does this 
say about you?
What is the worst 
that could 
happen?
Write factual 
evidence to 
support his 
conclusion.
Try to avoid 
mind reading / 
emotional 
reasoning.
Write factual 
evidence that 
does not 
support this 
conclusion.
Based upon the 
evidence what 
would be a 
balanced 
alternative 
thought?
Rate how much 
you believe this 
thought 0-100%
Copy the 
emotions 
from 
column 2. 
Re-rate 
their 
intensity 
from 0-
100%
What should 
you now do 
based upon the 
balanced 
thought?
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Useful questions: 
 What evidence do you have that supports this thought? Are there other 
times/experiences that have made you think this?  
 
 Is there any evidence that does not support this thought? Before you got 
anxious/depressed , when you were younger? 
 
 Are there any experiences that show the thought is not completely true all the 
time? 
 
 What would I say to a friend? 
 
 What would a friend say to me? 
 
 When I’m not feeling like this do I think about this situation in a different way? 
 
 When I felt this way in the past, what did I think about to help me feel better? 
 
 What have I learnt in my prior experience that might help me now?  
 
 Action plan – does the new thought suggest any action?  
 
In many situations the alternative evidence for thoughts will not be immediately 
available. In this instance, intervention will be focused on setting up experiments in 
order to gather information to test thoughts and assumptions. Behavioural 
experiments may be set up in relation to NATs or underlying/conditional 
assumptions.  
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This session is used to review work to date, revisit the presenting issues and goals 
agreed at assessment and plan the next phase of work. The intention is to support 
patient learning up until this point, celebrate any positive change, ensure the focus 
for therapy remains collaboratively agreed and appropriate and map out the work 
that will take place in Phase II. 
 
Normally at this stage the client will be socialised to the model, comfortable with the 
therapy format and therapist, able to use behavioural skills and identify and 
challenge automatic thoughts. The next phase turns to beliefs that underpin 
automatic thoughts and behavioural repertoires involved in maintaining depression. 
 
However, every client is different and the rate of progress will be different for every 
client.  
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Once the client can skilfully and effectively challenge NATs the focus of cognitive 
intervention shifts to the level of underlying/conditional assumptions. In this stage the 
therapist works to identify the rules or assumptions that the client holds. This level of 
focus is more consistent with a cross-sectional level of formulation (Kuyken, Padesky 
& Dudley, 2009). This is focused on identifying the typical themes and patterns that 
repeatedly occur across different situations.  
 
Underlying assumptions may be explored by the therapist and client by considering 
the themes in thinking that occur across time and different situations. A further 
approach is the downward arrow technique where the client is asked specifically 
about the meaning of NATs or what NATs say about them e.g.:  
 
What does this mean to you? 
 
If this was true, what does this say about you as a person? 
 
What is the worst thing about that? 
 
Underlying assumptions may be best identified in the ‘if_________ then 
__________’ format as identified by Mooney and Padesky (2000). These are the 
rules or assumptions that the person makes in different situations (e.g. if ‘I don’t do 
things perfectly or make a mistake then I am worthless’). Underlying/conditional 
assumptions expressed in this format are more amenable to experimentation. 
Behavioural experiments are one method for challenging such beliefs. 
 
Underlying assumptions should be integrated into the formulation and considered in 
terms of their impact upon the client and how they fit with the client’s goals for 
treatment. It is also important to consider with the client the context of the 
development of these rules and assumptions, which they may have needed in order 
to survive difficult or toxic situations. However the invitation in treatment is to now 
consider whether these rules are optimal for the client’s goals and current life 
situation.  
 
The therapist also aims to assist the client in identifying that the underlying/ 
conditional beliefs are beliefs rather than facts. One approach for this is to consider 
the prejudice model outlined by Padesky (1990). 
 
Steps involved in working with underlying/conditional assumptions: 
Formulation of the conditional belief - what is the belief held by the client? 
Observation of the belief in action in everyday situations – what is the impact 
of this belief? Formulate this and consider this in relation to treatment goals. 
Socratic questioning/discussion of evidence for and against belief(s) 
 Consequences of beliefs: self-fulfilling? 
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Is change seen as advantageous? 
 Advantages and disadvantages of conditional belief 
Identifying alternative rule 
 Behavioural experiments  
 
Socratic Qs of conditional beliefs 
Are there times when this rule does/does not work for you? 
What experiences have you had that support this belief? 
What experiences have you had that don’t support this belief? 
How does this belief fit with what is realistic or possible for you/for other 
people? 
 How does this belief fit with the rules you expect other people to fit to (are you 
setting very tough standards for yourself)? 
 
Exploring the consequences of CBs 
What are the consequences of having this rule? 
Compensatory behaviours 
Feelings/reactions when the rule is activated 
 
Generating an alternative, balanced conditional belief 
What might be a more helpful rule to have? 
What sort of new rule could you come up with that would better reflect the 
realities of your situation? 
What sort of alternative rule could you have which would help you have the 
sort of life/relationships that you want? E.g. my value as a father and a 
husband depends on more than just the amount I am paid. 
 Flashcards for modifying conditional beliefs. 
 
There are different types of behavioural experiments (Figure below). It is important to 
take in to account when designing behavioural experiments how much the activity is 
driven by the conditional belief and how often the behavior occurs in the client’s 
normal repertoire of behavior.  
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Improving Access to Psychological Therapies - High Intensity
Types of behavioural experiment
Client primarily actor
Client primarily observer
Testing clear hypothesis Open-ended discovery
E.g. client does something 
and sees if predicted 
consequences occur
E.g. client does something 
and sees what happens in 
an open-ended way
E.g. a survey of other 
people’s reactions
E.g. therapist does 
something and client 
observes what happens
Planning and Implementing Behavioural Experiments 
 
 Collaborative, logical, planned, rationalised 
Behavioural experiments should be developed in partnership with the client and 
make sense to the client both in terms of why the experiment is being undertaken 
and how the client will carry this out.  
 
 Be clear about the belief you are testing (e.g., “So your prediction is that you 
go to this party you will end up standing by yourself most of the time and you 
believe this 95%”) 
The behavioural experiment should be clearly focused on a specific belief. 
 
 Design experiment collaboratively ‘how could we test this out?’ 
As well as developing the experiment collaboratively it is important to consider the 
opportunity to learn and develop whatever the outcome. In this sense the experiment 
is a no lose experiment, as whatever the outcome we learn more about how to cope. 
 
 Make clear prediction(s) and rate conviction 
In advance of completing the experiment the client should be able to state clearly 
what the outcome of the experiment will be if the assumption is true and what will 
illustrate that the rule may not be true. In this way disconfirmatory experience upon 
completion of the experiment is less like to be discounted. 
 
 Open-minded approach 
All parties should consider the experiment in an empirical way, with all outcomes 
being seen as possible. 
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 Anticipate negative outcomes and rehearse coping strategies 
Consider how the client will cope if there is difficulty in completion of the experiment. 
Can any barriers be anticipated and problems solved or planned for? 
 
 Experiment can be in-session too! 
 
Reviewing behavioural experiments: 
 
 What actually happened: thoughts, feelings, outcomes? Match to prediction(s) 
– review the specific outcome of the experiment in light of the prediction made 
 
 Integrating meaning of BE: 
What new information does this give us? 
How can we make sense of what happened? 
What does this mean for similar situations in the future? 
Attending to ‘yes, but ’ 
What is the next step (extend or generalise conclusions? Improve 
design of current experiment?) 
Re-rate belief in cognition(s) 
Consider a new conditional belief (theory A, theory B) 
Using behavioural experiments to test out conditional beliefs 
 
 Test old versus new conditional beliefs – complete further experiments 
designed. 
 
(See BE experiment sheet in clinical tools section, potentially include example). 
 
Responsibility pie chart: 
 
Responsibility pie charts are useful when the person attributes a higher than 
appropriate level of responsibility for a negative outcome or event to him or herself, 
leading to mood based difficulties. This may well touch on an underlying/conditional 
assumption that they hold, which predisposes them to hold a high level of 
responsibility for negative events.  
 
In this instance the level of responsibility for such events or outcomes can be elicited 
from the client (e.g. I am 100% responsible) which then forms the basis for 
intervention. 
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Steps in creating a responsibility pie chart: 
 
I am 100% responsible for . . .  
Gather as much information as possible on who or what else may share 
this responsibility - list these (theirs first). 
Get the client to rate how much each item on the list is responsible as a 
percentage, in reverse order (leaving the client as the last item). 
Place these in the responsibility pie chart as you go. 
 The slice that is left is their responsibility.  
If my son contracts toxoplasmosis it will be my fault.
 
Surveys  
 
Survey methods can provide a good way to judge whether the ‘normal’ beliefs or 
experiences that a client has are also normal and typical for others. This can help to 
normalise concerns and reduce the strength of belief in metacognition in relation to 
these beliefs (‘the fact that I have this belief means....’). 
 
In this method the client and the therapist draw up a list of questions to test whether 
others have similar experiences/thoughts. The client and therapist then work 
together to identify the client’s expectations on how others will respond to these 
questions (based on their beliefs, what do they expect people will say?). It is also 
considered what it would mean about the client’s belief if people do not respond in 
the way that the client predicts. Then either the client or the therapist (or both) ask 
people they come into contact with to respond to the questions and responses are 
recorded. These responses are then discussed in the session and considered 
against the prediction the client made and what this may mean in terms of alternative 
beliefs. 
Dog Owner
25%
Council
25%Son
5%
Chance 
Conditions
5%
Health Info from 
GP
20%
Husband
10%
ME
10%
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Identifying and working with core beliefs 
 
For the main part, intervention will be at the level of underlying/conditional 
assumptions. There may be some occasions, however, when it is necessary to 
consider working at the level of unconditional belief (schema/core belief).  
 
What are core beliefs? 
 
Core beliefs are unconditional beliefs that a person may hold about themselves. 
They reflect our understanding of our early experiences and statements about the 
self that are of an absolute, global and stable nature. 
 I am unlovable; I am worthless; I am a failure. 
Core beliefs may lie dormant until activated by a situation that matches with them. 
Once activated they work to filter out all information that is not consistent with them 
and focus attention on the information that supports and maintains the core belief. 
 
Core beliefs are at times the least accessible thoughts helped by a person and may 
not be available in a precise verbal form. 
 
Identifying core beliefs 
 
 Core beliefs may be expressed as NATs at times, e.g. ‘I am _____’ 
statements made by the client in relation to specific events. 
 
 Downward arrow technique using guided discovery –  
 ‘What’s the worst that could happen?’ 
 ‘What does that say/mean about you/other people/the future?’ 
 ‘As we are talking about this, do you have any images in your 
mind?’ (describe and use downward arrow technique) 
 ‘If you play that image forwards, what happens?’  
 
 Working back ‘have you felt like this before / found yourself thinking this about 
yourself before?’ 
 
 Can be ‘then ’ part of conditional beliefs 
 
 Looking out for themes, e.g. in thought record – themes in meaning of 
different situations and contexts 
 
 Completing three phrases (Padesky, 1994): 
 I am  
 Others are . 
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The world is  
 
 Following strong and pervasive emotion, especially shame, guilt or feelings of 
self-hatred. 
 
When Do I Use a Longitudinal Conceptualisation? 
 
Use when: 
 
Longstanding issues are part of the presenting issues 
 
The client needs a sense of ‘why?’ At times clients will express a desire to 
understand why their difficulties are present. A longitudinal formulation gives 
the opportunity to develop this understanding of onset, to normalise and 
validate the ways of understanding the world as necessary in a difficult or 
toxic situation, and to consider alternative rules or coping that may fit the 
person’s current life situation and goals better.  
 
There is an inadequate response to well-delivered therapy – where schemas 
or core beliefs held by the client are treatment-interfering if left unaddressed. 
 
It strengthens resilience and reduces the chances of relapse – developing 
understanding, coping and alternative responses through continua methods 
can help reduce vulnerability and promote resilience. 
 
Identifying positive core beliefs 
 
Identify alternative (positive) core beliefs: creating/re-accessing alternative ‘file 
drawer’ for experience 
 
 Look at negative belief and look for exceptions: what alternative belief would 
fit these exceptions? 
 
 ‘How would you like to be?’ 
 
 Should be inconsistent with negative belief (but not necessarily the opposite). 
However, positive alternative schemas should also be expressed in absolute 
terms. Whilst negative schemas imply total absence (unlovable meaning 
never being loved) a positive schema contains greater flexibility (some 
experience show it is possible for me to be lovable). 
 
 Careful attention to wording 
 
Exploring beliefs to weaken negative schemas and build positive alternatives is 
explored by Padesky (1993) through the use of continua methods.  
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1. A continua is developed focused upon the positive alternative schema (e.g. I 
am lovable). This is scaled from 0 to 100%. This focus automatically seeks 
the focus of attention on to discovery of instances of the positive quality. This 
also immediately moves the person to a more balanced midpoint between 
unlovable and lovable. In other words rather than starting from 100% 
unlovable, the start point is halfway to lovable at 0% lovable. 
Endpoints of the scale can be defined in absolute terms to help shift the person’s 
perception of themselves (e.g. 100% unlovable must mean never ever being liked in 
the slightest by anyone ever in the history of their life). Friends may also be plotted 
on the scale, followed by disliked people (e.g. a cruel boss, an abusive family 
member or neighbour, even figures from history). This is also helpful in anchoring the 
end points of the scale. 
 
2. Behavioural sub-continua of the global scale are then developed. What are 
the behavioural qualities that show someone is loveable; what are the 
qualities that embody this? This can be facilitated by considering someone 
they know that represents the alternative belief (i.e. who is someone you 
know you would consider lovable) and by identifying what the qualities they 
possess are that demonstrate this. The attention to wording is important in 
helping to reframe these beliefs. Also, the therapist needs to explain the 
rationale for the start point of the continuum scale not being opposite to 
positive belief as progress may be hampered by thinking errors, e.g., black or 
white thinking, negative bias etc. Therapists may have covered thinking errors 
in earlier sessions, but progress in therapy may not be linear and thinking 
errors are probably likely to still be problematic when tackling core beliefs and 
this work provides an opportunity to build on earlier work. 
 
3. These qualities are developed in sub-continua, with clearly defined endpoints. 
The person is then asked to rate themselves on these specific criteria, as 
people will rate themselves less negative on specific items than global criteria.  
 
4. The differences between specific and global ratings are discussed to shift 
global ratings. 
 
5. Experiments are based on meeting sub-continua and developing competence 
in these, or having the opportunity to do so (e.g. contacting other friends). 
 
6. These help to create a positive data log. 
 
Positive data log 
 
Positive data logs are a form of behavioural experiment. 
 
Evidence consistent with positive beliefs is clearly recorded. This is then 
reviewed in order to consider the client’s confidence rating (0-100%) in this 
alternative belief. 
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Positive data does not need to fit with the positive belief 100% and the 
positive belief may not need to reach a 100% rating either.  
 
One of the main aims of this log is to help the client become increasingly alert 
for prejudice or negative filtering of information at work. 
 
The therapist will need to be alert to instances consistent with the alternative 
belief and help the client to identify these, particularly in the early stages. It 
can be difficult to identify evidence unprompted. Therefore adding structure to 
the collection of this evidence as identified below may be important. 
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What sort of evidence might you look out for? 
 
Category  Example  %  
I didn’t ‘cave in’ to an 
unreasonable request  
  
I organised myself in advance 
for activities  
  
People trusted me with 
responsibility  
  
 
Behavioural change 
 
A clear goal of developing these alternatives is to translate this into behaviour, which 
will further increase the collection of evidence in support of them.  
 
Acting/living according to the new belief: 
 
 Identify occasions in past week when client acted according to new 
belief. 
 
 Identify opportunities to act in accordance with new belief in next week 
‘if you really believe X, how would you approach this situation?’  
 
 ‘What would someone who believed X about themselves do in this 
situation?’ 
 
 Review outcomes: not just the outcome itself but also how well the 
client’s action fitted with the new belief. 
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This session consolidates all the gains thus far against the previous list of presenting 
issues and goals and maps out the final phase which is focused on relapse 
prevention and building long-term resilience. 
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Relapse prevention 
 
Doing a relapse plan or blueprint for change can make a difference in long-term 
outcomes (Hollon et al., 2005). This work involves working with the patient using all 
that has been learned in therapy to devise a relapse signature that will support the 
patient in:  
 
Detecting early warning signs for relapse 
Accessing action plans for tackling setbacks 
 
A blueprint for change typically includes: 
 
What have I learnt in cognitive therapy? 
How do I plan to build on what I have learnt in everyday life? 
What obstacles are there for building on my gains? 
How am I going to overcome these? 
What might lead to a setback for me?  
If I did have a setback what would I do about it? 
 
Typically this phase of therapy involves very explicitly planning further behavioural 
experiments that will expose the client to situations that will activate old 
conditional/underlying beliefs and provide an opportunity to challenge these, activate 
new more functional conditional/underlying beliefs and behave more functionally. 
They can use their relapse signature and blueprints for change and have the 
knowledge that ongoing therapy sessions are available to support them in this work.   
 
It is really important in this phase of therapy to support patients become more self-
sufficient in using the tools of CBT, including setting time aside for self-therapy and 
reviewing their therapy folder. 
 
Finally, in this phase of therapy, the focus of formulation moves to a formulation of 
the client’s resilience. That is to say applying the formulations developed so far, but 
now the explicit focus is on thoughts, feelings, behaviours, physical sensations and 
underlying assumption that are supportive of progress made in therapy. This is best 
linked to explicit skills that will help to move the client towards coping resiliently with 
challenges. 
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The booster sessions are used very flexibly and have the main aim of supporting 
clients in maintaining gains, practising skills they learned in therapy and staying well 
in the long term. A model that works best is offering these sessions to clients on an 
as-needed basis during the trial follow-up period, so they can phone up and make an 
appointment when they need it. However, some clients may prefer the security of 
having a session in the diary and with others the therapist may judge that it would be 
best for whatever reason to pre-schedule these appointments.  
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